FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Strottmann, DM
   Zanluca, C
   Mosimann, ALP
   Koishi, AC
   Auwerter, NC
   Faoro, H
   Cataneo, AHD
   Kuczera, D
   Wowk, PF
   Bordignon, J
   dos Santos, CND
AF Strottmann, Daisy Maria
   Zanluca, Camila
   Pamplona Mosimann, Ana Luiza
   Koishi, Andrea C.
   Auwerter, Nathalia Cavalheiro
   Faoro, Helisson
   Depieri Cataneo, Allan Henrique
   Kuczera, Diogo
   Wowk, Pryscilla Fanini
   Bordignon, Juliano
   Duarte dos Santos, Claudia Nunes
TI Genetic and biological characterisation of Zika virus isolates from
   different Brazilian regions
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE Zika virus; Flavivirus; molecular markers; biological characterisation
ID MEMBRANE TOPOLOGY; INFECTION
AB BACKGROUND Zika virus (ZIKV) infections reported in recent epidemics have been linked to clinical complications that had never been associated with ZIKV before. Adaptive mutations could have contributed to the successful emergence of ZIKV as a global health threat to a nonimmune population. However, the causal relationships between the ZIKV genetic determinants, the pathogenesis and the rapid spread in Latin America and in the Caribbean remain widely unknown.
   OBJECTIVES The aim of this study was to characterise three ZIKV isolates obtained from patient samples during the 2015/2016 Brazilian epidemics.
   METHODS The ZIKV genomes of these strains were completely sequenced and in vitro infection kinetics experiments were carried out in cell lines and human primary cells.
   FINDINGS Eight nonsynonymous substitutions throughout the viral genome of the three Brazilian isolates were identified. Infection kinetics experiments were carried out with mammalian cell lines A549, Huh7.5, Vero E6 and human monocyte-derived dendritic cells (mdDCs) and insect cells (Aag2, C6/36 and AP61) and suggest that some of these mutations might be associated with distinct viral fitness. The clinical isolates also presented differences in their infectivity rates when compared to the well-established ZIKV strains (MR766 and PE243), especially in their abilities to infect mammalian cells.
   MAIN CONCLUSIONS Genomic analysis of three recent ZIKV isolates revealed some nonsynonymous substitutions, which could have an impact on the viral fitness in mammalian and insect cells.
C1 [Strottmann, Daisy Maria; Zanluca, Camila; Pamplona Mosimann, Ana Luiza; Koishi, Andrea C.; Auwerter, Nathalia Cavalheiro; Depieri Cataneo, Allan Henrique; Kuczera, Diogo; Wowk, Pryscilla Fanini; Bordignon, Juliano; Duarte dos Santos, Claudia Nunes] Fundacao Oswaldo Cruz Fiocruz, Lab Virol Mol, Inst Carlos Chagas, Curitiba, Parana, Brazil.
   [Faoro, Helisson] Fundacao Oswaldo Cruz Fiocruz, Lab Regulacao Expressao Genica, Inst Carlos Chagas, Curitiba, Parana, Brazil.
RP dos Santos, CND (corresponding author), Fundacao Oswaldo Cruz Fiocruz, Lab Virol Mol, Inst Carlos Chagas, Curitiba, Parana, Brazil.
EM claudia.dossantos@fiocruz.br
RI Wowk, Pryscilla/AAA-3281-2019; Faoro, Helisson/F-7163-2012; Wowk,
   Pryscilla Fanini/AAR-7230-2020; Cataneo, Allan/AAB-7997-2020; Bordignon,
   Juliano/Z-6268-2019; Mosimann, Ana Luiza Pamplona/AAB-4714-2019
OI Faoro, Helisson/0000-0002-0146-8639; Bordignon,
   Juliano/0000-0002-1965-6152; Mosimann, Ana Luiza
   Pamplona/0000-0002-3504-5562; Wowk, Pryscilla/0000-0002-8976-2647;
   Zanluca, Camila/0000-0001-7350-9105
FU FIOCRUZ; BNDES; CNPqNational Council for Scientific and Technological
   Development (CNPq) [439968/2016-0]; CAPESCAPES [88887.116626/201601,
   88887.130200/2017-01]; Fundacao AraucariaFundacao Araucaria [CP 04/2016]
FX FIOCRUZ, BNDES, CNPq (439968/2016-0), CAPES (88887.116626/201601 and
   88887.130200/2017-01), Fundacao Araucaria (CP 04/2016).; CNDS and JB
   have a CNPq fellowship.
CR Alpuche-Lazcano SP, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020053
   Altizer S, 2006, ECOL LETT, V9, P467, DOI 10.1111/j.1461-0248.2005.00879.x
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   CDC-Centers for Disease Control and Prevention, 2017, ZIK MAC ELISA
   DESPRES P, 1993, VIROLOGY, V196, P209, DOI 10.1006/viro.1993.1469
   Duggal NK, 2019, VIROLOGY, V530, P19, DOI 10.1016/j.virol.2019.02.004
   Elazar M, 2004, J VIROL, V78, P11393, DOI 10.1128/JVI.78.20.11393-11400.2004
   Emery SL, 2004, EMERG INFECT DIS, V10, P311, DOI 10.3201/eid1002.030759
   Hamel R, 2015, J VIROL, V89, P8880, DOI 10.1128/JVI.00354-15
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Li Y, 2015, BBA-BIOMEMBRANES, V1848, P3150, DOI 10.1016/j.bbamem.2015.09.016
   Lindenbach B., 2013, FIELDS VIROLOGY, V1, P712
   Liu ZY, 2019, NAT REV MICROBIOL, V17, P131, DOI 10.1038/s41579-018-0134-9
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Marquez-Jurado S, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10100547
   Michlmayr D, 2017, NAT MICROBIOL, V2, P1462, DOI 10.1038/s41564-017-0035-0
   Musso D, 2014, CLIN MICROBIOL INFEC, V20, pO595, DOI 10.1111/1469-0691.12707
   Rodriguez-Barraquer I, 2019, SCIENCE, V363, P607, DOI 10.1126/science.aav6618
   Russo FB, 2017, BIOCHEM BIOPH RES CO, V492, P603, DOI 10.1016/j.bbrc.2017.01.074
   Shrivastava S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34147-7
   Tajima S, 2007, J GEN VIROL, V88, P2214, DOI 10.1099/vir.0.82661-0
   Villordo SM, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004604
   Xia HJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02816-2
   Xie XP, 2013, J VIROL, V87, P4609, DOI 10.1128/JVI.02424-12
   Yokoyama S, 2017, MOL BIOL EVOL, V34, P525, DOI 10.1093/molbev/msw270
   Yoon KJ, 2017, CELL STEM CELL, V21, P349, DOI 10.1016/j.stem.2017.07.014
   Yuan L, 2017, SCIENCE, V358, P933, DOI 10.1126/science.aam7120
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
   Zanluca C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110620
   Zhu Z, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.48
NR 30
TC 2
Z9 2
U1 0
U2 1
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PY 2019
VL 114
AR e190150
DI 10.1590/0074-02760190150
PG 11
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA IS2YU
UT WOS:000482021100001
PM 31432892
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Cataneo, AHD
   Kuczera, D
   Mosimann, ALP
   Silva, EG
   Ferreira, AGA
   Marques, JT
   Wowk, PF
   dos Santos, CND
   Bordignon, J
AF Depieri Cataneo, Allan Henrique
   Kuczera, Diogo
   Pamplona Mosimann, Ana Luiza
   Silva, Emanuele Guimaraes
   Araujo Ferreira, Alvaro Gil
   Marques, Joao Trindade
   Wowk, Pryscilla Fanini
   Duarte dos Santos, Claudia Nunes
   Bordignon, Juliano
TI Detection and clearance of a mosquito densovirus contaminant from
   laboratory stocks of Zika virus
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE arixwirus isolation; contamination; C6/36 cultures; densovirus;
   vertebrate cells; Zika virus
ID AEDES-ALBOPICTUS; A549 CELLS; INFECTION; IDENTIFICATION; PATHOGENICITY;
   SEQUENCE; LINE
AB BACKGROUND The Zika virus (ZIKV) epidemics that affected South America in 2016 raised several research questions and prompted an increase in studies in the field. The transient and low viraemia observed in the course of ZIKV infection is a challenge for viral isolation from patient serum, which leads to many laboratories around the world sharing viral strains for their studies. C6/36 cells derived from Aedes albopictus larvae are commonly used for arbovirus isolation from clinical samples and for the preparation of viral stocks.
   OBJECTIVES Here, we report the contamination of two widely used ZIKV strains by Brevidensovirus, here designated as mosquito densovirus (MDV).
   METHODS Molecular and immunological techniques were used to analyse the MDV contamination of ZIKV stocks. Also, virus passages in mammalian cell line and infecting susceptible mice were used to MDV clearance from ZIKV stocks.
   FINDINGS MDV contamination was confirmed by molecular and immunological techniques and likely originated from C6/36 cultures commonly used to grow viral stocks. We applied two protocols that successfully eliminated MDV contamination from ZIKV stocks, and these protocols can be widely applied in the field. As MDV does not infect vertebrate cells, we performed serial passages of contaminated stocks using a mammalian cell line and infecting susceptible mice prior to re-isolating ZIKV from the animals' blood scrum. MDV elimination was confirmed with immunostaining, polymerase chain reaction (PCR), and analysis of the mosquitoes that were allowed to feed on the infected mice.
   MAIN CONCLUSIONS Since the putative impact of viral contaminants in ZIKV strains generally used for research purposes is unknown, researchers working in the field must be aware of potential contaminants and test viral stocks to certify sample purity.
C1 [Depieri Cataneo, Allan Henrique; Kuczera, Diogo; Pamplona Mosimann, Ana Luiza; Wowk, Pryscilla Fanini; Duarte dos Santos, Claudia Nunes; Bordignon, Juliano] Fundacao Oswaldo Cruz Fiocruz, Inst Carlos Chagas, Lab Virol Mol, Curitiba, Parana, Brazil.
   [Silva, Emanuele Guimaraes; Araujo Ferreira, Alvaro Gil; Marques, Joao Trindade] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, Belo Horizonte, MG, Brazil.
RP Bordignon, J (corresponding author), Fundacao Oswaldo Cruz Fiocruz, Inst Carlos Chagas, Lab Virol Mol, Curitiba, Parana, Brazil.
EM juliano.bordignon@fiocruz.br
RI Cataneo, Allan/AAB-7997-2020; Santos, Claudia Duarte dos/P-4868-2019;
   Bordignon, Juliano/Z-6268-2019; Mosimann, Ana Luiza
   Pamplona/AAB-4714-2019; Ferreira, Alvaro G A/O-3649-2015; Wowk,
   Pryscilla/AAA-3281-2019; Wowk, Pryscilla Fanini/AAR-7230-2020; Marques,
   Joao T/F-7683-2012
OI Santos, Claudia Duarte dos/0000-0001-8707-6638; Bordignon,
   Juliano/0000-0002-1965-6152; Mosimann, Ana Luiza
   Pamplona/0000-0002-3504-5562; Marques, Joao T/0000-0002-3457-3320; Wowk,
   Pryscilla/0000-0002-8976-2647
FU Ministerio da Saude e Fundacao Araucaria (PPSUS/2013); Fundacao
   Araucaria/SESA-PR/CNPq/MS-Decit PPSUS/2015 [019/2017]
FX Ministerio da Saude e Fundacao Araucaria (PPSUS/2013), Fundacao
   Araucaria/SESA-PR/CNPq/MS-Decit PPSUS/2015 - (019/2017). JTM
   (305357/2014-0), CNDS (309432/2015-4) and JB (303306/2017-3) are CNPq
   fellows.
CR AFANASIEV BN, 1991, VIROLOGY, V185, P323, DOI 10.1016/0042-6822(91)90780-F
   Barreau C, 1996, J INVERTEBR PATHOL, V68, P299, DOI 10.1006/jipa.1996.0100
   Bergoin M, 2000, CONTRIB MICROBIOL, V4, P12
   Carlson J, 2006, ADV VIRUS RES, V68, P361, DOI 10.1016/S0065-3527(06)68010-X
   Cotmore SF, 2014, ARCH VIROL, V159, P1239, DOI 10.1007/s00705-013-1914-1
   DESPRES P, 1993, VIROLOGY, V196, P209, DOI 10.1006/viro.1993.1469
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   dos Santos T, 2016, NEW ENGL J MED, V375, P1598, DOI 10.1056/NEJMc1609015
   Faye O, 2008, J CLIN VIROL, V43, P96, DOI 10.1016/j.jcv.2008.05.005
   FONG CKY, 1975, J CLIN MICROBIOL, V1, P219, DOI 10.1128/JCM.1.2.219-224.1975
   FONG CKY, 1992, J CLIN MICROBIOL, V30, P1611, DOI 10.1128/JCM.30.6.1611-1613.1992
   Frumence E, 2016, VIROLOGY, V493, P217, DOI 10.1016/j.virol.2016.03.006
   Hall T.A., 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1021/BK-1999-0734.CH008
   HIRUMI H, 1976, IN VITRO CELL DEV B, V12, P83
   Horbach SPJM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186281
   JOUSSET FX, 1993, VIRUS RES, V29, P99, DOI 10.1016/0168-1702(93)90052-O
   LEBEDEVA OP, 1973, ACTA VIROL, V17, P253
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Moser LA, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006880
   Olmo RP, 2018, NAT MICROBIOL, V3, P1385, DOI 10.1038/s41564-018-0268-6
   ONEILL SL, 1995, J GEN VIROL, V76, P2067, DOI 10.1099/0022-1317-76-8-2067
   Mosimann ALP, 2011, MEM I OSWALDO CRUZ, V106, P285, DOI 10.1590/S0074-02762011000300006
   Paterson A, 2005, VIROLOGY, V337, P253, DOI 10.1016/j.virol.2005.04.037
   Sivaram A, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-95
   Stapleford KA, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004402
   Suchman EL, 2006, BIOL CONTROL, V39, P465, DOI 10.1016/j.biocontrol.2006.05.001
   TESH RB, 1979, AM J TROP MED HYG, V28, P1053, DOI 10.4269/ajtmh.1979.28.1053
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Wei W, 2006, AM J TROP MED HYG, V75, P1118, DOI 10.4269/ajtmh.2006.75.1118
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 30
TC 2
Z9 2
U1 0
U2 1
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PY 2019
VL 114
AR e180432
DI 10.1590/0074-02760180432
PG 8
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA HL3KY
UT WOS:000458615100001
PM 30758394
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Tomiotto-Pellissier, F
   Bortoleti, BTD
   Assolini, JP
   Goncalves, MD
   Carloto, ACM
   Miranda-Sapla, MM
   Conchon-Costa, I
   Bordignon, J
   Pavanelli, WR
AF Tomiotto-Pellissier, Fernanda
   da Silva Bortoleti, Bruna Taciane
   Assolini, Joao Paulo
   Goncalves, Manoela Daiele
   Machado Carloto, Amanda Cristina
   Miranda-Sapla, Milena Menegazzo
   Conchon-Costa, Ivete
   Bordignon, Juliano
   Pavanelli, Wander Rogerio
TI Macrophage Polarization in Leishmaniasis: Broadening Horizons
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE classical macrophage; non-classical macrophage; vector saliva;
   Leishmania; immunomodulation; chemokine
ID SAND FLY SALIVA; LUTZOMYIA-LONGIPALPIS; ALTERNATIVE ACTIVATION;
   CUTANEOUS LEISHMANIASIS; VISCERAL LEISHMANIASIS; AMAZONENSIS INFECTION;
   IMMUNE-RESPONSES; MAJOR INFECTION; PPAR-GAMMA; IN-VITRO
AB Leishmaniasis is a vector-borne neglected tropical disease that affects more than 700,000 people annually. Leishmania parasites cause the disease, and different species trigger a distinct immune response and clinical manifestations. Macrophages are the final host cells for the proliferation of Leishmania parasites, and these cells are the key to a controlled or exacerbated response that culminates in clinical manifestations. M1 and M2 are the two main macrophage phenotypes. M1 is a pro-inflammatory subtype with microbicidal properties, and M2, or alternatively activated, is an anti-inflammatory/regulatory subtype that is related to inflammation resolution and tissue repair. The present review elucidates the roles of M1 and M2 polarization in leishmaniasis and highlights the role of the salivary components of the vector and the action of the parasite in the macrophage plasticity.
C1 [Tomiotto-Pellissier, Fernanda; da Silva Bortoleti, Bruna Taciane; Bordignon, Juliano; Pavanelli, Wander Rogerio] Fiocruz MS, Carlos Chagas Inst ICC, Biosci & Biotechnol Postgrad Program, Curitiba, Parana, Brazil.
   [Tomiotto-Pellissier, Fernanda; da Silva Bortoleti, Bruna Taciane; Assolini, Joao Paulo; Machado Carloto, Amanda Cristina; Miranda-Sapla, Milena Menegazzo; Conchon-Costa, Ivete; Pavanelli, Wander Rogerio] Univ Estadual Londrina, Dept Pathol Sci, Lab Immunoparasitol, Londrina, Brazil.
   [Goncalves, Manoela Daiele] Univ Estadual Londrina, Univ Hosp, Dept Chem, Lab Biotransformat & Phytochem, Londrina, Brazil.
   [Bordignon, Juliano] Fiocruz MS, Carlos Chagas Inst ICC, Lab Mol Virol, Curitiba, Parana, Brazil.
RP Bordignon, J; Pavanelli, WR (corresponding author), Fiocruz MS, Carlos Chagas Inst ICC, Biosci & Biotechnol Postgrad Program, Curitiba, Parana, Brazil.; Pavanelli, WR (corresponding author), Univ Estadual Londrina, Dept Pathol Sci, Lab Immunoparasitol, Londrina, Brazil.; Bordignon, J (corresponding author), Fiocruz MS, Carlos Chagas Inst ICC, Lab Mol Virol, Curitiba, Parana, Brazil.
EM bordignonjuliano@gmail.com; wanderpavanelli@yahoo.com.br
RI Assolini, Joao Paulo/U-3748-2017; Miranda-Sapla, Milena M/D-1231-2017;
   Bordignon, Juliano/Z-6268-2019; Tomiotto-Pellissier,
   Fernanda/Q-9679-2018
OI Assolini, Joao Paulo/0000-0003-4190-8835; Miranda-Sapla, Milena
   M/0000-0001-8324-9642; Bordignon, Juliano/0000-0002-1965-6152;
   Bortoleti, Bruna/0000-0003-2631-6719; Tomiotto-Pellissier,
   Fernanda/0000-0002-7273-8237
FU CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior)CAPES
FX This work was conducted during scholarships supported by CAPES
   (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior).
CR Abdeladhim M, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001345
   Abebe T, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002134
   Abebe T, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001684
   Allman WR, 2015, P NATL ACAD SCI USA, V112, pE4094, DOI 10.1073/pnas.1421580112
   Anderson CF, 2002, J LEUKOCYTE BIOL, V72, P101
   [Anonymous], 2016, Wkly Epidemiol Rec, V91, P287
   Araujo-Santos T, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000873
   Asai A, 2012, J LEUKOCYTE BIOL, V92, P859, DOI 10.1189/jlb.0212107
   Bashir S, 2016, INFLAMM RES, V65, P1, DOI 10.1007/s00011-015-0874-1
   Belkaid Y, 1998, J EXP MED, V188, P1941, DOI 10.1084/jem.188.10.1941
   Bhattacharya P, 2015, INFECT IMMUN, V83, P3800, DOI 10.1128/IAI.00184-15
   Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937
   Brodie TM, 2007, INFECT IMMUN, V75, P2359, DOI 10.1128/IAI.01812-06
   Carlsen ED, 2015, J INNATE IMMUN, V7, P354, DOI 10.1159/000373923
   Carregaro V, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003600
   Chan M. M., 2012, PPAR RES, V2012, P1, DOI DOI 10.1155/2012/796235
   Chistiakov DA, 2017, IMMUNOBIOLOGY, V223, P101, DOI 10.1016/j.imbio.2017.10.005
   Covarrubias A, 2013, CELL RES, V23, P984, DOI 10.1038/cr.2013.88
   Csoka B, 2012, FASEB J, V26, P376, DOI 10.1096/fj.11-190934
   Dameshghi S, 2016, IMMUNOL LETT, V170, P15, DOI 10.1016/j.imlet.2015.12.002
   Davis MJ, 2013, MBIO, V4, DOI 10.1128/mBio.00264-13
   de Freitas EO, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00153
   de Santana FR, 2017, CYTOKINE, V92, P33, DOI 10.1016/j.cyto.2017.01.004
   Diaz-Gandarilla JA, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/215283
   Duque GA, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00491
   Falcao SAC, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003601
   Farias LHS, 2017, PARASITOLOGY, V144, P1458, DOI 10.1017/S0031182017000944
   Farrow AL, 2011, MOL CELL BIOCHEM, V350, P47, DOI 10.1007/s11010-010-0681-5
   Ferrante CJ, 2013, INFLAMMATION, V36, P921, DOI 10.1007/s10753-013-9621-3
   Finnin M, 1999, J LEUKOCYTE BIOL, V66, P953
   Franca-Costa J, 2015, J INFECT DIS, V211, P426, DOI 10.1093/infdis/jiu455
   Fraternale A, 2015, J CLIN CELL IMMUNOL, V6, P319, DOI DOI 10.4172/2155-9899.1000319
   Gallardo-Soler A, 2008, MOL ENDOCRINOL, V22, P1394, DOI 10.1210/me.2007-0525
   Giraud E, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006794
   Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978
   Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007
   Graff JW, 2012, J BIOL CHEM, V287, P21816, DOI 10.1074/jbc.M111.327031
   Guimaraes-Costa AB, 2009, P NATL ACAD SCI USA, V106, P6748, DOI 10.1073/pnas.0900226106
   HALL LR, 1995, J IMMUNOL, V155, P3501
   Hammami A, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006616
   Hazlett LD, 2010, INVEST OPHTH VIS SCI, V51, P1524, DOI 10.1167/iovs.09-3983
   Hosono K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162532
   Hu SS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00001
   Hurrell BP, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004929
   Jablonski KA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145342
   Jian X, 2013, MEDIAT INFLAMM, DOI DOI 10.1155/2013/548073
   Kamhawi S, 2000, MICROBES INFECT, V2, P1765, DOI 10.1016/S1286-4579(00)01331-9
   Kim YG, 2014, CELL HOST MICROBE, V15, P95, DOI 10.1016/j.chom.2013.12.010
   Kong FP, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006165
   Kumar A, 2018, PARASITE IMMUNOL, V40, DOI 10.1111/pim.12586
   Kurowska-Stolarska M, 2009, J IMMUNOL, V183, P6469, DOI 10.4049/jimmunol.0901575
   Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088
   Lee SH, 2018, J EXP MED, V215, P357, DOI 10.1084/jem.20171389
   Lehtonen A, 2007, J LEUKOCYTE BIOL, V82, P710, DOI 10.1189/jlb.0307194
   Lestinova T, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005600
   Ley K, 2011, ARTERIOSCL THROM VAS, V31, P1506, DOI 10.1161/ATVBAHA.110.221127
   Li H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01175
   Liu D, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00083
   Silva RLL, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005486
   Lu JY, 2013, KIDNEY INT, V84, P745, DOI 10.1038/ki.2013.135
   Lucey DR, 1996, CLIN MICROBIOL REV, V9, P532, DOI 10.1128/CMR.9.4.532
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   Maroli M, 2013, MED VET ENTOMOL, V27, P123, DOI 10.1111/j.1365-2915.2012.01034.x
   Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532
   Mbow ML, 1998, J IMMUNOL, V161, P5571
   McCartney-Francis N, 2014, J LEUKOCYTE BIOL, V96, P917, DOI 10.1189/jlb.4A0612-295RR
   McFarlane E, 2008, INFECT IMMUN, V76, P532, DOI 10.1128/IAI.01388-07
   Mendonca SCF, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1777-x
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Mukhopadhyay D, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004145
   Muraille E, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00603
   Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008
   Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073
   Muxel SM, 2018, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02682
   Mylonas KJ, 2009, J IMMUNOL, V182, P3084, DOI 10.4049/jimmunol.0803463
   Norsworthy NB, 2004, INFECT IMMUN, V72, P1240, DOI 10.1128/IAI.72.3.1240-1247.2004
   Novais FO, 2009, J IMMUNOL, V183, P8088, DOI 10.4049/jimmunol.0803720
   Odegaard JI, 2007, NATURE, V447, P1116, DOI 10.1038/nature05894
   Oliveira F, 2013, J INVEST DERMATOL, V133, P452, DOI 10.1038/jid.2012.315
   Ontoria E, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00197
   Parisi L, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/8917804
   Park-Min KH, 2005, IMMUNOBIOLOGY, V210, P77, DOI 10.1016/j.imbio.2005.05.002
   Pesce J, 2006, J CLIN INVEST, V116, P2044, DOI 10.1172/JCI27727
   Peters NC, 2008, SCIENCE, V321, P970, DOI 10.1126/science.1159194
   Pushpanjali, 2016, CYTOKINE, V86, P79, DOI 10.1016/j.cyto.2016.07.017
   Regli IB, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01558
   Moreira PRR, 2016, VET PARASITOL, V226, P69, DOI 10.1016/j.vetpar.2016.06.032
   RIBEIRO JMC, 1986, COMP BIOCHEM PHYS A, V83, P683, DOI 10.1016/0300-9629(86)90709-7
   Ribeiro-Gomes FL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002536
   Rigamonti E, 2008, ARTERIOSCL THROM VAS, V28, P1050, DOI 10.1161/ATVBAHA.107.158998
   Rochael NC, 2015, SCI REP-UK, V5, DOI 10.1038/srep18302
   Rodriguez NE, 2014, IMMUNOL RES, V59, P129, DOI 10.1007/s12026-014-8536-x
   Rogers KA, 2003, PARASITE IMMUNOL, V25, P127, DOI 10.1046/j.1365-3024.2003.00623.x
   Rogers M, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000555
   Rohousova I, 2005, PARASITE IMMUNOL, V27, P469, DOI 10.1111/j.1365-3024.2005.00787.x
   Rohousova I, 2006, FOLIA PARASIT, V53, P161, DOI 10.14411/fp.2006.022
   Roy S, 2018, PARASITE IMMUNOL, V40, DOI 10.1111/pim.12535
   Ruan CC, 2015, ARTERIOSCL THROM VAS, V35, P598, DOI 10.1161/ATVBAHA.114.304927
   Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933
   Sarkar A, 2011, CYTOM PART A, V79A, P35, DOI 10.1002/cyto.a.21001
   Scorza BM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061296
   Scott P, 2016, NAT REV IMMUNOL, V16, P581, DOI 10.1038/nri.2016.72
   Self-Fordham JB, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01062
   Serafim TD, 2018, NAT MICROBIOL, V3, P548, DOI 10.1038/s41564-018-0125-7
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   Siewe N, 2016, MATH BIOSCI, V276, P28, DOI 10.1016/j.mbs.2016.02.015
   Soares RPP, 2003, AN ACAD BRAS CIENC, V75, P301, DOI 10.1590/S0001-37652003000300005
   Srivastava S, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1553-y
   Steverding D, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2028-5
   Stout RD, 2005, J IMMUNOL, V175, P342, DOI 10.4049/jimmunol.175.1.342
   Szanto A, 2010, IMMUNITY, V33, P699, DOI 10.1016/j.immuni.2010.11.009
   Tavares NM, 2014, J INFECT DIS, V210, P656, DOI 10.1093/infdis/jiu158
   Teixeira CR, 2005, J IMMUNOL, V175, P8346, DOI 10.4049/jimmunol.175.12.8346
   Terry RL, 2014, CELL IMMUNOL, V291, P16, DOI 10.1016/j.cellimm.2014.02.008
   THEODOS CM, 1991, INFECT IMMUN, V59, P1592, DOI 10.1128/IAI.59.5.1592-1598.1991
   TITUS RG, 1988, SCIENCE, V239, P1306, DOI 10.1126/science.3344436
   Van den Bossche J, 2016, CELL REP, V17, P684, DOI 10.1016/j.celrep.2016.09.008
   van Zandbergen G, 2004, J IMMUNOL, V173, P6521, DOI 10.4049/jimmunol.173.11.6521
   Vellozo NS, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01560
   Venturin GL, 2016, PARASITE IMMUNOL, V38, P698, DOI 10.1111/pim.12353
   Wang N, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00614
   Wang QS, 2010, CELL RES, V20, P701, DOI 10.1038/cr.2010.52
   Wang Z, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115855
   Wheat WH, 2008, J IMMUNOL, V180, P8286, DOI 10.4049/jimmunol.180.12.8286
   Wolfs IMJ, 2011, THROMB HAEMOSTASIS, V106, P763, DOI 10.1160/TH11-05-0320
   World Health Organization, 2018, LEISHMANIASIS
   Xu W, 2013, MOL IMMUNOL, V53, P179, DOI 10.1016/j.molimm.2012.07.005
   Xu XQ, 2011, J BIOL CHEM, V286, P32383, DOI 10.1074/jbc.M111.268904
   Zanluqui N. G., 2015, Journal of Clinical and Cellular Immunology, V6, P317
NR 129
TC 25
Z9 25
U1 0
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD OCT 31
PY 2018
VL 9
AR 2529
DI 10.3389/fimmu.2018.02529
PG 12
WC Immunology
SC Immunology
GA GY8PK
UT WOS:000448894600001
PM 30429856
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Martins, SD
   Kuczera, D
   Lotvall, J
   Bordignon, J
   Alves, LR
AF Martins, Sharon de T.
   Kuczera, Diogo
   Lotvall, Jan
   Bordignon, Juliano
   Alves, Lysangela R.
TI Characterization of Dendritic Cell-Derived Extracellular Vesicles During
   Dengue Virus Infection
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE extracellular vesicles; dengue; infection; neglected diseases; RNA
   sequencing
ID HEPATITIS-C VIRUS; ANTIGEN PRESENTATION; ENDOTHELIAL-CELLS;
   IMMUNE-RESPONSES; INTERFERON-ALPHA; BLOOD MONOCYTES; NK CELLS; T-CELLS;
   HIV NEF; EXOSOMES
AB The dengue virus (DENV), transmitted by Aedes spp. mosquitoes, is one of the most important arboviral infections in the world. Dengue begins as a febrile condition, and in certain patients, it can evolve severe clinical outcomes, such as dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The reasons why certain patients develop DHF or DSS have not been thoroughly elucidated to date, and both patient and viral factors have been implicated. Previous work has shown that a severe immune dysfunction involving dendritic cells and T cells plays a key role in increasing the disease severity, especially in secondary heterologous infections. Extracellular vesicles (EVs) are membranous particles that are secreted by several cell types involved in homeostatic and pathological processes. Secretion of EVs by infected cells can enhance immune responses or favor viral evasion. In this study, we compare the molecular content of EVs that are secreted by human primary dendritic cells under different conditions: uninfected or infected with DENV3 strains isolated from patients with different infection phenotypes (a severe case involving DSS and a mild case). Human monocyte-derived dendritic cells (mdDCs) were infected with the dengue virus strains DENV3 5532 (severe) or DENV3 290 (mild), and the EVs were isolated. The presence of cup-shaped EVs was confirmed by electron microscopy and immunostaining with CD9, CD81, and CD83. The RNA content from the mdDC-infected cells contained several mRNAs and miRNAs related to immune responses compared to the EVs from mock-infected mdDCs. A number of these RNAs were detected exclusively during infection with DENV3 290 or DENV3 5532. This result suggests that the differential immune modulation of mdDCs by dengue strains can be achieved through the EV pathway. Additionally, we observed an association of EVs with DENV-infectious particles that seem to be protected from antibodies targeting the DENV envelope protein. We also showed that EVs derived from cells treated with IFN alpha have a protective effect against DENV infection in other cells. These results suggested that during DENV infection, the EV pathway could be exploited to favor viral viability, although immune mechanisms to counteract viral infection can also involve DC-derived EVs.
C1 [Martins, Sharon de T.; Alves, Lysangela R.] Fiocruz MS, Carlos Chagas Inst, Lab Gene Express Regulat, Curitiba, Parana, Brazil.
   [Kuczera, Diogo; Bordignon, Juliano] Fiocruz MS, Carlos Chagas Inst, Lab Mol Virol, Curitiba, Parana, Brazil.
   [Lotvall, Jan] Univ Gothenburg, Krefting Res Ctr, Gothenburg, Sweden.
RP Alves, LR (corresponding author), Fiocruz MS, Carlos Chagas Inst, Lab Gene Express Regulat, Curitiba, Parana, Brazil.
EM lysangel.alves@fiocruz.br
RI Bordignon, Juliano/Z-6268-2019; Alves, Lysangela Ronalte/H-5599-2012
OI Bordignon, Juliano/0000-0002-1965-6152; Alves, Lysangela
   Ronalte/0000-0002-1972-2658
FU CAPESCAPES; CNPQNational Council for Scientific and Technological
   Development (CNPq); Fundacao AraucariaFundacao Araucaria
FX This work was funded by CAPES, CNPQ, and Fundacao Araucaria.
CR Alenquer M, 2015, VIRUSES-BASEL, V7, P5066, DOI 10.3390/v7092862
   Angelova M, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002959
   Aqil M, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.23129
   Auer PL, 2010, GENETICS, V185, P405, DOI 10.1534/genetics.110.114983
   Auffray C, 2009, ANNU REV IMMUNOL, V27, P669, DOI 10.1146/annurev.immunol.021908.132557
   Azeredo EL, 2006, CLIN EXP IMMUNOL, V143, P345, DOI 10.1111/j.1365-2249.2006.02996.x
   Barba-Spaeth G, 2016, NATURE, V536, P48, DOI 10.1038/nature18938
   Bardina SV, 2017, SCIENCE, V356, P175, DOI 10.1126/science.aal4365
   Beltran D, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00192
   Bernard MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106006
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77
   Buschow SI, 2009, TRAFFIC, V10, P1528, DOI 10.1111/j.1600-0854.2009.00963.x
   Carpp LN, 2011, MICROBES INFECT, V13, P85, DOI 10.1016/j.micinf.2010.10.010
   Ramirez JAC, 2015, J INTERF CYTOK RES, V35, P421, DOI 10.1089/jir.2014.0129
   Chahar HS, 2015, VIRUSES-BASEL, V7, P3204, DOI 10.3390/v7062770
   Chen K, 2007, NAT REV GENET, V8, P93, DOI 10.1038/nrg1990
   Chivero ET, 2014, J GEN VIROL, V95, P1307, DOI 10.1099/vir.0.063016-0
   Cui WW, 2007, NUCLEIC ACIDS RES, V35, pD805, DOI 10.1093/nar/gkl767
   Dalrymple NA, 2012, ADV VIROL, V2012, DOI 10.1155/2012/840654
   DEJANA E, 1994, CLIN EXP RHEUMATOL, V12, pS25
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   den Boon JA, 2010, CELL HOST MICROBE, V8, P77, DOI 10.1016/j.chom.2010.06.010
   Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623
   DESPRES P, 1993, VIROLOGY, V196, P209, DOI 10.1006/viro.1993.1469
   Dubois B, 1998, J IMMUNOL, V161, P2223
   Dubois B, 1997, J EXP MED, V185, P941, DOI 10.1084/jem.185.5.941
   Feneant L, 2014, VIRUSES-BASEL, V6, P535, DOI 10.3390/v6020535
   Giugliano S, 2015, GASTROENTEROLOGY, V148, P392, DOI 10.1053/j.gastro.2014.10.040
   Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828
   Guo L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00247
   HALSTEAD SB, 1977, J EXP MED, V146, P201, DOI 10.1084/jem.146.1.201
   Hayward S Diane, 2006, Sci STKE, V2006, pre4
   He TP, 2007, BIOCHEM BIOPH RES CO, V359, P202, DOI 10.1016/j.bbrc.2007.05.099
   Ho LJ, 2001, J IMMUNOL, V166, P1499, DOI 10.4049/jimmunol.166.3.1499
   Hosseini Hamideh Mahmoodzadeh, 2013, Inflammation & Allergy Drug Targets, V12, P29
   HOTTA H, 1984, MICROBIOL IMMUNOL, V28, P1099, DOI 10.1111/j.1348-0421.1984.tb00767.x
   Hou WQ, 2012, BLOOD, V119, P3128, DOI 10.1182/blood-2011-09-379479
   Izquierdo-Useros N, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000740
   Jaworski E, 2014, J BIOL CHEM, V289, P22284, DOI 10.1074/jbc.M114.549659
   Jego G, 2003, IMMUNITY, V19, P225, DOI 10.1016/S1074-7613(03)00208-5
   Kadiu I, 2012, J IMMUNOL, V189, P744, DOI 10.4049/jimmunol.1102244
   Kal AJ, 1999, MOL BIOL CELL, V10, P1859, DOI 10.1091/mbc.10.6.1859
   Kim KM, 2017, WIRES RNA, V8, DOI 10.1002/wrna.1413
   King CA, 2002, J VIROL, V76, P8408, DOI 10.1128/JVI.76.16.8408-8419.2002
   Kouwaki T, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00335
   Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536
   KURANE I, 1988, J GEN VIROL, V69, P445, DOI 10.1099/0022-1317-69-2-445
   Kwissa M, 2014, CELL HOST MICROBE, V16, P115, DOI 10.1016/j.chom.2014.06.001
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Lasser C, 2012, JOVE-J VIS EXP, DOI 10.3791/3037
   Leitmeyer KC, 1999, J VIROL, V73, P4738, DOI 10.1128/JVI.73.6.4738-4747.1999
   Li K, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003124
   Libraty DH, 2001, J VIROL, V75, P3501, DOI 10.1128/JVI.75.8.3501-3508.2001
   Limonta D, 2007, J CLIN VIROL, V40, P50, DOI 10.1016/j.jcv.2007.04.024
   Linggi B, 2006, TRENDS CELL BIOL, V16, P649, DOI 10.1016/j.tcb.2006.10.008
   Long HT, 2009, J INFECT DIS, V199, P537, DOI 10.1086/596507
   Lotvall J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.26913
   Mack M, 2000, NAT MED, V6, P769, DOI 10.1038/77498
   Manicassamy S, 2010, SCIENCE, V329, P849, DOI 10.1126/science.1188510
   Matsuoka T, 2014, CANCERS, V6, P1441, DOI 10.3390/cancers6031441
   Meckes DG, 2011, J VIROL, V85, P12844, DOI 10.1128/JVI.05853-11
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Moran E, 2008, EUR J IMMUNOL, V38, P1050, DOI 10.1002/eji.200737699
   Moreno-Altamirano MMB, 2015, INTERVIROLOGY, V58, P250, DOI 10.1159/000440723
   Muratori C, 2009, CELL HOST MICROBE, V6, P218, DOI 10.1016/j.chom.2009.06.009
   Navarro-Sanchez E, 2005, ARCH MED RES, V36, P425, DOI 10.1016/j.arcmed.2005.04.007
   Nolte-'t Hoen ENM, 2012, CURR PHARM DESIGN, V18, P2357
   Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd
   Paixao ES, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2017-000530
   Palmer DR, 2005, J VIROL, V79, P2432, DOI 10.1128/JVI.79.4.2432-2439.2005
   Pan-American Health Organization [PAHO], 1995, WKLY EPIDEMIOL REC, V70, P41
   PANG T, 1988, MICROBIOL IMMUNOL, V32, P511, DOI 10.1111/j.1348-0421.1988.tb01411.x
   Pegtel DM, 2010, P NATL ACAD SCI USA, V107, P6328, DOI 10.1073/pnas.0914843107
   Qi YM, 2013, MOL MED REP, V7, P791, DOI 10.3892/mmr.2013.1288
   Ramakrishnaiah V, 2013, P NATL ACAD SCI USA, V110, P13109, DOI 10.1073/pnas.1221899110
   Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161
   Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138
   Riedl E, 1997, J IMMUNOL, V158, P1591
   Rozmyslowicz T, 2003, AIDS, V17, P33, DOI 10.1097/00002030-200301030-00006
   SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109
   Sampey GC, 2014, J NEUROVIROL, V20, P199, DOI 10.1007/s13365-014-0238-6
   Saxena T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079886
   Schoggins John W, 2018, F1000Res, V7, P309, DOI 10.12688/f1000research.12450.1
   Schoggins JW, 2011, CURR OPIN VIROL, V1, P519, DOI 10.1016/j.coviro.2011.10.008
   Schorey JS, 2015, EMBO REP, V16, P24, DOI 10.15252/embr.201439363
   Schuster N, 2002, CELL TISSUE RES, V307, P1, DOI 10.1007/s00441-001-0479-6
   Shenoda BB, 2016, CLIN MED INSIGHTS-PA, V9, P1, DOI 10.4137/CPath.S39925
   Sierra BDC, 2006, VIRAL IMMUNOL, V19, P662, DOI 10.1089/vim.2006.0042
   Silveira GF, 2011, J VIROL, V85, P5374, DOI 10.1128/JVI.01915-10
   Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007
   Srikiatkhachorn A, 2009, THROMB HAEMOSTASIS, V102, P1042, DOI 10.1160/TH09-03-0208
   STEINMAN RM, 1975, J EXP MED, V141, P804
   Sun L, 2016, ANTIVIR RES, V134, P167, DOI 10.1016/j.antiviral.2016.07.013
   Swafford D, 2015, DISCOV MED, V19, P303
   Tambyah PA, 2016, ANN CLIN BIOCHEM, V53, P466, DOI 10.1177/0004563215604001
   Teijaro JR, 2016, CURR OPIN VIROL, V16, P31, DOI 10.1016/j.coviro.2016.01.001
   Thery C, 2002, NAT IMMUNOL, V3, P1156, DOI 10.1038/ni854
   Troupin A, 2016, J IMMUNOL, V197, P4382, DOI 10.4049/jimmunol.1600846
   Ubol S, 2010, CLIN VACCINE IMMUNOL, V17, P1829, DOI 10.1128/CVI.00316-10
   Utsugi-Kobukai S, 2003, IMMUNOL LETT, V89, P125, DOI 10.1016/S0165-2478(03)00128-7
   van der Grein SG, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00542
   Vlachos IS, 2012, NUCLEIC ACIDS RES, V40, pW498, DOI 10.1093/nar/gks494
   Watarai H, 2005, PROTEOMICS, V5, P4001, DOI 10.1002/pmic.200401258
   Welsch Christoph, 2009, Gastroenterology, V137, P2170, DOI 10.1053/j.gastro.2009.10.024
   Wilson ME, 2015, CURR INFECT DIS REP, V17, DOI 10.1007/s11908-014-0457-2
   World Health Organization, 2016, DENG GUID DIAGN TREA
   Wu SJL, 2000, NAT MED, V6, P816, DOI 10.1038/77553
   Wurdinger T, 2012, ADV VIROL, V2012, DOI 10.1155/2012/767694
NR 109
TC 11
Z9 11
U1 0
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD AUG 6
PY 2018
VL 9
AR 1792
DI 10.3389/fmicb.2018.01792
PG 19
WC Microbiology
SC Microbiology
GA GP3YT
UT WOS:000440792700001
PM 30131785
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU da Silva, SS
   Mizokami, SS
   Fanti, JR
   Costa, IN
   Bordignon, J
   Felipe, I
   Pavanelli, WR
   Verri, WA
   Costa, IC
AF da Silva, Suelen S.
   Mizokami, Sandra S.
   Fanti, Jacqueline R.
   Costa, Idessania N.
   Bordignon, Juliano
   Felipe, Ionice
   Pavanelli, Wander R.
   Verri, Waldiceu A., Jr.
   Costa, Ivete Conchon
TI Glucantime reduces mechanical hyperalgesia in cutaneous leishmaniasis
   and complete Freund's adjuvant models of chronic inflammatory pain
SO JOURNAL OF PHARMACY AND PHARMACOLOGY
LA English
DT Article
DE complete Freund's adjuvant; Glucantime; hyperalgesia; Leishmania
   amazonensis
ID NERVE GROWTH-FACTOR; NF-KAPPA-B; UP-REGULATION; ANTIMONIAL THERAPY;
   TNF-ALPHA; CYTOKINES; MICE; INTERLEUKIN-1-BETA; INFECTION; AMAZONENSIS
AB Objectives To evaluate the analgesic effect of Glucantime (antimoniate N-methylglucamine) in Leishmania amazonensis infection and complete Freund's adjuvant (CFA), chronic paw inflammation model, in BALB/c mice.
   Methods Two models of chronic inflammatory pain in BALB/c mice paw were used: infection with L. amazonensis and CFA stimulation. Both animals models received daily treatment with Glucantime (10 mg/kg, i.p.) and during the treatment was measured the mechanical hyperalgesia with electronic version of von Frey filaments. After the treatment, the paw skin sample was collected for analysis of myeloperoxidase (MPO) and N-acetyl-beta-glucosaminidase (NAG) activity, and IL-1 beta, TNF-alpha, IL-6, IFN-gamma and IL-10 cytokines production by ELISA.
   Key findings Leishmania amazonensis-induced chronic inflammation with significant increase in mechanical hyperalgesia, MPO and NAG activity, and IL-1 beta, TNF-alpha and IL-6 production in the paw skin. Glucantime (10 mg/kg, i.p.) inhibited L. amazonensis-induced mechanical hyperalgesia and IL-1 beta and IL-6 cytokines productions. In chronic inflammatory model induced by CFA, Glucantime treatment during 7 days inhibited CFA-induced mechanical hyperalgesia, MPO and NAG activity, and IL-1 beta, TNF-alpha, IL-6 and IFN-gamma production as well as increased IL-10 production.
   Conclusions Our data demonstrated that Glucantime reduced the chronic inflammatory pain induced by L. amazonensis and CFA stimuli by inhibiting the hyperalgesic cytokines production.
C1 [da Silva, Suelen S.; Fanti, Jacqueline R.; Costa, Idessania N.; Felipe, Ionice; Pavanelli, Wander R.; Costa, Ivete Conchon] Univ Estadual Londrina, Ctr Ciencias Bool, Dept Ciencias Patol, Lab Parasitol Expt, Londrina, PR, Peoples R China.
   [Mizokami, Sandra S.; Verri, Waldiceu A., Jr.] Univ Estadual Londrina, Ctr Ciencias Biol, Dept Ciencias Patol, Lab Dor & Inflamacao, Londrina, PR, Peoples R China.
   [Bordignon, Juliano] ICC Fiocruz PR, Inst Carlos Chagas, Lab Virol Mol, Curitiba, Parana, Brazil.
RP da Silva, SS (corresponding author), Univ Estadual Londrina, Dept Ciencias Patol, Lab Parasitol Expt, BR-86057970 Londrina, Brazil.
EM suelenbiomedica@gmail.com
RI da Silva, Suelen Santos/AAS-5789-2020; WA, Verri/I-1330-2013; Bordignon,
   Juliano/Z-6268-2019
OI da Silva, Suelen Santos/0000-0002-6251-0386; WA,
   Verri/0000-0003-2756-9283; Bordignon, Juliano/0000-0002-1965-6152
FU Coordenadoria de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq)National Council for Scientific and Technological
   Development (CNPq); Secretaria da Ciencia, Tecnologia e Ensino Superior
   (SETI)/Fundacao Araucaria; Governo do Estado do Parana
FX This work was supported by Brazilian grants from Coordenadoria de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico (CNPq), Secretaria da
   Ciencia, Tecnologia e Ensino Superior (SETI)/Fundacao Araucaria and
   Governo do Estado do Parana.
CR Ahmed AA, 1998, NEUROREPORT, V9, P3271, DOI 10.1097/00001756-199810050-00025
   Macedo SRA, 2015, INT IMMUNOPHARMACOL, V28, P554, DOI 10.1016/j.intimp.2015.07.020
   Ayres DC, 2011, REV INST MED TROP SP, V53, P329, DOI 10.1590/S0036-46652011000600006
   BERMAN JD, 1988, REV INFECT DIS, V10, P560
   Borghi SM, 2017, CHEM-BIOL INTERACT, V268, P1, DOI 10.1016/j.cbi.2017.02.009
   Borghi SM, 2017, PARASITOL RES, V116, P465, DOI 10.1007/s00436-016-5340-7
   Campanelli AP, 2010, HUM IMMUNOL, V71, P1220, DOI 10.1016/j.humimm.2010.09.002
   Cangussu SD, 2013, EXP PARASITOL, V133, P193, DOI 10.1016/j.exppara.2012.11.015
   Cecilio P, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00480
   Cunha TM, 2004, BRAZ J MED BIOL RES, V37, P401, DOI 10.1590/S0100-879X2004000300018
   Cunha TM, 2005, P NATL ACAD SCI USA, V102, P1755, DOI 10.1073/pnas.0409225102
   da Silva MD, 2015, MOL NEUROBIOL, V51, P19, DOI 10.1007/s12035-014-8790-x
   da Silva SS, 2016, PARASITOL RES, V115, P1557, DOI 10.1007/s00436-015-4890-4
   Daboul MW, 2008, J GEN PRACT, V2, P1
   de Santana FR, 2017, CYTOKINE, V92, P33, DOI 10.1016/j.cyto.2017.01.004
   Demicheli C, 2002, BBA-GEN SUBJECTS, V1570, P192, DOI 10.1016/S0304-4165(02)00198-8
   Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004
   Ferreira CDS, 2006, BIOMETALS, V19, P573, DOI 10.1007/s10534-006-0001-4
   Frezard F, 2009, MOLECULES, V14, P2317, DOI 10.3390/molecules14072317
   Gonzalez-Fajardo L, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003820
   Gupta G, 2013, ADV APPL MICROBIOL, V82, P155, DOI 10.1016/B978-0-12-407679-2.00005-3
   Haber ME, 2009, EXP PARASITOL, V121, P224, DOI 10.1016/j.exppara.2008.11.004
   Haimeur A, 2000, MOL BIOCHEM PARASIT, V108, P131, DOI 10.1016/S0166-6851(00)00187-0
   Kanaan SA, 2000, PAIN, V85, P477, DOI 10.1016/S0304-3959(99)00297-3
   Karam MC, 2007, J NEUROIMMUNOL, V183, P43, DOI 10.1016/j.jneuroim.2006.11.003
   Karam MC, 2013, EXP PARASITOL, V134, P200, DOI 10.1016/j.exppara.2013.02.005
   Karam MC, 2011, J NEUROIMMUNOL, V234, P49, DOI 10.1016/j.jneuroim.2011.02.003
   Karam MC, 2006, EXP PARASITOL, V113, P168, DOI 10.1016/j.exppara.2006.01.003
   Kocyigit A, 2002, INFECT IMMUN, V70, P6589, DOI 10.1128/IAI.70.12.6589-6591.2002
   Leitl MD, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-62
   Miranda MM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125101
   Morris-Jones S, 2004, NEW ENGL J MED, V350, P2313, DOI 10.1056/NEJMc045252
   Muniz-Junqueira MI, 2008, INT IMMUNOPHARMACOL, V8, P1633, DOI 10.1016/j.intimp.2008.07.011
   Oghumu S, 2010, EXP PARASITOL, V126, P389, DOI 10.1016/j.exppara.2010.02.010
   Pathak MK, 2001, J IMMUNOL, V167, P3391, DOI 10.4049/jimmunol.167.6.3391
   Raghavendra V, 2004, EUR J NEUROSCI, V20, P467, DOI 10.1111/j.1460-9568.2004.03514.x
   Ren Ke, 1999, ILAR J, V40, P111
   Ruiz-Miyazawa KW, 2015, CHEM-BIOL INTERACT, V237, P9, DOI 10.1016/j.cbi.2015.05.007
   SAFIEHGARABEDIAN B, 1995, BRIT J PHARMACOL, V115, P1265, DOI 10.1111/j.1476-5381.1995.tb15035.x
   Saldanha A C, 2000, Rev Soc Bras Med Trop, V33, P383, DOI 10.1590/S0037-86822000000400009
   Pereira BAS, 2008, VET PARASITOL, V158, P239, DOI 10.1016/j.vetpar.2008.09.015
   Silva S. S. da, 2015, Semina: Ciencias Biologicas e da Saude (Londrina), V36, P25
   Sommer C, 1999, NEUROSCI LETT, V270, P25, DOI 10.1016/S0304-3940(99)00450-4
   Sommer C, 2004, NEUROSCI LETT, V361, P184, DOI 10.1016/j.neulet.2003.12.007
   Sotiropoulos G, 2001, J EMERG MED, V20, P353, DOI 10.1016/S0736-4679(01)00311-0
   Sundar S, 2006, INDIAN J MED RES, V123, P345
   Sundar S, 2013, EXPERT OPIN PHARMACO, V14, P53, DOI 10.1517/14656566.2013.755515
   Sundar Shyam, 2007, Ther Clin Risk Manag, V3, P733
   Verri WA, 2006, PHARMACOL THERAPEUT, V112, P116, DOI 10.1016/j.pharmthera.2006.04.001
   Woolf CJ, 1997, BRIT J PHARMACOL, V121, P417, DOI 10.1038/sj.bjp.0701148
   Zhang JM, 2007, INT ANESTHESIOL CLIN, V45, P27, DOI 10.1097/AIA.0b013e318034194e
NR 51
TC 4
Z9 4
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3573
EI 2042-7158
J9 J PHARM PHARMACOL
JI J. Pharm. Pharmacol.
PD JUN
PY 2018
VL 70
IS 6
BP 768
EP 777
DI 10.1111/jphp.12896
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA GF5OI
UT WOS:000432017000008
PM 29532470
DA 2020-12-01
ER

PT J
AU Silveira, GF
   Wowk, PF
   Cataneo, AHD
   dos Santos, PF
   Delgobo, M
   Stimamiglio, MA
   Lo Sarzi, M
   Thomazelli, APFS
   Conchon-Costa, I
   Pavanelli, WR
   Antonelli, LRV
   Bafica, A
   Mansur, DS
   dos Santos, CND
   Bordignon, J
AF Silveira, Guilherme F.
   Wowk, Pryscilla F.
   Cataneo, Allan H. D.
   dos Santos, Paula F.
   Delgobo, Murilo
   Stimamiglio, Marco A.
   Lo Sarzi, Maria
   Thomazelli, Ana Paula F. S.
   Conchon-Costa, Ivete
   Pavanelli, Wander R.
   Antonelli, Lis R. V.
   Bafica, Andre
   Mansur, Daniel S.
   Duarte dos Santos, Claudia N.
   Bordignon, Juliano
TI Human T Lymphocytes Are Permissive for Dengue Virus Replication
SO JOURNAL OF VIROLOGY
LA English
DT Article
DE dengue virus; replication; T lymphocytes
ID HUMAN ENDOTHELIAL-CELLS; PRINCIPAL TARGET-CELLS; B-CELLS; INFECTION;
   APOPTOSIS; ACTIVATION; INTERFERON; EXPRESSION; MONOCYTES; PATHOGENESIS
AB Dengue virus (DV) infection can cause either a self-limiting flu-like disease or a threatening hemorrhage that may evolve to shock and death. A variety of cell types, such as dendritic cells, monocytes, and B cells, can be infected by DV. However, despite the role of T lymphocytes in the control of DV replication, there remains a paucity of information on possible DV-T cell interactions during the disease course. In the present study, we have demonstrated that primary human naive CD4(+) and CD8(+) T cells are permissive for DV infection. Importantly, both T cell sub-types support viral replication and secrete viable virus particles. DV infection triggers the activation of both CD4(+) and CD8(+) T lymphocytes, but preactivation of T cells reduces the susceptibility of T cells to DV infection. Interestingly, the cytotoxicity-inducing protein granzyme A is highly secreted by human CD4(+) but not CD8(+) T cells after exposure to DV in vitro. Additionally, using annexin V and polycaspase assays, we have demonstrated that T lymphocytes, in contrast to monocytes, are resistant to DV-induced apoptosis. Strikingly, both CD4(+) and CD8(+) T cells were found to be infected with DV in acutely infected dengue patients. Together, these results show that T cells are permissive for DV infection in vitro and in vivo, suggesting that this cell population may be a viral reservoir during the acute phase of the disease. IMPORTANCE Infection by dengue virus (DV) causes a flu-like disease that can evolve to severe hemorrhaging and death. T lymphocytes are important cells that regulate antibody secretion by B cells and trigger the death of infected cells. However, little is known about the direct interaction between DV and T lymphocytes. Here, we show that T lymphocytes from healthy donors are susceptible to infection by DV, leading to cell activation. Additionally, T cells seem to be resistant to DV-induced apoptosis, suggesting a potential role as a viral reservoir in humans. Finally, we show that both CD4(+) and CD8(+) T lymphocytes from acutely infected DV patients are infected by DV. Our results raise new questions about DV pathogenesis and vaccine development.
C1 [Silveira, Guilherme F.; Wowk, Pryscilla F.; Cataneo, Allan H. D.; Duarte dos Santos, Claudia N.; Bordignon, Juliano] Fiocruz PR, ICC, Lab Virol Mol, Curitiba, Parana, Brazil.
   [dos Santos, Paula F.; Delgobo, Murilo; Bafica, Andre; Mansur, Daniel S.] Univ Fed Santa Catarina, Lab Imunobiol, Florianopolis, SC, Brazil.
   [Stimamiglio, Marco A.] Fiocruz PR, ICC, Lab Celulas Tronco, Curitiba, Parana, Brazil.
   [Lo Sarzi, Maria] Secretaria Municipal Saude Cambe, Saude Familia, Cambe, Parana, Brazil.
   [Thomazelli, Ana Paula F. S.; Conchon-Costa, Ivete; Pavanelli, Wander R.] Univ Estadual Londrina, Lab Protozool Expt, Londrina, Parana, Brazil.
   [Antonelli, Lis R. V.] Fundacao Oswaldo Cruz, Inst Rene Rachou, Lab Biol & Imunol Doencas Infecciosas & Parasitar, Belo Horizonte, MG, Brazil.
RP dos Santos, CND; Bordignon, J (corresponding author), Fiocruz PR, ICC, Lab Virol Mol, Curitiba, Parana, Brazil.
EM clsantos@fiocruz.br; juliano.bordignon@fiocruz.br
RI Bordignon, Juliano/Z-6268-2019; Wowk, Pryscilla Fanini/AAR-7230-2020;
   Bafica, Andre/ABF-5986-2020; Silveira, Guilherme/Z-6230-2019; Antonelli,
   Lis/R-4910-2019; Mansur, Daniel/AAQ-8062-2020; Stimamiglio, Marco
   Augusto/AAA-8129-2019; Wowk, Pryscilla/AAA-3281-2019; Stimamiglio, Marco
   Augusto A/D-6239-2013; Cataneo, Allan/AAB-7997-2020; Santos, Claudia
   Duarte dos/P-4868-2019
OI Bordignon, Juliano/0000-0002-1965-6152; Bafica,
   Andre/0000-0002-5148-600X; Silveira, Guilherme/0000-0002-1866-0563;
   Antonelli, Lis/0000-0002-4969-8812; Mansur, Daniel/0000-0001-6773-9334;
   Stimamiglio, Marco Augusto/0000-0001-8537-2812; Stimamiglio, Marco
   Augusto A/0000-0001-8537-2812; Santos, Claudia Duarte
   dos/0000-0001-8707-6638; Wowk, Pryscilla/0000-0002-8976-2647
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [309239/2015-0, 307408/2016-7, 304875/2014-7, 309432/2015-4]
FX W.R.P. (grant number 309239/2015-0), L.R.V.A. (grant number
   307408/2016-7), A.B. (grant number 304875/2014-7), and C.N.D.D.S. (grant
   number 309432/2015-4) received CNPq scholarships.
CR Avirutnan P, 1998, J IMMUNOL, V161, P6338
   Bade B, 2005, EUR J IMMUNOL, V35, P2940, DOI 10.1002/eji.200526249
   Belmokhtar CA, 2001, ONCOGENE, V20, P3354, DOI 10.1038/sj.onc.1204436
   Blackley S, 2007, J VIROL, V81, P13325, DOI 10.1128/JVI.01568-07
   Chen YP, 1997, NAT MED, V3, P866, DOI 10.1038/nm0897-866
   Dalrymple N, 2011, J VIROL, V85, P9478, DOI 10.1128/JVI.05008-11
   de Matos AM, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003520
   DESPRES P, 1993, VIROLOGY, V196, P209, DOI 10.1006/viro.1993.1469
   Durbin AP, 2008, VIROLOGY, V376, P429, DOI 10.1016/j.virol.2008.03.028
   Espina LM, 2003, AM J TROP MED HYG, V68, P48, DOI 10.4269/ajtmh.2003.68.48
   Geleziunas R, 2001, NATURE, V410, P834, DOI 10.1038/35071111
   Germi R, 2002, VIROLOGY, V292, P162, DOI 10.1006/viro.2001.1232
   Gibellini D, 2005, J CELL PHYSIOL, V203, P547, DOI 10.1002/jcp.20252
   Gould EA, 1985, VIROLOGY PRACTICAL A, P43
   Green AM, 2014, J MOL BIOL, V426, P1148, DOI 10.1016/j.jmb.2013.11.023
   Green S, 1999, J INFECT DIS, V180, P1429, DOI 10.1086/315072
   Green S, 1999, J INFECT DIS, V179, P755, DOI 10.1086/314680
   Hilgard P, 2000, HEPATOLOGY, V32, P1069, DOI 10.1053/jhep.2000.18713
   King Alan D., 1999, Southeast Asian Journal of Tropical Medicine and Public Health, V30, P718
   Klomporn P, 2011, VIROLOGY, V409, P189, DOI 10.1016/j.virol.2010.10.010
   Kou Z, 2008, J MED VIROL, V80, P134, DOI 10.1002/jmv.21051
   Kuczera D, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0548-9
   KURANE I, 1987, J EXP MED, V166, P999, DOI 10.1084/jem.166.4.999
   KURANE I, 1990, ARCH VIROL, V110, P91, DOI 10.1007/BF01310705
   KURANE I, 1991, J VIROL, V65, P1823, DOI 10.1128/JVI.65.4.1823-1828.1991
   KURANE I, 1991, J CLIN INVEST, V88, P1473, DOI 10.1172/JCI115457
   Laskus T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075921
   Libraty DH, 2001, J VIROL, V75, P3501, DOI 10.1128/JVI.75.8.3501-3508.2001
   Limonta D, 2008, DIABETES VASC DIS RE, V5, P213, DOI 10.3132/dvdr.2008.034
   Lin YW, 2002, J VIROL, V76, P12242, DOI 10.1128/JVI.76.23.12242-12249.2002
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Marianneau P, 1997, J VIROL, V71, P3244, DOI 10.1128/JVI.71.4.3244-3249.1997
   Mathew A, 2014, FUTURE MICROBIOL, V9, P411, DOI 10.2217/fmb.13.171
   Mentor NA, 1997, ACTA VIROL, V41, P175
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Mota J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020762
   Nogueira MB, 2008, MEM I OSWALDO CRUZ, V103, P483, DOI 10.1590/S0074-02762008000500013
   Pang T, 2007, IMMUNOL CELL BIOL, V85, P43, DOI 10.1038/sj.icb.7100008
   Rothman Alan L, 2014, Curr Trop Med Rep, V1, P13
   Silveira GF, 2011, J VIROL, V85, P5374, DOI 10.1128/JVI.01915-10
   STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x
   Correa ARV, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143391
   Villa NY, 2015, BLOOD, V125, P3778, DOI 10.1182/blood-2014-07-587329
   Voskoboinik I, 2015, NAT REV IMMUNOL, V15, P388, DOI 10.1038/nri3839
   Weiskopf D, 2015, P NATL ACAD SCI USA, V112, pE4256, DOI 10.1073/pnas.1505956112
   World Health Organization, 2009, DENG GUID DIAGN TREA
   Xu XN, 2001, IMMUNITY, V15, P867, DOI 10.1016/S1074-7613(01)00255-2
   Yauch LE, 2009, J IMMUNOL, V182, P4865, DOI 10.4049/jimmunol.0801974
NR 48
TC 10
Z9 10
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD MAY
PY 2018
VL 92
IS 10
AR e02181-17
DI 10.1128/JVI.02181-17
PG 19
WC Virology
SC Virology
GA GF5HT
UT WOS:000431998000023
PM 29514900
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Thomazelli, APFD
   Tomiotto-Pellissier, F
   Miranda-Sapla, MM
   da Silva, SS
   Alvarenga, DS
   Panis, C
   Cataneo, AHD
   Bordignon, J
   Silveira, GF
   Yamauchi, LM
   de Sa, JPSR
   Felipe, I
   Pavanelli, WR
   Conchon-Costa, I
AF Fortes dos Santos Thomazelli, Ana Paula
   Tomiotto-Pellissier, Fernanda
   Miranda-Sapla, Milena Menegazzo
   da Silva, Suelen Santos
   Alvarenga, Daniele Sapede
   Panis, Carolina
   Depieri Cataneo, Allan Henrique
   Bordignon, Juliano
   Silveira, Guilherme Ferreira
   Yamauchi, Lucy Megumi
   Santos Rubro de Sa, Jussevania Pereira
   Felipe, Ionice
   Pavanelli, Wander Rogerio
   Conchon-Costa, Ivete
TI Concanavalin-A displays leishmanicidal activity by inducing ROS
   production in human peripheral blood mononuclear cells
SO IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
LA English
DT Article
DE Leishmania amazonensis; Con-A; PBMC; cytokine; reactive oxygen species;
   iNOS
ID TOLL-LIKE RECEPTORS; OXYGEN SPECIES ROS; CANDIDA-ALBICANS; IN-VITRO;
   AMAZONENSIS INFECTION; CYTOKINE PRODUCTION; EXPRESSION; MICE;
   LIPOPOLYSACCHARIDE; INTERLEUKIN-10
AB The context of the article: Leishmania amazonensis has a wide geographical distribution throughout South American countries and can cause self-healing to severe cases as mucocutaneous or visceral forms. Leishmaniasis presents a balance of inflammatory and anti-inflammatory cytokines which is responsible for promoting the activation of phagocytes, essential to control the infection and lead to tissue repair/resolution of the disease, respectively.
   Results and discussion: Our model revealed that the treatment with Con-A was capable to stimulate human PBMC cells by increasing the phagocytic capacity and promoting parasite elimination. The pretreatment with Con-A promoted inflammatory (IFN-gamma, TNF-alpha, IL-2 and IL-6) and anti-inflammatory (IL-4 and IL-10) cytokines production, increased the reactive oxygen species (ROS) sinthesys as well as the expression and presence of iNOS enzyme, but not nitric oxide production.
   Conclusion: Based on the data obtained, it was possible to infer that Con-A induces the ROS production, responsible for eliminating parasites in addition to regulatory cytokines synthesis which are important for disease resolution.
C1 [Fortes dos Santos Thomazelli, Ana Paula; Tomiotto-Pellissier, Fernanda; Miranda-Sapla, Milena Menegazzo; da Silva, Suelen Santos; Alvarenga, Daniele Sapede; Depieri Cataneo, Allan Henrique; Felipe, Ionice; Pavanelli, Wander Rogerio; Conchon-Costa, Ivete] Univ Estadual Londrina, Ctr Biol Sci, Dept Pathol Sci, Londrina, Parana, Brazil.
   [Panis, Carolina] Univ Western Parana, UNIOESTE, Lab Inflammatory Mediators, Francisco Beltrao, Parana, Brazil.
   [Bordignon, Juliano; Silveira, Guilherme Ferreira] Fiocruz MS, Carlos Chagas Inst, Curitiba, Parana, Brazil.
   [Yamauchi, Lucy Megumi; Santos Rubro de Sa, Jussevania Pereira] Univ Estadual Londrina, Ctr Biol Sci, Dept Microbiol, Londrina, Parana, Brazil.
RP Tomiotto-Pellissier, F; Conchon-Costa, I (corresponding author), Celso Garcia Rod,PR 445,Km380, Londrina, Parana, Brazil.
EM fernandatomiotto@gmail.com; icconchon@uel.br
RI Miranda-Sapla, Milena M/D-1231-2017; Cataneo, Allan/AAB-7997-2020; da
   Silva, Suelen Santos/AAS-5789-2020; Bordignon, Juliano/Z-6268-2019;
   Silveira, Guilherme/Z-6230-2019; Yamauchi, Lucy M/O-1859-2016;
   Tomiotto-Pellissier, Fernanda/Q-9679-2018; PANIS, CAROLINA/O-1490-2015
OI Miranda-Sapla, Milena M/0000-0001-8324-9642; da Silva, Suelen
   Santos/0000-0002-6251-0386; Bordignon, Juliano/0000-0002-1965-6152;
   Silveira, Guilherme/0000-0002-1866-0563; Yamauchi, Lucy
   M/0000-0003-2241-8814; Tomiotto-Pellissier,
   Fernanda/0000-0002-7273-8237; Cataneo, Allan Henrique
   Depieri/0000-0002-3567-7471; PANIS, CAROLINA/0000-0002-0104-4369
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Fundacao AraucariaFundacao Araucaria [37364-24/2012];
   State University of Londrina
FX This work was financially supported by Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES), Fundacao Araucaria (37364-24/2012)
   and State University of Londrina.
CR AFONSO LCC, 1993, INFECT IMMUN, V61, P2952, DOI 10.1128/IAI.61.7.2952-2959.1993
   Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312
   Azeredo-Coutinho RBG, 2007, T ROY SOC TROP MED H, V101, P735, DOI 10.1016/j.trstmh.2007.01.005
   Bao B, 2011, BIOCHEM BIOPH RES CO, V407, P703, DOI 10.1016/j.bbrc.2011.03.084
   de Carvalho PGC, 2012, FEMS IMMUNOL MED MIC, V64, P273, DOI 10.1111/j.1574-695X.2011.00904.x
   CUNHA FQ, 1992, BIOCHEM BIOPH RES CO, V182, P1155, DOI 10.1016/0006-291X(92)91852-H
   da Silva SH, 2013, ELECTRON J DIFFER EQ
   DWYER JM, 1981, CLIN EXP IMMUNOL, V46, P237
   Faria MS, 2012, J NUTR METAB, V2012, P1, DOI DOI 10.1155/2012/802924
   FELIPE I, 1995, BRAZ J MED BIOL RES, V28, P477
   Thomazelli APFD, 2017, CELL IMMUNOL, V311, P22, DOI 10.1016/j.cellimm.2016.09.014
   GOLDSTEIN IJ, 1965, BIOCHEMISTRY-US, V4, P876, DOI 10.1021/bi00881a013
   Huang WC, 2009, IMMUNOLOGY, V128, pe275, DOI 10.1111/j.1365-2567.2008.02959.x
   Katial RK, 1998, CLIN DIAGN LAB IMMUN, V5, P78, DOI 10.1128/CDLI.5.1.78-81.1998
   Kavoosi G, 2009, PARASITOLOGY, V136, P1193, DOI 10.1017/S0031182009990473
   Kaye P, 2011, NAT REV MICROBIOL, V9, P604, DOI 10.1038/nrmicro2608
   KITAO T, 1977, NATURE, V265, P81, DOI 10.1038/265081a0
   Kleinert H, 2004, EUR J PHARMACOL, V500, P255, DOI 10.1016/j.ejphar.2004.07.030
   Lijnen P, 1997, CLIN CHIM ACTA, V264, P91, DOI 10.1016/S0009-8981(97)00076-4
   Liu Z, 2013, CELL PROLIFERAT, V46, P509, DOI 10.1111/cpr.12054
   Loyola W, 2002, FEMS IMMUNOL MED MIC, V33, P201, DOI 10.1111/j.1574-695X.2002.tb00591.x
   Mengome LE, 2014, MOLECULES, V19, P18543, DOI 10.3390/molecules191118543
   Nylen S, 2010, J GLOB INFECT DIS, V2, P135, DOI 10.4103/0974-777X.62876
   Olivier M, 2005, CLIN MICROBIOL REV, V18, P293, DOI 10.1128/CMR.18.2.293-305.2005
   OLSON MOJ, 1967, BIOCHEMISTRY-US, V6, P3801, DOI 10.1021/bi00864a025
   Pautz A, 2010, NITRIC OXIDE-BIOL CH, V23, P75, DOI 10.1016/j.niox.2010.04.007
   Pawate S, 2004, J NEUROSCI RES, V77, P540, DOI 10.1002/jnr.20180
   Reithinger R, 2007, LANCET INFECT DIS, V7, P581, DOI 10.1016/S1473-3099(07)70209-8
   Roma EH, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1472-y
   Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933
   Silveira FT, 2009, PARASITE IMMUNOL, V31, P423, DOI 10.1111/j.1365-3024.2009.01116.x
   Sodhi A, 2007, INT IMMUNOPHARMACOL, V7, P454, DOI 10.1016/j.intimp.2006.11.014
   Tarang S, 2007, INT IMMUNOL, V19, P635, DOI 10.1093/intimm/dxm029
   Ueno N, 2012, TRENDS PARASITOL, V28, P335, DOI 10.1016/j.pt.2012.05.002
   Wang HX, 2012, WORLD J GASTROENTERO, V18, P119, DOI 10.3748/wjg.v18.i2.119
   Yang ZY, 2007, J IMMUNOL, V178, P1077, DOI 10.4049/jimmunol.178.2.1077
   Yaqoob P, 1998, CYTOKINE, V10, P790, DOI 10.1006/cyto.1998.0358
NR 37
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0892-3973
EI 1532-2513
J9 IMMUNOPHARM IMMUNOT
JI Immunopharmacol. Immunotoxicol.
PY 2018
VL 40
IS 5
BP 387
EP 392
DI 10.1080/08923973.2018.1510960
PG 6
WC Immunology; Pharmacology & Pharmacy; Toxicology
SC Immunology; Pharmacology & Pharmacy; Toxicology
GA HI3CO
UT WOS:000456324400004
PM 30183425
DA 2020-12-01
ER

PT J
AU Ricciardi-Jorge, T
   Bordignon, J
   Koishi, A
   Zanluca, C
   Mosimann, AL
   dos Santos, CND
AF Ricciardi-Jorge, Taissa
   Bordignon, Juliano
   Koishi, Andrea
   Zanluca, Camila
   Mosimann, Ana Luiza
   Duarte dos Santos, Claudia Nunes
TI Development of a quantitative NS1-capture enzyme-linked immunosorbent
   assay for early detection of yellow fever virus infection
SO SCIENTIFIC REPORTS
LA English
DT Article
ID NONSTRUCTURAL PROTEIN NS1; ANTIBODY; CELLS; GLYCOSYLATION; REPLICATION;
   EXPRESSION; SECRETION; DIAGNOSIS; REVEALS; SURFACE
AB Yellow fever is an arboviral disease that causes thousands of deaths every year in Africa and the Americas. However, few commercial diagnostic kits are available. Non-structural protein 1 (NS1) is an early marker of several flavivirus infections and is widely used to diagnose dengue virus (DENV) infection. Nonetheless, little is known about the dynamics of Yellow fever virus (YFV) NS1 expression and secretion, to encourage its use in diagnosis. To tackle this issue, we developed a quantitative NS1-capture ELISA specific for YFV using a monoclonal antibody and recombinant NS1 protein. This test was used to quantify NS1 in mosquito and human cell line cultures infected with vaccine and wild YFV strains. Our results showed that NS1 was detectable in the culture supernatants of both cell lines; however, a higher concentration was maintained as cell-associated rather than secreted into the extracellular milieu. A panel of 73 human samples was used to demonstrate the suitability of YFV NS1 as a diagnostic tool, resulting in 80% sensitivity, 100% specificity, a 100% positive predictive value and a 95.5% negative predictive value compared with RT-PCR. Overall, the developed NS1-capture ELISA showed potential as a promising assay for the detection of early YF infection.
C1 [Ricciardi-Jorge, Taissa; Bordignon, Juliano; Koishi, Andrea; Zanluca, Camila; Mosimann, Ana Luiza; Duarte dos Santos, Claudia Nunes] FIOCRUZ PR, Inst Carlos Chagas, Lab Virol Mol, Curitiba, Parana, Brazil.
RP dos Santos, CND (corresponding author), FIOCRUZ PR, Inst Carlos Chagas, Lab Virol Mol, Curitiba, Parana, Brazil.
EM clsantos@fiocruz.br
RI Mosimann, Ana Luiza Pamplona/AAB-4714-2019; Santos, Claudia Duarte
   dos/P-4868-2019; Duarte dos Santos, Claudia/E-1857-2018; Koishi,
   Andrea/N-2484-2013; Bordignon, Juliano/Z-6268-2019
OI Mosimann, Ana Luiza Pamplona/0000-0002-3504-5562; Santos, Claudia Duarte
   dos/0000-0001-8707-6638; Duarte dos Santos, Claudia/0000-0001-8707-6638;
   Koishi, Andrea/0000-0002-3542-1353; Bordignon,
   Juliano/0000-0002-1965-6152; Zanluca, Camila/0000-0001-7350-9105;
   Ricciardi-Jorge, Taissa/0000-0003-1110-2128
FU Fiocruz; CNPqNational Council for Scientific and Technological
   Development (CNPq); CAPESCAPES; Fundacao AraucariaFundacao Araucaria;
   Brazilian Ministry of Health/SVS
FX Fiocruz, CNPq, CAPES, Fundacao Araucaria and Brazilian Ministry of
   Health/SVS.
CR Alcon-LePoder S, 2005, J VIROL, V79, P11403, DOI 10.1128/JVI.79.17.11403-11411.2005
   Avirutnan P, 2007, PLOS PATHOG, V3, P1798, DOI 10.1371/journal.ppat.0030183
   Avirutnan P, 2011, J IMMUNOL, V187, P424, DOI 10.4049/jimmunol.1100750
   Avirutnan P, 2010, J EXP MED, V207, P793, DOI 10.1084/jem.20092545
   CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245
   Chung KM, 2008, J MED VIROL, V80, P547, DOI 10.1002/jmv.21091
   DESPRES P, 1991, J GEN VIROL, V72, P1331, DOI 10.1099/0022-1317-72-6-1331
   Flamand M, 1999, J VIROL, V73, P6104, DOI 10.1128/JVI.73.7.6104-6110.1999
   Fry SR, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001199
   Garske T, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001638
   Gutsche I, 2011, P NATL ACAD SCI USA, V108, P8003, DOI 10.1073/pnas.1017338108
   Jentes ES, 2011, LANCET INFECT DIS, V11, P622, DOI 10.1016/S1473-3099(11)70147-5
   Jorge TR, 2017, ACTA TROP, V166, P114, DOI 10.1016/j.actatropica.2016.09.030
   Kumar JS, 2011, J MED VIROL, V83, P1063, DOI 10.1002/jmv.22097
   Lindenbach BD, 1997, J VIROL, V71, P9608, DOI 10.1128/JVI.71.12.9608-9617.1997
   Macdonald J, 2005, J VIROL, V79, P13924, DOI 10.1128/JVI.79.22.13924-13933.2005
   MASON PW, 1989, VIROLOGY, V169, P354, DOI 10.1016/0042-6822(89)90161-X
   Muller DA, 2012, J GEN VIROL, V93, P771, DOI 10.1099/vir.0.039321-0
   Muylaert IR, 1997, J VIROL, V71, P291, DOI 10.1128/JVI.71.1.291-298.1997
   POST PR, 1991, VIRUS RES, V18, P291, DOI 10.1016/0168-1702(91)90025-Q
   Saxena D, 2013, J CLIN VIROL, V58, P528, DOI 10.1016/j.jcv.2013.08.033
   SCHLESINGER JJ, 1990, J GEN VIROL, V71, P593, DOI 10.1099/0022-1317-71-3-593
   Stock NK, 2015, J VIROL METHODS, V222, P110, DOI 10.1016/j.jviromet.2015.06.006
   Tricou V, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001309
   WINKLER G, 1988, VIROLOGY, V162, P187, DOI 10.1016/0042-6822(88)90408-4
   WINKLER G, 1989, VIROLOGY, V171, P302, DOI 10.1016/0042-6822(89)90544-8
   Wisdom G Brian, 2005, Methods Mol Biol, V295, P127
   Youn S, 2010, J VIROL, V84, P9516, DOI 10.1128/JVI.00775-10
   Young PR, 2000, J CLIN MICROBIOL, V38, P1053, DOI 10.1128/JCM.38.3.1053-1057.2000
NR 29
TC 9
Z9 10
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 24
PY 2017
VL 7
AR 16229
DI 10.1038/s41598-017-16231-6
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FN6OL
UT WOS:000416135000028
PM 29176643
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU de Freitas, RC
   Lonien, SCH
   Malvezi, AD
   Silveira, GF
   Wowk, PF
   da Silva, RV
   Yamauchi, LM
   Yamada-Ogatta, SF
   Rizzo, LV
   Bordignon, J
   Pinge, P
AF de Freitas, Rafael Carvalho
   Heim Lonien, Sandra Cristina
   Malvezi, Aparecida Donizette
   Silveira, Guilherme Ferreira
   Wowk, Pryscilla Fanini
   da Silva, Rosiane Valeriano
   Yamauchi, Lucy Megumi
   Yamada-Ogatta, Sueli Fumie
   Rizzo, Luiz Vicente
   Bordignon, Juliano
   Pinge-Filho, Phileno
TI Trypanosoma cruzi: Inhibition of infection of human monocytes by aspirin
SO EXPERIMENTAL PARASITOLOGY
LA English
DT Article
DE Trypanosoma cruzi; Cell invasion; Aspirin; Adenylate-cyclase
ID NF-KAPPA-B; CYCLIC-AMP; NITRIC-OXIDE; PGE(2) INVOLVEMENT; PROSTAGLANDIN
   E-2; DENDRITIC CELLS; IMMUNE-SYSTEM; TNF-ALPHA; MACROPHAGES;
   CYCLOOXYGENASE-2
AB Cell invasion by Trypanosoma cruzi and its intracellular replication are essential for progression of the parasite life cycle and development of Chagas disease. Prostaglandin E2 (PGE(2)) and other eicosanoids potently modulate host response and contribute to Chagas disease progression. In this study, we evaluated the effect of aspirin (ASA), a non-selective cyclooxygenase (COX) inhibitor on the T. cruzi invasion and its influence on nitric oxide and cytokine production in human monocytes. The pretreatment of monocytes with ASA or SQ 22536 (adenylate-cyclase inhibitor) induced a marked inhibition of T. cruzi infection. On the other hand, the treatment of monocytes with SQ 22536 after ASA restored the invasiveness of T cruzi. This reestablishment was associated with a decrease in nitric oxide and PGE(2) production, and also an increase of interleukin-10 and interleukin-12 by cells pre-treated with ASA. Altogether, these results reinforce the idea that the cyclooxygenase pathway plays a fundamental role in the process of parasite invasion in an in vitro model of T. cruzi infection. (C) 2017 Elsevier Inc. All rights reserved.
C1 [de Freitas, Rafael Carvalho; Heim Lonien, Sandra Cristina; Malvezi, Aparecida Donizette; da Silva, Rosiane Valeriano; Pinge-Filho, Phileno] Univ Estadual Londrina, Dept Ciencias Patol, Ctr Ciencias Biol, Lab Imunopatol Expt, BR-86051970 Londrina, Parana, Brazil.
   [Silveira, Guilherme Ferreira; Wowk, Pryscilla Fanini; Bordignon, Juliano] Inst Carlos Chagas ICC Fiocruz, Lab Virol Mol, BR-81350010 Curitiba, Parana, Brazil.
   [Yamauchi, Lucy Megumi; Yamada-Ogatta, Sueli Fumie] Univ Estadual Londrina, Dept Microbiol, Ctr Ciencias Biol, Lab Biol Mol Microrganismos, BR-86051970 Londrina, Parana, Brazil.
   [Rizzo, Luiz Vicente] Hosp Israelita Albert Einstein, Ave Albert Einstein 627-701,Subsolo Bloco A, BR-05651901 Sao Paulo, SP, Brazil.
RP Pinge, P (corresponding author), Univ Estadual Londrina, Dept Ciencias Patol, Ctr Ciencias Biol, BR-86051970 Londrina, Parana, Brazil.
EM pingefilho@uel.br
RI Yamauchi, Lucy M/O-1859-2016; Silveira, Guilherme/Z-6230-2019; Rizzo,
   Luiz Vicente/B-4458-2009; Wowk, Pryscilla/AAA-3281-2019; Wowk, Pryscilla
   Fanini/AAR-7230-2020; Pinge-Filho, Phileno/G-2844-2012; Bordignon,
   Juliano/Z-6268-2019; Yamada-Ogatta, Sueli Fumie/C-7020-2019
OI Yamauchi, Lucy M/0000-0003-2241-8814; Silveira,
   Guilherme/0000-0002-1866-0563; Bordignon, Juliano/0000-0002-1965-6152;
   Yamada-Ogatta, Sueli Fumie/0000-0003-1183-146X; Wowk,
   Pryscilla/0000-0002-8976-2647
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [474792/2011-0, 306497/2013, 307787/2015-0]; Fundacao AraucariaFundacao
   Araucaria [419/2009]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES)CAPES [4442012026P9]; Fundacao AraucariaFundacao
   Araucaria
FX This work was supported by CNPq (Edital Universal 14/11, process
   474792/2011-0, process 306497/2013) and Fundacao Araucaria (process
   419/2009). RCF, SCHL, and RV da Silva received scholarships from
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
   (4442012026P9). LVR and PPF received research fellowship from CNPq
   (307787/2015-0). PFW and JB received research fellowship from Fundacao
   Araucaria.
CR Abrahamsohn IA, 1996, EXP PARASITOL, V84, P231, DOI 10.1006/expr.1996.0109
   Aliberti JCS, 1996, INFECT IMMUN, V64, P1961, DOI 10.1128/IAI.64.6.1961-1967.1996
   Alvarez JM, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/912965
   Andrade DV, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003010
   Aronoff DM, 2006, J INTERF CYTOK RES, V26, P827, DOI 10.1089/jir.2006.26.827
   BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.iy.12.040194.001041
   Barrias ES, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0007764
   Borges MM, 1998, IMMUNOL LETT, V63, P1, DOI 10.1016/S0165-2478(98)00034-0
   Caler EV, 2000, INFECT IMMUN, V68, P6602, DOI 10.1128/IAI.68.12.6602-6610.2000
   Cardillo F, 1996, INFECT IMMUN, V64, P128, DOI 10.1128/IAI.64.1.128-134.1996
   CELENTANO AM, 1995, PROSTAGLANDINS, V49, P141, DOI 10.1016/0090-6980(95)00002-R
   Cunha-Neto E, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/683230
   Gadea A, 1999, BRAIN RES, V838, P200, DOI 10.1016/S0006-8993(99)01683-2
   GEMSA D, 1979, EXP CELL RES, V118, P55, DOI 10.1016/0014-4827(79)90583-4
   Guerrero NA, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004025
   Gutierrez FRS, 2009, MEM I OSWALDO CRUZ, V104, P236, DOI 10.1590/S0074-02762009000900030
   Hackstein H, 2001, J IMMUNOL, V166, P7053, DOI 10.4049/jimmunol.166.12.7053
   Hartel C, 2004, SCAND J IMMUNOL, V60, P412, DOI 10.1111/j.0300-9475.2004.01481.x
   Abel LCJ, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/345659
   Kalathil AA, 2016, CHEM COMMUN, V52, P140, DOI 10.1039/c5cc07316b
   KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854
   KRAAN TCTMV, 1995, J EXP MED, V181, P775, DOI 10.1084/jem.181.2.775
   Lopez-Lluch G, 2005, ARCH BIOCHEM BIOPHYS, V436, P32, DOI 10.1016/j.abb.2004.12.031
   Lopez-Munoz R, 2010, EXP PARASITOL, V124, P167, DOI 10.1016/j.exppara.2009.09.005
   Machado FS, 2011, ADV PARASIT, V76, P1, DOI 10.1016/B978-0-12-385895-5.00001-3
   Malvezi AD, 2014, ANTIMICROB AGENTS CH, V58, P6157, DOI 10.1128/AAC.02752-14
   Malvezi AD, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/580919
   Matasic R, 2000, IMMUNOLOGY, V101, P53, DOI 10.1046/j.1365-2567.2000.00065.x
   Mazzeo D, 1998, EUR J IMMUNOL, V28, P3205, DOI 10.1002/(SICI)1521-4141(199810)28:10<3205::AID-IMMU3205>3.0.CO;2-8
   Medeiros A, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/327568
   Menard G, 2007, CLIN EXP IMMUNOL, V150, P340, DOI 10.1111/j.1365-2249.2007.03492.x
   Molina-Berrios A, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002173
   Moon HG, 2010, EXP MOL MED, V42, P47, DOI 10.3858/emm.2010.42.1.005
   Moraes KCM, 2015, MEM I OSWALDO CRUZ, V110, P181, DOI 10.1590/0074-02760140311
   Mukherjee S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016959
   Mullet D, 1997, J Immunol, V158, P897
   Park JY, 2006, CLIN IMMUNOL, V119, P229, DOI 10.1016/j.clim.2006.01.016
   Peters-Golden M, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.275pe37
   Pinge P, 1999, CELL IMMUNOL, V193, P90, DOI 10.1006/cimm.1999.1463
   Procopio DO, 1999, BRIT J PHARMACOL, V127, P1195, DOI 10.1038/sj.bjp.0702624
   Rocca B, 2002, INT IMMUNOPHARMACOL, V2, P603, DOI 10.1016/S1567-5769(01)00204-1
   Rodriguez A, 1999, J BIOL CHEM, V274, P16754, DOI 10.1074/jbc.274.24.16754
   Salvemini D, 1997, CELL MOL LIFE SCI, V53, P576, DOI 10.1007/s000180050074
   Schmunis GA, 2010, ACTA TROP, V115, P14, DOI 10.1016/j.actatropica.2009.11.003
   Serezani CH, 2008, AM J RESP CELL MOL, V39, P127, DOI 10.1165/rcmb.2008-0091TR
   Gomes JAS, 2014, HUM IMMUNOL, V75, P20, DOI 10.1016/j.humimm.2013.09.009
   SterinBorda L, 1996, CLIN IMMUNOL IMMUNOP, V81, P122, DOI 10.1006/clin.1996.0167
   Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200
   Talvani A, 2009, PARASITOL RES, V104, P1141, DOI 10.1007/s00436-008-1300-1
   Tatakihara VLH, 2008, FEMS IMMUNOL MED MIC, V52, P47, DOI 10.1111/j.1574-695X.2007.00340.x
   VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0
   Yin MJ, 1998, NATURE, V396, P77
   Zingales B, 2009, MEM I OSWALDO CRUZ, V104, P1051, DOI 10.1590/S0074-02762009000700021
NR 53
TC 4
Z9 4
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4894
EI 1090-2449
J9 EXP PARASITOL
JI Exp. Parasitol.
PD NOV
PY 2017
VL 182
BP 26
EP 33
DI 10.1016/j.exppara.2017.09.019
PG 8
WC Parasitology
SC Parasitology
GA FL0FS
UT WOS:000413887600005
PM 28939444
OA Bronze
DA 2020-12-01
ER

PT J
AU Lonien, SCH
   Malvezi, AD
   Suzukawa, HT
   Yamauchi, LM
   Yamada-Ogatta, SF
   Rizzo, LV
   Bordignon, J
   Pinge, P
AF Lonien, Sandra C. H.
   Malvezi, Aparecida D.
   Suzukawa, Helena T.
   Yamauchi, Lucy M.
   Yamada-Ogatta, Sueli F.
   Rizzo, Luiz V.
   Bordignon, Juliano
   Pinge-Filho, Phileno
TI Response to Trypanosoma cruzi by Human Blood Cells Enriched with
   Dentritic Cells Is Controlled by Cyclooxygenase-2 Pathway
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE Trypanosoma cruzi; cell invasion; human monocyte-derived dendritic
   cells; aspirin; celecoxib
ID HUMAN DENDRITIC CELLS; CHAGAS-DISEASE; NITRIC-OXIDE;
   EXPERIMENTAL-INFECTION; TRYPANOCIDAL ACTIVITY; SIGNALING PATHWAYS;
   PGE(2) INVOLVEMENT; IMMUNE-RESPONSE; CYCLIC-AMP; MACROPHAGES
AB Chagas disease (Cd) or American human trypanosomiasis is caused by Trypanosoma cruzi and affects similar to 7 million people, mostly in Latin America. The infective trypomastigote forms of the parasite can invade several human blood cell populations, including monocytes and dendritic cells (DC). Although these cells display a wide functional diversity, their interactions with T cruzi via cyclooxygenase (COX) and cyclic adenosine monophosphate (cAMP) dependent pathways have not been analyzed. To exploiting this mechanism, DC-enriched peripheral human blood mononuclear cell populations (DC-PBMC) were used as our model. Our results showed that the treatment of these cell populations with celecoxib (CEL), a cyclooxygenase-2 selective inhibitor or SQ 22,536, an adenilate cyclase inhibitor, significantly caused marked inhibition of T cruzi infection. In contrast, aspirin (ASA, a non-selective COX-1 and COX-2 inhibitor) treatment did not inhibit the infection of the cells by the parasite and was independent of nitric oxide (NO) production. The expression of co-stimulatory molecules CD80 and CD86 were similar on cells treated or not with both COX-inhibitors. The infection stimulated the release of INF-alpha, IL-1 beta IL-6, IL-8, and IL-10 production by infected cells. Treatment with ASA or CEL did not affect TNF-alpha, IL-6, IL-8, IL-10, and NO production by infected cells, but increased IL-1 beta) production by them. Our results suggest a key role of COX-2 and cAMP pathways in T cruzi invasion process of human blood cells and these pathways may represent targets of new therapeutic options for Cd.
C1 [Lonien, Sandra C. H.; Malvezi, Aparecida D.; Suzukawa, Helena T.; Pinge-Filho, Phileno] Univ Estadual Londrina, Lab Imunopatol Expt, Dept Ciencias Patol, Ctr Ciencias Biol, Londrina, Brazil.
   [Yamauchi, Lucy M.; Yamada-Ogatta, Sueli F.] Univ Estadual Londrina, Lab Biol Mol Microrganismos, Dept Microbiol, Ctr Ciencias Biol, Londrina, Brazil.
   [Rizzo, Luiz V.] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
   [Bordignon, Juliano] Inst Carlos Chagas Fiocruz, Lab Virol Mol, Curitiba, Parana, Brazil.
RP Pinge, P (corresponding author), Univ Estadual Londrina, Lab Imunopatol Expt, Dept Ciencias Patol, Ctr Ciencias Biol, Londrina, Brazil.
EM pingefilho@uel.br
RI Bordignon, Juliano/Z-6268-2019; Rizzo, Luiz Vicente/B-4458-2009;
   Pinge-Filho, Phileno/G-2844-2012; Yamauchi, Lucy M/O-1859-2016
OI Bordignon, Juliano/0000-0002-1965-6152; Yamauchi, Lucy
   M/0000-0003-2241-8814
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [14/11, 474792/2011, 306497/2013-2015]; Fundacao AraucariaFundacao
   Araucaria [419, 658/2014-24.718]; Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES)CAPES; CNPqNational Council for
   Scientific and Technological Development (CNPq)
FX This work was funded by CNPq (Edital Universal 14/11, grant numbers:
   474792/2011, 306497/2013-2015), by Fundacao Araucaria (grant number
   419). SL was supported by Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES). HS was supported by PROIC-Fellowship by CNPq. LR
   and PP are recipients of personal fellowships from CNPq. JB received
   research fellowship from Fundacao Araucaria (grant number
   658/2014-24.718).
CR Abdalla GK, 2008, EXP PARASITOL, V118, P514, DOI 10.1016/j.exppara.2007.11.003
   Amorim KNS, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/2926436
   Bern C, 2015, NEW ENGL J MED, V373, P456, DOI [10.1056/NEJMra1410150, 10.1056/NEJMc1510996]
   Brodskyn C, 2002, INFECT IMMUN, V70, P3736, DOI 10.1128/IAI.70.7.3736-3743.2002
   Caler EV, 2000, INFECT IMMUN, V68, P6602, DOI 10.1128/IAI.68.12.6602-6610.2000
   CELENTANO AM, 1995, PROSTAGLANDINS, V49, P141, DOI 10.1016/0090-6980(95)00002-R
   Costa RW, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00388
   Coura JR, 2010, NATURE, V465, pS6, DOI 10.1038/nature09221
   DEARAUJOJORGE TC, 1989, MEM I OSWALDO CRUZ, V84, P441, DOI 10.1590/S0074-02761989000400001
   Maya JD, 2010, BIOL RES, V43, P323, DOI [10.4067/S0716-97602010000300009, /S0716-97602010000300009]
   DosReis GA, 2009, MEM I OSWALDO CRUZ, V104, P259, DOI 10.1590/S0074-02762009000900033
   Durand JL, 2009, AM J TROP MED HYG, V80, P782, DOI 10.4269/ajtmh.2009.80.782
   Freire-de-Lima CG, 2000, NATURE, V403, P199, DOI 10.1038/35003208
   Ganzinelli S, 2009, INT J CARDIOL, V134, P212, DOI 10.1016/j.ijcard.2008.02.008
   Gil-Jaramillo N, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01076
   Gorak PMA, 1998, EUR J IMMUNOL, V28, P687, DOI 10.1002/(SICI)1521-4141(199802)28:02&lt;687::AID-IMMU687&gt;3.0.CO;2-N
   Guerrero NA, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004025
   Harizi H, 2003, J LEUKOCYTE BIOL, V73, P756, DOI 10.1189/jlb.1002483
   Henderson RA, 1997, J IMMUNOL, V159, P635
   Kalinski P, 1999, IMMUNOL TODAY, V20, P561, DOI 10.1016/S0167-5699(99)01547-9
   Lopes MF, 2000, APOPTOSIS, V5, P221, DOI 10.1023/A:1009648311490
   Lopez-Munoz R, 2010, EXP PARASITOL, V124, P167, DOI 10.1016/j.exppara.2009.09.005
   Machado FS, 2012, SEMIN IMMUNOPATHOL, V34, P753, DOI 10.1007/s00281-012-0351-7
   Machado FS, 2011, ADV PARASIT, V76, P1, DOI 10.1016/B978-0-12-385895-5.00001-3
   Machado FS, 2000, CIRCULATION, V102, P3003, DOI 10.1161/01.CIR.102.24.3003
   Malvezi AD, 2014, ANTIMICROB AGENTS CH, V58, P6157, DOI 10.1128/AAC.02752-14
   Malvezi AD, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/580919
   Medeiros MM, 2007, J LEUKOCYTE BIOL, V82, P488, DOI 10.1189/jlb.0706478
   Molina-Berrios A, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002173
   MOLL H, 1995, EUR J IMMUNOL, V25, P693, DOI 10.1002/eji.1830250310
   Moraes KCM, 2015, MEM I OSWALDO CRUZ, V110, P181, DOI 10.1590/0074-02760140311
   Mukherjee S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016959
   Palucka K, 2002, CURR OPIN IMMUNOL, V14, P420, DOI 10.1016/S0952-7915(02)00365-5
   Pinge P, 1999, CELL IMMUNOL, V193, P90, DOI 10.1006/cimm.1999.1463
   Dias JCP, 2016, REV SOC BRAS MED TRO, V49, P3, DOI 10.1590/0037-8682-0505-2016
   Procopio DO, 1999, BRIT J PHARMACOL, V127, P1195, DOI 10.1038/sj.bjp.0702624
   Rodriguez A, 1999, J BIOL CHEM, V274, P16754, DOI 10.1074/jbc.274.24.16754
   Rodriguez P, 2012, MED MICROBIOL IMMUN, V201, P157, DOI [10.1007/s00430-011-0217-y, 10.1007/s00430-012-0230-9]
   Saini SS, 2003, INFLAMMATION, V27, P79, DOI 10.1023/A:1023226616526
   SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109
   Silva JS, 2003, FRONT BIOSCI-LANDMRK, V8, pS314, DOI 10.2741/1012
   SterinBorda L, 1996, CLIN IMMUNOL IMMUNOP, V81, P122, DOI 10.1006/clin.1996.0167
   Tatakihara VLH, 2008, FEMS IMMUNOL MED MIC, V52, P47, DOI 10.1111/j.1574-695X.2007.00340.x
   Van Overtvelt L, 1999, INFECT IMMUN, V67, P4033, DOI 10.1128/IAI.67.8.4033-4040.1999
   Wilkinson SR, 2011, CURR TOP MED CHEM, V11, P2072
   World Health Organization, 2017, WHO CHAG DIS
   Yamamoto K, 1998, CLIN EXP IMMUNOL, V114, P94
   Zingales B, 2009, MEM I OSWALDO CRUZ, V104, P1051, DOI 10.1590/S0074-02762009000700021
NR 48
TC 3
Z9 3
U1 0
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD OCT 25
PY 2017
VL 8
AR 2020
DI 10.3389/fmicb.2017.02020
PG 11
WC Microbiology
SC Microbiology
GA FK6PM
UT WOS:000413627700001
PM 29118740
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Sanfelice, RA
   Machado, LF
   Bosqui, LR
   Miranda-Sapla, MM
   Tomiotto-Pellissier, F
   Dalevedo, GD
   Ioris, D
   Reis, GF
   Panagio, LA
   Navarro, IT
   Bordignon, J
   Conchon-Costa, I
   Pavanelli, WR
   Almeida, RS
   Costa, IN
AF Sanfelice, Raquel Arruda
   Machado, Lais Fernanda
   Bosqui, Larissa Rodrigues
   Miranda-Sapla, Milena Menegazzo
   Tomiotto-Pellissier, Fernanda
   Dalevedo, Gabriela de Alcantara
   Ioris, Dielle
   Reis, Guilherme Fonseca
   Panagio, Luciano Aparecido
   Navarro, Italmar Teodorico
   Bordignon, Juliano
   Conchon-Costa, Ivete
   Pavanelli, Wander Rogerio
   Almeida, Ricardo Sergio
   Costa, Idessania Nazareth
TI Activity of rosuvastatin in tachyzoites of Toxoplasma gondii (RH strain)
   in HeLa cells
SO EXPERIMENTAL PARASITOLOGY
LA English
DT Article
DE Rosuvastatin; Toxoplasmosis; Statins
ID MICROARRAY ANALYSIS; MOLECULAR-BASIS; IN-VITRO; INFECTION; CHOLESTEROL;
   APICOPLAST; ANIMALS; STATINS; PROLIFERATION; REPLICATION
AB Due to the toxicity of conventional medication in toxoplasmosis, some drugs are being studied for treating this infection, such as statins, especially rosuvastatin compound, which is efficient in inhibiting the initial isoprenoid biosynthesis processes in humans and the parasite. The goal of this study was to assess the activity of rosuvastatin in HeLa cells infected with the RH strain of T. gondii. In the experiment, HeLa cells (1 x 10(5)) were infected with tachyzoites of T. gondii (5 x 10(5)). After the experimental infection, we assessed the number of infected cells and the amount of intracellular tachyzoites. In addition, culture supernatants were collected to determine the amount of cytokines by cytometric bead array. We observed that there was no cytotoxicity in the concentrations tested in this cell line. The effect of rosuvastatin showed a significant reduction in both the number of infected cells and the proliferation index of the intracellular parasite, when compared with the conventional treatment combining sulfadiazine and pyrimethamine for toxoplasmosis. There were also reduced levels of cytokines IL-6 and IL-17. Therefore, it was concluded that rosuvastatin exhibited antiproliferative activity. The data presented are significant to promote further studies and the search for alternative treatment for toxoplasmosis. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Sanfelice, Raquel Arruda; Machado, Lais Fernanda; Bosqui, Larissa Rodrigues; Miranda-Sapla, Milena Menegazzo; Tomiotto-Pellissier, Fernanda; Dalevedo, Gabriela de Alcantara; Ioris, Dielle; Conchon-Costa, Ivete; Pavanelli, Wander Rogerio; Costa, Idessania Nazareth] Univ Estadual Londrina, Dept Ciancias Patol, Lab Protozool Expt, BR-86051990 Londrina, Parana, Brazil.
   [Reis, Guilherme Fonseca; Panagio, Luciano Aparecido; Almeida, Ricardo Sergio] Univ Estadual Londrina, Dept Microbiol, Lab Micol Med & Microbiol Bucal, BR-86057970 Londrina, Parana, Brazil.
   [Navarro, Italmar Teodorico] Univ Estadual Londrina, Dept Med Vet Prevent, Lab Zoonose & Saude Publ, BR-86051990 Londrina, Parana, Brazil.
   [Bordignon, Juliano] ICC Fiocruz, Inst Carlos Chagas, Lab Virol Mol, BR-81350010 Curitiba, Parana, Brazil.
RP Costa, IN (corresponding author), Univ Estadual Londrina, Lab Protozool Expt, CCB, Dept Ciencias Patol, Rodovia Celso Garcia Cid Campus Univ, BR-86051990 Londrina, PR, Brazil.
EM idessania@hotmail.com
RI Reis, Guilherme/AAW-5825-2020; Panagio, Luciano Aparecido/V-3027-2019;
   Bordignon, Juliano/Z-6268-2019; Miranda-Sapla, Milena M/D-1231-2017;
   Tomiotto-Pellissier, Fernanda/Q-9679-2018
OI Panagio, Luciano Aparecido/0000-0002-2484-3147; Bordignon,
   Juliano/0000-0002-1965-6152; Miranda-Sapla, Milena
   M/0000-0001-8324-9642; Tomiotto-Pellissier, Fernanda/0000-0002-7273-8237
CR Anderson AC, 2005, DRUG DISCOV TODAY, V10, P121, DOI 10.1016/S1359-6446(04)03308-2
   Atilla A, 2015, JPN J INFECT DIS, V68, P407, DOI 10.7883/yoken.JJID.2014.422
   Barbosa BF, 2012, VET PARASITOL, V187, P44, DOI 10.1016/j.vetpar.2011.12.039
   BEAMAN MH, 1994, J IMMUNOL, V153, P4583
   Bernardes ES, 2006, AM J PATHOL, V168, P1910, DOI 10.2353/ajpath.2006.050636
   Blader IJ, 2001, J BIOL CHEM, V276, P24223, DOI 10.1074/jbc.M100951200
   Cenci-Goga BT, 2011, FOODBORNE PATHOG DIS, V8, P751, DOI 10.1089/fpd.2010.0795
   Churchward MA, 2014, MOL BRAIN, V7, DOI 10.1186/s13041-014-0085-7
   Coppens I, 2013, NAT REV MICROBIOL, V11, P823, DOI 10.1038/nrmicro3139
   Cortese F, 2016, PHARMACOL RES, V107, P1, DOI 10.1016/j.phrs.2016.02.012
   Cortez E, 2009, INT J ANTIMICROB AG, V33, P185, DOI 10.1016/j.ijantimicag.2008.07.026
   DeRocher AE, 2012, TRAFFIC, V13, P694, DOI 10.1111/j.1600-0854.2012.01335.x
   Dinesh N, 2015, PARASITOL RES, V114, P3873, DOI 10.1007/s00436-015-4618-5
   Dubey JP, 2008, INT J PARASITOL, V38, P1257, DOI 10.1016/j.ijpara.2008.03.007
   Elsheikha HM, 2008, PUBLIC HEALTH, V122, P335, DOI 10.1016/j.puhe.2007.08.009
   ENDO A, 1992, J LIPID RES, V33, P1569
   Fonseca F.A.H., 2005, ARQ BRAS CARDIOL, V85, P9, DOI DOI 10.1590/S0066-782X2005002400003
   Gaddi PJ, 2007, IMMUNOL CELL BIOL, V85, P155, DOI 10.1038/sj.icb.7100038
   Garcia-Sabina A, 2012, Farm Hosp, V36, P97, DOI 10.1016/j.farma.2011.02.010
   Gazzerro P, 2012, PHARMACOL REV, V64, P102, DOI 10.1124/pr.111.004994
   Golan D.E., 2009, PRINCLPIOS FARMACOLO
   Guiton R, 2010, J INFECT DIS, V202, P427, DOI 10.1086/653738
   KATZUNG BC, 2006, FARMACOLOGIA BASICA, P546
   Kesller R.L., 2013, PLOS ONE, V8
   Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485
   Kuckelhaus CS, 2011, EXP PARASITOL, V127, P658, DOI 10.1016/j.exppara.2010.12.003
   Kuipers HF, 2007, BIOMED PHARMACOTHER, V61, P400, DOI 10.1016/j.biopha.2007.06.005
   Kumar GA, 2016, BBA-BIOMEMBRANES, V1858, P2088, DOI 10.1016/j.bbamem.2016.06.010
   Li ZH, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003665
   Mason RP, 2006, AM J CARDIOL, V98, p34P, DOI 10.1016/j.amjcard.2006.09.018
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Munoz M, 2011, IMMUNOL REV, V240, P269, DOI 10.1111/j.1600-065X.2010.00992.x
   Nair SC, 2011, J EXP MED, V208, P1547, DOI 10.1084/jem.20110039
   Nishikawa Y, 2011, J VET MED SCI, V73, P633, DOI 10.1292/jvms.10-0496
   Okomo-Adhiambo M, 2006, INFECT IMMUN, V74, P4254, DOI 10.1128/IAI.00386-05
   Othman AA, 2016, PARASITOL INT, V65, P105, DOI 10.1016/j.parint.2015.11.001
   Page C., 2004, FARMACOLOGIA INTEGRA, p[302, e 361]
   Passos ST, 2010, J IMMUNOL, V184, P1776, DOI 10.4049/jimmunol.0901843
   Pifer R, 2011, TRENDS PARASITOL, V27, P388, DOI 10.1016/j.pt.2011.03.009
   Qidwai T, 2012, CHEM BIOL DRUG DES, V80, P155, DOI 10.1111/j.1747-0285.2012.01389.x
   Sanfelice RA, 2017, ACTA TROP, V167, P208, DOI 10.1016/j.actatropica.2016.12.006
   Seeber F, 2010, INT REV CEL MOL BIO, V281, P161, DOI 10.1016/S1937-6448(10)81005-6
   Serrano M.G.I., 2016, TOXOPLASMOSE GRAVIDE
   Silva RR, 2012, MEM I OSWALDO CRUZ, V107, P513, DOI 10.1590/S0074-02762012000400012
   Tenter AM, 2000, INT J PARASITOL, V30, P1217, DOI 10.1016/S0020-7519(00)00124-7
   Wong RPM, 2009, ANTIMICROB AGENTS CH, V53, P2212, DOI 10.1128/AAC.01469-08
   Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158
   Zeiser R, 2007, BLOOD, V110, P4588, DOI 10.1182/blood-2007-08-106005
NR 48
TC 3
Z9 3
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4894
EI 1090-2449
J9 EXP PARASITOL
JI Exp. Parasitol.
PD OCT
PY 2017
VL 181
BP 75
EP 81
DI 10.1016/j.exppara.2017.07.009
PG 7
WC Parasitology
SC Parasitology
GA FH6PB
UT WOS:000411298100010
PM 28774497
DA 2020-12-01
ER

PT J
AU Staurengo-Ferrari, L
   Ruiz-Miyazawa, KW
   Pinho-Ribeiro, FA
   Domiciano, TP
   Fattori, V
   Mizokami, SS
   Pelayo, JS
   Bordignon, J
   Figueiredo, F
   Casagrande, R
   Miranda, KM
   Verri, WA
AF Staurengo-Ferrari, Larissa
   Ruiz-Miyazawa, Kenji W.
   Pinho-Ribeiro, Felipe A.
   Domiciano, Talita P.
   Fattori, Victor
   Mizokami, Sandra S.
   Pelayo, Jacinta S.
   Bordignon, Juliano
   Figueiredo, Florencio
   Casagrande, Rubia
   Miranda, Katrina M.
   Verri, Waldiceu A., Jr.
TI The nitroxyl donor Angeli's salt ameliorates Staphylococcus
   aureus-induced septic arthritis in mice
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Nitroxyl; Angeli's salt; Septic arthritis; Pain; Leukocytes; Cytokines;
   Oxidative stress; Nitric oxide
ID NF-KAPPA-B; NITRIC-OXIDE; SYNTHETIC PEROXYNITRITE; SIGNALING PATHWAY;
   OXIDATIVE STRESS; NEUROPATHIC PAIN; REACTIVE OXYGEN; FREE-RADICALS; HNO;
   NO
AB Septic arthritis is a severe and rapidly debilitating disease associated with severe joint pain, inflammation and oxidative stress. Nitroxyl (HNO) has become a nitrogen oxide of significant interest due to its pharmacological endpoints that are potentially favorable for treating varied diseases. However, whether HNO also serves as a treatment to septic arthritis is currently unknown. The aim of this study was to investigate the effect of the HNO donor, Angeli's salt (AS), in the outcome of chronic Staphylococcus aureus (S. aureus)-induced septic arthritis in mice. Daily treatment with AS inhibited mechanical hyperalgesia and inflammation (edema, leukocyte migration, cytokines release and NF-kappa B activation, and oxidative stress) resulting in reduced disease severity (clinical course, histopathological changes, proteoglycan levels in the joints, and osteoclastogenesis). In addition, AS decreased the number of S. aureus colony forming unities in synovial tissue, enhanced the bactericidal effect of macrophages and inhibited the worsening of systemic inflammatory response (leukocyte counts in the lung and systemic proinflammatory cytokine concentration). Our results suggest for the first time the therapeutic potential of AS in a model of septic arthritis by mechanisms involving microbicidal effects, anti-inflammatory actions and reduction of disease severity.
C1 [Staurengo-Ferrari, Larissa; Ruiz-Miyazawa, Kenji W.; Pinho-Ribeiro, Felipe A.; Domiciano, Talita P.; Fattori, Victor; Mizokami, Sandra S.; Verri, Waldiceu A., Jr.] Univ Estadual Londrina, Ctr Ciencias Biol, Dept Patol, Rod Celso Garcia Cid KM480 PR445,Cx Postal 10011, BR-86057970 Londrina, Parana, Brazil.
   [Pelayo, Jacinta S.] Univ Estadual Londrina, Ctr Ciencias Biol, Dept Microbiol, Rod Celso Garcia Cid KM480 PR445,Cx Postal 10011, BR-86057970 Londrina, Parana, Brazil.
   [Bordignon, Juliano] Fiocruz MS, Inst Carlos Chagas, Lab Virol Mol, BR-81350010 Curitiba, Parana, Brazil.
   [Figueiredo, Florencio] Univ Brasilia, Fac Med, Pathol Lab, BR-70910900 Brasilia, DF, Brazil.
   [Casagrande, Rubia] Univ Estadual Londrina, Hlth Sci Ctr, Dept Pharmaceut Sci, Av Robert Koch 60, BR-86038350 Londrina, Parana, Brazil.
   [Miranda, Katrina M.] Univ Arizona, Dept Chem & Biochem, Tucson, AZ 85721 USA.
RP Verri, WA (corresponding author), Univ Estadual Londrina, Ctr Ciencias Biol, Dept Patol, Rod Celso Garcia Cid KM480 PR445,Cx Postal 10011, BR-86057970 Londrina, Parana, Brazil.
EM waverri@uel.br
RI Fattori, Victor/C-2745-2016; Domiciano, Talita P/N-4746-2014;
   Casagrande, Rubia/U-6019-2019; WA, Verri/I-1330-2013; de Pinho Ribeiro,
   Felipe Almeida/AAI-8107-2020; Bordignon, Juliano/Z-6268-2019; Miyazawa,
   Kenji/AAS-5833-2020
OI Fattori, Victor/0000-0002-4565-7706; Domiciano, Talita
   P/0000-0002-0927-496X; WA, Verri/0000-0003-2756-9283; de Pinho Ribeiro,
   Felipe Almeida/0000-0003-4264-9839; Bordignon,
   Juliano/0000-0002-1965-6152; Miyazawa, Kenji/0000-0002-5792-2175
FU CNPq (Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico)National Council for Scientific and Technological
   Development (CNPq); MCTI/SETI/Fundacao Araucaria (Ministerio da Ciencia,
   Tecnologia e Inovacao/Secretaria da Ciencia, Tecnologia, e Ensino
   Superior do Parana/Fundacao Araucaria); Decit/SCTIE/MS (Departamento de
   Ciencia e Tecnologia da Secretaria de Ciencia, Tecnologia e Insumos
   Estrategicos, Ministerio da Saude); Fundacao AraucariaFundacao
   Araucaria; Coordenadoria de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; INCT (National Institutes of Science and Technology) -
   MCTI/CNPq/CAPES/Fundacao Araucaria, Brazil; CAPESCAPES [PDSE -
   99999.007507/2014-03]; CNPqNational Council for Scientific and
   Technological Development (CNPq) [161279/2015-5]; CAPES/Fundacao
   Araucaria; CAPESCAPES
FX This work was supported by grants from CNPq (Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico), MCTI/SETI/Fundacao Araucaria
   (Ministerio da Ciencia, Tecnologia e Inovacao/Secretaria da Ciencia,
   Tecnologia, e Ensino Superior do Parana/Fundacao Araucaria),
   Decit/SCTIE/MS (Departamento de Ciencia e Tecnologia da Secretaria de
   Ciencia, Tecnologia e Insumos Estrategicos, Ministerio da Saude)
   Intermediated by CNPq and support of Fundacao Araucaria, Coordenadoria
   de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), INCT (National
   Institutes of Science and Technology) - MCTI/CNPq/CAPES/Fundacao
   Araucaria, Brazil. LSF received a scholarship from CAPES during her
   Ph.D. and to conduct sandwich Ph.D. at University of Arizona (Process:
   PDSE - 99999.007507/2014-03), and received a CNPq post-doctoral
   fellowship (Process: 161279/2015-5). TPD received a post-doctoral
   fellowship from CAPES/Fundacao Araucaria. KWR-M, FAP-R, VF and SSM
   received Ph.D. fellowship from CAPES.
CR Alves JC, 2010, NAT MED, V16, P708, DOI 10.1038/nm.2156
   Andrews KL, 2016, CLIN SCI, V130, P1629, DOI 10.1042/CS20160097
   Basudhar D, 2015, FREE RADICAL BIO MED, V83, P101, DOI 10.1016/j.freeradbiomed.2015.01.029
   Bergendi L, 1999, LIFE SCI, V65, P1865, DOI 10.1016/S0024-3205(99)00439-7
   Bullen ML, 2011, ANTIOXID REDOX SIGN, V14, P1675, DOI 10.1089/ars.2010.3327
   Calil IL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090013
   Chiu IM, 2013, NATURE, V501, P52, DOI 10.1038/nature12479
   Cury Y, 2011, NITRIC OXIDE-BIOL CH, V25, P243, DOI 10.1016/j.niox.2011.06.004
   DeMaster EG, 1998, BIOCHEM PHARMACOL, V55, P2007, DOI 10.1016/S0006-2952(98)00080-X
   Eberhardt M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5381
   Fang FC, 2004, NAT REV MICROBIOL, V2, P820, DOI 10.1038/nrmicro1004
   Fattori V., 2015, PHARM RES, V112, P84
   Fattori V, 2017, PHARMACOL RES, V120, P10, DOI 10.1016/j.phrs.2016.12.039
   Fukuto JM, 2009, FREE RADICAL BIO MED, V47, P1318, DOI 10.1016/j.freeradbiomed.2009.06.014
   Gjertsson I, 2001, MICROBES INFECT, V3, P527, DOI 10.1016/S1286-4579(01)01408-3
   Gjertsson I, 2012, J INFECT DIS, V205, P305, DOI 10.1093/infdis/jir713
   Guedes RP, 2006, NEUROCHEM RES, V31, P603, DOI 10.1007/s11064-006-9058-2
   Hellvard A, 2013, J INFECT DIS, V207, P768, DOI 10.1093/infdis/jis729
   Hohmann MSN, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/627046
   Irvine JC, 2008, TRENDS PHARMACOL SCI, V29, P601, DOI 10.1016/j.tips.2008.08.005
   Johnson GM, 2013, FREE RADICAL BIO MED, V63, P476, DOI 10.1016/j.freeradbiomed.2013.05.011
   Jorolan JH, 2015, NITRIC OXIDE-BIOL CH, V44, P39, DOI 10.1016/j.niox.2014.11.002
   Katalinic V, 2005, COMP BIOCHEM PHYS C, V140, P47, DOI 10.1016/j.cca.2005.01.005
   Lin EQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034892
   Lin L, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000703
   Longhi-Balbinot DT, 2016, CHEM-BIOL INTERACT, V256, P1, DOI 10.1016/j.cbi.2016.06.009
   Mal P, 2013, INFLAMM RES, V62, P259, DOI 10.1007/s00011-012-0574-z
   MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013
   Martinez-Revelles S, 2013, ANTIOXID REDOX SIGN, V18, P51, DOI 10.1089/ars.2011.4335
   Mathew AJ, 2014, BEST PRACT RES CL RH, V28, P935, DOI 10.1016/j.berh.2015.04.009
   McInnes IB, 1998, J IMMUNOL, V160, P308
   Meseguer V, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4125
   Miller AA, 2013, FREE RADICAL BIO MED, V60, P264, DOI 10.1016/j.freeradbiomed.2013.02.025
   Miranda KM, 2003, P NATL ACAD SCI USA, V100, P9196, DOI 10.1073/pnas.1430507100
   Miranda KM, 2002, ARCH BIOCHEM BIOPHYS, V401, P134, DOI 10.1016/S0003-9861(02)00031-0
   Naughton P, 2002, CELL MOL BIOL, V48, P885
   Norris AJ, 2008, INT J CANCER, V122, P1905, DOI 10.1002/ijc.23305
   Pagliaro P, 2003, FREE RADICAL BIO MED, V34, P33, DOI 10.1016/S0891-5849(02)01179-6
   Paolocci N, 2007, PHARMACOL THERAPEUT, V113, P442, DOI 10.1016/j.pharmthera.2006.11.002
   Phillipson M, 2011, NAT MED, V17, P1381, DOI 10.1038/nm.2514
   Pinho-Ribeiro FA, 2015, CHEM-BIOL INTERACT, V228, P88, DOI 10.1016/j.cbi.2015.01.011
   Pinto LG, 2010, PAIN, V148, P247, DOI 10.1016/j.pain.2009.11.006
   Rowton J., 2013, BMJ CASE REP, V2013
   Ryan MJ, 1997, BRIT J RHEUMATOL, V36, P370
   Shirtliff ME, 2002, CLIN MICROBIOL REV, V15, P527, DOI 10.1128/CMR.15.4.527-544.2002
   Skaar EP, 2004, SCIENCE, V305, P1626, DOI 10.1126/science.1099930
   Staurengo-Ferrari L, 2014, PHARMACOL REP, V66, P691, DOI 10.1016/j.pharep.2014.04.003
   STAURENGOFERRARI L, 2013, SEMIN CIENC BIOL SAU, V34, P33, DOI DOI 10.5433/1679-0367.2013v34n1p33
   Tarkowski A, 2006, BEST PRACT RES CL RH, V20, P1029, DOI 10.1016/j.berh.2006.08.001
   Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001
   Verri WA, 2008, P NATL ACAD SCI USA, V105, P2723, DOI 10.1073/pnas.0712116105
   Vieira SM, 2012, J IMMUNOL, V188, P5116, DOI 10.4049/jimmunol.1004190
   Wanner S, 2017, NAT MICROBIOL, V2, DOI [10.1038/nmicrobiol.2016.257, 10.1038/nmicrobiol.2017.48]
   White R J, 2009, J Wound Care, V18, P245
   Wink DA, 1998, ARCH BIOCHEM BIOPHYS, V351, P66, DOI 10.1006/abbi.1997.0565
   Yu LX, 1998, P NATL ACAD SCI USA, V95, P7993, DOI 10.1073/pnas.95.14.7993
   Zarpelon AC, 2013, NEUROPHARMACOLOGY, V71, P1, DOI 10.1016/j.neuropharm.2013.03.009
NR 57
TC 13
Z9 13
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD JUL
PY 2017
VL 108
BP 487
EP 499
DI 10.1016/j.freeradbiomed.2017.04.016
PG 13
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA EX7XS
UT WOS:000403463500044
PM 28419865
OA Bronze, Green Accepted
DA 2020-12-01
ER

PT J
AU Frabasile, S
   Koishi, AC
   Kuczera, D
   Silveira, GF
   Verri, WA
   dos Santos, CND
   Bordignon, J
AF Frabasile, Sandra
   Koishi, Andrea Cristine
   Kuczera, Diogo
   Silveira, Guilherme Ferreira
   Verri, Waldiceu Aparecido, Jr.
   Duarte dos Santos, Claudia Nunes
   Bordignon, Juliano
TI The citrus flavanone naringenin impairs dengue virus replication in
   human cells (vol 7, 41864, 2017)
SO SCIENTIFIC REPORTS
LA English
DT Correction
C1 [Duarte dos Santos, Claudia Nunes; Bordignon, Juliano] Fiocruz MS, ICC, PR, Mol Virol Lab, Curitiba, Parana, Brazil.
RI Bordignon, Juliano/Z-6268-2019; WA, Verri/I-1330-2013; Santos, Claudia
   Duarte dos/P-4868-2019; Duarte dos Santos, Claudia/E-1857-2018; Koishi,
   Andrea/N-2484-2013
OI Bordignon, Juliano/0000-0002-1965-6152; WA, Verri/0000-0003-2756-9283;
   Santos, Claudia Duarte dos/0000-0001-8707-6638; Duarte dos Santos,
   Claudia/0000-0001-8707-6638; Koishi, Andrea/0000-0002-3542-1353
CR Frabasile S, 2017, SCI REP-UK, V7, DOI 10.1038/srep41864
NR 1
TC 1
Z9 1
U1 1
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 14
PY 2017
VL 7
AR 43976
DI 10.1038/srep43976
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EN7XP
UT WOS:000396215800001
PM 28290539
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Sanfelice, RA
   da Silva, SS
   Bosqui, LR
   Miranda-Sapla, MM
   Barbosa, BF
   Silva, RJ
   Ferro, EAV
   Panagio, LA
   Navarro, IT
   Bordignon, J
   Conchon-Costa, I
   Pavanelli, WR
   Almeida, RS
   Costa, IN
AF Sanfelice, Raquel Arruda
   da Silva, Suelen Santos
   Bosqui, Larissa Rodrigues
   Miranda-Sapla, Milena Menegazzo
   Barbosa, Bellisa Freitas
   Silva, Rafaela Jose
   Ferro, Eloisa A. Vieira
   Panagio, Luciano Aparecido
   Navarro, Italmar Teodorico
   Bordignon, Juliano
   Conchon-Costa, Ivete
   Pavanelli, Wander Rogerio
   Almeida, Ricardo Sergio
   Costa, Idessania Nazareth
TI Pravastatin and simvastatin inhibit the adhesion, replication and
   proliferation of Toxoplasma gondii (RH strain) in HeLa cells
SO ACTA TROPICA
LA English
DT Article
DE Toxoplasma gondii; HeLa cell; Statins
ID CONGENITAL TOXOPLASMOSIS; IN-VITRO; INFECTION; APICOPLAST; BIOSYNTHESIS;
   STATINS; BRAZIL; EPIDEMIOLOGY; TRANSMISSION; PARASITES
AB The conventional treatment for toxoplasmosis with pyrimethamine and sulfadiazine shows toxic effects to the host, and it is therefore necessary to search for new drugs. Some studies suggest the use of statins, which inhibit cholesterol synthesis in humans and also the initial processes of isoprenoid biosynthesis in the parasite. Thus, the objective of this study was to evaluate the activity of the statins pravastatin and simvastatin in HeLa cells infected in vitro with the RH strain of T. gondii. HeLa cells (1 x 10(5)) were infected with T. gondii tachyzoites (5 x 10(5)) following two different treatment protocols. In the first protocol, T. gondii tachyzoites were pretreated with pravastatin (50 and 100 mu g/mL) and simvastatin (1.56 and 3.125 mu g/mL) for 30 min prior to infection. In the second, HeLa cells were first infected (5 x 10(5)) with tachyzoites and subsequently treated with pravastatin and simvastatin for 24 h at the concentrations noted above. Initially, we evaluated the cytotoxicity of drugs by the IVITT assay, number of tachyzoites adhered to cells, number of infected cells, and viability of tachyzoites by trypan blue exclusion. The supernatant of the cell cultures was collected post -treatment for determination of the pattern of Thl /Th2/Th17 cytokines by cytometric bead array. There was no cytotoxicity to HeLa cells with 50 and 100 mu g/mL pravastatin and 1.56 and 3.125 mu g/mL simvastatin. There was no change in the viability of tachyzoites that received pretreatment. Regarding the pre- and post-treatment of the cells with pravastatin and simvastatin alone, there was a reduction in adhesion, invasion and proliferation of cells to T. gondii. As for the production of cytokines, we found that IL-6 and IL-17 were significantly reduced in cells infected with T. gondii and treated with pravastatin and simvastatin, when compared to control. Based on these results, we can infer that pravastatin and simvastatin alone possess antiproliferative effects on tachyzoites forms of T. gondii, giving these drugs new therapeutic uses. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Sanfelice, Raquel Arruda; da Silva, Suelen Santos; Bosqui, Larissa Rodrigues; Miranda-Sapla, Milena Menegazzo; Conchon-Costa, Ivete; Pavanelli, Wander Rogerio; Costa, Idessania Nazareth] Univ Estadual Londrina, Dept Patol Expt, Lab Protozool Expt, Londrina, PR, Brazil.
   [Panagio, Luciano Aparecido; Almeida, Ricardo Sergio] Univ Fed Uberltindia, Inst Ciencias Biomed, Lab Micol Med Microbiol Bucal, Uberltindia, MG, Brazil.
   [Navarro, Italmar Teodorico] Univ Estadual Londrina, Dept Medicina Vet Preventiva, Lab Zoonoses & Saude Publ, Londrina, PR, Brazil.
   [Bordignon, Juliano] Inst Carlos Chagas, Lab Virologia Mol, ICC Fiocruz, Curitiba, PR, Brazil.
RP Costa, IN (corresponding author), Univ Estadual Londrina, Dept Ciencias Patol, CCB, Lab Parasitol Expt, Celso Garcia Cid Campus Univ,Cx Postal 6001, BR-86051990 Londrina, PR, Brazil.
EM idessania@hotmail.com
RI Ferro, Eloisa/K-5533-2016; Miranda-Sapla, Milena M/D-1231-2017; Panagio,
   Luciano Aparecido/V-3027-2019; da Silva, Suelen Santos/AAS-5789-2020;
   Bordignon, Juliano/Z-6268-2019
OI Ferro, Eloisa/0000-0002-7447-2583; Miranda-Sapla, Milena
   M/0000-0001-8324-9642; Panagio, Luciano Aparecido/0000-0002-2484-3147;
   da Silva, Suelen Santos/0000-0002-6251-0386; Bordignon,
   Juliano/0000-0002-1965-6152; Jose da Silva, Rafaela/0000-0002-6772-4658
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES
FX This study was supported by grants from the Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES). Dr. A. Leyva (USA)
   helped with the English editing of the manuscript.
CR Anderson AC, 2005, DRUG DISCOV TODAY, V10, P121, DOI 10.1016/S1359-6446(04)03308-2
   Barbosa BF, 2012, VET PARASITOL, V187, P44, DOI 10.1016/j.vetpar.2011.12.039
   Barbosa Matheus Azevedo, 2015, Revista de Patologia Tropical, V44, P1, DOI 10.5216/rpt.v44i1.34798
   BEAMAN MH, 1994, J IMMUNOL, V153, P4583
   Bernardes ES, 2006, AM J PATHOL, V168, P1910, DOI 10.2353/ajpath.2006.050636
   Bienvenu AL, 2008, ANTIMICROB AGENTS CH, V52, P4203, DOI 10.1128/AAC.00513-08
   Blader IJ, 2009, APMIS, V117, P458, DOI 10.1111/j.1600-0463.2009.02453.x
   Capobiango JD, 2014, BRAZ J INFECT DIS, V18, P364, DOI 10.1016/j.bjid.2013.11.009
   Churchward MA, 2014, MOL BRAIN, V7, DOI 10.1186/s13041-014-0085-7
   Coppens I, 2000, J CELL BIOL, V149, P167, DOI 10.1083/jcb.149.1.167
   Coppens I, 2014, INT J PARASITOL, V44, P109, DOI 10.1016/j.ijpara.2013.09.003
   Coppens I, 2013, NAT REV MICROBIOL, V11, P823, DOI 10.1038/nrmicro3139
   Cortez E, 2009, INT J ANTIMICROB AG, V33, P185, DOI 10.1016/j.ijantimicag.2008.07.026
   Costa IN, 2009, PLACENTA, V30, P884, DOI 10.1016/j.placenta.2009.08.002
   Denkers EY, 1998, CLIN MICROBIOL REV, V11, P569, DOI 10.1128/CMR.11.4.569
   Dubey JP, 2014, VET PARASITOL, V202, P270, DOI 10.1016/j.vetpar.2014.01.006
   Dubey JP, 2012, PARASITOLOGY, V139, P1375, DOI 10.1017/S0031182012000765
   Garweg JG, 2009, MEM I OSWALDO CRUZ, V104, P211, DOI 10.1590/S0074-02762009000200014
   Gazzinelli RT, 2006, NAT REV IMMUNOL, V6, P895, DOI 10.1038/nri1978
   Gobel A, 2007, SCI TOTAL ENVIRON, V372, P361, DOI 10.1016/j.scitotenv.2006.07.039
   Guiton R, 2010, J INFECT DIS, V202, P427, DOI 10.1086/653738
   Inaba Akiko, 2014, Rinsho Ketsueki, V55, P456
   Iwata A, 2012, CLIN EXP IMMUNOL, V168, P234, DOI 10.1111/j.1365-2249.2012.04564.x
   Kawazoe U., 2011, PARASITOLOGIA HUMANA, P163
   Kelly MN, 2005, INFECT IMMUN, V73, P617, DOI 10.1128/IAI.73.1.617-621.2005
   Kessler RL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055497
   Kuckelhaus CS, 2011, EXP PARASITOL, V127, P658, DOI 10.1016/j.exppara.2010.12.003
   Kuipers HF, 2007, BIOMED PHARMACOTHER, V61, P400, DOI 10.1016/j.biopha.2007.06.005
   Lahmar I, 2009, J INFECT DIS, V199, P1239, DOI 10.1086/597478
   Li ZH, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003665
   MCAULEY JB, 2014, J PEDIAT INFECT DIS, V3, P30
   McFadden GI, 2011, PROTOPLASMA, V248, P641, DOI 10.1007/s00709-010-0250-5
   Montoya JG, 2008, CLIN INFECT DIS, V47, P554, DOI 10.1086/590149
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Nair SC, 2011, J EXP MED, V208, P1547, DOI 10.1084/jem.20110039
   Nishikawa Y, 2011, J VET MED SCI, V73, P633, DOI 10.1292/jvms.10-0496
   Nyilasi I, 2010, FEMS MICROBIOL LETT, V307, P175, DOI 10.1111/j.1574-6968.2010.01972.x
   Pahan K, 2006, CELL MOL LIFE SCI, V63, P1165, DOI 10.1007/s00018-005-5406-7
   Passos ST, 2010, J IMMUNOL, V184, P1776, DOI 10.4049/jimmunol.0901843
   Qidwai T, 2012, CHEM BIOL DRUG DES, V80, P155, DOI 10.1111/j.1747-0285.2012.01389.x
   Ramakrishnan S, 2013, PROG LIPID RES, V52, P488, DOI 10.1016/j.plipres.2013.06.003
   Ramakrishnan S, 2012, J BIOL CHEM, V287, P4957, DOI 10.1074/jbc.M111.310144
   Sauer A, 2012, J INFECT DIS, V206, P1319, DOI 10.1093/infdis/jis486
   Seeber F, 2010, INT REV CEL MOL BIO, V281, P161, DOI 10.1016/S1937-6448(10)81005-6
   Silveira C, 2015, AM J OPHTHALMOL, V159, P1013, DOI 10.1016/j.ajo.2015.02.017
   Strober W., 2015, CURR PROTOC IMMUNOL, V2, P1, DOI DOI 10.1002/0471142735.IMA03
NR 46
TC 12
Z9 12
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
EI 1873-6254
J9 ACTA TROP
JI Acta Trop.
PD MAR
PY 2017
VL 167
BP 208
EP 215
DI 10.1016/j.actatropica.2016.12.006
PG 8
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA EK6YD
UT WOS:000394071300029
PM 28012901
OA Bronze
DA 2020-12-01
ER

PT J
AU Frabasile, S
   Koishi, AC
   Kuczera, D
   Silveira, GF
   Verri, WA
   dos Santos, CND
   Bordignon, J
AF Frabasile, Sandra
   Koishi, Andrea Cristine
   Kuczera, Diogo
   Silveira, Guilherme Ferreira
   Verri, Waldiceu Aparecido, Jr.
   Duarte dos Santos, Claudia Nunes
   Bordignon, Juliano
TI The citrus flavanone naringenin impairs dengue virus replication in
   human cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ANTIVIRAL ACTIVITY; IN-VITRO; INFLAMMATORY PAIN; FLAVONOIDS; INHIBITION;
   TYPE-1; AGENTS
AB Dengue is one of the most significant health problems in tropical and sub-tropical regions throughout the world. Nearly 390 million cases are reported each year. Although a vaccine was recently approved in certain countries, an anti-dengue virus drug is still needed. Fruits and vegetables may be sources of compounds with medicinal properties, such as flavonoids. This study demonstrates the anti-dengue virus activity of the citrus flavanone naringenin, a class of flavonoid. Naringenin prevented infection with four dengue virus serotypes in Huh7.5 cells. Additionally, experiments employing subgenomic RepDV-1 and RepDV-3 replicon systems confirmed the ability of naringenin to inhibit dengue virus replication. Antiviral activity was observed even when naringenin was used to treat Huh7.5 cells 24 h after dengue virus exposure. Finally, naringenin anti-dengue virus activity was demonstrated in primary human monocytes infected with dengue virus sertoype-4, supporting the potential use of naringenin to control dengue virus replication. In conclusion, naringenin is a suitable candidate molecule for the development of specific dengue virus treatments.
C1 [Frabasile, Sandra; Duarte dos Santos, Claudia Nunes; Bordignon, Juliano] Univ Republica, Fac Ciencias, Secc Virol, Montevideo 11400, Uruguay.
   [Frabasile, Sandra; Koishi, Andrea Cristine; Kuczera, Diogo; Silveira, Guilherme Ferreira] Inst Carlos Chagas, Mol Virol Lab, ICC FIOCRUZ PR, Curitiba, Parana, Brazil.
   [Verri, Waldiceu Aparecido, Jr.] Univ Estadual Londrina, Ctr Ciencias Biol, Dept Ciencias Patol, Londrina, Parana, Brazil.
RP Bordignon, J (corresponding author), Univ Republica, Fac Ciencias, Secc Virol, Montevideo 11400, Uruguay.
EM julianobordignon@fiocruz.br
RI WA, Verri/I-1330-2013; Silveira, Guilherme/Z-6230-2019; Bordignon,
   Juliano/Z-6268-2019
OI WA, Verri/0000-0003-2756-9283; Silveira, Guilherme/0000-0002-1866-0563;
   Bordignon, Juliano/0000-0002-1965-6152
FU CNPq (PROCAD/Casadinho, Universal, PAPES/Fiocruz); Brazilian Ministry of
   Health (PPSUS)/Fundacao Araucaria)
FX The authors thank the Program for Technological Development in Tools for
   Health-PDTIS-FIOCRUZ for the use of their facilities (RPT07C; Microscopy
   Facility and RPT08 L; Flow Cytometry Facility at the Carlos Chagas
   Institute/Fiocruz-PR, Brazil). The authors thank CNPq (PROCAD/Casadinho,
   Universal/2013, PAPES/Fiocruz) and the Brazilian Ministry of Health
   (PPSUS-2013)/Fundacao Araucaria for their financial support. CNDS and
   WAVJr are CNPq scholars, and JB is a Fundacao Araucaria scholar.
CR Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77
   BRANDT WE, 1979, INFECT IMMUN, V26, P534, DOI 10.1128/IAI.26.2.534-541.1979
   CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245
   Cotin S, 2012, ANTIVIR RES, V96, P181, DOI 10.1016/j.antiviral.2012.09.010
   Cushnie TPT, 2005, INT J ANTIMICROB AG, V26, P343, DOI 10.1016/j.ijantimicag.2005.09.002
   De Burghgraeve T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037244
   DEBIAGGI M, 1990, MICROBIOLOGICA, V13, P207
   Dong WJ, 2014, SCI REP-UK, V4, DOI 10.1038/srep07237
   de Sousa LRF, 2015, BIOORGAN MED CHEM, V23, P466, DOI 10.1016/j.bmc.2014.12.015
   Gould E. A., 1985, GROWTH TITRATION PUR
   GRANGE JM, 1990, J ROY SOC MED, V83, P159
   Grienke U, 2016, SCI REP-UK, V6, DOI 10.1038/srep27156
   Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223
   Harborne J.B, 1999, HDB NATURAL FLAVONOI
   HAVSTEEN B, 1983, BIOCHEM PHARMACOL, V32, P1141, DOI 10.1016/0006-2952(83)90262-9
   Havsteen BH, 2002, PHARMACOL THERAPEUT, V96, P67, DOI 10.1016/S0163-7258(02)00298-X
   HENCHAL EA, 1990, CLIN MICROBIOL REV, V3, P376, DOI 10.1128/CMR.3.4.376-396.1990
   ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048
   Jassim SAA, 2003, J APPL MICROBIOL, V95, P412, DOI 10.1046/j.1365-2672.2003.02026.x
   Kato F, 2016, ANTIVIR RES, V131, P141, DOI 10.1016/j.antiviral.2016.04.014
   Khachatoorian R, 2012, VIROLOGY, V433, P346, DOI 10.1016/j.virol.2012.08.029
   Koishi AC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051089
   Kuczera D, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0548-9
   Kwon HJ, 2010, BIOORGAN MED CHEM, V18, P7668, DOI 10.1016/j.bmc.2010.07.073
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Lani R, 2016, ANTIVIR RES, V133, P50, DOI 10.1016/j.antiviral.2016.07.009
   Li BQ, 2000, BIOCHEM BIOPH RES CO, V276, P534, DOI 10.1006/bbrc.2000.3485
   Lim H., 2016, BIOTECHNOL IN PRESS, DOI [10.1007/s10529-016-2261-6, DOI 10.1007/S10529-016-2261-6]
   Lulu SS, 2016, NAT PROD RES, V30, P464, DOI 10.1080/14786419.2015.1020490
   Lyu SY, 2005, ARCH PHARM RES, V28, P1293, DOI 10.1007/BF02978215
   Matias AA, 2010, INT J FOOD SCI NUTR, V61, P357, DOI 10.3109/09637480903430990
   Middleton E., 1993, FLAVONOIDS ADV RES, V1986, DOI [10.1007/978-1-4899-2911-2_15, DOI 10.1007/978-1-4899-2911-2_15]
   Mosimann ALP, 2010, J VIROL METHODS, V163, P147, DOI 10.1016/j.jviromet.2009.09.004
   Pinho-Ribeiro FA, 2016, J NUTR BIOCHEM, V33, P8, DOI 10.1016/j.jnutbio.2016.03.013
   Pinho-Ribeiro FA, 2016, NEUROPHARMACOLOGY, V105, P508, DOI 10.1016/j.neuropharm.2016.02.019
   Pohjala L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028923
   Repetto G, 2008, NAT PROTOC, V3, P1125, DOI 10.1038/nprot.2008.75
   Silveira GF, 2011, J VIROL, V85, P5374, DOI 10.1128/JVI.01915-10
   Su XW, 2013, FOOD ENVIRON VIROL, V5, P97, DOI 10.1007/s12560-013-9106-4
   Suzuki R, 2007, VIROLOGY, V362, P374, DOI 10.1016/j.virol.2006.11.026
   Verri WA, 2012, STUD NAT PROD CHEM, V36, P297, DOI 10.1016/B978-0-444-53836-9.00026-8
   Wang QY, 2011, ANTIMICROB AGENTS CH, V55, P4072, DOI 10.1128/AAC.00620-11
   World Health Organization (WHO), 2009, SPEC PROGRAM RES TRA, P147
   Xie XP, 2011, J VIROL, V85, P11183, DOI 10.1128/JVI.05468-11
   Zandi K, 2011, J MED PLANTS RES, V5, P5534
   Zanello PR, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0443-9
NR 47
TC 34
Z9 35
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 3
PY 2017
VL 7
AR 41864
DI 10.1038/srep41864
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EJ4EZ
UT WOS:000393171000001
PM 28157234
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU dos Santos, JS
   de Almeida, SM
   Ferreira, GS
   Bordignon, J
   Teixeira, SLM
   Lima, ACM
   Raboni, SM
AF dos Santos, Jucelia Stadinicki
   de Almeida, Sergio Monteiro
   Ferreira, Guilherme Silveira
   Bordignon, Juliano
   Maia Teixeira, Sylvia Lopes
   Martins Lima, Alberto Cardoso
   Raboni, Sonia Mara
TI Host Factor Predictors in Long-term Nonprogressors HIV-1 Infected with
   Distinct Viral Clades
SO CURRENT HIV RESEARCH
LA English
DT Article
DE HIV-LTNP; IL-8; IP-10; HLA-B alleles; rs12979860 polymorphism; chemokine
ID IMMUNODEFICIENCY-VIRUS TYPE-1; SINGLE-NUCLEOTIDE POLYMORPHISM;
   HEPATITIS-C PATIENTS; DISEASE PROGRESSION; HIV-1 INFECTION; IMMUNE
   ACTIVATION; ASSOCIATIONS; POPULATION; THERAPY; CXCL10/IP-10
AB Background: HIV-1+ long-term nonprogressors (LTNPs) maintain natural control of viral infection. This study sought to identify and characterize HIV-LTNPs series case, regarding the presence of possible host factors that may be associated with this status.
   Methods: We evaluated the plasma levels of IP-10/IL-8 chemokines, HLA-B alleles, and IL28B rs12979860 polymorphism in 24 LTNPs who presented with infection by different clades of HIV-1.
   Results: IL-8 chemokine was significantly higher in progressors than in LTNPs, but there was no difference between the LTNP subgroups. There was a negative correlation in CD4+ T cell (TC) count and IL-8 dosage, and a positive correlation with CD8+ TC. IP-10 chemokine levels were associated with viremia, and the elite controller (EC) subgroup showed nearly the same level than healthy individuals and progressors with viral load suppressed. Furthermore, the CD4+ TC count, percentage of CD4+ TC, and CD4/CD8 ratio were negatively correlated with IP-10. No association was found in plasma levels of IL-8 and IP-10 chemokines and HIV-1 clades. In the EC/viremic controller subgroup, 80% presented with at least one HLA-B allele previously considered as potentially protective for AIDS progression. No association was observed between the HLA-B alleles and HIV-1 clades. The IL28B CC genotype was identified in 87.5% of LTNPs.
   Conclusion: In this LTNP series case we observed different host factors that may be contributing to their nonprogressor status, and the association of these factors with the control of infection progression may be critically important for future therapeutic and prophylactic options in HIV-1 infection.
C1 [dos Santos, Jucelia Stadinicki; Raboni, Sonia Mara] Univ Fed Parana, Postgrad Program Internal Med & Hlth Sci, Curitiba, Parana, Brazil.
   [de Almeida, Sergio Monteiro; Raboni, Sonia Mara] Univ Fed Parana, Hosp Clin, Virol Lab, Curitiba, Parana, Brazil.
   [de Almeida, Sergio Monteiro] Fac Pequeno Principe Curitiba, Curitiba, Parana, Brazil.
   [de Almeida, Sergio Monteiro] Inst Pesquisa Pele Pequeno Principecuritiba, Curitiba, Parana, Brazil.
   [Ferreira, Guilherme Silveira; Bordignon, Juliano] Fiocruz MS, Inst Carlos Chagas, Lab Mol Virol, Curitiba, Parana, Brazil.
   [Maia Teixeira, Sylvia Lopes] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Mol Immunol, Rio De Janeiro, Brazil.
   [Martins Lima, Alberto Cardoso] Univ Fed Parana, Hosp Clin, Immunogenet Lab, Curitiba, Parana, Brazil.
   [Raboni, Sonia Mara] Univ Fed Parana, Infect Dis Div, Curitiba, Parana, Brazil.
RP Raboni, SM (corresponding author), Univ Fed Parana, Hosp Clin, 180 Gen Carneiro St,3rd Floor, BR-8006090 Curitiba, Parana, Brazil.
EM sraboni@ufpr.br
RI Bordignon, Juliano/Z-6268-2019; Silveira, Guilherme/Z-6230-2019; Raboni,
   Sonia M/AAF-7142-2020
OI Bordignon, Juliano/0000-0002-1965-6152; Silveira,
   Guilherme/0000-0002-1866-0563; Raboni, Sonia M/0000-0001-7907-7585
FU Program for Technological Development in Tools for Health-PDTIS-FIOCRUZ
   [RPT07C, RPT08 L]
FX The authors thank all patients involved in this study and the
   Immunogenetics Laboratory, Hospital de Clinicas, Universidade Federal do
   Parana, Curitiba, Brazil, and Laboratory of AIDS and Molecular
   Immunology, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil, for
   the HLA-B typing. The authors thank the Program for Technological
   Development in Tools for Health-PDTIS-FIOCRUZ for the use of its
   facilities (RPT07C; Microscopy Facility and RPT08 L; Flow Cytometry
   Facility at the Carlos Chagas Institute/Fiocruz-PR, Brazil).
CR Aalaei-Andabili SH, 2014, HEPAT MON, V14, DOI 10.5812/hepatmon.15895
   Adland E, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004954
   Asensio VC, 2001, J VIROL, V75, P7067, DOI 10.1128/JVI.75.15.7067-7077.2001
   Avanzi V. M., 2016, Journal of AIDS and Clinical Research, V7, P610
   Bertol BC, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00153
   Boisvert M, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00628
   Casado C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011079
   Cavalcante LN, 2012, LIVER INT, V32, P476, DOI 10.1111/j.1478-3231.2011.02653.x
   de Almeida SM, 2016, J NEUROVIROL, V22, P715, DOI 10.1007/s13365-016-0437-4
   Ferreira CD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078142
   Flores-Villanueva PO, 2003, J IMMUNOL, V170, P1925, DOI 10.4049/jimmunol.170.4.1925
   Geretti AM, 2006, CURR OPIN INFECT DIS, V19, P1, DOI 10.1097/01.qco.0000200293.45532.68
   Geretti AM, 2009, CLIN INFECT DIS, V48, P1296, DOI 10.1086/598502
   Honeyborne I, 2007, J VIROL, V81, P3667, DOI 10.1128/JVI.02689-06
   Huang X, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-201
   Imran M, 2016, APMIS, V124, P817, DOI 10.1111/apm.12579
   Kamat A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030881
   Keating SM, 2011, AIDS, V25, P1823, DOI 10.1097/QAD.0b013e3283489d1f
   Kiwanuka N, 2008, J INFECT DIS, V197, P707, DOI 10.1086/527416
   Klatt NR, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004345
   Klatt NR, 2013, IMMUNOL REV, V254, P326, DOI 10.1111/imr.12065
   Lane BR, 2003, VIROLOGY, V307, P122, DOI 10.1016/S0042-6822(02)00045-4
   Lee S, 2015, J MED VIROL, V87, P782, DOI 10.1002/jmv.24026
   Liu ML, 2011, CYTOKINE GROWTH F R, V22, P121, DOI 10.1016/j.cytogfr.2011.06.001
   Machmach K, 2013, J INFECT DIS, V207, P651, DOI 10.1093/infdis/jis717
   Malherbe G, 2014, MEDIAT INFLAMM, V2014, P1
   Martin MP, 2013, IMMUNOL REV, V254, P245, DOI 10.1111/imr.12071
   Michael NL, 1997, NAT MED, V3, P1160, DOI 10.1038/nm1097-1160
   Mohan T, 2014, MICROB PATHOGENESIS, V73, P60, DOI 10.1016/j.micpath.2014.06.003
   Muenchhoff M, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag1048
   Noel N, 2014, AIDS, V28, P467, DOI 10.1097/QAD.0000000000000174
   Pananghat AN, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003734
   Pereyra F, 2008, J INFECT DIS, V197, P563, DOI 10.1086/526786
   Pereyra FP, 2010, SCIENCE, V330, P1551, DOI 10.1126/science.1195271
   Peterson TA, 2013, TISSUE ANTIGENS, V81, P93, DOI 10.1111/tan.12051
   Platten M, 2016, AIDS RES HUM RETROV, V32, P579, DOI [10.1089/AID.2015.0226, 10.1089/aid.2015.0226]
   Ramos JA, 2012, MEM I OSWALDO CRUZ, V107, P888, DOI 10.1590/S0074-02762012000700008
   Roberts L, 2010, AIDS, V24, P819, DOI 10.1097/QAD.0b013e3283367836
   Ruiz TM, 2005, TRANSPL P, V37, P2293, DOI 10.1016/j.transproceed.2005.03.036
   Sajadi MM, 2011, CTS-CLIN TRANSL SCI, V4, P282, DOI 10.1111/j.1752-8062.2011.00307.x
   Sandonis V, 2009, VIROLOGY, V391, P73, DOI 10.1016/j.virol.2009.05.022
   Santos J. S., 2015, Journal of AIDS and Clinical Research, V6, P502
   Stephens HAF, 2012, INFECT GENET EVOL, V12, P1481, DOI 10.1016/j.meegid.2012.04.011
   Tang JM, 2011, J VIROL, V85, P8894, DOI 10.1128/JVI.00439-11
   Tebit DM, 2007, AIDS REV, V9, P75
   Williams R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005709
   Zhang H, 2013, HUM IMMUNOL, V74, P1636, DOI 10.1016/j.humimm.2013.08.287
NR 47
TC 1
Z9 1
U1 0
U2 2
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570-162X
EI 1873-4251
J9 CURR HIV RES
JI Curr. HIV Res.
PY 2017
VL 15
IS 6
BP 440
EP 447
DI 10.2174/1570162X16666171206120024
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA FS9SB
UT WOS:000422757500008
PM 29210660
DA 2020-12-01
ER

PT J
AU Thomazelli, APFD
   Tomiotto-Pellissier, F
   da Silva, SS
   Panis, C
   Orsini, TM
   Cataneo, AHD
   Miranda-Sapla, MM
   Custodio, LA
   Tatakihara, VLH
   Bordignon, J
   Silveira, GF
   Sforcin, JM
   Pavanelli, WR
   Conchon-Costa, I
AF Fortes dos Santos Thomazelli, Ana Paula
   Tomiotto-Pellissier, Fernanda
   da Silva, Suelen Santos
   Panis, Carolina
   Orsini, Tatiane Marcusso
   Depieri Cataneo, Allan Henrique
   Miranda-Sapla, Milena Menegazzo
   Custodio, Luiz Antonio
   Hideko Tatakihara, Vera Lucia
   Bordignon, Juliano
   Silveira, Guilherme Ferreira
   Sforcin, Jose Mauricio
   Pavanelli, Wander Rogerio
   Conchon-Costa, Ivete
TI Brazilian propolis promotes immunomodulation on human cells from
   American Tegumentar Leishmaniasis patients and healthy donors infected
   with L. braziliensis
SO CELLULAR IMMUNOLOGY
LA English
DT Article
DE Th17; IL-4; IL-6; IL-10; Human PBMC; In vitro
ID CUTANEOUS LEISHMANIASIS; NITRIC-OXIDE; GREEN PROPOLIS; IN-VITRO; MICE;
   CYTOKINES; IL-10; AMAZONENSIS; EXPRESSION; INTERLEUKIN-4
AB American Tegumentar Leishmaniasis (ATL) is an infectious disease caused by Leishmania parasites with ineffective treatment. The properties of propolis have been studied in different experimental studies, however, few works have investigated the effects of propolis on human-derived peripheral blood mononuclear cells (PBMC) in leishmaniasis models. Thus, we investigate the immunomodulatory effects of propolis treatment on PBMC from ATL patients and on PBMC from healthy donors infected with Leishmania braziliensis. Our data demonstrate that propolis pretreatment shows immunomodulatory effects on both healthy donors and ATL patients adherent cells, increasing IL-4 and IL-17 and decreasing IL-10, in either the presence or absence of the L. braziliensis infection, demonstrating that propolis contributes with the decrease of the inflammation and could also contribute with parasite control. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Fortes dos Santos Thomazelli, Ana Paula; Tomiotto-Pellissier, Fernanda; da Silva, Suelen Santos; Orsini, Tatiane Marcusso; Depieri Cataneo, Allan Henrique; Miranda-Sapla, Milena Menegazzo; Pavanelli, Wander Rogerio; Conchon-Costa, Ivete] Univ Estadual Londrina, Dept Ciencias Patol, Ctr Ciencias Biol, BR-86057970 Londrina, Parana, Brazil.
   [Panis, Carolina] Univ Oeste Parana, Lab Mediadores Inflamatorios, UNIOESTE, BR-85605010 Francisco Beltrao, Parana, Brazil.
   [Custodio, Luiz Antonio; Hideko Tatakihara, Vera Lucia] Ambulatorio Especialidades Hosp Univ Londrina, BR-86057970 Londrina, Parana, Brazil.
   [Bordignon, Juliano; Silveira, Guilherme Ferreira] Fundacao Oswaldo Cruz, Inst Carlos Chagas, Lab Virol Mol, BR-81350010 Curitiba, Parana, Brazil.
   [Sforcin, Jose Mauricio] Univ Estadual Paulista, Inst Biociencia, Dept Microbiol & Imunol, UNESP, BR-18618970 Sao Paulo, Brazil.
RP Tomiotto-Pellissier, F (corresponding author), Univ Estadual Londrina, Dept Ciencias Patol, Ctr Ciencias Biol, BR-86057970 Londrina, Parana, Brazil.
EM fernandatomiotto@gmail.com
RI Bordignon, Juliano/Z-6268-2019; Miranda-Sapla, Milena M/D-1231-2017;
   Cataneo, Allan/AAB-7997-2020; Silveira, Guilherme/Z-6230-2019; da Silva,
   Suelen Santos/AAS-5789-2020; PANIS, CAROLINA/O-1490-2015;
   Tomiotto-Pellissier, Fernanda/Q-9679-2018
OI Bordignon, Juliano/0000-0002-1965-6152; Miranda-Sapla, Milena
   M/0000-0001-8324-9642; Silveira, Guilherme/0000-0002-1866-0563; da
   Silva, Suelen Santos/0000-0002-6251-0386; PANIS,
   CAROLINA/0000-0002-0104-4369; Tomiotto-Pellissier,
   Fernanda/0000-0002-7273-8237
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) -
   BrazilCAPES; Fundacao Araucaria - BrazilFundacao Araucaria
FX This work was supported by the Coordenacao de Aperfeicoamento de Pessoal
   de Nivel Superior (CAPES) - Brazil and Fundacao Araucaria - Brazil.
CR Amarante MK, 2012, J PHARM PHARMACOL, V64, P154, DOI 10.1111/j.2042-7158.2011.01385.x
   Ansorge S, 2003, Z NATURFORSCH C, V58, P580
   Ayres DC, 2007, MEM I OSWALDO CRUZ, V102, P215, DOI 10.1590/S0074-02762007005000020
   Ayres DC, 2011, REV INST MED TROP SP, V53, P329, DOI 10.1590/S0036-46652011000600006
   Belkaid Y, 2001, J EXP MED, V194, P1497, DOI 10.1084/jem.194.10.1497
   Boaventura VS, 2010, EUR J IMMUNOL, V40, P2830, DOI 10.1002/eji.200940115
   Cheung KW, 2011, J ETHNOPHARMACOL, V138, P463, DOI 10.1016/j.jep.2011.09.031
   Croft SL, 2006, INDIAN J MED RES, V123, P399
   da Silva SS, 2016, PARASITOL RES, V115, P1557, DOI 10.1007/s00436-015-4890-4
   da Silva SS, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/673058
   Machado GMD, 2007, MEM I OSWALDO CRUZ, V102, P73, DOI 10.1590/S0074-02762007000100012
   Duran G, 2008, PARASITOL RES, V102, P1217, DOI 10.1007/s00436-008-0896-5
   FERTIN C, 1991, CELL MOL BIOL, V37, P823
   GILLERY P, 1992, FEBS LETT, V296, P297, DOI 10.1016/0014-5793(92)80308-4
   Girgin G, 2009, IMMUNOBIOLOGY, V214, P129, DOI 10.1016/j.imbio.2008.07.002
   Gonzalez-Lombana C, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003243
   Guimaraes-Costa AB, 2009, P NATL ACAD SCI USA, V106, P6748, DOI 10.1073/pnas.0900226106
   Gupta G, 2013, ADV APPL MICROBIOL, V82, P155, DOI 10.1016/B978-0-12-407679-2.00005-3
   Hepburn NC, 2000, CLIN EXP DERMATOL, V25, P363, DOI 10.1046/j.1365-2230.2000.00664.x
   Ikeda R., 2011, BIOCHIM BIOPHYS ACTA, P695
   Iyer SS, 2012, CRIT REV IMMUNOL, V32, P23, DOI 10.1615/CritRevImmunol.v32.i1.30
   Kane MM, 2001, J IMMUNOL, V166, P1141, DOI 10.4049/jimmunol.166.2.1141
   Kaye P, 2011, NAT REV MICROBIOL, V9, P604, DOI 10.1038/nrmicro2608
   Kimura A, 2010, EUR J IMMUNOL, V40, P1830, DOI 10.1002/eji.201040391
   Kostka SL, 2009, J IMMUNOL, V182, P3039, DOI 10.4049/jimmunol.0713598
   Kumar R, 2009, FEMS IMMUNOL MED MIC, V57, P239, DOI 10.1111/j.1574-695X.2009.00607.x
   Lazarski CA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071949
   Nascimento MSL, 2015, J INFECT DIS, V211, P1015, DOI 10.1093/infdis/jiu531
   Lira R, 2000, INFECT IMMUN, V68, P5176, DOI 10.1128/IAI.68.9.5176-5182.2000
   Miranda MM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125101
   Missima F, 2008, EVID-BASED COMPL ALT, V5, P71, DOI 10.1093/ecam/nel112
   Novoa R, 2011, PARASITE IMMUNOL, V33, P132, DOI 10.1111/j.1365-3024.2010.01256.x
   Nylen S, 2010, J GLOB INFECT DIS, V2, P135, DOI 10.4103/0974-777X.62876
   Olczyk P, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/423809
   Olczyk P, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/356737
   Oliveira WN, 2014, CYTOKINE, V66, P127, DOI 10.1016/j.cyto.2013.12.016
   Orsi R. O., 2000, Journal of Venomous Animals and Toxins including Tropical Diseases, V6, P205, DOI 10.1590/S0104-79302000000200006
   Ozbilge H, 2010, AFR J MICROBIOL RES, V4, P556
   Panis C, 2011, EXP PARASITOL, V127, P58, DOI 10.1016/j.exppara.2010.06.030
   Pitta MGR, 2009, J CLIN INVEST, V119, P2379, DOI 10.1172/JCI38813
   Pontin K, 2008, PARASITOL RES, V103, P487, DOI 10.1007/s00436-008-0970-z
   POSTLETHWAITE AE, 1992, J CLIN INVEST, V90, P1479, DOI 10.1172/JCI116015
   Proudfoot L, 1996, P NATL ACAD SCI USA, V93, P10984, DOI 10.1073/pnas.93.20.10984
   REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.iy.13.040195.001055
   Reithinger R, 2007, LANCET INFECT DIS, V7, P581, DOI 10.1016/S1473-3099(07)70209-8
   Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933
   Salhi A, 2008, J IMMUNOL, V180, P6139, DOI 10.4049/jimmunol.180.9.6139
   Sforcin JM, 2007, J ETHNOPHARMACOL, V113, P1, DOI 10.1016/j.jep.2007.05.012
   Sforcin JM, 2011, J ETHNOPHARMACOL, V133, P253, DOI 10.1016/j.jep.2010.10.032
   Sundar S, 2013, EXPERT OPIN PHARMACO, V14, P53, DOI 10.1517/14656566.2013.755515
   Tan-No K, 2006, BIOL PHARM BULL, V29, P96, DOI 10.1248/bpb.29.96
   Wanasen N, 2008, IMMUNOL RES, V41, P15, DOI 10.1007/s12026-007-8012-y
   Yao YX, 2005, J EXP MED, V201, P1899, DOI 10.1084/jem.20050324
NR 53
TC 6
Z9 6
U1 2
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0008-8749
EI 1090-2163
J9 CELL IMMUNOL
JI Cell. Immunol.
PD JAN
PY 2017
VL 311
BP 22
EP 27
DI 10.1016/j.cellimm.2016.09.014
PG 6
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA EI3AR
UT WOS:000392362600003
PM 27702443
OA Green Published
DA 2020-12-01
ER

PT J
AU Fleith, RC
   Lobo, FP
   dos Santos, PF
   Rocha, MM
   Bordignon, J
   Strottmann, DM
   Patricio, DO
   Pavanelli, WR
   Lo Sarzi, M
   Santos, CND
   Ferguson, BJ
   Mansur, DS
AF Fleith, Renata C.
   Lobo, Francisco P.
   dos Santos, Paula F.
   Rocha, Mariana M.
   Bordignon, Juliano
   Strottmann, Daisy M.
   Patricio, Daniel O.
   Pavanelli, Wander R.
   Lo Sarzi, Maria
   Santos, Claudia N. D.
   Ferguson, Brian J.
   Mansur, Daniel S.
TI Genome-wide analyses reveal a highly conserved Dengue virus envelope
   peptide which is critical for virus viability and antigenic in humans
SO SCIENTIFIC REPORTS
LA English
DT Article
ID INFLUENZA-A VIRUSES; NEUTRALIZING ANTIBODY; MONOCLONAL-ANTIBODY;
   E-GLYCOPROTEIN; PROTEIN; INFECTION; FLAVIVIRUS; SEQUENCE; MUTATION;
   DESIGN
AB Targeting regions of proteins that show a high degree of structural conservation has been proposed as a method of developing immunotherapies and vaccines that may bypass the wide genetic variability of RNA viruses. Despite several attempts, a vaccine that protects evenly against the four circulating Dengue virus (DV) serotypes remains elusive. To find critical conserved amino acids in dengue viruses, 120 complete genomes of each serotype were selected at random and used to calculate conservation scores for nucleotide and amino acid sequences. The identified peptide sequences were analysed for their structural conservation and localisation using crystallographic data. The longest, surface exposed, highly conserved peptide of Envelope protein was found to correspond to amino acid residues 250 to 270. Mutation of this peptide in DV1 was lethal, since no replication of the mutant virus was detected in human cells. Antibodies against this peptide were detected in DV naturally infected patients indicating its potential antigenicity. Hence, this study has identified a highly conserved, critical peptide in DV that is a target of antibodies in infected humans.
C1 [Fleith, Renata C.; dos Santos, Paula F.; Rocha, Mariana M.; Patricio, Daniel O.; Mansur, Daniel S.] Univ Fed Santa Catarina, Dept Microbiol Immunol & Parasitol, Immunobiol Lab, Florianopolis, SC, Brazil.
   [Lobo, Francisco P.] Univ Fed Minas Gerais, Dept Gen Biol, Belo Horizonte, MG, Brazil.
   [Bordignon, Juliano; Strottmann, Daisy M.; Santos, Claudia N. D.] Inst Carlos Chagas, Mol Virol Lab, Curitiba, Parana, Brazil.
   [Pavanelli, Wander R.] Univ Estadual Londrina, Dept Pathol, Londrina, PR, Brazil.
   [Lo Sarzi, Maria] Secretary Hlth, Cambe, Brazil.
   [Ferguson, Brian J.] Univ Cambridge, Dept Pathol, Cambridge, England.
RP Mansur, DS (corresponding author), Univ Fed Santa Catarina, Dept Microbiol Immunol & Parasitol, Immunobiol Lab, Florianopolis, SC, Brazil.
EM daniel.mansur@ufsc.br
RI Mansur, Daniel/AAQ-8062-2020; Bordignon, Juliano/Z-6268-2019; Santos,
   Claudia Duarte dos/P-4868-2019; Duarte dos Santos, Claudia/E-1857-2018
OI Mansur, Daniel/0000-0001-6773-9334; Bordignon,
   Juliano/0000-0002-1965-6152; Santos, Claudia Duarte
   dos/0000-0001-8707-6638; Duarte dos Santos, Claudia/0000-0001-8707-6638;
   Pereira Lobo, Francisco/0000-0002-9671-9313
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES
   [Biocomputacional 23038.010048/2013-27]; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (Cnpq)National Council for
   Scientific and Technological Development (CNPq) [404339/2012-3,
   552258/2011-3]; CAPESCAPES; Isaac Newton Trust/Wellcome Trust
   ISSF/University of Cambridge
FX We thank Andre Bafica that contributed to data discussion and critical
   reading of the manuscript. This work had financial support from
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES,
   grant number: Biocomputacional 23038.010048/2013-27) and Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (Cnpq, grant
   number: 404339/2012-3; Cnpq, Grant number: 552258/2011-3). Fleith, R.C.
   is currently enrolled at the Bioinformatics programme at Universidade
   Federal de Minas Gerais and is supported by CAPES. Ferguson, B.J. is
   supported by an Isaac Newton Trust/Wellcome Trust ISSF/University of
   Cambridge research grant.
CR Balazs AB, 2012, NATURE, V481, P81, DOI 10.1038/nature10660
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Butrapet S, 2011, VIROLOGY, V413, P118, DOI 10.1016/j.virol.2011.01.030
   Caskey M, 2015, NATURE, V522, P487, DOI 10.1038/nature14411
   CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245
   Christian EA, 2013, P NATL ACAD SCI USA, V110, P18662, DOI 10.1073/pnas.1310962110
   Cockburn JJB, 2012, STRUCTURE, V20, P303, DOI 10.1016/j.str.2012.01.001
   Corti D, 2011, SCIENCE, V333, P850, DOI 10.1126/science.1205669
   Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004
   Dejnirattisai W, 2010, SCIENCE, V328, P745, DOI 10.1126/science.1185181
   Drake JW, 1999, P NATL ACAD SCI USA, V96, P13910, DOI 10.1073/pnas.96.24.13910
   Ekiert DC, 2011, SCIENCE, V333, P843, DOI 10.1126/science.1204839
   Goncalvez AP, 2007, P NATL ACAD SCI USA, V104, P9422, DOI 10.1073/pnas.0703498104
   HALSTEAD SB, 1977, NATURE, V265, P739, DOI 10.1038/265739a0
   Holmes EC, 2003, INFECT GENET EVOL, V3, P19, DOI 10.1016/S1567-1348(03)00004-2
   Khan AM, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000272
   Klein DE, 2013, J VIROL, V87, P2287, DOI 10.1128/JVI.02957-12
   Kroschewski H, 2009, J GEN VIROL, V90, P2457, DOI 10.1099/vir.0.011486-0
   Kuno G, 1998, J VIROL, V72, P73, DOI 10.1128/JVI.72.1.73-83.1998
   LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351
   Lok SM, 2008, NAT STRUCT MOL BIOL, V15, P312, DOI 10.1038/nsmb.1382
   LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0
   Mareze VA, 2016, APPL MICROBIOL BIOT, V100, P125, DOI 10.1007/s00253-015-6973-7
   Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291
   Modis Y, 2004, NATURE, V427, P313, DOI 10.1038/nature02165
   Ramanathan B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155900
   ROEHRIG JT, 1989, VIROLOGY, V171, P49, DOI 10.1016/0042-6822(89)90509-6
   ROEHRIG JT, 1990, VIROLOGY, V177, P668, DOI 10.1016/0042-6822(90)90532-V
   Rouvinski A, 2015, NATURE, V520, P109, DOI 10.1038/nature14130
   SABIN ALBERT B., 1952, AMER JOUR TROP MED AND HYG, V1, P30
   Scharf L, 2015, CELL, V162, P1379, DOI 10.1016/j.cell.2015.08.035
   Schwartz LM, 2015, VACCINE, V33, P3293, DOI 10.1016/j.vaccine.2015.05.010
   Seligman SJ, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-27
   Stajich JE, 2002, GENOME RES, V12, P1611, DOI 10.1101/gr.361602
   Sui JH, 2009, NAT STRUCT MOL BIOL, V16, P265, DOI 10.1038/nsmb.1566
   Suzuki R, 2007, VIROLOGY, V362, P374, DOI 10.1016/j.virol.2006.11.026
   Tharakaraman K, 2014, CELL HOST MICROBE, V15, P644, DOI 10.1016/j.chom.2014.04.009
   VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V
   Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373
   Wang TT, 2010, P NATL ACAD SCI USA, V107, P18979, DOI 10.1073/pnas.1013387107
   Wang TT, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000796
   Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659
   Zanluca C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110620
NR 43
TC 5
Z9 5
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 2
PY 2016
VL 6
AR 36339
DI 10.1038/srep36339
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EA6TI
UT WOS:000386761500001
PM 27805018
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Pinho-Ribeiro, FA
   Zarpelon, AC
   Mizokami, SS
   Borghi, SM
   Bordignon, J
   Silva, RL
   Cunha, TM
   Alves, JC
   Cunha, FQ
   Casagrande, R
   Verri, WA
AF Pinho-Ribeiro, Felipe A.
   Zarpelon, Ana C.
   Mizokami, Sandra S.
   Borghi, Sergio M.
   Bordignon, Juliano
   Silva, Rangel L.
   Cunha, Thiago M.
   Alves-Filho, Jose C.
   Cunha, Fernando Q.
   Casagrande, Rubia
   Verri, Waldiceu A., Jr.
TI The citrus flavonone naringenin reduces lipopolysaccharide-induced
   inflammatory pain and leukocyte recruitment by inhibiting NF-kappa B
   activation
SO JOURNAL OF NUTRITIONAL BIOCHEMISTRY
LA English
DT Article
DE Inflammatory pain; Cytokines; Oxidative stress; Leukocyte recruitment;
   NF-kappa B
ID INDUCED OXIDATIVE STRESS; HAIRLESS MICE; TOPICAL FORMULATIONS; CYTOKINE
   PRODUCTION; SENSORY NEURONS; HYPERALGESIA; RECEPTOR; BACTERIOLYSIS;
   ANTIBIOTICS; NOCICEPTORS
AB Lipopolysaccharide (LPS) is the major structural component of Gram-negative bacteria cell wall and a highly pro-inflammatory toxin. Naringenin is found in Citrus fruits and exhibits antioxidant and anti-inflammatory properties through inhibition of NF-kappa B activation but its effects in LPS-induced inflammatory pain and leukocyte recruitment were not investigated yet. We investigated the effects of naringenin in mechanical hyperalgesia, thermal hyperalgesia and leukocyte recruitment induced by intraplantar injection of LPS in mice. We found that naringenin reduced hyperalgesia to mechanical and thermal stimuli, myeloperoxidase (MPO, a neutrophil and macrophage marker) and N-acetyl-beta-D-glucosaminidase (NAG, a macrophage marker) activities, oxidative stress and cytokine (TNF-alpha, IL-1 beta, IL-6, and IL-12) production in the paw skin. In the peritoneal cavity, naringenin reduced neutrophil and mononuclear cell recruitment, and abrogated MPO and NAG activity, cytokine and superoxide anion production, and lipid peroxidation. In vitro, pre-treatment with naringenin inhibited superoxide anion and cytokine (TNF-alpha, IL-1 beta, IL-6, and IL-12) production by LPS-stimulated RAW 264.7 macrophages. Finally, we demonstrated that naringenin inhibited NF-kappa B activation in vitro and in vivo. Therefore, naringenin is a promising compound to treat LPS-induced inflammatory pain and leukocyte recruitment. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Pinho-Ribeiro, Felipe A.; Zarpelon, Ana C.; Mizokami, Sandra S.; Borghi, Sergio M.; Verri, Waldiceu A., Jr.] Univ Estadual Londrina, Ctr Ciencias Biol, Dept Ciencias Patol, Rod Celso Garcia Cid,Km 380,PR445, BR-PR445860 Londrina, Parana, Brazil.
   [Bordignon, Juliano] Fiocruz MS, Carlos Chagas Inst, Rua Prof Algacyr Munhoz Mader 3775, BR-81350010 Curitiba, Parana, Brazil.
   [Silva, Rangel L.; Cunha, Thiago M.; Alves-Filho, Jose C.; Cunha, Fernando Q.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pharmacol, Ave Bandeirantes, BR-14050490 Ribeirao Preto, SP, Brazil.
   [Casagrande, Rubia] Univ Estadual Londrina, Ctr Ciencias Saude, Univ Hosp, Dept Ciencias Farmaceut, Ave Robert Koch 60, BR-86038350 Londrina, Parana, Brazil.
RP Verri, WA (corresponding author), Univ Estadual Londrina, Dept Pathol, Rod Celso Garcia Cid Km 480 Pr 445, BR-86057970 Londrina, Parana, Brazil.
EM waverri@uel.br
RI WA, Verri/I-1330-2013; Casagrande, Rubia/U-6019-2019; Borghi, Sergio
   M/H-7137-2017; de Pinho Ribeiro, Felipe Almeida/AAI-8107-2020;
   Bordignon, Juliano/Z-6268-2019; Alves-Filho, Jose Carlos/B-5814-2008;
   Cunha, Fernando Q/M-3090-2014; Cunha, Thiago M/B-7729-2012; Silva,
   Rangel Leal/G-2009-2016
OI WA, Verri/0000-0003-2756-9283; de Pinho Ribeiro, Felipe
   Almeida/0000-0003-4264-9839; Bordignon, Juliano/0000-0002-1965-6152;
   Alves-Filho, Jose Carlos/0000-0002-9918-8714; Cunha, Thiago
   M/0000-0003-1084-0065; Silva, Rangel Leal/0000-0002-1322-7808; Cunha,
   Fernando Queiroz/0000-0003-4755-1670; Borghi, Sergio
   Marques/0000-0002-6978-7505
FU Coordenadoria de Aperfeicoamento de Pessoal de Nivel Superior (CAPES,
   Brazil)CAPES; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq)National Council for Scientific and Technological
   Development (CNPq); Sao Paulo Research Foundation, Ministerio da
   Ciencia, Tecnologia e Inovacao (MCTI) [2011/19670-0, 2013/08216-2];
   SETI; Fundacao AraucariaFundacao Araucaria; Parana State Government;
   CAPES/ Fundacao Araucaria
FX The authors gratefully acknowledge the technical assistance of Thacyana
   T. Carvalho, who received a technician fellowship from Secretaria da
   Ciencia, Tecnologia e Inovacao (SETI)/Fundacao Araucaria and Parana
   State Government. This work was supported by Brazilian grants from
   Coordenadoria de Aperfeicoamento de Pessoal de Nivel Superior (CAPES,
   Brazil), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq), Sao Paulo Research Foundation under grant agreements no
   2011/19670-0 (Thematic project) and 2013/08216-2 (Center for Research in
   Inflammatory Disease), Ministerio da Ciencia, Tecnologia e Inovacao
   (MCTI), SETI, Fundacao Araucaria, and Parana State Government. ACZ
   received a post-doctoral fellowship from CAPES/ Fundacao Araucaria. The
   authors declare no conflict of interests.
CR Al-Rejaie SS, 2015, NEUROL RES, V37, P924, DOI 10.1179/1743132815Y.0000000079
   Binshtok AM, 2008, J NEUROSCI, V28, P14062, DOI 10.1523/JNEUROSCI.3795-08.2008
   Borghi SM, 2013, J NAT PROD, V76, P1141, DOI 10.1021/np400222v
   BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462
   Bugianesi R, 2002, J NUTR, V132, P3349
   Calil IL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090013
   Calixto-Campos C, 2015, ANAL CELL PATHOL, V2015, DOI 10.1155/2015/285708
   Campanini MZ, 2013, J PHOTOCH PHOTOBIO B, V127, P153, DOI 10.1016/j.jphotobiol.2013.08.007
   Casagrande R, 2006, J PHOTOCH PHOTOBIO B, V84, P21, DOI 10.1016/j.jphotobiol.2006.01.006
   Chiu IM, 2013, NATURE, V501, P52, DOI 10.1038/nature12479
   Cunha TM, 2007, EUR J PHARMACOL, V573, P221, DOI 10.1016/j.ejphar.2007.07.007
   Cunha TM, 2004, BRAZ J MED BIOL RES, V37, P401, DOI 10.1590/S0100-879X2004000300018
   DERRIEN M, 1993, NEUROSCI LETT, V160, P193, DOI 10.1016/0304-3940(93)90411-D
   Dibbert B, 1999, P NATL ACAD SCI USA, V96, P13330, DOI 10.1073/pnas.96.23.13330
   Dou W, 2013, BRIT J NUTR, V110, P599, DOI 10.1017/S0007114512005594
   Ginsburg I, 2002, APMIS, V110, P753, DOI 10.1034/j.1600-0463.2002.1101101.x
   Ginsburg I, 2004, MED HYPOTHESES, V62, P367, DOI 10.1016/j.mehy.2003.11.017
   Ginsburg I, 2008, EXPERT REV ANTI-INFE, V6, P453, DOI 10.1586/14787210.6.4.453
   Ho J, 2010, CURR OPIN INFECT DIS, V23, P546, DOI 10.1097/QCO.0b013e32833f0d3e
   Hohmann MSN, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/627046
   Hu CY, 2014, BIOMED REP, V2, P569, DOI 10.3892/br.2014.267
   Hutchinson MR, 2014, BRAIN BEHAV IMMUN, V41, P44, DOI 10.1016/j.bbi.2014.06.008
   Jeong KW, 2009, J NAT PROD, V72, P719, DOI 10.1021/np800698d
   Jin XC, 2006, J NEUROSCI, V26, P246, DOI 10.1523/JNEUROSCI.3858-05.2006
   Karuppagounder V, 2015, INT IMMUNOPHARMACOL, V28, P154, DOI 10.1016/j.intimp.2015.05.050
   Kaulaskar Shyam, 2012, Zhong Xi Yi Jie He Xue Bao, V10, P1482, DOI 10.3736/jcim20121223
   Lin LZ, 2007, J FOOD COMPOS ANAL, V20, P361, DOI 10.1016/j.jfca.2006.09.005
   Coelho RCLA, 2013, PLANT FOOD HUM NUTR, V68, P1, DOI 10.1007/s11130-013-0343-3
   Manjavachi MN, 2010, PAIN, V151, P345, DOI 10.1016/j.pain.2010.07.018
   Martinez RM, 2015, J NAT PROD, V78, P1647, DOI 10.1021/acs.jnatprod.5b00198
   Meseguer V, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4125
   Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073
   Park HH, 2013, INT IMMUNOPHARMACOL, V15, P296, DOI 10.1016/j.intimp.2012.12.005
   Park M, 2014, NUTR RES PRACT, V8, P146, DOI [10.4162/nrp.2014.8.1.146, 10.4162/nrp.2014.8.2.146]
   Pinho-Ribeiro FA, 2015, CHEM-BIOL INTERACT, V228, P88, DOI 10.1016/j.cbi.2015.01.011
   Ruiz-Miyazawa KW, 2015, CHEM-BIOL INTERACT, V237, P9, DOI 10.1016/j.cbi.2015.05.007
   Seeram NP, 2006, J AGR FOOD CHEM, V54, P7036, DOI 10.1021/jf0614948
   Seyedrezazadeh E, 2015, PHYTOTHER RES, V29, P591, DOI 10.1002/ptr.5292
   Silva RL, 2015, J NAT PROD, V78, P241, DOI 10.1021/np500796f
   Verri WA, 2005, J PHARMACOL EXP THER, V315, P609, DOI 10.1124/jpet.105.089409
   Verri WA, 2006, PHARMACOL THERAPEUT, V112, P116, DOI 10.1016/j.pharmthera.2006.04.001
   Wadachi R, 2006, J DENT RES, V85, P49, DOI 10.1177/154405910608500108
   Wang ZQ, 2004, J PHARMACOL EXP THER, V309, P869, DOI 10.1124/jpet.103.064154
   Wegner A, 2014, BRAIN BEHAV IMMUN, V41, P46, DOI 10.1016/j.bbi.2014.05.001
   Yilma AN, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/102457
   Zarpelon AC, 2013, BRIT J PHARMACOL, V169, P90, DOI 10.1111/bph.12110
   Zygmunt K, 2010, BIOCHEM BIOPH RES CO, V398, P178, DOI 10.1016/j.bbrc.2010.06.048
NR 47
TC 49
Z9 50
U1 2
U2 21
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0955-2863
EI 1873-4847
J9 J NUTR BIOCHEM
JI J. Nutr. Biochem.
PD JUL
PY 2016
VL 33
BP 8
EP 14
DI 10.1016/j.jnutbio.2016.03.013
PG 7
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA DO8CY
UT WOS:000378011400002
PM 27260463
DA 2020-12-01
ER

PT J
AU Kuczera, D
   Bavia, L
   Mosimann, ALP
   Koishi, AC
   Mazzarotto, GACA
   Aoki, MN
   Mansano, AMF
   Tomeleri, EI
   Costa, WL
   Miranda, MM
   Lo Sarzi, M
   Pavanelli, WR
   Conchon-Costa, I
   dos Santos, CND
   Bordignon, J
AF Kuczera, Diogo
   Bavia, Lorena
   Pamplona Mosimann, Ana Luiza
   Koishi, Andrea Cristine
   Camacho Antevere Mazzarotto, Giovanny Augusto
   Aoki, Mateus Nobrega
   Ferrari Mansano, Ana Maria
   Tomeleri, Edileia Ines
   Costa Junior, Wilson Liuti
   Miranda, Milena Menegazzo
   Lo Sarzi, Maria
   Pavanelli, Wander Rogerio
   Conchon-Costa, Ivete
   Duarte dos Santos, Claudia Nunes
   Bordignon, Juliano
TI Isolation of dengue virus serotype 4 genotype II from a patient with
   high viral load and a mixed Th1/Th17 inflammatory cytokine profile in
   South Brazil
SO VIROLOGY JOURNAL
LA English
DT Article
DE Dengue virus serotype 4; Parana State; Genetic characterization;
   Cytokines; IL-6; IFN-gamma; IL-17; Viremia
ID HEMORRHAGIC-FEVER; RORAIMA STATE; IFN-GAMMA; INFECTION; APOPTOSIS;
   DAMAGE
AB Background: We report the isolation and characterization of dengue virus (DENV) serotype 4 from a resident of Santa Fe, state of Parana, South Brazil, in March 2013. This patient presented with hemorrhagic manifestations, high viral load and, interestingly, a mixed Th1/Th17 cytokine profile.
   Case presentation: The patient presented with classical dengue symptoms, such as fever, rash, myalgia, arthralgia, and hemorrhagic manifestations including petechiae, gum bleeding and a positive tourniquet test result. A serum sample obtained 1 day after the initial appearance of clinical symptoms was positive for NS1 viral antigen, but this sample was negative for both IgM and IgG against DENV. Dengue virus infection was confirmed by isolation of the virus from C6/36 cells, and dengue virus serotyping was performed via one-step RT-PCR. The infection was confirmed to be caused by a serotype 4 dengue virus. Additionally, based on multiple alignment and phylogeny analyses of its complete genome sequence, the viral strain was classified as genotype II (termed LRV13/422). Moreover, a mixed Th1/Th17 cytokine profile was detected in the patient's serum, and this result demonstrated significant inflammation. Biological characterization of the virus via in vitro assays comparing LRV13/422 with a laboratory-adapted reference strain of dengue virus serotype 4 (TVP/360) showed that LRV13/422 infects both vertebrate and invertebrate cell lines more efficiently than TVP/360. However, LRV13/422 was unable to inhibit type I interferon responses, as suggested by the results obtained for other dengue virus strains. Furthermore, LRV13/422 is the first completely sequenced serotype 4 dengue virus isolated in South Brazil.
   Conclusion: The high viral load and mixed Th1/Th17 cytokine profile observed in the patient's serum could have implications for the development of the hemorrhagic signs observed, and these potential relationships can now be further studied using suitable animal models and/or in vitro systems.
C1 [Kuczera, Diogo; Bavia, Lorena; Pamplona Mosimann, Ana Luiza; Koishi, Andrea Cristine; Camacho Antevere Mazzarotto, Giovanny Augusto; Aoki, Mateus Nobrega; Duarte dos Santos, Claudia Nunes; Bordignon, Juliano] Fiocruz MS, Inst Carlos Chagas, Lab Virol Mol, Curitiba, Parana, Brazil.
   [Ferrari Mansano, Ana Maria; Tomeleri, Edileia Ines; Costa Junior, Wilson Liuti; Lo Sarzi, Maria] Secretaria Municipal Saude Cambe, Cambe, PR, Brazil.
   [Miranda, Milena Menegazzo; Pavanelli, Wander Rogerio; Conchon-Costa, Ivete] Univ Estadual Londrina, Lab Imunoparasitol Expt, Londrina, PR, Brazil.
RP dos Santos, CND; Bordignon, J (corresponding author), Fiocruz MS, Inst Carlos Chagas, Lab Virol Mol, Curitiba, Parana, Brazil.
EM clsantos@fiocruz.br; julianobordignon@fiocruz.br
RI Mosimann, Ana Luiza Pamplona/AAB-4714-2019; Koishi, Andrea/N-2484-2013;
   Miranda-Sapla, Milena M/D-1231-2017; Santos, Claudia Duarte
   dos/P-4868-2019; Bavia, Lorena/H-3750-2014; Duarte dos Santos,
   Claudia/E-1857-2018; Bordignon, Juliano/Z-6268-2019
OI Mosimann, Ana Luiza Pamplona/0000-0002-3504-5562; Koishi,
   Andrea/0000-0002-3542-1353; Miranda-Sapla, Milena M/0000-0001-8324-9642;
   Santos, Claudia Duarte dos/0000-0001-8707-6638; Duarte dos Santos,
   Claudia/0000-0001-8707-6638; Bordignon, Juliano/0000-0002-1965-6152;
   Bavia, Lorena/0000-0003-1702-2284
FU CNPq PROCAD/CasadinhoNational Council for Scientific and Technological
   Development (CNPq); PAPES/Fiocruz; Brazilian Ministry of Health
   (PPSUS)/Fundacao Araucaria
FX The authors thank the Program for Technological Development in Tools for
   Health-PDTIS-FIOCRUZ for use of its facilities (RPT07C; Microscopy
   Facility and RPT08 L; Flow Cytometry Facility at the Carlos Chagas
   Institute/Fiocruz-PR, Brazil). The authors also thank Bruna Hilzendeger
   Marcon for assistance with microscopic analysis, as well as Dra.
   Pryscilla F. Wowk (ICC/Fiocruz) and Dra. Alessandra Abel Borges (UFAL)
   for critically reading the manuscript. The authors thank Itamar Crispim
   for producing Additional file 1: Figure S1. The authors thank CNPq
   PROCAD/Casadinho, PAPES/Fiocruz, Brazilian Ministry of Health
   (PPSUS-2012)/Fundacao Araucaria, for providing financial support.
CR Acosta PO, 2011, EMERG INFECT DIS, V17, P80
   Acosta POA, 2011, EMERG INFECT DIS, V17, P1979, DOI 10.3201/eid1710.110776
   Arias J, 2014, VIROLOGY, V452, P42, DOI 10.1016/j.virol.2013.12.027
   Atrasheuskaya A, 2003, FEMS IMMUNOL MED MIC, V35, P33, DOI 10.1111/j.1574-695X.2003.tb00646.x
   Bozza FA, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-86
   Butthep P, 2012, PEDIATR INFECT DIS J, V31, pE232, DOI 10.1097/INF.0b013e31826fd456
   Chaturvedi UC, 2000, FEMS IMMUNOL MED MIC, V28, P183, DOI 10.1111/j.1574-695X.2000.tb01474.x
   Chen QS, 2013, MEDIAT INFLAMM, V2013, DOI [10.1155/2013/434010, 10.1155/2013/928315]
   de Melo FL, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000390
   DESPRES P, 1993, VIROLOGY, V196, P209, DOI 10.1006/viro.1993.1469
   Erra EO, 2013, PLOS ONE, V8
   Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186
   Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175
   Eyerich S, 2010, TRENDS IMMUNOL, V31, P354, DOI 10.1016/j.it.2010.06.004
   Fagundes CT, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001449
   Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195
   Gordon D, 2001, GENOME RES, V11, P614, DOI 10.1101/gr.171401
   Guabiraba R, 2013, EUR J IMMUNOL, V43, P1529, DOI 10.1002/eji.201243229
   HENCHAL EA, 1982, AM J TROP MED HYG, V31, P830, DOI 10.4269/ajtmh.1982.31.830
   Jain A, 2013, J CLIN IMMUNOL, V33, P613, DOI 10.1007/s10875-012-9855-0
   Koishi AC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051089
   Levy A, 2010, T ROY SOC TROP MED H, V104, P16, DOI 10.1016/j.trstmh.2009.06.013
   Mishra B, 2011, J CLIN LAB ANAL, V25, P76, DOI 10.1002/jcla.20434
   Osanai C H, 1983, Rev Inst Med Trop Sao Paulo, V25, P53
   Pang T, 2007, IMMUNOL CELL BIOL, V85, P43, DOI 10.1038/sj.icb.7100008
   de Figueiredo RMP, 2008, EMERG INFECT DIS, V14, P667, DOI 10.3201/eid1404.071185
   Rachman Andhika, 2006, Acta Med Indones, V38, P105
   Silveira GF, 2011, J VIROL, V85, P5374, DOI 10.1128/JVI.01915-10
   Temporao JG, 2011, EMERG INFECT DIS, V17, P938, DOI 10.3201/eid1705.101681
   Umareddy I, 2008, J GEN VIROL, V89, P3052, DOI 10.1099/vir.0.2008/001594-0
   Villabona-Arenas CJ, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002620
NR 31
TC 8
Z9 8
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1743-422X
J9 VIROL J
JI Virol. J.
PD JUN 6
PY 2016
VL 13
AR 93
DI 10.1186/s12985-016-0548-9
PG 8
WC Virology
SC Virology
GA DO0ZH
UT WOS:000377507300003
PM 27267473
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Lonien, SCH
   de Freitas, RC
   Suzukawa, HT
   dos Santos, FF
   Lovo-Martins, MI
   Silveira, GF
   Wowk, PF
   Bordignon, J
   Pinge, P
AF Heim Lonien, Sandra Cristina
   de Freitas, Rafael Carvalho
   Suzukawa, Helena Tiemi
   dos Santos, Fernando Fernandes
   Lovo-Martins, Maria Isabel
   Silveira, Guilherme Ferreira
   Wowk, Pryscilla Fanini
   Bordignon, Juliano
   Pinge-Filho, Phileno
TI Role of Cox Pathway in Human Monocytes and Monocyte-Derived Dendritic
   Cells infected by Trypanosoma cruzi
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Experimental Biology Meeting
CY APR 02-06, 2016
CL San Diego, CA
SP Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut
C1 [Heim Lonien, Sandra Cristina; de Freitas, Rafael Carvalho; Suzukawa, Helena Tiemi; dos Santos, Fernando Fernandes; Lovo-Martins, Maria Isabel] Univ Estadual Londrina, Ciencias Patol, Londrina, Brazil.
   [Pinge-Filho, Phileno] Univ Estadual Londrina, Londrina, Brazil.
   [Silveira, Guilherme Ferreira; Wowk, Pryscilla Fanini; Bordignon, Juliano; Pinge-Filho, Phileno] Fiocruz MS, ICC, Curitiba, Parana, Brazil.
RI Bordignon, Juliano/Z-6268-2019; Wowk, Pryscilla/AAA-3281-2019;
   Pinge-Filho, Phileno/G-2844-2012
OI Bordignon, Juliano/0000-0002-1965-6152; 
FU CAPESCAPES; CNPQNational Council for Scientific and Technological
   Development (CNPq); Fundacao AraucariaFundacao Araucaria
FX CAPES, CNPQ, Fundacao Araucaria
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD APR
PY 2016
VL 30
SU 1
MA 925.20
PG 2
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA FB9FJ
UT WOS:000406444703488
DA 2020-12-01
ER

PT J
AU Silveira, GF
   Strottmann, DM
   de Borba, L
   Mansur, DS
   Zanchin, NIT
   Bordignon, J
   dos Santos, CND
AF Silveira, G. F.
   Strottmann, D. M.
   de Borba, L.
   Mansur, D. S.
   Zanchin, N. I. T.
   Bordignon, J.
   Duarte dos Santos, C. N.
TI Single point mutations in the helicase domain of the NS3 protein enhance
   dengue virus replicative capacity in human monocyte-derived dendritic
   cells and circumvent the type I interferon response
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE dendritic cells; dengue virus; NS3 helicase; type I IFN; viral
   replicative capacity
ID INFLUENZA-A VIRUS; NUCLEOTIDE-SEQUENCE; GENE-EXPRESSION; INNATE
   IMMUNITY; T-CELLS; INFECTION; FLAVIVIRUS; INHIBITION; TARGETS; FEVER
AB Dengue is the most prevalent arboviral disease worldwide. The outcome of the infection is determined by the interplay of viral and host factors. In the present study, we evaluated the cellular response of human monocyte-derived DCs (mdDCs) infected with recombinant dengue virus type 1 (DV1) strains carrying a single point mutation in the NS3(hel) protein (L435S or L480S). Both mutated viruses infect and replicate more efficiently and produce more viral progeny in infected mdDCs compared with the parental, non-mutated virus (vBACDV1). Additionally, global gene expression analysis using cDNA microarrays revealed that the mutated DVs induce the up-regulation of the interferon (IFN) signalling and pattern recognition receptor (PRR) canonical pathways in mdDCs. Pronounced production of type I IFN were detected specifically in mdDCs infected with DV1-NS3(hel)-mutated virus compared with mdDCs infected with the parental virus. In addition, we showed that the type I IFN produced by mdDCs is able to reduce DV1 infection rates, suggesting that cytokine function is effective but not sufficient to mediate viral clearance of DV1-NS3hel-mutated strains. Our results demonstrate that single point mutations in subdomain 2 have important implications for adenosine triphosphatase (ATPase) activity of DV1-NS3hel. Although a direct functional connection between the increased ATPase activity and viral replication still requires further studies, these mutations speed up viral RNA replication and are sufficient to enhance viral replicative capacity in human primary cell infection and circumvent type I IFN activity. This information may have particular relevance for attenuated vaccine protocols designed for DV.
C1 [Silveira, G. F.; Strottmann, D. M.; de Borba, L.; Bordignon, J.; Duarte dos Santos, C. N.] Inst Carlos Chagas, Lab Virol Mol, Curitiba, Parana, Brazil.
   [Mansur, D. S.] Univ Fed Santa Catarina, Lab Imunobiol, Florianopolis, SC, Brazil.
   [Zanchin, N. I. T.] Inst Carlos Chagas, Lab Proteom & Engn Prot, Curitiba, Parana, Brazil.
RP dos Santos, CND (corresponding author), Fiocruz MS, Inst Carlos Chagas, CIC, Rua Prof Algacyr Munhoz Mader 3775, BR-81350010 Curitiba, Parana, Brazil.
EM clsantos@tecpar.br
RI Bordignon, Juliano/Z-6268-2019; Duarte dos Santos, Claudia/E-1857-2018;
   Silveira, Guilherme/Z-6230-2019; Santos, Claudia Duarte dos/P-4868-2019;
   Zanchin, Nilson Ivo Tonin/AAB-4907-2019; Mansur, Daniel/AAQ-8062-2020
OI Bordignon, Juliano/0000-0002-1965-6152; Duarte dos Santos,
   Claudia/0000-0001-8707-6638; Silveira, Guilherme/0000-0002-1866-0563;
   Santos, Claudia Duarte dos/0000-0001-8707-6638; Zanchin, Nilson Ivo
   Tonin/0000-0002-1153-0694; Mansur, Daniel/0000-0001-6773-9334
CR Ashour J, 2009, J VIROL, V83, P5408, DOI 10.1128/JVI.02188-08
   BAZAN JF, 1989, VIROLOGY, V171, P637, DOI 10.1016/0042-6822(89)90639-9
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Blaschke V, 2000, J IMMUNOL METHODS, V246, P79, DOI 10.1016/S0022-1759(00)00304-5
   Bowie AG, 2008, NAT REV IMMUNOL, V8, P911, DOI 10.1038/nri2436
   Byrd CM, 2013, ANTIMICROB AGENTS CH, V57, P1902, DOI 10.1128/AAC.02251-12
   CARTER SG, 1982, J BIOCHEM BIOPH METH, V7, P7, DOI 10.1016/0165-022X(82)90031-8
   CASALS J, 1954, J EXP MED, V99, P429, DOI 10.1084/jem.99.5.429
   CASALS J, 1953, P SOC EXP BIOL MED, V83, P170, DOI 10.3181/00379727-83-20299
   de Borba L, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001624
   Dejnirattisai W, 2008, J IMMUNOL, V181, P5865, DOI 10.4049/jimmunol.181.9.5865
   Dejnirattisai W, 2011, J INFECT DIS, V203, P1775, DOI 10.1093/infdis/jir173
   Despres P, 1998, J VIROL, V72, P823
   Gould EA, 1985, VIROLOGY PRACTICAL A, P43
   Green AM, 2014, J MOL BIOL, V426, P1148, DOI 10.1016/j.jmb.2013.11.023
   Grimm D, 2007, P NATL ACAD SCI USA, V104, P6806, DOI 10.1073/pnas.0701849104
   GRUN JB, 1987, J VIROL, V61, P3641, DOI 10.1128/JVI.61.11.3641-3644.1987
   HENCHAL EA, 1990, CLIN MICROBIOL REV, V3, P376, DOI 10.1128/CMR.3.4.376-396.1990
   HENCHAL EA, 1982, AM J TROP MED HYG, V31, P830, DOI 10.4269/ajtmh.1982.31.830
   Holm CK, 2012, NAT IMMUNOL, V13, P737, DOI 10.1038/ni.2350
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Kuno G, 1998, J VIROL, V72, P73, DOI 10.1128/JVI.72.1.73-83.1998
   Li SD, 2006, VIROLOGY, V349, P13, DOI 10.1016/j.virol.2006.01.005
   Liang Z, 2011, PLOS ONE, V6
   Liu WJ, 2003, J VIROL, V77, P7804, DOI 10.1128/JVI.77.14.7804-7813.2003
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luo DH, 2008, EMBO J, V27, P3209, DOI 10.1038/emboj.2008.232
   Malavige GN, 2004, POSTGRAD MED J, V80, P588, DOI 10.1136/pgmj.2004.019638
   Marcus PI, 1998, J VIROL, V72, P542, DOI 10.1128/JVI.72.1.542-549.1998
   Marovich M, 2001, J INVEST DERM SYMP P, V6, P219, DOI 10.1046/j.0022-202x.2001.00037.x
   Matusan AE, 2001, J VIROL, V75, P9633, DOI 10.1128/JVI.75.20.9633-9643.2001
   Muller DA, 2013, ANTIVIR RES, V98, P192, DOI 10.1016/j.antiviral.2013.03.008
   Munoz-Jordan JL, 2003, P NATL ACAD SCI USA, V100, P14333, DOI 10.1073/pnas.2335168100
   Murray KO, 2013, VECTOR-BORNE ZOONOT, V13, P835, DOI 10.1089/vbz.2013.1413
   Nasirudeen AMA, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000926
   Navarro-Sanchez E, 2005, ARCH MED RES, V36, P425, DOI 10.1016/j.arcmed.2005.04.007
   Nemesio H, 2012, BBA-BIOMEMBRANES, V1818, P2818, DOI 10.1016/j.bbamem.2012.06.022
   Nightingale ZD, 2008, J LEUKOCYTE BIOL, V84, P1028, DOI 10.1189/jlb.0208105
   Niyomrattanakit P, 2004, J VIROL, V78, P13708, DOI 10.1128/JVI.78.24.13708-13716.2004
   Pagni S, 2012, IMMUNOL RES, V54, P152, DOI 10.1007/s12026-012-8334-2
   Pryor MJ, 2001, AM J TROP MED HYG, V65, P427, DOI 10.4269/ajtmh.2001.65.427
   Puri B, 1998, VIRUS GENES, V17, P85, DOI 10.1023/A:1008009202695
   Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422
   Rajsbaum R, 2014, J MOL BIOL, V426, P1265, DOI 10.1016/j.jmb.2013.12.005
   RICE CM, 1985, SCIENCE, V229, P726, DOI 10.1126/science.4023707
   Rodriguez-Madoz JR, 2010, J VIROL, V84, P9760, DOI 10.1128/JVI.01051-10
   Rothman AL, 1999, VIROLOGY, V257, P1, DOI 10.1006/viro.1999.9656
   Sariol CA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019323
   Silveira GF, 2011, J VIROL, V85, P5374, DOI 10.1128/JVI.01915-10
   Umareddy I, 2008, J GEN VIROL, V89, P3052, DOI 10.1099/vir.0.2008/001594-0
   Vaughn DW, 2000, J INFECT DIS, V181, P2, DOI 10.1086/315215
   Wang CC, 2009, FEBS LETT, V583, P691, DOI 10.1016/j.febslet.2009.01.008
   WHO, 2009, WHO REC CLASS PEST H, V1, P1
   Wu SJL, 2000, NAT MED, V6, P816, DOI 10.1038/77553
   Xie XP, 2013, J VIROL, V87, P4609, DOI 10.1128/JVI.02424-12
   YAMSHCHIKOV VF, 1995, J VIROL, V69, P1995, DOI 10.1128/JVI.69.4.1995-2003.1995
   Yu CY, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002780
   Zust R, 2014, J VIROL, V88, P7276, DOI 10.1128/JVI.03827-13
NR 58
TC 4
Z9 4
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9104
EI 1365-2249
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD JAN
PY 2016
VL 183
IS 1
BP 114
EP 128
DI 10.1111/cei.12701
PG 15
WC Immunology
SC Immunology
GA DC0SS
UT WOS:000368928600012
PM 26340409
OA Bronze, Green Published
DA 2020-12-01
ER

PT J
AU Zanello, PR
   Koishi, AC
   Rezende, CD
   Oliveira, LA
   Pereira, AA
   de Almeida, MV
   dos Santos, CND
   Bordignon, J
AF Zanello, Paula Rodrigues
   Koishi, Andrea Cristine
   Rezende Junior, Celso de Oliveira
   Oliveira, Larissa Albuquerque
   Pereira, Adriane Antonia
   de Almeida, Mauro Vieira
   Duarte dos Santos, Claudia Nunes
   Bordignon, Juliano
TI Quinic acid derivatives inhibit dengue virus replication in vitro
SO VIROLOGY JOURNAL
LA English
DT Article
DE Dengue; Replication; Antivirals; Quinic acid
ID ANTIVIRAL ACTIVITY; CAFFEIC ACID; NEUTRAL RED; CELL; TYPE-1; HIV-1;
   ASSAY; CONSTRUCTION; INTEGRASE; COMPOUND
AB Background: Dengue is the most prevalent arboviral disease in tropical and sub-tropical areas of the world. The incidence of infection is estimated to be 390 million cases and 25,000 deaths per year. Despite these numbers, neither a specific treatment nor a preventive vaccine is available to protect people living in areas of high risk.
   Results: With the aim of seeking a treatment that can mitigate dengue infection, we demonstrated that the quinic acid derivatives known as compound 2 and compound 10 were effective against all four dengue virus serotypes and safe for use in a human hepatoma cell line (Huh7.5). Both compounds were non-virucidal to dengue virus particles and did not interfere with early steps of the dengue virus life cycle, including binding and internalization. Experiments using a replicon system demonstrated that compounds 2 and 10 impaired dengue virus replication in Huh7.5 cells. Additionally, the anti-dengue virus effects of the quinic acid derivatives were preserved in human peripheral blood mononuclear cells.
   Conclusions: Taken together, these data suggest that quinic acid derivatives represent a novel chemical class of active compounds that could be used to combat dengue virus infection.
C1 [Zanello, Paula Rodrigues; Koishi, Andrea Cristine; Duarte dos Santos, Claudia Nunes; Bordignon, Juliano] ICC Fiocruz, Inst Carlos Chagas, Mol Virol Lab, BR-81350010 Curitiba, PR, Brazil.
   [Rezende Junior, Celso de Oliveira; Oliveira, Larissa Albuquerque; Pereira, Adriane Antonia; de Almeida, Mauro Vieira] Univ Fed Juiz De Fora, Dept Quim, BR-36036330 Juiz De Fora, MG, Brazil.
RP dos Santos, CND (corresponding author), ICC Fiocruz, Inst Carlos Chagas, Mol Virol Lab, BR-81350010 Curitiba, PR, Brazil.
EM clsantos@tecpar.br; bordignonjuliano@gmail.com
RI Oliveira, Larissa/G-3517-2016; Duarte dos Santos, Claudia/E-1857-2018;
   Pereira, Adriane Antonia/R-5180-2019; Santos, Claudia Duarte
   dos/P-4868-2019; Koishi, Andrea/N-2484-2013; Almeida, Mauro/U-8931-2019;
   Bordignon, Juliano/Z-6268-2019; junior, celso oliveira
   rezende/O-2589-2013
OI Duarte dos Santos, Claudia/0000-0001-8707-6638; Santos, Claudia Duarte
   dos/0000-0001-8707-6638; Koishi, Andrea/0000-0002-3542-1353; Bordignon,
   Juliano/0000-0002-1965-6152; junior, celso oliveira
   rezende/0000-0003-1402-2035
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); Fundacao Flora de Apoio a Botanica; Fundacao AraucariaFundacao
   Araucaria; FAPEMIGMinas Gerais State Research Foundation (FAPEMIG);
   CAPES/CNPq Procad Casadinho
FX The authors thank Guilherme F. Silveira for assistance with flow
   cytometry, and Ana L.P. Mosimann and Daisy M. Strottmann for help with
   replicon assays. The authors would also like to thank Waldiceu A. Verri
   Jr from Universidade Estadual de Londrina (Londrina, Brazil) for the
   critical reading of the manuscript and valuable suggestions. This work
   was supported by the following funding sources: CNPq, Fundacao Flora de
   Apoio a Botanica, Fundacao Araucaria, FAPEMIG, CAPES/CNPq Procad
   Casadinho. The authors would also like to thank the Program for
   Technological Development in Tools for Health-PDTIS-FIOCRUZ for use of
   its facilities. CNDS and MVA are CNPq fellows; JB is a Fundacao
   Araucaria fellow; and ACK and PRZ are Fundacao Araucaria/CAPES fellows.
CR Barco A, 1997, TETRAHEDRON-ASYMMETR, V8, P3515, DOI 10.1016/S0957-4166(97)00471-0
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   CHAN YC, 1971, B WORLD HEALTH ORGAN, V44, P651
   Chiba K, 1998, TOXICOL IN VITRO, V12, P251, DOI 10.1016/S0887-2333(97)00107-0
   Cinkilic N, 2013, FOOD CHEM TOXICOL, V53, P359, DOI 10.1016/j.fct.2012.12.008
   Cruz DJM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002073
   De Burghgraeve T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037244
   De Maria C. A. B., 1999, Journal of Food Composition and Analysis, V12, P289, DOI 10.1006/jfca.1999.0833
   DESPRES P, 1993, VIROLOGY, V196, P209, DOI 10.1006/viro.1993.1469
   dos Santos PA, 2003, Z NATURFORSCH C, V58, P590
   Federspiel M, 1999, ORG PROCESS RES DEV, V3, P266, DOI 10.1021/op9900176
   Fu YL, 2014, J VIROL METHODS, V196, P18, DOI 10.1016/j.jviromet.2013.09.009
   FUNASA, 2002, DENG DIAGN MAN CLIN
   Halstead S, 2008, TROPICAL MED SCI PRA
   HENCHAL EA, 1990, CLIN MICROBIOL REV, V3, P376, DOI 10.1128/CMR.3.4.376-396.1990
   Ikeda K, 2011, INT J MOL MED, V28, P595, DOI 10.3892/ijmm.2011.739
   Junior COR, 2013, CURR MED CHEM, V20, P724, DOI 10.2174/092986713804999349
   Kalitzky M, 2006, MOL BIOL FLAVIVIRUS
   Kamng'ona A, 2011, J ENZYM INHIB MED CH, V26, P843, DOI 10.3109/14756366.2011.566220
   Koishi AC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051089
   Kuhn RJ, 2002, CELL, V108, P717, DOI 10.1016/S0092-8674(02)00660-8
   Kwon HC, 2000, CHEM PHARM BULL, V48, P1796, DOI 10.1248/cpb.48.1796
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Li YL, 2005, ANTIVIR RES, V68, P1, DOI 10.1016/j.antiviral.2005.06.004
   Maramorosch K., 2000, ADV VIRUS RES
   McDougall B, 1998, ANTIMICROB AGENTS CH, V42, P140, DOI 10.1128/AAC.42.1.140
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Ng CY, 2007, ANTIVIR RES, V76, P222, DOI 10.1016/j.antiviral.2007.06.007
   Ojwang JO, 2005, ANTIVIR RES, V68, P163, DOI 10.1016/j.antiviral.2005.09.003
   OMS, 2009, DENG GUID DIAGN TREA
   PAHO, 2014, GEN INF DENG
   Mosimann ALP, 2010, J VIROL METHODS, V163, P147, DOI 10.1016/j.jviromet.2009.09.004
   Repetto G, 2008, NAT PROTOC, V3, P1125, DOI 10.1038/nprot.2008.75
   Rezende CO, 2015, CHEM BIOL DRUG DES, V86, P344, DOI 10.1111/cbdd.12498
   Rezende Jr C.O., 2014, BIOMEDICINE PREVENTI, V4, P35, DOI DOI 10.1016/j.bionut.2013.09.007
   Ruzek D., 2011, ENCEPHALITIC FLAVIVI
   Sheng YZ, 2005, J ETHNOPHARMACOL, V96, P577, DOI 10.1016/j.jep.2004.10.002
   Soh YJ, 2003, BIOL PHARM BULL, V26, P803, DOI 10.1248/bpb.26.803
   Suzuki R, 2007, VIROLOGY, V362, P374, DOI 10.1016/j.virol.2006.11.026
   Talarico LB, 2005, ANTIVIR RES, V66, P103, DOI 10.1016/j.antiviral.2005.02.001
   Thompson KE, 2014, DRUG DEVELOP RES, V75, P29, DOI 10.1002/ddr.21164
   Wang GF, 2009, ANTIVIR RES, V83, P186, DOI 10.1016/j.antiviral.2009.05.002
   Yates C, 2007, ANTIINFLAMMATORY QUI
   Zeng K, 2009, BIOORG MED CHEM LETT, V19, P5458, DOI 10.1016/j.bmcl.2009.07.096
NR 44
TC 11
Z9 11
U1 1
U2 17
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1743-422X
J9 VIROL J
JI Virol. J.
PD DEC 22
PY 2015
VL 12
AR 223
DI 10.1186/s12985-015-0443-9
PG 13
WC Virology
SC Virology
GA CZ1UH
UT WOS:000366890500003
PM 26695767
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Zanluca, C
   Mazzarotto, GACA
   Bordignon, J
   dos Santos, CND
AF Zanluca, Camila
   Mazzarotto, Giovanny Augusto Camacho Antevere
   Bordignon, Juliano
   Duarte dos Santos, Claudia Nunes
TI Development, Characterization and Application of Monoclonal Antibodies
   against Brazilian Dengue Virus Isolates
SO PLOS ONE
LA English
DT Article
ID RAPID IMMUNOCHROMATOGRAPHIC TEST; ANTIGEN CAPTURE IMMUNOASSAY;
   LINKED-IMMUNOSORBENT-ASSAY; ENCEPHALITIS-VIRUS; ENVELOPE GLYCOPROTEIN;
   DIAGNOSIS; ELISA; NEUTRALIZATION; FEVER; IGM
AB Dengue is the most prevalent human arboviral disease. The morbidity related to dengue infection supports the need for an early, quick and effective diagnostic test. Brazil is a hotspot for dengue, but no serological diagnostic test has been produced using Brazilian dengue virus isolates. This study aims to improve the development of immunodiagnostic methods for dengue virus (DENV) detection through the production and characterization of 22 monoclonal antibodies (mAbs) against Brazilian isolates of DENV-1, -2 and -3. The mAbs include IgG2b kappa, IgG2a kappa and IgG1 kappa isotypes, and most were raised against the envelope or the pre-membrane proteins of DENV. When the antibodies were tested against the four DENV serotypes, different reactivity patterns were identified: group-specific, subcomplex specific (DENV-1, -3 and -4 and DENV-2 and -3) and dengue serotype-specific (DENV-2 or -3). Additionally, some mAbs cross-reacted with yellow fever virus (YFV), West Nile virus (WNV) and Saint Louis encephalitis virus (SLEV). None of the mAbs recognized the alphavirus Venezuelan equine encephalitis virus (VEEV). Furthermore, mAbs D3 424/8G, D1 606/A12/B9 and D1 695/12C/2H were used to develop a capture enzyme-linked immunosorbent assay (ELISA) for anti-dengue IgM detection in sera from patients with acute dengue. To our knowledge, these are the first monoclonal antibodies raised against Brazilian DENV isolates, and they may be of special interest in the development of diagnostic assays, as well as for basic research.
C1 [Zanluca, Camila; Mazzarotto, Giovanny Augusto Camacho Antevere; Bordignon, Juliano; Duarte dos Santos, Claudia Nunes] Inst Carlos Chagas, ICC Fiocruz PR, Mol Virol Lab, Curitiba, Parana, Brazil.
   [Zanluca, Camila] Univ Fed Parana UFPR, Programa Posgrad Biol Celular & Mol, Curitiba, Parana, Brazil.
RP Bordignon, J (corresponding author), Inst Carlos Chagas, ICC Fiocruz PR, Mol Virol Lab, Curitiba, Parana, Brazil.
EM julianobordignon@fiocruz.br; clsantos@tecpar.br
RI Bordignon, Juliano/Z-6268-2019; Santos, Claudia Duarte dos/P-4868-2019;
   Duarte dos Santos, Claudia/E-1857-2018
OI Bordignon, Juliano/0000-0002-1965-6152; Santos, Claudia Duarte
   dos/0000-0001-8707-6638; Duarte dos Santos, Claudia/0000-0001-8707-6638;
   Zanluca, Camila/0000-0001-7350-9105
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CNPq/ProsulNational Council for Scientific and Technological
   Development (CNPq); Fiocruz; Fundacao AraucariaFundacao Araucaria; Fundo
   Parana; CNPq/CAPES PROCAD/Casadinho
FX The authors thank CNPq, CNPq/Prosul, Fiocruz, Fundacao Araucaria and
   Fundo Parana and CNPq/CAPES PROCAD/Casadinho for financial support. CNDS
   is a CNPq fellowship recipient. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Austin SK, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002930
   BERGE TO, 1961, AM J HYG, V73, P209, DOI 10.1093/oxfordjournals.aje.a120178
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Brasil. Ministerio de Saude. Secretaria de Vigilancia em Saude, 2010, RES PREL AV DET OC O
   Bressanelli S, 2004, EMBO J, V23, P728, DOI 10.1038/sj.emboj.7600064
   Brien JD, 2010, J VIROL, V84, P10630, DOI 10.1128/JVI.01190-10
   CALISHER CH, 1988, ACTA VIROL, V32, P469
   CARDIFF RD, 1973, INFECT IMMUN, V7, P809, DOI 10.1128/IAI.7.5.809-816.1973
   Chan AHY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033451
   Chiang CF, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-115
   Chong C F, 1994, Clin Diagn Virol, V1, P335, DOI 10.1016/0928-0197(94)90063-9
   DESPRES P, 1993, VIROLOGY, V196, P209, DOI 10.1006/viro.1993.1469
   DITTMAR D, 1980, J CLIN MICROBIOL, V12, P74, DOI 10.1128/JCM.12.1.74-78.1980
   Groen J, 2000, CLIN DIAGN LAB IMMUN, V7, P867, DOI 10.1128/CDLI.7.6.867-871.2000
   Guzman A, 2010, INT J ANTIMICROB AG, V36, pS40, DOI 10.1016/j.ijantimicag.2010.06.018
   Guzman MG, 2004, INT J INFECT DIS, V8, P69, DOI 10.1016/j.ijid.2003.03.003
   HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268
   HENCHAL EA, 1982, AM J TROP MED HYG, V31, P830, DOI 10.4269/ajtmh.1982.31.830
   Huang KJ, 2000, J GEN VIROL, V81, P2177, DOI 10.1099/0022-1317-81-9-2177
   INNIS BL, 1989, AM J TROP MED HYG, V40, P418, DOI 10.4269/ajtmh.1989.40.418
   Johnson AJ, 1999, J VIROL, V73, P783, DOI 10.1128/JVI.73.1.783-786.1999
   Kang XP, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-56
   Klein DE, 2013, J VIROL, V87, P2287, DOI 10.1128/JVI.02957-12
   KOBAYASHI Y, 1985, MICROBIOL IMMUNOL, V29, P1069, DOI 10.1111/j.1348-0421.1985.tb00897.x
   KUNO G, 1985, J VIROL METHODS, V12, P93, DOI 10.1016/0166-0934(85)90011-4
   Kuroda JK, 1986, J GEN VIROL, V67, P2663
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lam SK, 1998, CLIN DIAGN VIROL, V10, P75, DOI 10.1016/S0928-0197(98)00002-6
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Lelli D, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-81
   Limonta D, 2007, J CLIN VIROL, V40, P50, DOI 10.1016/j.jcv.2007.04.024
   Mazzarotto GCA, 2009, J VIROL METHODS, V162, P96, DOI 10.1016/j.jviromet.2009.07.022
   MITCHELL CJ, 1985, AM J TROP MED HYG, V34, P945, DOI 10.4269/ajtmh.1985.34.945
   Mondotte JA, 2007, J VIROL, V81, P7136, DOI 10.1128/JVI.00116-07
   Morales MA, 2006, EMERG INFECT DIS, V12, P1559, DOI 10.3201/eid1210.060852
   Nelson PN, 2000, J CLIN PATHOL-MOL PA, V53, P111
   Nybakken GE, 2005, NATURE, V437, P764, DOI 10.1038/nature03956
   Palmer CJ, 1999, J CLIN MICROBIOL, V37, P1600, DOI 10.1128/JCM.37.5.1600-1601.1999
   Perrin P., 1996, P433
   Pierson T.C., 2013, FIELDS VIROLOGY, V6, P747
   Post PR, 2001, MEM I OSWALDO CRUZ, V96, P849, DOI 10.1590/S0074-02762001000600019
   Qiu LW, 2009, CLIN VACCINE IMMUNOL, V16, P88, DOI 10.1128/CVI.00212-08
   REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0
   Romero-Vivas CME, 1998, MED VET ENTOMOL, V12, P284, DOI 10.1046/j.1365-2915.1998.00117.x
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Schul W, 2007, J INFECT DIS, V195, P665, DOI 10.1086/511310
   Shrestha B, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000823
   SINGH KRP, 1969, B WORLD HEALTH ORGAN, V40, P982
   Stiasny K, 2006, J VIROL, V80, P9557, DOI 10.1128/JVI.00080-06
   Sukupolvi-Petty S, 2013, J VIROL, V87, P8826, DOI 10.1128/JVI.01314-13
   Takasaki T, 2002, J VIROL METHODS, V102, P61, DOI 10.1016/S0166-0934(01)00449-9
   Teixeira MG, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002520
   Trainor NB, 2007, VIROLOGY, V360, P398, DOI 10.1016/j.virol.2006.10.033
   Vaughn DW, 1998, J CLIN MICROBIOL, V36, P234, DOI 10.1128/JCM.36.1.234-238.1998
   Vazquez S, 2003, J VIROL METHODS, V110, P179, DOI 10.1016/S0166-0934(03)00128-9
   Wan SW, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-37
   Wisdom G Brian, 2005, Methods Mol Biol, V295, P127
   Wu SJL, 1997, CLIN DIAGN LAB IMMUN, V4, P452, DOI 10.1128/CDLI.4.4.452-457.1997
   Xu H, 2006, J CLIN MICROBIOL, V44, P2872, DOI 10.1128/JCM.00777-06
NR 59
TC 9
Z9 9
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 20
PY 2014
VL 9
IS 11
AR e110620
DI 10.1371/journal.pone.0110620
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AT9ND
UT WOS:000345253000005
PM 25412181
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Malvezi, AD
   Panis, C
   da Silva, RV
   de Freitas, RC
   Lovo-Martins, MI
   Tatakihara, VLH
   Zanluqui, NG
   Neto, EC
   Goldenberg, S
   Bordignon, J
   Yamada-Ogatta, SF
   Martins-Pinge, MC
   Cecchini, R
   Pinge, P
AF Malvezi, Aparecida D.
   Panis, Carolina
   da Silva, Rosiane V.
   de Freitas, Rafael Carvalho
   Lovo-Martins, Maria I.
   Tatakihara, Vera L. H.
   Zanluqui, Ngela G.
   Neto, Edecio Cunha
   Goldenberg, Samuel
   Bordignon, Juliano
   Yamada-Ogatta, Sueli F.
   Martins-Pinge, Marli C.
   Cecchini, Rubens
   Pinge-Filho, Phileno
TI Inhibition of Cyclooxygenase-1 and Cyclooxygenase-2 Impairs Trypanosoma
   cruzi Entry into Cardiac Cells and Promotes Differential Modulation of
   the Inflammatory Response
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID GROWTH-FACTOR-BETA; NITRIC-OXIDE; PHOSPHATIDYLINOSITOL 3-KINASE;
   EXPERIMENTAL-INFECTION; PGE(2) INVOLVEMENT; OXIDATIVE STRESS;
   IMMUNE-RESPONSE; CHAGAS-DISEASE; ACUTE-PHASE; PROSTAGLANDIN
AB The intracellular protozoan parasite Trypanosoma cruzi is the etiologic agent of Chagas disease, a serious disorder that affects millions of people in Latin America. Cell invasion by T. cruzi and its intracellular replication are essential to the parasite's life cycle and for the development of Chagas disease. Here, we present evidence suggesting the involvement of the host's cyclooxygenase (COX) enzymes during T. cruzi invasion. Pharmacological antagonists for COX-1 (aspirin) and COX-2 (celecoxib) caused marked inhibition of T. cruzi infection when rat cardiac cells were pretreated with these nonsteroidal anti-inflammatory drugs (NSAIDs) for 60 min at 37 degrees C before inoculation. This inhibition was associated with an increase in the production of NO and interleukin-1 beta and decreased production of transforming growth factor beta (TGF-beta) by cells. Taken together, these results indicate that COX-1 more than COX-2 is involved in the regulation of anti-T. cruzi activity in cardiac cells, and they provide a better understanding of the influence of TGF-beta-interfering therapies on the innate inflammatory response to T. cruzi infection and may represent a very pertinent target for new therapeutic treatments of Chagas disease.
C1 [Malvezi, Aparecida D.; da Silva, Rosiane V.; de Freitas, Rafael Carvalho; Lovo-Martins, Maria I.; Tatakihara, Vera L. H.; Zanluqui, Ngela G.; Pinge-Filho, Phileno] Univ Estadual Londrina, Dept Ciencias Patol, Ctr Ciencias Biol, Lab Imunopatol Expt, Londrina, Parana, Brazil.
   [Neto, Edecio Cunha] Univ Sao Paulo, Fac Med, Immunol Lab, Inst Coracao, Sao Paulo, Brazil.
   [Goldenberg, Samuel; Bordignon, Juliano] Fiocruz MS, Inst Carlos Chagas, Curitiba, Parana, Brazil.
   [Yamada-Ogatta, Sueli F.] Univ Estadual Londrina, Ctr Ciencias Biol, Dept Microbiol, Lab Biol Mol Microrganismos, Londrina, Parana, Brazil.
   [Martins-Pinge, Marli C.] Univ Estadual Londrina, Ctr Ciencias Biol, Dept Ciencias Fisiol, Londrina, Parana, Brazil.
   [Panis, Carolina; Cecchini, Rubens] Univ Estadual Londrina, Ctr Ciencias Biol, Dept Ciencias Biol, Lab Patofisiol & Radicais Livres, Londrina, Parana, Brazil.
RP Pinge, P (corresponding author), Univ Estadual Londrina, Dept Ciencias Patol, Ctr Ciencias Biol, Lab Imunopatol Expt, Londrina, Parana, Brazil.
EM pingefilho@uel.br
RI Pinge, Marli C Martins/C-4417-2014; Pinge-Filho, Phileno/G-2844-2012;
   Cecchini, Rubens/D-9811-2013; Cunha-Neto, Edecio/B-4157-2009; Bordignon,
   Juliano/Z-6268-2019; GOLDENBERG, SAMUEL/B-4116-2009; PANIS,
   CAROLINA/O-1490-2015
OI Pinge, Marli C Martins/0000-0002-9444-1530; Cecchini,
   Rubens/0000-0001-9941-2344; Cunha-Neto, Edecio/0000-0002-3699-3345;
   Bordignon, Juliano/0000-0002-1965-6152; GOLDENBERG,
   SAMUEL/0000-0002-4892-163X; PANIS, CAROLINA/0000-0002-0104-4369
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brasil
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [302097/2010-474792/2011-0]; Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES)CAPES; Fundacao AraucariaFundacao
   Araucaria [419/2009]
FX This work was supported by the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico, Brasil (CNPq; 302097/2010-474792/2011-0),
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), and
   by the Fundacao Araucaria (Convenio 419/2009).
CR Abdalla GK, 2008, EXP PARASITOL, V118, P514, DOI 10.1016/j.exppara.2007.11.003
   Araujo-Jorge TC, 2008, CYTOKINE GROWTH F R, V19, P405, DOI 10.1016/j.cytogfr.2008.08.002
   Barrias ES, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0007764
   Borges MM, 1998, IMMUNOL LETT, V63, P1, DOI 10.1016/S0165-2478(98)00034-0
   Calvet CM, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00327
   CELENTANO AM, 1995, PROSTAGLANDINS, V49, P141, DOI 10.1016/0090-6980(95)00002-R
   Corral RS, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002034
   Freire-de-Lima CG, 2000, NATURE, V403, P199, DOI 10.1038/35003208
   GAZZINELLI RT, 1992, EUR J IMMUNOL, V22, P2501, DOI 10.1002/eji.1830221006
   KIERSZENBAUM F, 1987, INFECT IMMUN, V55, P2461, DOI 10.1128/IAI.55.10.2461-2464.1987
   KIKUCHI K, 1993, J BIOL CHEM, V268, P23106
   Lima DS, 2013, NAT MED, V19, P909, DOI 10.1038/nm.3221
   Liu B, 2008, CELL BIOL INT, V32, P494, DOI 10.1016/j.cellbi.2007.10.008
   Lopez-Munoz R, 2010, EXP PARASITOL, V124, P167, DOI 10.1016/j.exppara.2009.09.005
   Machado FS, 2012, SEMIN IMMUNOPATHOL, V34, P753, DOI 10.1007/s00281-012-0351-7
   Machado FS, 2011, ADV PARASIT, V76, P1, DOI 10.1016/B978-0-12-385895-5.00001-3
   Machado FS, 2008, MICROBES INFECT, V10, P1558, DOI 10.1016/j.micinf.2008.09.009
   Machado FS, 2000, CIRCULATION, V102, P3003, DOI 10.1161/01.CIR.102.24.3003
   Manque PA, 2011, INFECT IMMUN, V79, P1855, DOI 10.1128/IAI.00643-10
   Michelin MA, 2005, EXP PARASITOL, V111, P71, DOI 10.1016/j.exppara.2005.05.001
   Molina-Berrios A, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002173
   Monick MM, 2002, J BIOL CHEM, V277, P32992, DOI 10.1074/jbc.M203218200
   Moon HG, 2010, EXP MOL MED, V42, P47, DOI 10.3858/emm.2010.42.1.005
   Mukherjee S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016959
   Park JY, 2006, CLIN IMMUNOL, V119, P229, DOI 10.1016/j.clim.2006.01.016
   Perez-Molina JA, 2012, CURR INFECT DIS REP, V14, P263, DOI 10.1007/s11908-012-0259-3
   Petersen CA, 2005, INFECT IMMUN, V73, P6974, DOI 10.1128/IAI.73.10.6974-6980.2005
   Petersen CA, 2003, INFECT IMMUN, V71, P4441, DOI 10.1128/IAI.71.8.4441-4447.2003
   Pfeiffer S, 1997, J BIOL CHEM, V272, P3465, DOI 10.1074/jbc.272.6.3465
   Pinge P, 1999, CELL IMMUNOL, V193, P90, DOI 10.1006/cimm.1999.1463
   Ren G, 2010, PHYTOTHER RES, V24, P404, DOI 10.1002/ptr.2964
   Rimon G, 2010, P NATL ACAD SCI USA, V107, P28, DOI 10.1073/pnas.0909765106
   Rocca B, 2002, INT IMMUNOPHARMACOL, V2, P603, DOI 10.1016/S1567-5769(01)00204-1
   Rodriguez A, 1999, J BIOL CHEM, V274, P16754, DOI 10.1074/jbc.274.24.16754
   Schmunis GA, 2010, ACTA TROP, V115, P14, DOI 10.1016/j.actatropica.2009.11.003
   SEAMON KB, 1981, J CYCLIC NUCL PROT, V7, P201
   Sharma J, 2013, INFECT IMMUN, V81, P2278, DOI 10.1128/IAI.00497-12
   Silva GK, 2013, J IMMUNOL, V191, P3373, DOI 10.4049/jimmunol.1203293
   Silva L. H. P., 1953, FOLIA CLIN BIOL, V20, P191
   Romano PS, 2012, IUBMB LIFE, V64, P387, DOI 10.1002/iub.1019
   SterinBorda L, 1996, CLIN IMMUNOL IMMUNOP, V81, P122, DOI 10.1006/clin.1996.0167
   Tatakihara VLH, 2008, FEMS IMMUNOL MED MIC, V52, P47, DOI 10.1111/j.1574-695X.2007.00340.x
   Uddin S, 2010, INT J CANCER, V126, P382, DOI 10.1002/ijc.24757
   Waghabi MC, 2007, ANTIMICROB AGENTS CH, V51, P2905, DOI 10.1128/AAC.00022-07
   Wilkowsky SE, 2001, EXP CELL RES, V264, P211, DOI 10.1006/excr.2000.5123
NR 45
TC 15
Z9 15
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD OCT
PY 2014
VL 58
IS 10
BP 6157
EP 6164
DI 10.1128/AAC.02752-14
PG 8
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA AS3DT
UT WOS:000344157500062
PM 25092706
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Silveira, GF
   Wowk, PF
   Machado, AMB
   dos Santos, CND
   Bordignon, J
AF Silveira, Guilherme Ferreira
   Wowk, Pryscilla Fanini
   Breckenfeld Machado, Analia Maria
   Duarte dos Santos, Claudia Nunes
   Bordignon, Juliano
TI Immature Dendritic Cells Generated from Cryopreserved Human Monocytes
   Show Impaired Ability to Respond to LPS and to Induce Allogeneic
   Lymphocyte Proliferation
SO PLOS ONE
LA English
DT Article
ID VIRUS; MATURATION; TOLERANCE; APOPTOSIS; MATURE
AB Dendritic cells play a key role in the immune system, in the sensing of foreign antigens and triggering of an adaptive immune response. Cryopreservation of human monocytes was investigated to understand its effect on differentiation into immature monocyte-derived dendritic cells (imdDCs), the response to inflammatory stimuli and the ability to induce allogeneic lymphocyte proliferation. Cryopreserved (crp)-monocytes were able to differentiate into imdDCs, albeit to a lesser extent than freshly (frh)-obtained monocytes. Furthermore, crp-imdDCs had lower rates of maturation and cytokine/chemokine secretion in response to LPS than frh-imdDCs. Lower expression of Toll-like receptor 4 (at 24 and 48 h) and higher susceptibility to apoptosis in crp-imdDCs than in fresh cells would account for the impaired maturation and cytokine/chemokine secretion observed. A mixed leukocyte reaction showed that lymphocyte proliferation was lower with crp-imdDCs than with frh-imdDCs. These findings suggested that the source of monocytes used to generate human imdDCs could influence the accuracy of results observed in studies of the immune response to pathogens, lymphocyte activation, vaccination and antigen sensing. It is not always possible to work with freshly isolated monocytes but the possible effects of freezing/thawing on the biology and responsiveness of imdDCs should be taken into account.
C1 [Silveira, Guilherme Ferreira; Wowk, Pryscilla Fanini; Duarte dos Santos, Claudia Nunes; Bordignon, Juliano] Fiocruz MS, Inst Carlos Chagas, Lab Virol Mol, Curitiba, Parana, Brazil.
   [Wowk, Pryscilla Fanini] Fiocruz MS, Inst Carlos Chagas, Lab Regulacao Expressa Genica, Curitiba, Parana, Brazil.
   [Breckenfeld Machado, Analia Maria] Ctr Hematol & Hemoterapia Parana, Prod Div, Curitiba, Parana, Brazil.
RP dos Santos, CND (corresponding author), Fiocruz MS, Inst Carlos Chagas, Lab Virol Mol, Curitiba, Parana, Brazil.
EM clsantos@tecpar.br
RI Wowk, Pryscilla Fanini/AAR-7230-2020; Duarte dos Santos,
   Claudia/E-1857-2018; Bordignon, Juliano/Z-6268-2019; Wowk,
   Pryscilla/AAA-3281-2019; Santos, Claudia Duarte dos/P-4868-2019;
   Silveira, Guilherme/Z-6230-2019
OI Duarte dos Santos, Claudia/0000-0001-8707-6638; Bordignon,
   Juliano/0000-0002-1965-6152; Santos, Claudia Duarte
   dos/0000-0001-8707-6638; Silveira, Guilherme/0000-0002-1866-0563; Wowk,
   Pryscilla/0000-0002-8976-2647
FU Fiocruz; CNPq National Counsel of Technological and Scientific
   DevelopmentNational Council for Scientific and Technological Development
   (CNPq) [477203/2009-4, 552258/2011-3]; Fundacao, AraucariaFundacao
   Araucaria [18707/2010]
FX Financial support was obtained from Fiocruz, CNPq National Counsel of
   Technological and Scientific Development(477203/2009-4 and
   552258/2011-3) and Fundacao, Araucaria (18707/2010). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767
   Blazquez AB, 2011, CURR OPIN ALLERGY CL, V11, P279, DOI 10.1097/ACI.0b013e3283489bab
   Campbell DE, 2009, CLIN VACCINE IMMUNOL, V16, P1648, DOI 10.1128/CVI.00259-09
   Dejnirattisai W, 2008, J IMMUNOL, V181, P5865, DOI 10.4049/jimmunol.181.9.5865
   Ghanekar Smita A, 2007, J Immune Based Ther Vaccines, V5, P7, DOI 10.1186/1476-8518-5-7
   HARRIS LW, 1977, CRYOBIOLOGY, V14, P662, DOI 10.1016/0011-2240(77)90021-9
   Hayden H, 2009, J IMMUNOTHER, V32, P638, DOI 10.1097/CJI.0b013e3181a5bc13
   Hori S, 2004, J IMMUNOTHER, V27, P27, DOI 10.1097/00002371-200401000-00003
   Huerta S, 2007, J SURG RES, V139, P143, DOI 10.1016/j.jss.2006.07.034
   INGALLS RR, 1995, J EXP MED, V181, P1473, DOI 10.1084/jem.181.4.1473
   Klagge IM, 1999, J GEN VIROL, V80, P823, DOI 10.1099/0022-1317-80-4-823
   Kushwah R, 2010, J IMMUNOL, V185, P795, DOI 10.4049/jimmunol.1000325
   Lewalle P, 2000, J IMMUNOL METHODS, V240, P69, DOI 10.1016/S0022-1759(00)00173-3
   Li CY, 2011, J CELL PHYSIOL, V226, P2338, DOI 10.1002/jcp.22576
   Maier M, 2009, HUM IMMUNOL, V70, P803, DOI 10.1016/j.humimm.2009.07.007
   Makino M, 1997, SCAND J IMMUNOL, V45, P618, DOI 10.1046/j.1365-3083.1997.d01-441.x
   Meijerink M, 2011, J IMMUNOL METHODS, V373, P136, DOI 10.1016/j.jim.2011.08.010
   Moussion C, 2011, NATURE, V479, P542, DOI 10.1038/nature10540
   Nestle FO, 2007, J CLIN INVEST, V117, P2382, DOI 10.1172/JCI33349
   ODOHERTY U, 1994, IMMUNOLOGY, V82, P487
   Palucka K, 2011, J INTERN MED, V269, P64, DOI 10.1111/j.1365-2796.2010.02317.x
   Patenaude J, 2011, CELL IMMUNOL, V271, P184, DOI 10.1016/j.cellimm.2011.06.020
   Rescigno M, 1999, IMMUNOL TODAY, V20, P200, DOI 10.1016/S0167-5699(98)01427-3
   SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109
   Shortman K, 2007, NAT REV IMMUNOL, V7, P19, DOI 10.1038/nri1996
   Silveira GF, 2011, J VIROL, V85, P5374, DOI 10.1128/JVI.01915-10
   Steinman RM, 2012, ANNU REV IMMUNOL, V30, P1, DOI 10.1146/annurev-immunol-100311-102839
   STEINMAN RM, 1973, J EXP MED, V137, P1142, DOI 10.1084/jem.137.5.1142
   STEINMAN RM, 1978, P NATL ACAD SCI USA, V75, P5132, DOI 10.1073/pnas.75.10.5132
   Torres-Aguilar H, 2010, AUTOIMMUN REV, V10, P8, DOI 10.1016/j.autrev.2010.07.015
   van Kooten C, 2011, TRANSPLANTATION, V91, P2, DOI 10.1097/TP.0b013e31820263b3
   Visintin A, 2001, J IMMUNOL, V166, P249, DOI 10.4049/jimmunol.166.1.249
   Willmann K, 2000, J LEUKOCYTE BIOL, V67, P536
NR 33
TC 10
Z9 10
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 31
PY 2013
VL 8
IS 7
AR e71291
DI 10.1371/journal.pone.0071291
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 194LB
UT WOS:000322633700084
PM 23936267
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Koishi, AC
   Zanello, PR
   Bianco, EM
   Bordignon, J
   dos Santos, CND
AF Koishi, Andrea Cristine
   Zanello, Paula Rodrigues
   Bianco, Everson Miguel
   Bordignon, Juliano
   Duarte dos Santos, Claudia Nunes
TI Screening of Dengue Virus Antiviral Activity of Marine Seaweeds by an In
   Situ Enzyme-Linked Immunosorbent Assay
SO PLOS ONE
LA English
DT Article
ID MOSQUITO CELLS; NEUTRAL RED; BROWN-ALGAE; OPTIMIZATION; IMMUNOASSAY;
   INHIBITION; VALIDATION; MONOLAYERS
AB Dengue is a significant public health problem worldwide. Despite the important social and clinical impact, there is no vaccine or specific antiviral therapy for prevention and treatment of dengue virus (DENV) infection. Considering the above, drug discovery research for dengue is of utmost importance; in addition natural marine products provide diverse and novel chemical structures with potent biological activities that must be evaluated. In this study we propose a target-free approach for dengue drug discovery based on a novel, rapid, and economic in situ enzyme-linked immunosorbent assay and the screening of a panel of marine seaweed extracts. The in situ ELISA was standardized and validated for Huh7.5 cell line infected with all four serotypes of DENV, among them clinical isolates and a laboratory strain. Statistical analysis showed an average S/B of 7.2 and Z-factor of 0.62, demonstrating assay consistency and reliability. A panel of fifteen seaweed extracts was then screened at the maximum non-toxic dose previously determined by the MTT and Neutral Red cytotoxic assays. Eight seaweed extracts were able to reduce DENV infection of at least one serotype tested. Four extracts (Phaeophyta: Canistrocarpus cervicornis, Padina gymnospora; Rhodophyta: Palisada perforate; Chlorophyta: Caulerpa racemosa) were chosen for further evaluation, and time of addition studies point that they might act at an early stage of the viral infection cycle, such as binding or internalization.
C1 [Koishi, Andrea Cristine; Zanello, Paula Rodrigues; Bordignon, Juliano; Duarte dos Santos, Claudia Nunes] Inst Carlos Chagas ICC FIOCRUZ PR, Mol Virol Lab, Curitiba, Parana, Brazil.
   [Koishi, Andrea Cristine] Univ Fed Parana UFPR, Programa Posgrad Biol Celular & Mol, Curitiba, Parana, Brazil.
   [Bianco, Everson Miguel] Univ Fed Pernambuco UFPE, Programa Posgrad Quim, Recife, PE, Brazil.
RP Bordignon, J (corresponding author), Inst Carlos Chagas ICC FIOCRUZ PR, Mol Virol Lab, Curitiba, Parana, Brazil.
EM jbordig@tecpar.br; clsantos@tecpar.br
RI Publica, Inct Saude/J-9544-2013; P, CM/B-1358-2013; Duarte dos Santos,
   Claudia/E-1857-2018; Koishi, Andrea/N-2484-2013; Santos, Claudia Duarte
   dos/P-4868-2019; Bordignon, Juliano/Z-6268-2019
OI Duarte dos Santos, Claudia/0000-0001-8707-6638; Koishi,
   Andrea/0000-0002-3542-1353; Santos, Claudia Duarte
   dos/0000-0001-8707-6638; Bordignon, Juliano/0000-0002-1965-6152
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); Fundacao AraucariaFundacao Araucaria; Fiocruz EMB; CAPESCAPES
FX The work was supported by CNPq, Fundacao Araucaria and Fiocruz EMB
   (post-doctoral fellowship PRODOC/DQF/UFPE jan2009-april2010) and PRZ are
   supported by fellowships from CAPES. ACK and CNDS are CNPq fellowship
   recipients. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Aliya R, 2003, PAKISTAN J BOT, V35, P659
   BERKOWITZ FE, 1985, ANTIMICROB AGENTS CH, V28, P207, DOI 10.1128/AAC.28.2.207
   BIO Ventures for Global Health, 2007, DENGUE FEVER
   BORENFREUND E, 1988, TOXICOL IN VITRO, V2, P1, DOI 10.1016/0887-2333(88)90030-6
   CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245
   Che PL, 2009, INT J CLIN EXP MED, V2, P363
   Chen YL, 2010, ANTIMICROB AGENTS CH, V54, P3255, DOI 10.1128/AAC.00397-10
   Chen YL, 2010, ANTIMICROB AGENTS CH, V54, P2932, DOI 10.1128/AAC.00140-10
   Chiba K, 1998, TOXICOL IN VITRO, V12, P251, DOI 10.1016/S0887-2333(97)00107-0
   Clercq ED, 2009, MED RES REV, V29
   Crance JM, 2003, ANTIVIR RES, V58, P73, DOI 10.1016/S0166-3542(02)00185-7
   De Burghgraeve T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037244
   de Oliveira AS, 2008, NAT PROD COMMUN, V3, P1469
   DESPRES P, 1993, VIROLOGY, V196, P209, DOI 10.1006/viro.1993.1469
   Ferreira LD, 2012, INT J ANAL CHEM, V2012, DOI 10.1155/2012/431954
   FIGUEIREDO LTM, 1989, T ROY SOC TROP MED H, V83, P702, DOI 10.1016/0035-9203(89)90403-3
   FIGUEIREDO LTM, 1987, J VIROL METHODS, V17, P191, DOI 10.1016/0166-0934(87)90129-7
   Fujii MT, 2011, REV BRAS FARMACOGN, V21, P268, DOI 10.1590/S0102-695X2011005000064
   Guha-Sapir D, 2005, EMERG THEMES EPIDEMI, V2, DOI 10.1186/1742-7622-2-1
   Guzman MG, 2010, NAT REV MICROBIOL, pS7, DOI 10.1038/nrmicro2460
   HALSTEAD SB, 1977, J EXP MED, V146, P201, DOI 10.1084/jem.146.1.201
   Harden EA, 2009, ANTIVIR RES, V83, P282, DOI 10.1016/j.antiviral.2009.06.007
   HENCHAL EA, 1990, CLIN MICROBIOL REV, V3, P376, DOI 10.1128/CMR.3.4.376-396.1990
   Hidari KIPJ, 2008, BIOCHEM BIOPH RES CO, V376, P91, DOI 10.1016/j.bbrc.2008.08.100
   Hong JY, 2011, CURR OPIN CHEM BIOL, V15, P350, DOI 10.1016/j.cbpa.2011.03.004
   Jamur MC, 2010, METHODS MOL BIOL, V588, P55, DOI 10.1007/978-1-59745-324-0_8
   Khanavi M, 2010, BIOL RES, V43, P31, DOI [10.4067/S0716-97602010000100005, /S0716-97602010000100005]
   Kim EJ, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-96
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Lescar J, 2008, ANTIVIR RES, V80, P94, DOI 10.1016/j.antiviral.2008.07.001
   Malavige GN, 2004, POSTGRAD MED J, V80, P588, DOI 10.1136/pgmj.2004.019638
   Marques CT, 2012, REV BRAS FARMACOGN, V22, P115, DOI 10.1590/S0102-695X2011005000206
   Mora C, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000606
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Myc A, 1999, J VIROL METHODS, V77, P165, DOI 10.1016/S0166-0934(98)00150-5
   Nielsen DG, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-211
   Qing M, 2010, ANTIVIR RES, V86, P163, DOI 10.1016/j.antiviral.2010.02.313
   Repetto G, 2008, NAT PROTOC, V3, P1125, DOI 10.1038/nprot.2008.75
   Rothman AL, 1999, VIROLOGY, V257, P1, DOI 10.1006/viro.1999.9656
   Sayce AC, 2010, TRENDS MICROBIOL, V18, P323, DOI 10.1016/j.tim.2010.04.003
   Shepard DS, 2011, AM J TROP MED HYG, V84, P200, DOI 10.4269/ajtmh.2011.10-0503
   Shum D, 2010, ASSAY DRUG DEV TECHN, V8, P553, DOI 10.1089/adt.2010.0321
   Stahle EL, 1998, ANTIVIR RES, V40, P105
   Stengel DB, 2011, BIOTECHNOL ADV, V29, P483, DOI 10.1016/j.biotechadv.2011.05.016
   Talarico LB, 2005, ANTIVIR RES, V66, P103, DOI 10.1016/j.antiviral.2005.02.001
   Wang QY, 2009, ANTIMICROB AGENTS CH, V53, P1823, DOI 10.1128/AAC.01148-08
   WHO, 2009, DENGUE GUIDELINES FO
   Yasuhara-Bell J, 2010, ANTIVIR RES, V86, P231, DOI 10.1016/j.antiviral.2010.03.009
   Yin Z, 2009, P NATL ACAD SCI USA, V106, P20435, DOI 10.1073/pnas.0907010106
   Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206
   Zhang XCG, 2009, ANTIVIR RES, V83, P21, DOI 10.1016/j.antiviral.2009.02.204
NR 51
TC 21
Z9 23
U1 0
U2 32
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 5
PY 2012
VL 7
IS 12
AR e51089
DI 10.1371/journal.pone.0051089
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 057TZ
UT WOS:000312588200098
PM 23227238
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Martins, SD
   Silveira, GF
   Alves, LR
   dos Santos, CND
   Bordignon, J
AF Martins, Sharon de T.
   Silveira, Guilherme F.
   Alves, Lysangela R.
   Duarte dos Santos, Claudia Nunes
   Bordignon, Juliano
TI Dendritic Cell Apoptosis and the Pathogenesis of Dengue
SO VIRUSES-BASEL
LA English
DT Review
DE Dendritic cell; apoptosis; dengue virus
ID NF-KAPPA-B; GENE TRANSCRIPT ABUNDANCE; HUMAN ENDOTHELIAL-CELLS;
   SWINE-FEVER VIRUS; HEMORRHAGIC-FEVER; T-CELLS; I INTERFERON; MONONUCLEAR
   PHAGOCYTES; RECEPTOR EXPRESSION; PHOSPHOLIPASE A(2)
AB Dengue viruses and other members of the Flaviviridae family are emerging human pathogens. Dengue is transmitted to humans by Aedes aegypti female mosquitoes. Following infection through the bite, cells of the hematopoietic lineage, like dendritic cells, are the first targets of dengue virus infection. Dendritic cells (DCs) are key antigen presenting cells, sensing pathogens, processing and presenting the antigens to T lymphocytes, and triggering an adaptive immune response. Infection of DCs by dengue virus may induce apoptosis, impairing their ability to present antigens to T cells, and thereby contributing to dengue pathogenesis. This review focuses on general mechanisms by which dengue virus triggers apoptosis, and possible influence of DC-apoptosis on dengue disease severity.
C1 [Martins, Sharon de T.; Silveira, Guilherme F.; Duarte dos Santos, Claudia Nunes; Bordignon, Juliano] CIC, Carlos Chagas Inst, Mol Virol Lab, ICC Fiocruz, BR-81350010 Curitiba, Parana, Brazil.
   [Martins, Sharon de T.; Alves, Lysangela R.] CIC, ICC Fiocruz, Carlos Chagas Inst, Lab Gene Express Regulat, BR-81350010 Curitiba, Parana, Brazil.
RP dos Santos, CND (corresponding author), CIC, Carlos Chagas Inst, Mol Virol Lab, ICC Fiocruz, Prof Algacyr Munhoz Mader St 3775, BR-81350010 Curitiba, Parana, Brazil.
EM sth_martins@yahoo.com.br; gfsilveira@gmail.com; lys.alves@tecpar.br;
   clsantos@tecpar.br; julianobordignon@fiocruz.br
RI P, CM/B-1358-2013; Silveira, Guilherme/Z-6230-2019; Publica, Inct
   Saude/J-9544-2013; Santos, Claudia Duarte dos/P-4868-2019; Bordignon,
   Juliano/Z-6268-2019; Duarte dos Santos, Claudia/E-1857-2018; Alves,
   Lysangela Ronalte/H-5599-2012
OI Silveira, Guilherme/0000-0002-1866-0563; Santos, Claudia Duarte
   dos/0000-0001-8707-6638; Bordignon, Juliano/0000-0002-1965-6152; Duarte
   dos Santos, Claudia/0000-0001-8707-6638; Alves, Lysangela
   Ronalte/0000-0002-1972-2658
FU Fundacao Oswaldo Cruz; Fundacao AraucariaFundacao Araucaria;
   CNPqNational Council for Scientific and Technological Development
   (CNPq); CAPESCAPES; Fiocruz fellowship
FX Authors are indebted to Daniel Mansur from the Federal University of
   Santa Catarina and Samuel Goldenberg from ICC/Fiocruz for critical
   reading of the manuscript. Authors also thank Itamar Crispim for figure
   2 design. Financial support: Fundacao Oswaldo Cruz, Fundacao Araucaria,
   CNPq and CAPES. CNDS and LRA hold CNPq fellowships, GFS holds a Fiocruz
   fellowship and STM holds a CAPES fellowship.
CR Anderson R, 2003, ADV VIRUS RES, V59, P229, DOI 10.1016/S0065-3527(03)59007-8
   Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305
   Ashour J, 2009, J VIROL, V83, P5408, DOI 10.1128/JVI.02188-08
   Avirutnan P, 2006, J INFECT DIS, V193, P1078, DOI 10.1086/500949
   Avirutnan P, 1998, J IMMUNOL, V161, P6338
   Avirutnan P, 2010, J EXP MED, V207, P793, DOI 10.1084/jem.20092545
   AXELROD J, 1988, TRENDS NEUROSCI, V11, P117, DOI 10.1016/0166-2236(88)90157-9
   BHAMARAP.N, 1967, ANN TROP MED PARASIT, V61, P500, DOI 10.1080/00034983.1967.11686519
   Bittencourt MD, 2012, J CLIN IMMUNOL, V32, P161, DOI 10.1007/s10875-011-9592-9
   Borkowski TA, 1996, EUR J IMMUNOL, V26, P110, DOI 10.1002/eji.1830260117
   Bowie AG, 2008, NAT REV IMMUNOL, V8, P911, DOI 10.1038/nri2436
   BRAM RJ, 1994, NATURE, V371, P355, DOI 10.1038/371355a0
   Cardier JE, 2005, CYTOKINE, V30, P359, DOI 10.1016/j.cyto.2005.01.021
   Carrasco CP, 2004, J GEN VIROL, V85, P1633, DOI 10.1099/vir.0.19716-0
   Catteau A, 2003, J GEN VIROL, V84, P2781, DOI 10.1099/vir.0.19163-0
   CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245
   Chang WLW, 2007, J IMMUNOL, V178, P7794, DOI 10.4049/jimmunol.178.12.7794
   Chen M., 2011, J CLIN CELL IMMUNOL, V11, DOI [10.4172/2155-9899.S3-005, DOI 10.4172/2155-9899.S3-005]
   Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401
   Colino J, 2003, J IMMUNOL, V171, P2354, DOI 10.4049/jimmunol.171.5.2354
   Cologna R, 2003, J VIROL, V77, P3929, DOI 10.1128/JVI.77.7.3929-3938.2003
   Courageot MP, 2003, ADV VIRUS RES, V60, P157, DOI 10.1016/S0065-3527(03)60005-9
   Dejnirattisai W, 2008, J IMMUNOL, V181, P5865, DOI 10.4049/jimmunol.181.9.5865
   Despres P, 1996, J VIROL, V70, P4090
   dos Santos CND, 2000, VIROLOGY, V274, P292, DOI 10.1006/viro.2000.0457
   Dubois B, 1998, J IMMUNOL, V161, P2223
   Dubois B, 1997, J EXP MED, V185, P941, DOI 10.1084/jem.185.5.941
   Egger JR, 2007, EMERG INFECT DIS, V13, P924, DOI 10.3201/eid1306.070008
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Fernandez-Mestre MT, 2004, TISSUE ANTIGENS, V64, P469, DOI 10.1111/j.1399-0039.2004.00304.x
   Flamand M, 1999, J VIROL, V73, P6104, DOI 10.1128/JVI.73.7.6104-6110.1999
   FugierVivier I, 1997, J EXP MED, V186, P813, DOI 10.1084/jem.186.6.813
   Galluzzi L, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000018
   Groettrup M, 1996, IMMUNOL TODAY, V17, P429, DOI 10.1016/0167-5699(96)10051-7
   Grouard G, 1997, J EXP MED, V185, P1101, DOI 10.1084/jem.185.6.1101
   Gubler DJ, 1999, ADV VIRUS RES, V53, P35, DOI 10.1016/S0065-3527(08)60342-5
   Guiducci C, 2008, J EXP MED, V205, P315, DOI 10.1084/jem.20070763
   HALSTEAD SB, 1977, J EXP MED, V146, P218, DOI 10.1084/jem.146.1.218
   HALSTEAD SB, 1977, J EXP MED, V146, P201, DOI 10.1084/jem.146.1.201
   Herrera OB, 2004, J IMMUNOL, V173, P4828, DOI 10.4049/jimmunol.173.8.4828
   Ho LJ, 2001, J IMMUNOL, V166, P1499, DOI 10.4049/jimmunol.166.3.1499
   Hopkins RA, 2012, IMMUNOL RES, V53, P91, DOI 10.1007/s12026-012-8300-z
   Hou WQ, 2012, BLOOD, V119, P3128, DOI 10.1182/blood-2011-09-379479
   Huang YH, 2000, AM J TROP MED HYG, V63, P71, DOI 10.4269/ajtmh.2000.63.71
   IMBERT JL, 1994, J MED VIROL, V42, P228, DOI 10.1002/jmv.1890420304
   INABA K, 1990, J EXP MED, V172, P631, DOI 10.1084/jem.172.2.631
   Irla M, 2010, J EXP MED, V207, P1891, DOI 10.1084/jem.20092627
   Ito M, 2006, J IMMUNOL, V176, P5637, DOI 10.4049/jimmunol.176.9.5637
   JAATTELA M, 1995, ONCOGENE, V10, P2297
   Jamin A, 2008, VET RES, V39, DOI 10.1051/vetres:2007045
   Jan JT, 2000, J VIROL, V74, P8680, DOI 10.1128/JVI.74.18.8680-8691.2000
   Jego G, 2003, IMMUNITY, V19, P225, DOI 10.1016/S1074-7613(03)00208-5
   Jin HL, 2007, J CELL BIOCHEM, V102, P980, DOI 10.1002/jcb.21332
   Kaminskyy V, 2010, J INTERN MED, V267, P473, DOI 10.1111/j.1365-2796.2010.02222.x
   Kessel A, 2009, J AUTOIMMUN, V32, P211, DOI 10.1016/j.jaut.2009.02.014
   Kim JO, 2003, FEBS LETT, V541, P163, DOI 10.1016/S0014-5793(03)00326-0
   King Alan D., 1999, Southeast Asian Journal of Tropical Medicine and Public Health, V30, P718
   Kingston D, 2009, BLOOD, V114, P835, DOI 10.1182/blood-2009-02-206318
   Kloetzel PM, 2004, CURR OPIN IMMUNOL, V16, P76, DOI 10.1016/j.coi.2003.11.004
   Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294
   Krishnadas DK, 2010, INT IMMUNOL, V22, P491, DOI 10.1093/intimm/dxq033
   KUO CH, 1992, AM J TROP MED HYG, V47, P265, DOI 10.4269/ajtmh.1992.47.265
   Kushwah R, 2011, IMMUNOLOGY, V133, P409, DOI 10.1111/j.1365-2567.2011.03457.x
   Kushwah R, 2010, J IMMUNOL, V185, P795, DOI 10.4049/jimmunol.1000325
   Kushwah R, 2009, J IMMUNOL, V183, P7104, DOI 10.4049/jimmunol.0900824
   Lechmann M, 2002, TRENDS IMMUNOL, V23, P273, DOI 10.1016/S1471-4906(02)02214-7
   Leitmeyer KC, 1999, J VIROL, V73, P4738, DOI 10.1128/JVI.73.6.4738-4747.1999
   Li JL, 2012, BIOCHEM BIOPH RES CO, V418, P622, DOI 10.1016/j.bbrc.2012.01.050
   Libraty DH, 2001, J VIROL, V75, P3501, DOI 10.1128/JVI.75.8.3501-3508.2001
   Limonta D, 2007, J CLIN VIROL, V40, P50, DOI 10.1016/j.jcv.2007.04.024
   Lindenbach BD, 2001, FIELDS VIROLOGY, VII, P991, DOI DOI 10.1016/J.JMB.2013.11.024
   Liu K, 2009, SCIENCE, V324, P392, DOI 10.1126/science.1170540
   Long HT, 2009, J INFECT DIS, V199, P537, DOI 10.1086/596507
   Lundqvist A, 2002, CANCER IMMUNOL IMMUN, V51, P139, DOI 10.1007/s00262-002-0265-7
   Luplerdlop N, 2006, EMBO REP, V7, P1176, DOI 10.1038/sj.embor.7400814
   MALEWICZ B, 1981, BIOCHEM BIOPH RES CO, V101, P404, DOI 10.1016/0006-291X(81)91274-2
   Marianneau P, 1997, J VIROL, V71, P3244, DOI 10.1128/JVI.71.4.3244-3249.1997
   Marriott HM, 2006, INT J BIOCHEM CELL B, V38, P1848, DOI 10.1016/j.biocel.2006.06.001
   Salgado DM, 2010, PEDIATR INFECT DIS J, V29, P238, DOI 10.1097/INF.0b013e3181bc3c5b
   Ministerio da Saude MS, BAL DENG SEM EP 1 26
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Morchang A, 2011, VIRUS RES, V156, P25, DOI 10.1016/j.virusres.2010.12.012
   Munoz-Jordan JL, 2005, J VIROL, V79, P8004, DOI 10.1128/JVI.79.13.8004-8013.2005
   Nagila A, 2011, BIOCHEM BIOPH RES CO, V410, P428, DOI 10.1016/j.bbrc.2011.05.151
   Navarro-Sanchez E, 2005, ARCH MED RES, V36, P425, DOI 10.1016/j.arcmed.2005.04.007
   Netsawang J, 2010, VIRUS RES, V147, P275, DOI 10.1016/j.virusres.2009.11.012
   Nevalainen TJ, 1997, J INFECTION, V35, P251, DOI 10.1016/S0163-4453(97)92966-2
   Nguyen TL, 1997, RES VIROLOGY, V148, P273, DOI 10.1016/S0923-2516(97)88364-1
   Nightingale ZD, 2008, J LEUKOCYTE BIOL, V84, P1028, DOI 10.1189/jlb.0208105
   Nogueira RMR, 2005, EMERG INFECT DIS, V11, P1376
   OMS, 2009, DENG DENG HAEM FEV
   Palmer DR, 2005, J VIROL, V79, P2432, DOI 10.1128/JVI.79.4.2432-2439.2005
   Pang T, 2007, IMMUNOL CELL BIOL, V85, P43, DOI 10.1038/sj.icb.7100008
   Portt L, 2011, BBA-MOL CELL RES, V1813, P238, DOI 10.1016/j.bbamcr.2010.10.010
   Reed DS, 2004, VIRAL IMMUNOL, V17, P390, DOI 10.1089/vim.2004.17.390
   Nogueira RMR, 2007, REV PANAM SALUD PUBL, V22, P358, DOI 10.1590/S1020-49892007001000009
   Rodriguez-Madoz JR, 2010, J VIROL, V84, P9760, DOI 10.1128/JVI.01051-10
   Sakahira H, 1998, NATURE, V391, P96
   Sakuntabhai A, 2005, NAT GENET, V37, P507, DOI 10.1038/ng1550
   Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N
   Satthaporn S, 2001, J ROY COLL SURG EDIN, V46, P9
   Servet-Delprat C, 2000, J VIROL, V74, P4387, DOI 10.1128/JVI.74.9.4387-4393.2000
   Sierra BDC, 2006, VIRAL IMMUNOL, V19, P662, DOI 10.1089/vim.2006.0042
   Silveira GF, 2011, J VIROL, V85, P5374, DOI 10.1128/JVI.01915-10
   Simmons CP, 2007, J INFECT DIS, V195, P1097, DOI 10.1086/512162
   Soundravally R, 2008, SCAND J IMMUNOL, V67, P618, DOI 10.1111/j.1365-3083.2008.02109.x
   Sozzani S, 1997, J IMMUNOL, V159, P1993
   Srikiatkhachorn A, 2009, THROMB HAEMOSTASIS, V102, P1042, DOI 10.1160/TH09-03-0208
   STEINMAN RM, 1973, J EXP MED, V137, P1142, DOI 10.1084/jem.137.5.1142
   Swiecki M, 2011, J EXP MED, V208, P2367, DOI 10.1084/jem.20110654
   Taweechaisupapong S, 1996, J MED MICROBIOL, V45, P138, DOI 10.1099/00222615-45-2-138
   Thepparit C, 2004, J VIROL, V78, P12647, DOI 10.1128/JVI.78.22.12647-12656.2004
   Watarai H, 2005, PROTEOMICS, V5, P4001, DOI 10.1002/pmic.200401258
   Weck MM, 2007, BLOOD, V109, P3890, DOI 10.1182/blood-2006-04-015719
   WINKLER G, 1989, VIROLOGY, V171, P302, DOI 10.1016/0042-6822(89)90544-8
   Woodberry T, 2012, J INFECT DIS, V206, P333, DOI 10.1093/infdis/jis366
   World Health Organization, 2009, DENG GUID DIAGN TREA
   Wu SJL, 2000, NAT MED, V6, P816, DOI 10.1038/77553
   Wykes M, 1998, J IMMUNOL, V161, P1313
   Xiao CC, 2005, ADV EXP MED BIOL, V560, P41
NR 120
TC 20
Z9 21
U1 0
U2 19
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD NOV
PY 2012
VL 4
IS 11
BP 2736
EP 2753
DI 10.3390/v4112736
PG 18
WC Virology
SC Virology
GA 041VS
UT WOS:000311429900015
PM 23202502
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Prestes, EB
   Bayer-Santos, E
   Stoco, PH
   Sincero, TCM
   Wagner, G
   Umaki, A
   Fragoso, SP
   Bordignon, J
   Steindel, M
   Grisard, EC
AF Prestes, Elisa Beatriz
   Bayer-Santos, Ethel
   Stoco, Patricia Hermes
   Marques Sincero, Thais Cristine
   Wagner, Glauber
   Umaki, Adriana
   Fragoso, Stenio Perdigao
   Bordignon, Juliano
   Steindel, Mario
   Grisard, Edmundo Carlos
TI Trypanosoma rangeli protein tyrosine phosphatase is associated with the
   parasite's flagellum
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE Trypanosoma rangeli; protein tyrosine phosphatase; flagellum
ID DIFFERENTIAL EXPRESSION; IN-VITRO; BRUCEI; METACYCLOGENESIS;
   IDENTIFICATION; ATTACHMENT; DOMAINS; TEJERA; FORMS
AB Protein tyrosine phosphatases (PTPs) play an essential role in the regulation of cell differentiation in pathogenic trypanosomatids. In this study, we describe a PTP expressed by the non-pathogenic protozoan Trypanosoma rangeli (TrPTP2). The gene for this PTP is orthologous to the T. brucei TbPTP1 and Trypanosoma cruzi (TcPTP2) genes. Cloning and expression of the TrPTP2 and TcPTP2 proteins allowed anti-PTP2 monoclonal antibodies to be generated in BALB/c mice. When expressed by T. rangeli epimastigotes and trypomastigotes, native TrPTP2 is detected as a similar to 65 kDa protein associated with the parasite's flagellum. Given that the flagellum is an important structure for cell differentiation in trypanosomatids, the presence of a protein responsible for tyrosine dephosphorylation in the T. rangeli flagellum could represent an interesting mechanism of regulation in this structure.
C1 [Prestes, Elisa Beatriz; Bayer-Santos, Ethel; Stoco, Patricia Hermes; Marques Sincero, Thais Cristine; Wagner, Glauber; Steindel, Mario; Grisard, Edmundo Carlos] Univ Fed Santa Catarina, Ctr Ciencias Biol, Dept Microbiol Imunol & Parasitol, Lab Protozool & Bioinformat, Florianopolis, SC, Brazil.
   [Umaki, Adriana; Fragoso, Stenio Perdigao; Bordignon, Juliano] Inst Carlos Chagas Fiocruz, Curitiba, Parana, Brazil.
RP Grisard, EC (corresponding author), Univ Fed Santa Catarina, Ctr Ciencias Biol, Dept Microbiol Imunol & Parasitol, Lab Protozool & Bioinformat, Florianopolis, SC, Brazil.
EM edmundo.grisard@ufsc.br
RI Bordignon, Juliano/Z-6268-2019; Grisard, Edmundo C/A-7338-2015;
   Bayer-Santos, Ethel/O-5505-2014; Steindel, Mario/H-2945-2015; Steindel,
   Mario/N-2040-2018; Fragoso, Stenio/AAB-4703-2019; Bayer-Santos,
   Ethel/Z-1923-2019; Sincero, Thais/B-7310-2013; P, CM/B-1358-2013;
   Grisard, Edmundo C/AAS-9429-2020; Wagner, Glauber/B-2369-2013
OI Bordignon, Juliano/0000-0002-1965-6152; Grisard, Edmundo
   C/0000-0001-8916-8296; Bayer-Santos, Ethel/0000-0003-3832-3449;
   Steindel, Mario/0000-0002-2768-7469; Steindel,
   Mario/0000-0002-2768-7469; Fragoso, Stenio/0000-0002-0909-7940;
   Bayer-Santos, Ethel/0000-0003-3832-3449; Sincero,
   Thais/0000-0001-8177-4195; Grisard, Edmundo C/0000-0001-8916-8296;
   Wagner, Glauber/0000-0001-5003-6595
FU CAPESCAPES; CNPqNational Council for Scientific and Technological
   Development (CNPq); FINEPCiencia Tecnologia e Inovacao (FINEP)
FX Financial support: CAPES, CNPq, FINEP
CR Aguirre-Garcia MM, 2006, PARASITOLOGY, V132, P641, DOI 10.1017/S0031182005009595
   Andreeva AV, 2008, INT J PARASITOL, V38, P1279, DOI 10.1016/j.ijpara.2008.04.003
   Brenchley R, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-434
   Chiou SH, 1999, ANAL CHIM ACTA, V383, P47, DOI 10.1016/S0003-2670(98)00487-5
   Cosentino-Gomes D, 2009, FREE RADICAL BIO MED, V47, P152, DOI 10.1016/j.freeradbiomed.2009.04.020
   D'Orso I, 2001, J BIOL CHEM, V276, P34801, DOI 10.1074/jbc.M102120200
   Dick CF, 2010, EXP PARASITOL, V124, P386, DOI 10.1016/j.exppara.2009.12.006
   Eger-Mangrich I, 2001, PARASITOL RES, V87, P505, DOI 10.1007/s004360000356
   Ersfeld K, 2001, J CELL SCI, V114, P141
   Ferreira LRP, 2008, AN ACAD BRAS CIENC, V80, P157, DOI 10.1590/S0001-37652008000100011
   Fonseca-De-Souza AL, 2009, EXP PARASITOL, V122, P242, DOI 10.1016/j.exppara.2009.03.006
   Gallo G, 2011, BIOCHEM BIOPH RES CO, V408, P427, DOI 10.1016/j.bbrc.2011.04.038
   Gomes SAO, 2006, EXP PARASITOL, V112, P253, DOI 10.1016/j.exppara.2005.11.015
   Grisard EC, 2010, MOL BIOCHEM PARASIT, V174, P18, DOI 10.1016/j.molbiopara.2010.06.008
   Koerich LB, 2002, PARASITOL RES, V88, P21, DOI 10.1007/s004360100501
   Mazzarotto GCA, 2009, J VIROL METHODS, V162, P96, DOI 10.1016/j.jviromet.2009.07.022
   Meirelles RMS, 2005, PARASITOL RES, V97, P259, DOI 10.1007/s00436-005-1433-4
   Nakajima A, 2005, J EXP BIOL, V208, P4411, DOI 10.1242/jeb.01906
   Nett IRE, 2009, EUKARYOT CELL, V8, P617, DOI 10.1128/EC.00366-08
   Sakurai T, 2008, MOL BIOCHEM PARASIT, V161, P1, DOI 10.1016/j.molbiopara.2008.05.003
   Sambrook J., 2001, MOL CLONING LAB MANU
   SCHENKMAN S, 1991, EXP PARASITOL, V72, P76, DOI 10.1016/0014-4894(91)90123-E
   Stoco PH, 2012, EXP PARASITOL, V130, P246, DOI 10.1016/j.exppara.2011.12.005
   Szoor B, 2010, GENE DEV, V24, P1306, DOI 10.1101/gad.570310
   Szoor B, 2006, J CELL BIOL, V175, P293, DOI 10.1083/jcb.200605090
   Vallejo GA, 2002, ACTA TROP, V81, P77, DOI 10.1016/S0001-706X(01)00186-3
   Williamson YM, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/942365
   WOODS A, 1989, J CELL SCI, V93, P501
NR 28
TC 4
Z9 5
U1 0
U2 2
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD SEP
PY 2012
VL 107
IS 6
BP 713
EP U159
DI 10.1590/S0074-02762012000600002
PG 8
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 008FX
UT WOS:000308943900002
PM 22990958
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Silveira, GF
   Meyer, F
   Delfraro, A
   Mosimann, ALP
   Coluchi, N
   Vasquez, C
   Probst, CM
   Bafica, A
   Bordignon, J
   dos Santos, CND
AF Silveira, Guilherme F.
   Meyer, Florencia
   Delfraro, Adriana
   Mosimann, Ana Luiza P.
   Coluchi, Norma
   Vasquez, Cyntia
   Probst, Christian M.
   Bafica, Andre
   Bordignon, Juliano
   Duarte dos Santos, Claudia N.
TI Dengue Virus Type 3 Isolated from a Fatal Case with Visceral
   Complications Induces Enhanced Proinflammatory Responses and Apoptosis
   of Human Dendritic Cells
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID NF-KAPPA-B; ENVELOPE GLYCOPROTEIN; HEMORRHAGIC-FEVER; ENDOTHELIAL-CELLS;
   GENE-EXPRESSION; HUMAN MONOCYTES; TNF-ALPHA; T-CELLS; INFECTION;
   PATHOGENESIS
AB A recent (2007 to 2009) dengue outbreak caused by dengue virus (DENV) in Paraguay presented unusual severe clinical outcomes associated with 50% mortality rates. Although it has been reported that inflammatory responses influence the severity of dengue virus infection (T. Pang, M. J. Cardosa, and M. G. Guzman, Immunol. Cell Biol. 85:43-45, 2007), there remains a paucity of information on virus-innate immunity interactions influencing clinical outcome. Using human dendritic cells from a major innate immune cell population as an in vitro model, we have investigated signature cytokine responses as well as infectivity-replicative profiles of DENV clinical isolates from either a nonfatal case of classical dengue fever (strain DENV3/290; isolated in Brazil in 2002) or a fatal case of dengue fever with visceral complications isolated in Paraguay in 2007 (strain DENV3/5532). Strain DENV3/5532 was found to display significantly higher replicative ability than DENV3/290 in monocyte-derived dendritic cells (mdDCs). In addition, compared to DENV3/290 results, mdDCs exposed to DENV3/5532 showed increased production of proinflammatory cytokines associated with higher rates of programmed cell death, as shown by annexin V staining. The observed phenotype was due to viral replication, and tumor necrosis factor alpha (TNF-alpha) appears to exert a protective effect on virus-induced mdDC apoptosis. These results suggest that the DENV3/5532 strain isolated from the fatal case replicates within human dendritic cells, modulating cell survival and synthesis of inflammatory mediators.
C1 [Bordignon, Juliano] Fiocruz MS, Inst Carlos Chagas, CIC, Mol Virol Lab, BR-81350010 Curitiba, PR, Brazil.
   [Probst, Christian M.] Fiocruz MS, Inst Carlos Chagas, Lab Genom Func, BR-81350010 Curitiba, PR, Brazil.
   [Delfraro, Adriana] Univ Republica, Fac Ciencias, Secc Virol, Montevideo, Uruguay.
   [Coluchi, Norma; Vasquez, Cyntia] Cent Hosp, Inst Previs Social, Serv Pediat, Lab Cent Salud Publ, Asuncion, Paraguay.
   [Bafica, Andre] Univ Fed Santa Catarina, Lab Imunofarmacol & Doencas Infecciosas, Florianopolis, SC, Brazil.
RP Bordignon, J (corresponding author), Fiocruz MS, Inst Carlos Chagas, CIC, Mol Virol Lab, Rua Prof Algacyr Munhoz Mader 3775, BR-81350010 Curitiba, PR, Brazil.
EM jbordig@tecpar.br; clsantos@tecpar.br
RI Santos, Claudia Duarte dos/P-4868-2019; Duarte dos Santos,
   Claudia/E-1857-2018; Meyer, Florencia/V-3406-2019; Silveira,
   Guilherme/Z-6230-2019; P, CM/B-1358-2013; Bordignon,
   Juliano/Z-6268-2019; Probst, Christian/B-8678-2009; Bafica,
   Andre/ABF-5986-2020; Publica, Inct Saude/J-9544-2013
OI Santos, Claudia Duarte dos/0000-0001-8707-6638; Duarte dos Santos,
   Claudia/0000-0001-8707-6638; Silveira, Guilherme/0000-0002-1866-0563;
   Bordignon, Juliano/0000-0002-1965-6152; Probst,
   Christian/0000-0001-9993-6375; Bafica, Andre/0000-0002-5148-600X;
   Delfraro, Adriana/0000-0003-3701-9621; Pamplona Mosimann, Ana
   Luiza/0000-0002-3504-5562
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); Fundacao AraucariaFundacao Araucaria; FIOCRUZ; PROSUL; Red
   Iberoamericana en Virosis Emergentes (RIVE-CYTED)
FX Financial support was received from CNPq, Fundacao Araucaria, FIOCRUZ,
   PROSUL, and Red Iberoamericana en Virosis Emergentes (RIVE-CYTED).
   C.N.D.D.S., A.D., A.L.P.M., A.B., and F.M. are CNPq fellows.
CR Ashour J, 2009, J VIROL, V83, P5408, DOI 10.1128/JVI.02188-08
   Balas C, 2011, J INFECT DIS, V203, P103, DOI 10.1093/infdis/jiq022
   Becerra A, 2009, J MED VIROL, V81, P1403, DOI 10.1002/jmv.21538
   Cardier JE, 2005, CYTOKINE, V30, P359, DOI 10.1016/j.cyto.2005.01.021
   CLARK GG, 1986, J AM MOSQUITO CONTR, V2, P529
   Clyde K, 2006, J VIROL, V80, P11418, DOI 10.1128/JVI.01257-06
   Cologna R, 2003, J VIROL, V77, P3929, DOI 10.1128/JVI.77.7.3929-3938.2003
   Courageot MP, 2003, ADV VIRUS RES, V60, P157, DOI 10.1016/S0065-3527(03)60005-9
   Dejnirattisai W, 2008, J IMMUNOL, V181, P5865, DOI 10.4049/jimmunol.181.9.5865
   Despres P, 1998, J VIROL, V72, P823
   Espina LM, 2003, AM J TROP MED HYG, V68, P48, DOI 10.4269/ajtmh.2003.68.48
   Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186
   Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175
   Fink J, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000086
   Fonseca SG, 2007, SCAND J IMMUNOL, V66, P362, DOI 10.1111/j.1365-3083.2007.01987.x
   Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195
   Gordon D, 2001, GENOME RES, V11, P614, DOI 10.1101/gr.171401
   Gould E.A., 1985, VIROLOGY PRACTICAL A
   Hack CE, 1997, ADV IMMUNOL, V66, P101, DOI 10.1016/S0065-2776(08)60597-0
   HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268
   HALSTEAD SB, 1977, J EXP MED, V146, P201, DOI 10.1084/jem.146.1.201
   Ho LJ, 2001, J IMMUNOL, V166, P1499, DOI 10.4049/jimmunol.166.3.1499
   Libraty DH, 2002, J INFECT DIS, V186, P1165, DOI 10.1086/343813
   LINDENBACH BD, 2001, XXXXX, P1101
   Lundqvist A, 2002, CANCER IMMUNOL IMMUN, V51, P139, DOI 10.1007/s00262-002-0265-7
   Marianneau P, 1997, J VIROL, V71, P3244, DOI 10.1128/JVI.71.4.3244-3249.1997
   Modis Y, 2003, P NATL ACAD SCI USA, V100, P6986, DOI 10.1073/pnas.0832193100
   Modis Y, 2005, J VIROL, V79, P1223, DOI 10.1128/JVI.79.2.1223-1231.2005
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Munoz-Jordan JL, 2003, P NATL ACAD SCI USA, V100, P14333, DOI 10.1073/pnas.2335168100
   Navarro-Sanchez E, 2005, ARCH MED RES, V36, P425, DOI 10.1016/j.arcmed.2005.04.007
   Nogueira MB, 2008, MEM I OSWALDO CRUZ, V103, P483, DOI 10.1590/S0074-02762008000500013
   Palmer DR, 2005, J VIROL, V79, P2432, DOI 10.1128/JVI.79.4.2432-2439.2005
   *PAN AM HLTH ORG, 2007, EM REEM INF DIS REG
   *PAN AM HLTH ORG, 1995, WKLY EP REC, V70, P41
   Pang T, 2007, IMMUNOL CELL BIOL, V85, P43, DOI 10.1038/sj.icb.7100008
   Park SM, 2003, J IMMUNOL, V171, P3955, DOI 10.4049/jimmunol.171.8.3955
   Pryor MJ, 2001, AM J TROP MED HYG, V65, P427, DOI 10.4269/ajtmh.2001.65.427
   Rachman Andhika, 2006, Acta Med Indones, V38, P105
   REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0
   Rodriguez-Madoz JR, 2010, J VIROL, V84, P9760, DOI 10.1128/JVI.01051-10
   Rothman AL, 1999, VIROLOGY, V257, P1, DOI 10.1006/viro.1999.9656
   Rothman Alan L., 1997, P245
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   Warke RV, 2003, J VIROL, V77, P11822, DOI 10.1128/JVI.77.21.11822-11832.2003
   *WHO, 2010, NAT MED, V6, P816
   World Health Organization, 1997, DENG HAEM FEV DIAGN
   ZUKER M, 1999, RNA BIOCH BIOTECHNOL
NR 48
TC 26
Z9 29
U1 0
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD JUN
PY 2011
VL 85
IS 11
BP 5374
EP 5383
DI 10.1128/JVI.01915-10
PG 10
WC Virology
SC Virology
GA 760CE
UT WOS:000290298700014
PM 21450836
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Mosimann, ALP
   Bordignon, J
   Mazzarotto, GCA
   Motta, MCM
   Hoffmann, F
   dos Santos, CND
AF Pamplona Mosimann, Ana Luiza
   Bordignon, Juliano
   Antevere Mazzarotto, Giovanny Camacho
   Motta, Maria Cristina M.
   Hoffmann, Federico
   Duarte dos Santos, Claudia Nunes
TI Genetic and biological characterization of a densovirus isolate that
   affects dengue virus infection
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE densovirus; Brevidensovirus; biological control; dengue virus
ID AEDES-ALBOPICTUS; CELL-LINE; MOSQUITO CELLS; AEGYPTI; SEQUENCE;
   PATHOGENICITY; COINFECTIONS; PERSISTENT; CULICIDAE; CULTURES
AB Brevidensoviruses have an encapsidated, single-stranded DNA genome that predominantly has a negative polarity. In recent years, they have received particular attention due to their potential role in the biological control of pathogenic arboviruses and to their unnoticed presence in cell cultures as contaminants. In addition, brevidensoviruses may also be useful as viral vectors. This study describes the first genetic and biological characterization of a mosquito densovirus that was isolated in Brazil; moreover, we examined the phylogenetic relationship between this isolate and the other brevidensoviruses. We further demonstrate that this densovirus has the potential to be used to biologically control dengue virus (DENV) infection with in vitro co-infection experiments. The present study provides evidence that this densovirus isolate is a fast-spreading virus that affects cell growth and DENV infection.
C1 [Pamplona Mosimann, Ana Luiza; Bordignon, Juliano; Antevere Mazzarotto, Giovanny Camacho; Duarte dos Santos, Claudia Nunes] Inst Carlos Chagas Filho, Curitiba, Parana, Brazil.
   [Motta, Maria Cristina M.] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Rio De Janeiro, Brazil.
   [Hoffmann, Federico] Mississippi State Univ, Dept Biochenisty & Mol Biol, Starkville, MS USA.
RP dos Santos, CND (corresponding author), Inst Carlos Chagas Filho, Rua Prof Algacyr Munhoz Mader 3775, Curitiba, Parana, Brazil.
EM clsantos@tecpar.br
RI Mosimann, Ana Luiza Pamplona/AAB-4714-2019; Santos, Claudia Duarte
   dos/P-4868-2019; Duarte dos Santos, Claudia/E-1857-2018; Bordignon,
   Juliano/Z-6268-2019; P, CM/B-1358-2013
OI Mosimann, Ana Luiza Pamplona/0000-0002-3504-5562; Santos, Claudia Duarte
   dos/0000-0001-8707-6638; Duarte dos Santos, Claudia/0000-0001-8707-6638;
   Bordignon, Juliano/0000-0002-1965-6152; Motta, Maria
   Cristina/0000-0002-0947-4830
FU FIOCRUZ; CNPqNational Council for Scientific and Technological
   Development (CNPq); CNPq/PROSULNational Council for Scientific and
   Technological Development (CNPq); Fundacao AraucariaFundacao Araucaria
FX Financial support: FIOCRUZ, CNPq, CNPq/PROSUL, Fundacao Araucaria ALPM
   is supported by a CNPq fellowship. CNDS is a CNPq fellowship recipient.
CR AFANASIEV BN, 1991, VIROLOGY, V185, P323, DOI 10.1016/0042-6822(91)90780-F
   AFANASIEV BN, 1994, EXP PARASITOL, V79, P322, DOI 10.1006/expr.1994.1095
   Bergoin M, 2000, CONTRIB MICROBIOL, V4, P12
   Bordignon J, 2002, J VIROL METHODS, V105, P181, DOI 10.1016/S0166-0934(02)00064-2
   Burivong P, 2004, VIROLOGY, V329, P261, DOI 10.1016/j.virol.2004.08.032
   Carlson J, 2006, ADV VIRUS RES, V68, P361, DOI 10.1016/S0065-3527(06)68010-X
   Chen SX, 2004, VIROLOGY, V318, P123, DOI 10.1016/j.virol.2003.09.013
   DeBeeck AO, 1997, J VIROL, V71, P5323, DOI 10.1128/JVI.71.7.5323-5329.1997
   DESPRES P, 1993, VIROLOGY, V196, P209, DOI 10.1006/viro.1993.1469
   Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186
   Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175
   FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x
   FRIED J, 1978, J HISTOCHEM CYTOCHEM, V26, P921, DOI 10.1177/26.11.82573
   Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195
   Gordon D, 2001, GENOME RES, V11, P614, DOI 10.1101/gr.171401
   GORZIGLIA M, 1980, INTERVIROLOGY, V13, P232, DOI 10.1159/000149130
   IGARASHI A, 1978, J GEN VIROL, V40, P531, DOI 10.1099/0022-1317-40-3-531
   Jones CT, 2005, VIROLOGY, V331, P247, DOI 10.1016/j.virol.2004.10.034
   Jousset FX, 2000, VIRUS RES, V67, P11, DOI 10.1016/S0168-1702(00)00128-3
   JOUSSET FX, 1993, VIRUS RES, V29, P99, DOI 10.1016/0168-1702(93)90052-O
   Kanthong N, 2008, DEV COMP IMMUNOL, V32, P1063, DOI 10.1016/j.dci.2008.02.008
   Kanthong N, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-14
   Ke GM, 2006, J VIROL METHODS, V133, P6, DOI 10.1016/j.jviromet.2005.09.011
   Kittayapong P, 1999, AM J TROP MED HYG, V61, P612, DOI 10.4269/ajtmh.1999.61.612
   Ledermann JP, 2004, J ECON ENTOMOL, V97, P1828, DOI 10.1603/0022-0493-97.6.1828
   Mazzarotto GCA, 2009, J VIROL METHODS, V162, P96, DOI 10.1016/j.jviromet.2009.07.022
   Nogueira MB, 2008, MEM I OSWALDO CRUZ, V103, P483, DOI 10.1590/S0074-02762008000500013
   Oleksiewicz MB, 1997, J VIROL, V71, P1386, DOI 10.1128/JVI.71.2.1386-1396.1997
   ONEILL SL, 1995, J GEN VIROL, V76, P2067, DOI 10.1099/0022-1317-76-8-2067
   Mosimann ALP, 2010, J VIROL METHODS, V163, P147, DOI 10.1016/j.jviromet.2009.09.004
   Paterson A, 2005, VIROLOGY, V337, P253, DOI 10.1016/j.virol.2005.04.037
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454
   Suchman EL, 2006, BIOL CONTROL, V39, P465, DOI 10.1016/j.biocontrol.2006.05.001
   Tamura K, 2002, MOL BIOL EVOL, V19, P1727, DOI 10.1093/oxfordjournals.molbev.a003995
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Wang D, 2003, PLOS BIOL, V1, P257, DOI 10.1371/journal.pbio.0000002
   Wei W, 2006, AM J TROP MED HYG, V75, P1118, DOI 10.4269/ajtmh.2006.75.1118
   Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595
NR 39
TC 13
Z9 14
U1 0
U2 3
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD MAY
PY 2011
VL 106
IS 3
BP 285
EP 292
DI 10.1590/S0074-02762011000300006
PG 8
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 773PM
UT WOS:000291319200006
PM 21655815
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Picchi, GFA
   Ferreira, AMT
   Souza, FSP
   Lourenco, EE
   Arauco, PRC
   Lorusso, A
   Bordignon, J
   Krieger, MA
   Goldenberg, S
   Fragoso, SP
AF Picchi, Gisele F. A.
   Ferreira, Alda M. T.
   Souza, Flavia S. P.
   Lourenco, Edio E.
   Arauco, Paulo R. C.
   Lorusso, Andre
   Bordignon, Juliano
   Krieger, Marco A.
   Goldenberg, Samuel
   Fragoso, Stenio P.
TI Trypanosoma cruzi: Identification of DNA targets of the nuclear
   periphery coiled-coil protein TcNUP-1
SO EXPERIMENTAL PARASITOLOGY
LA English
DT Article
DE Nuclear organization; Nuclear lamina protein; Trypanosoma cruzi; NUP-1;
   ChIP assay
ID COMPARATIVE GENOMICS; ENVELOPE; LAMINA; ORGANIZATION; TOPOISOMERASE;
   BRUCEI; FAMILY; PLANTS; CELLS
AB The nuclear lamina is a structure that lines the inner nuclear membrane. In metazoans, lamins are the primary structural components of the nuclear lamina and are involved in several processes. Eukaryotes that lack lamins have distinct proteins with homologous functions. Some years ago, a coiled-coil protein in Trypanosoma brucei, NUP-1, was identified as the major filamentous component of its nuclear lamina. However, its precise role has not been determined. We characterized a homologous protein in Trypanosoma cruzi, TcNUP-1, and identified its in vivo DNA binding sites using a chromatin immunoprecipitation assay. We demonstrate for the first time that TcNUP-1 associates with chromosomal regions containing large non-tandem arrays of genes encoding surface proteins. We therefore suggest that TcNUP-1 is a structural protein that plays an essential role in nuclear organization by anchoring T. cruzi chromosomes to the nuclear envelope. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Picchi, Gisele F. A.; Ferreira, Alda M. T.; Souza, Flavia S. P.; Lourenco, Edio E.; Arauco, Paulo R. C.; Lorusso, Andre; Bordignon, Juliano; Krieger, Marco A.; Goldenberg, Samuel; Fragoso, Stenio P.] Inst Carlos Chagas, Fdn Oswaldo Cruz, BR-81350010 Curitiba, Parana, Brazil.
   [Ferreira, Alda M. T.] Univ Fed Mato Grosso do Sul, Dept Patol, Cuiaba, MS, Brazil.
   [Lourenco, Edio E.] Univ Fed Parana, Dept Biol Celular & Mol, BR-80060000 Curitiba, Parana, Brazil.
RP Picchi, GFA (corresponding author), Inst Carlos Chagas, Fdn Oswaldo Cruz, R Prof Algacyr Munhoz Mader 3775,Cidade Ind Paran, BR-81350010 Curitiba, Parana, Brazil.
EM gpicchi@tecpar.br
RI Krieger, Marco/AAE-8611-2020; P, CM/B-1358-2013; Fragoso,
   Stenio/AAB-4703-2019; Bordignon, Juliano/Z-6268-2019; GOLDENBERG,
   SAMUEL/B-4116-2009; Publica, Inct Saude/J-9544-2013
OI Fragoso, Stenio/0000-0002-0909-7940; Bordignon,
   Juliano/0000-0002-1965-6152; GOLDENBERG, SAMUEL/0000-0002-4892-163X;
   Picchi, Gisele/0000-0002-2516-3178
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FIOCRUZ; PRONEX (Fundacao Araucaria)Fundacao Araucaria;
   CAPESCAPES
FX We thank Alejandro Correa, Anne-Lise Haenni, Bruno Dallagiovanna,
   Daniela Pavoni, Daniele Hernandez-Verdun, Marco Randi, Maurilio Soares,
   Nilson Fidencio and Thierry Grange for their help on different aspects
   of the paper. This work received financial support from CNPq, FIOCRUZ,
   and PRONEX (Fundacao Araucaria). GFAP was supported by a CAPES
   fellowship. SG is a research fellow of the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico.
CR AARONSON RP, 1975, P NATL ACAD SCI USA, V72, P1007, DOI 10.1073/pnas.72.3.1007
   Bartholomeu DC, 2009, NUCLEIC ACIDS RES, V37, P3407, DOI 10.1093/nar/gkp172
   Blumenthal SSD, 2004, PLANTA, V218, P965, DOI 10.1007/s00425-003-1182-5
   BONALDO MC, 1988, J CELL BIOL, V106, P1349, DOI 10.1083/jcb.106.4.1349
   Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5
   CamargO E. P., 1964, Revista do Instituto de Medicina Tropical de Sao Paulo, V6, P93
   D'Angelo MA, 2006, CELL MOL LIFE SCI, V63, P316, DOI 10.1007/s00018-005-5361-3
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   El-Sayed NM, 2005, SCIENCE, V309, P404, DOI 10.1126/science.1112181
   ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541
   FAWCETT DW, 1966, AM J ANAT, V119, P129, DOI 10.1002/aja.1001190108
   FRAGOSO SP, 1992, MOL BIOCHEM PARASIT, V55, P127, DOI 10.1016/0166-6851(92)90133-5
   Gindullis F, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-9
   Gindullis F, 1999, PLANT CELL, V11, P1117, DOI 10.1105/tpc.11.6.1117
   Harder PA, 2000, PLANT PHYSIOL, V122, P225, DOI 10.1104/pp.122.1.225
   Horton P, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P147
   KARLINSEY J, 1989, ANAL BIOCHEM, V180, P303, DOI 10.1016/0003-2697(89)90435-1
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lourenco EE, 2006, FEMS MICROBIOL LETT, V257, P163, DOI 10.1111/j.1574-6968.2006.00164.x
   Mans BJ, 2004, CELL CYCLE, V3, P1612
   Masuda K, 1997, EXP CELL RES, V232, P173, DOI 10.1006/excr.1997.3531
   Mazzarotto GCA, 2009, J VIROL METHODS, V162, P96, DOI 10.1016/j.jviromet.2009.07.022
   PARRY DAD, 1982, BIOSCIENCE REP, V2, P1017, DOI 10.1007/BF01122170
   RAGHAVA GPS, 2001, BIOTECH SOFTWARE INT, V2, P198
   Rout MP, 2001, J BIOL CHEM, V276, P38261
   Sambrook J., 1989, MOL CLONING LAB
   Scherf A, 2008, ANNU REV MICROBIOL, V62, P445, DOI 10.1146/annurev.micro.61.080706.093134
   Spector DL, 2003, ANNU REV BIOCHEM, V72, P573, DOI 10.1146/annurev.biochem.72.121801.161724
   Taddei A, 2004, ANNU REV GENET, V38, P305, DOI 10.1146/annurev.genet.37.110801.142705
   TAKLE GB, 1991, MOL BIOCHEM PARASIT, V48, P185, DOI 10.1016/0166-6851(91)90114-L
   WATSON ML, 1955, J BIOPHYS BIOCHEM CY, V1, P257, DOI 10.1083/jcb.1.3.257
   Weatherly DB, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-255
   Worman HJ, 2005, INT REV CYTOL, V246, P231, DOI 10.1016/S0074-7696(05)46006-4
   Yang XF, 2009, CELL, V137, P99, DOI 10.1016/j.cell.2009.01.037
NR 34
TC 5
Z9 5
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4894
EI 1090-2449
J9 EXP PARASITOL
JI Exp. Parasitol.
PD JAN
PY 2011
VL 127
IS 1
BP 147
EP 152
DI 10.1016/j.exppara.2010.07.009
PG 6
WC Parasitology
SC Parasitology
GA 710BV
UT WOS:000286486800024
PM 20647012
DA 2020-12-01
ER

PT J
AU Nogueira, L
   Cardoso, FC
   Mattos, AM
   Bordignon, J
   Figueiredo, CP
   Dahlstrom, P
   Frota, CC
   dos Santos, CND
   Chalhoub, M
   Cavada, BS
   Teixeira, HC
   Oliveira, SC
   Barral-Netto, M
   Bafica, A
AF Nogueira, Lucas
   Cardoso, Fernanda C.
   Mattos, Ana M.
   Bordignon, Juliano
   Figueiredo, Claudia P.
   Dahlstrom, Pedro
   Frota, Cristiane C.
   Duarte dos Santos, Claudia N.
   Chalhoub, Marcelo
   Cavada, Benildo S.
   Teixeira, Henrique C.
   Oliveira, Sergio C.
   Barral-Netto, Manoel
   Bafica, Andre
TI Mycobacterium tuberculosis Rv1419 encodes a secreted 13 kDa lectin with
   immunological reactivity during human tuberculosis
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE Biomarkers; Lectin; Mycobacterium tuberculosis
ID HEPARIN-BINDING HEMAGGLUTININ; CULTURE FILTRATE ANTIGENS; T-CELL;
   IMMUNE-RESPONSE; PROTEINS; INFECTION; VIRULENCE; ADHESIN; MICE;
   PATHOGENESIS
AB In this study, we have identified a secreted 13 kDa lectin from Mtb (Mtb, Mycobacterium tuberculosis; sMTL-13) by homology search of a non-redundant lectin database. Bioinformatic analysis revealed that sMTL-13 belongs to the ricin-type beta-trefoil family of proteins containing a Sec-type signal peptide present in Mtb complex species, but not in non-tuberculous mycobacteria. Following heterologous expression of sMTL-13 and generation of an mAb (clone 276.B7/IgG1 kappa), we confirmed that this lectin is present in culture filtrate proteins from Mtb H37Rv, but not in non-tuberculous mycobacteria-derived culture filtrate proteins. In addition, sMTL-13 leads to an increased IFN-gamma production by PBMC from active tuberculosis (ATB) patients. Furthermore, sera from ATB patients displayed high titers of IgG Ab against sMTL-13, a response found to be decreased following successful anti-tuberculosis therapy. Together, our findings reveal a secreted 13 kDa ricin-like lectin from Mtb, which is immunologically recognized during ATB and could serve as a biomarker of disease treatment.
C1 [Nogueira, Lucas; Dahlstrom, Pedro; Bafica, Andre] Univ Fed Santa Catarina, Dept Microbiol & Parasitol, Lab Imunol & Doencas Infecciosas, BR-88040900 Florianopolis, SC, Brazil.
   [Cardoso, Fernanda C.; Oliveira, Sergio C.] Univ Fed Minas Gerais, Dept Bioquim & Imunol, Belo Horizonte, MG, Brazil.
   [Mattos, Ana M.; Teixeira, Henrique C.] Univ Fed Juiz de Fora, Lab Imunol, Juiz De Fora, MG, Brazil.
   [Frota, Cristiane C.; Cavada, Benildo S.] Univ Fed Ceara, BioMol Lab, Fortaleza, Ceara, Brazil.
   [Chalhoub, Marcelo] Hosp Octavio Mangabeira, Salvador, BA, Brazil.
RP Bafica, A (corresponding author), Univ Fed Santa Catarina, Dept Microbiol & Parasitol, Lab Imunol & Doencas Infecciosas, R Joao Pio Duarte Silva S-N,Bloco A,Sala 309,Camp, BR-88040900 Florianopolis, SC, Brazil.
EM abafica@ccb.ufsc.br
RI Duarte dos Santos, Claudia/E-1857-2018; P, CM/B-1358-2013; Cardoso,
   Fernanda C/J-7147-2013; Publica, Inct Saude/J-9544-2013; Bordignon,
   Juliano/Z-6268-2019; Bafica, Andre/ABF-5986-2020; Teixeira, Henrique
   C/R-2133-2019; de+Lima+Nogueira, Lucas/AAD-3447-2020; Barral-Netto,
   Manoel/B-3904-2009; , Cristiane/M-7424-2018; Santos, Claudia Duarte
   dos/P-4868-2019; Figueiredo, Claudia P/F-8424-2012
OI Duarte dos Santos, Claudia/0000-0001-8707-6638; Cardoso, Fernanda
   C/0000-0002-0068-9974; Bordignon, Juliano/0000-0002-1965-6152; Bafica,
   Andre/0000-0002-5148-600X; Teixeira, Henrique C/0000-0002-0172-9720;
   de+Lima+Nogueira, Lucas/0000-0003-3907-777X; Barral-Netto,
   Manoel/0000-0002-5823-7903; , Cristiane/0000-0003-0018-7736; Santos,
   Claudia Duarte dos/0000-0001-8707-6638; Figueiredo,
   Claudia/0000-0001-9467-9891; Cavada, Benildo/0000-0002-5791-6170
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [472477/2007-2, 565496/2008-5]; CAPESCAPES [210/2007]; FAPESC
   [04524/2008-1]; WHO/TDRWorld Health Organization [2008-8734-0]
FX The authors thank Mr. Jorge Tolentino and Dr. Bruno Bezerril
   (Fiocruz/BA) for technical support and Prof. Mario Steindel for critical
   reading of this manuscript. They also thank Marcos L'Hotellier and the
   staff of the DRD-CPHC/JF for helping with the TB patients. They are
   indebted to Drs. Luciana Leite and Ivan Nascimento (I. Butantan) as well
   as Profa. Maria Luiza Bazzo (UFSC) for providing the M. bovis BCG CFP
   and non-tuberculous mycobacteria strains, respectively. L.N. received
   CAPES/CNPq fellowship. A.B. received funding from CNPq (472477/2007-2
   and 565496/2008-5), CAPES (210/2007), FAPESC (04524/2008-1) and WHO/TDR
   (2008-8734-0). C.D.S., B.S.C., H.C.T., S.C.O., M.B.N., and A.B. are CNPq
   investigators.
CR Abdallah AM, 2007, NAT REV MICROBIOL, V5, P883, DOI 10.1038/nrmicro1773
   ANDERSEN P, 1994, INFECT IMMUN, V62, P2536, DOI 10.1128/IAI.62.6.2536-2544.1994
   BEN AY, 2005, SCAND J IMMUNOL, V61, P139
   BOESEN H, 1995, INFECT IMMUN, V63, P1491, DOI 10.1128/IAI.63.4.1491-1497.1995
   Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732
   Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159
   Coler RN, 1998, J IMMUNOL, V161, P2356
   COOPER AM, 1995, CURR OPIN IMMUNOL, V7, P512, DOI 10.1016/0952-7915(95)80096-4
   Coutte L, 2003, J EXP MED, V197, P735, DOI 10.1084/jem.20021153
   Emanuelsson O, 2007, NAT PROTOC, V2, P953, DOI 10.1038/nprot.2007.131
   Feng CG, 2005, J IMMUNOL, V174, P4185, DOI 10.4049/jimmunol.174.7.4185
   Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93
   Frigui W, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040033
   Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563
   Glatman-Freedman A, 2006, TUBERCULOSIS, V86, P191, DOI 10.1016/j.tube.2006.01.008
   Guinn KM, 2004, MOL MICROBIOL, V51, P359, DOI 10.1046/j.1365-2958.2003.03844.x
   Hartley MR, 2004, BBA-PROTEINS PROTEOM, V1701, P1, DOI 10.1016/j.bbapap.2004.06.004
   Hazes B, 1996, PROTEIN SCI, V5, P1490, DOI 10.1002/pro.5560050805
   HIRSCHFIELD GR, 1990, J BACTERIOL, V172, P1005, DOI 10.1128/jb.172.2.1005-1013.1990
   HUBBARD RD, 1992, CLIN EXP IMMUNOL, V87, P94
   Imaz MS, 2000, INT J TUBERC LUNG D, V4, P562
   Kinhikar AG, 2006, MOL MICROBIOL, V60, P999, DOI 10.1111/j.1365-2958.2006.05151.x
   Laal S, 1997, CLIN DIAGN LAB IMMUN, V4, P49, DOI 10.1128/CDLI.4.1.49-56.1997
   LEE BY, 1992, INFECT IMMUN, V60, P2066, DOI 10.1128/IAI.60.5.2066-2074.1992
   Maartens G, 2007, LANCET, V370, P2030, DOI 10.1016/S0140-6736(07)61262-8
   Maglione PJ, 2009, EUR J IMMUNOL, V39, P676, DOI 10.1002/eji.200839148
   Malen H, 2007, PROTEOMICS, V7, P1702, DOI 10.1002/pmic.200600853
   Masungi C, 2002, J INFECT DIS, V185, P513, DOI 10.1086/338833
   Menozzi FD, 1996, J EXP MED, V184, P993, DOI 10.1084/jem.184.3.993
   MORENO FB, 2003, ONLINE J BIOINFORM, V4, P96
   Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042
   ORME IM, 1988, INFECT IMMUN, V56, P3310, DOI 10.1128/IAI.56.12.3310-3312.1988
   ORME IM, 1993, J INFECT DIS, V167, P1481, DOI 10.1093/infdis/167.6.1481
   Pathak SK, 2007, NAT IMMUNOL, V8, P610, DOI 10.1038/ni1468
   Pethe K, 2001, NATURE, V412, P190, DOI 10.1038/35084083
   PRINCE A, 1992, MICROB PATHOGENESIS, V13, P251, DOI 10.1016/0882-4010(92)90035-M
   Raghavan S, 2008, NATURE, V454, P717, DOI 10.1038/nature07219
   Reece ST, 2008, INT J MED MICROBIOL, V298, P143, DOI 10.1016/j.ijmm.2007.07.004
   Rosenkrands I, 2000, ELECTROPHORESIS, V21, P3740, DOI 10.1002/1522-2683(200011)21:17<3740::AID-ELPS3740>3.3.CO;2-V
   Samanich KM, 1998, J INFECT DIS, V178, P1534, DOI 10.1086/314438
   Shin AR, 2006, CLIN VACCINE IMMUNOL, V13, P869, DOI 10.1128/CVI.00103-06
   Singh DD, 2007, PROTEIN PEPTIDE LETT, V14, P683
   Smith I, 2003, CLIN MICROBIOL REV, V16, P463, DOI 10.1128/CMR.16.3.463-496.2003
   Sonnenberg MG, 1997, INFECT IMMUN, V65, P4515, DOI 10.1128/IAI.65.11.4515-4524.1997
   Soto GE, 1999, J BACTERIOL, V181, P1059, DOI 10.1128/JB.181.4.1059-1071.1999
   Stanley SA, 2007, J IMMUNOL, V178, P3143, DOI 10.4049/jimmunol.178.5.3143
   Tuteja R, 2005, ARCH BIOCHEM BIOPHYS, V441, P107, DOI 10.1016/j.abb.2005.07.013
   Van Weyenbergh J, 2001, IMMUNOL LETT, V75, P117, DOI 10.1016/S0165-2478(00)00303-5
   Verma RK, 2007, FEMS IMMUNOL MED MIC, V51, P453, DOI 10.1111/j.1574-695X.2007.00302.x
   *WHO, 2006, 104 WHO
NR 50
TC 8
Z9 8
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD MAR
PY 2010
VL 40
IS 3
BP 744
EP 753
DI 10.1002/eji.200939747
PG 10
WC Immunology
SC Immunology
GA 573SQ
UT WOS:000275935600027
PM 20017196
OA Green Published
DA 2020-12-01
ER

PT J
AU Mosimann, ALP
   de Borba, L
   Bordignon, J
   Mason, PW
   dos Santos, CND
AF Pamplona Mosimann, Ana Luiza
   de Borba, Luana
   Bordignon, Juliano
   Mason, Peter W.
   Duarte dos Santos, Claudia N.
TI Construction and characterization of a stable subgenomic replicon system
   of a Brazilian dengue virus type 3 strain (BR DEN3 290-02)
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE Flavivirus; Dengue virus serotype 3; Replicon
ID WEST-NILE-VIRUS; JAPANESE ENCEPHALITIS-VIRUS; FEVER VIRUS;
   HEMORRHAGIC-FEVER; INFECTIOUS CLONE; RNA REPLICATION; CDNA-CLONE;
   FLAVIVIRUS; TRANSLATION; EXPRESSION
AB Dengue viruses (DENV) cause the most common arboviral disease afflicting men. Clinical manifestations range from asymptomatic to dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). The mechanisms involved in the disease pathogenesis are not fully understood. The severity of the disease seems to be influenced by both viral and host factors. Subgenomic replicons of DENV can be used to study viral replication mechanisms and evaluate the effects of antiviral drugs on viral replication. The objective was to generate and characterize biologically a replicon from a clinical isolate of DENV-3, as part of our studies to understand how this new isolate interacts with cells. To obtain this replicon several RT-PCR fragments encoding the non-structural proteins genes were cloned in high-copy vectors, and used to assemble the replicon in a BAC plasmid vector containing a synthetic DNA molecule encoding the 5' and 31 ends of a viral cDNA with a T7 DNA-dependent RNA polymerase promoter and a ribozyme. In vitro transcribed RNA recovered from this BAC plasmid was transfected into C6/36 mosquito cells, and dengue virus protein expression was assessed by indirect immunofluorescence using polyclonal antibodies. The results showed that the replicon was replicated efficiently in cells, demonstrating successful assembly of a DENV-3 replicon. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Pamplona Mosimann, Ana Luiza; de Borba, Luana; Bordignon, Juliano; Duarte dos Santos, Claudia N.] Inst Carlos Chagas Fiocruz PR, BR-3775 Curitiba, Parana, Brazil.
   [Mason, Peter W.] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA.
RP dos Santos, CND (corresponding author), Inst Carlos Chagas Fiocruz PR, Rua Prof Algacyr Munhoz Mader, BR-3775 Curitiba, Parana, Brazil.
EM clsantos@tecpar.br
RI Publica, Inct Saude/J-9544-2013; Bordignon, Juliano/Z-6268-2019; Duarte
   dos Santos, Claudia/E-1857-2018; P, CM/B-1358-2013; Santos, Claudia
   Duarte dos/P-4868-2019
OI Bordignon, Juliano/0000-0002-1965-6152; Duarte dos Santos,
   Claudia/0000-0001-8707-6638; Santos, Claudia Duarte
   dos/0000-0001-8707-6638; Pamplona Mosimann, Ana
   Luiza/0000-0002-3504-5562
FU Fiocruz; CNPqNational Council for Scientific and Technological
   Development (CNPq); CNPq/PROSULNational Council for Scientific and
   Technological Development (CNPq); Fundacao AraucariaFundacao Araucaria;
   CAPESCAPES
FX The authors are indebted with Paulo Arauco and Vanessa Stella for
   technical help with sequencing and cell cultures procedures,
   respectively. Financial support: Fiocruz, CNPq, CNPq/PROSUL, Fundacao
   Araucaria. ALPM and LB are supported by fellowships from CAPES. CNDS is
   a CNPq fellowship recipient.
CR Alvarez DE, 2005, VIROLOGY, V339, P200, DOI 10.1016/j.virol.2005.06.009
   Alvarez DE, 2005, J VIROL, V79, P6631, DOI 10.1128/JVI.79.11.6631-6643.2005
   [Anonymous], 2008, INF EP DENG JAN NOV
   BARNES WM, 1977, SCIENCE, V195, P393, DOI 10.1126/science.318764
   Bredenbeek PJ, 2003, J GEN VIROL, V84, P1261, DOI 10.1099/vir.0.18860-0
   CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245
   Corver J, 2003, J VIROL, V77, P2265, DOI 10.1128/JVI.77.3.2265-2270.2003
   DESPRES P, 1993, VIROLOGY, V196, P209, DOI 10.1006/viro.1993.1469
   Gehrke R, 2003, J VIROL, V77, P8924, DOI 10.1128/JVI.77.16.8924-8933.2003
   GENTRY MK, 1982, AM J TROP MED HYG, V31, P548, DOI 10.4269/ajtmh.1982.31.548
   Gritsun TS, 1998, J VIROL METHODS, V76, P109, DOI 10.1016/S0166-0934(98)00130-X
   HALSTEAD SB, 1977, NATURE, V265, P739, DOI 10.1038/265739a0
   HALSTEAD SB, 1973, NATURE-NEW BIOL, V243, P24
   Holden KL, 2006, VIROLOGY, V344, P439, DOI 10.1016/j.virol.2005.08.034
   Hurrelbrink RJ, 1999, J GEN VIROL, V80, P3115, DOI 10.1099/0022-1317-80-12-3115
   Ishikawa T, 2008, VACCINE, V26, P2772, DOI 10.1016/j.vaccine.2008.03.010
   Jones CT, 2005, VIROLOGY, V331, P247, DOI 10.1016/j.virol.2004.10.034
   Jones M, 2005, J VIROL, V79, P5414, DOI 10.1128/JVI.79.9.5414-5420.2005
   Khromykh AA, 1997, J VIROL, V71, P1497, DOI 10.1128/JVI.71.2.1497-1505.1997
   Kofler RM, 2004, P NATL ACAD SCI USA, V101, P1951, DOI 10.1073/pnas.0307145101
   Lo MK, 2003, J VIROL, V77, P10004, DOI 10.1128/JVI.77.18.10004-10014.2003
   MASON PW, 1990, J GEN VIROL, V71, P2107, DOI 10.1099/0022-1317-71-9-2107
   Messer WB, 2003, EMERG INFECT DIS, V9, P800
   *MIN SAUD, 2006, SIT EP DENG AT DEZ 2
   *MIN SAUD, 2007, INF EP DENG JAN DEZ
   *MIN SAUD, 2008, CAS CONF FHD SEG AN
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   NG YC, 2007, ANTIVIR RES, V76, P222
   Nogueira MB, 2008, MEM I OSWALDO CRUZ, V103, P483, DOI 10.1590/S0074-02762008000500013
   Pang X, 2001, BMC Microbiol, V1, P18, DOI 10.1186/1471-2180-1-18
   Pierro DJ, 2006, J GEN VIROL, V87, P2263, DOI 10.1099/vir.0.81958-0
   Poersch CD, 2005, J CLIN VIROL, V32, P272, DOI 10.1016/j.jcv.2004.08.008
   Nogueira RMR, 2007, REV PANAM SALUD PUBL, V22, P358, DOI 10.1590/S1020-49892007001000009
   ROSEN L, 1977, AM J TROP MED HYG, V26, P337, DOI 10.4269/ajtmh.1977.26.337
   Rossi SL, 2005, VIROLOGY, V331, P457, DOI 10.1016/j.virol.2004.10.046
   Scholle F, 2004, J VIROL, V78, P11605, DOI 10.1128/JVI.78.21.11605-11614.2004
   Shi PY, 2002, VIROLOGY, V296, P219, DOI 10.1006/viro.2002.1453
   Silva RLA, 2008, VIRUS RES, V135, P320, DOI 10.1016/j.virusres.2008.03.007
   Suzuki R, 2007, VIROLOGY, V362, P374, DOI 10.1016/j.virol.2006.11.026
   Widman DG, 2008, VACCINE, V26, P2762, DOI 10.1016/j.vaccine.2008.03.009
   Yamshchikov VF, 2001, VIROLOGY, V281, P294, DOI 10.1006/viro.2000.0795
   Yoshii K, 2009, ARCH VIROL, V154, P573, DOI 10.1007/s00705-009-0345-5
   Yun SI, 2007, J NEUROVIROL, V13, P522, DOI 10.1080/13550280701684651
   Yun SI, 2003, J VIROL, V77, P6450, DOI 10.1128/JVI.77.11.6450-6465.2003
NR 44
TC 9
Z9 10
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD JAN
PY 2010
VL 163
IS 1
BP 147
EP 152
DI 10.1016/j.jviromet.2009.09.004
PG 6
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA 549IZ
UT WOS:000274042900021
PM 19761796
DA 2020-12-01
ER

PT J
AU Mazzarotto, GCA
   Raboni, SM
   Stella, V
   Carstensen, S
   de Noronha, L
   Levis, S
   Zanluca, C
   Zanetti, CR
   Bordignon, J
   dos Santos, CND
AF Mazzarotto, GiovannyA. C. A.
   Raboni, Sonia M.
   Stella, Vanessa
   Carstensen, Suzana
   de Noronha, Lucia
   Levis, Silvana
   Zanluca, Camila
   Zanetti, Carlos R.
   Bordignon, Juliano
   Duarte dos Santos, Claudia N.
TI Production and characterization of monoclonal antibodies against the
   recombinant nucleoprotein of Araucaria hantavirus
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE Hantavirus; Monoclonal Antibody; Araucaria strain
ID VIRUS NUCLEOCAPSID PROTEIN; MAJOR ANTIGENIC DOMAIN; HEMORRHAGIC-FEVER;
   RENAL SYNDROME; HANTAAN VIRUS; EXPRESSION; PUUMALA; BRAZIL; INFECTION;
   DIAGNOSIS
AB Hantaviruses are rodent-borne RNA viruses that cause hemorrhagic fever with renal syndrome (HFRS) or hantavirus pulmonary syndrome (HPS). From the first detection of infection in Brazil in 1993 until 2009, 1161 cases of HIPS have been reported, with mortality rates of around similar to 40%. Currently, due to the absence of a vaccine or specific antiviral therapy, the only way to reduce mortality by hantavirus infection is a fast and precise diagnosis that allows for supportive clinical health care. To improve the detection of hantavirus infection, we developed monoclonal antibodies (Mabs) against the nucleoprotein (rN Delta(85)) of the Araucaria hantavirus strain (ARAUV). The specificity of generated Mabs for rN Delta(85) was demonstrated by western blot, indirect immunofluorescence and immunohistochemistry. These are the first monoclonal antibodies to be produced and characterized against the South American hantavirus strain, and may be of special interest in the development of diagnostic assays and epidemiological studies. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Mazzarotto, GiovannyA. C. A.; Raboni, Sonia M.; Stella, Vanessa; Carstensen, Suzana; Bordignon, Juliano; Duarte dos Santos, Claudia N.] ICC Fiocruz, Inst Carlos Chagas, Virol Lab, BR-81350010 Curitiba, Parana, Brazil.
   [Raboni, Sonia M.] UFPR, Dept Saude Comunitaria, BR-80060900 Curitiba, Parana, Brazil.
   [de Noronha, Lucia] PUC PR, Lab Patol Expt, BR-80215901 Curitiba, Parana, Brazil.
   [Levis, Silvana] Inst Nacl Enfermedades Virales Humanas Dr Julio I, RA-2700 Pergamino, Argentina.
   [Zanluca, Camila; Zanetti, Carlos R.] Univ Fed Santa Catarina, Lab Imunol Aplicada, BR-88040900 Florianopolis, SC, Brazil.
RP Bordignon, J (corresponding author), ICC Fiocruz PR, Inst Carlos Chagas, Rua Prof Algacyr Munhoz Mader 3775,CIC, BR-81350010 Curitiba, Parana, Brazil.
EM jbordig@tecpar.br; clsantos@tecpar.br
RI Duarte dos Santos, Claudia/E-1857-2018; noronha, lucia/F-6339-2015;
   Raboni, Sonia Mara/F-7537-2012; Santos, Claudia Duarte dos/P-4868-2019;
   Bordignon, Juliano/Z-6268-2019; Publica, Inct Saude/J-9544-2013; P,
   CM/B-1358-2013; Raboni, Sonia M/AAF-7142-2020
OI Duarte dos Santos, Claudia/0000-0001-8707-6638; noronha,
   lucia/0000-0003-0310-7164; Santos, Claudia Duarte
   dos/0000-0001-8707-6638; Bordignon, Juliano/0000-0002-1965-6152; Raboni,
   Sonia M/0000-0001-7907-7585; Zanluca, Camila/0000-0001-7350-9105
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CNPq/PROSULNational Council for Scientific and Technological
   Development (CNPq); CYTED/RIVE; Fiocruz; Fundacao AraucariaFundacao
   Araucaria
FX The authors thank Dr. Alexandre Dias Tavares Costa for critical reading
   of the manuscript. This work was supported by grants from CNPq,
   CNPq/PROSUL, CYTED/RIVE, Fiocruz and Fundacao Araucaria. GACAM, JB, CRZ
   and CNDS are fellowships from CNPq.
CR BEATY BJ, 1991, CURR TOP MICROBIOL, V169, P27
   *BRAZ MIN HLTH, 2009, CAS OB HANT UN FED P
   Chen ZT, 2008, HYBRIDOMA, V27, P467, DOI 10.1089/hyb.2008.0048
   CLARK MR, 1981, SOMAT CELL GENET, V7, P657, DOI 10.1007/BF01538755
   Elgh F, 1996, J VIROL METHODS, V59, P161, DOI 10.1016/0166-0934(96)02042-3
   FRANKO MC, 1983, P NATL ACAD SCI-BIOL, V80, P4149, DOI 10.1073/pnas.80.13.4149
   Gott P, 1997, VIRUS GENES, V14, P31, DOI 10.1023/A:1007983306341
   HA IS, 1995, CLIN DIAGN LAB IMMUN, V2, P439, DOI 10.1128/CDLI.2.4.439-442.1995
   Hager-Braun C, 2005, EXPERT REV PROTEOMIC, V2, P745, DOI 10.1586/14789450.2.5.745
   LUNDKVIST A, 1993, ARCH VIROL, V132, P255, DOI 10.1007/BF01309537
   Monroe MC, 1999, EMERG INFECT DIS, V5, P75, DOI 10.3201/eid0501.990109
   NICHOL ST, 1993, SCIENCE, V262, P914, DOI 10.1126/science.8235615
   Plyusnin A, 1996, J GEN VIROL, V77, P2677, DOI 10.1099/0022-1317-77-11-2677
   Raboni SM, 2005, J MED VIROL, V76, P553, DOI 10.1002/jmv.20398
   Raboni SM, 2005, AM J TROP MED HYG, V72, P800, DOI 10.4269/ajtmh.2005.72.800
   Raboni SM, 2007, DIAGN MICR INFEC DIS, V58, P89, DOI 10.1016/j.diagmicrobio.2006.11.012
   Raboni SM, 2009, J CLIN VIROL, V45, P153, DOI 10.1016/j.jcv.2009.03.015
   RUO SL, 1991, ARCH VIROL, V119, P1, DOI 10.1007/BF01314318
   Schmaljohn C, 1997, EMERG INFECT DIS, V3, P95, DOI 10.3201/eid0302.970202
   Schmidt J, 2005, VIRUS GENES, V30, P37, DOI 10.1007/s11262-004-4580-2
   Silva M. V. da, 1997, Revista do Instituto de Medicina Tropical de Sao Paulo, V39, P231, DOI 10.1590/S0036-46651997000400010
   Wang CY, 2007, HYBRIDOMA, V26, P42, DOI 10.1089/hyb.2006.035
   ZAKI SR, 1995, AM J PATHOL, V146, P552
   ZOLLER LG, 1993, J CLIN MICROBIOL, V31, P1194
NR 24
TC 19
Z9 19
U1 1
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD DEC
PY 2009
VL 162
IS 1-2
BP 96
EP 100
DI 10.1016/j.jviromet.2009.07.022
PG 5
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA 517BA
UT WOS:000271586500015
PM 19654026
DA 2020-12-01
ER

PT J
AU Raboni, SM
   Hoffmann, FG
   Oliveira, RC
   Teixeira, BR
   Bonvicino, CR
   Stella, V
   Carstensen, S
   Bordignon, J
   D'Andrea, PS
   Lemos, ERS
   dos Santos, CND
AF Raboni, Sonia Mara
   Hoffmann, Federico G.
   Oliveira, Renata C.
   Teixeira, Bernardo R.
   Bonvicino, Cibele R.
   Stella, Vanessa
   Carstensen, Suzana
   Bordignon, Juliano
   D'Andrea, Paulo S.
   Lemos, Elba R. S.
   Duarte dos Santos, Claudia Nunes
TI Phylogenetic characterization of hantaviruses from wild rodents and
   hantavirus pulmonary syndrome cases in the state of Parana (southern
   Brazil)
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
ID ENZYME-IMMUNOASSAY; ARGENTINA; EASTERN; GENOME; HPS
AB Over 1100 cases of hantavirus pulmonary syndrome (H PS) have occurred in Brazil since 1993, but little is known about Brazilian hantaviruses, and many of their rodent hosts remain unknown. The Araucaria hantavirus (ARAUV) was described recently from HIPS patients from Parana, in southern Brazil, but its host could not be identified. In this study, rodents were captured from regions with high HIPS prevalence to address this issue. ARAUV RNA was detected in three distantly related rodent species: Oligoryzomys nigripes, Oxymycterus judex and Akodon montensis. Furthermore, a specimen of A. montensis was infected with a Jabora-like virus, implying that A. montensis can be infected by at least two different hantaviruses. The presence of the same hantavirus strain in three different rodent species and the co-circulation of two different strains in the same rodent species highlight the potential for genomic reassortment, which could have an impact on hantavirus transmission dynamics in nature and on human epidemiology.
C1 [Raboni, Sonia Mara; Hoffmann, Federico G.; Stella, Vanessa; Carstensen, Suzana; Bordignon, Juliano; Duarte dos Santos, Claudia Nunes] Inst Biofis Carlos Chagas Filho, Fiocurz, PR, Brazil.
   [Raboni, Sonia Mara] Univ Fed Parana, BR-80060000 Curitiba, Parana, Brazil.
   [Oliveira, Renata C.; Teixeira, Bernardo R.; D'Andrea, Paulo S.; Lemos, Elba R. S.] Inst Oswaldo Cruz, BR-20001 Rio De Janeiro, Brazil.
   [Bonvicino, Cibele R.] Inst Nacl Canc, Rio De Janeiro, Brazil.
RP dos Santos, CND (corresponding author), Inst Biofis Carlos Chagas Filho, Fiocurz, PR, Brazil.
EM clsantos@tecpar.br
RI Santos, Claudia Duarte dos/P-4868-2019; Duarte dos Santos,
   Claudia/E-1857-2018; Raboni, Sonia Mara/F-7537-2012; P, CM/B-1358-2013;
   Bonvicino, Cibele/O-3390-2014; Teixeira, Bernardo R/D-7664-2013; Raboni,
   Sonia M/AAF-7142-2020; Oliveira, Renata/C-1124-2014; Publica, Inct
   Saude/J-9544-2013; Bordignon, Juliano/Z-6268-2019; D'Andrea, Paulo
   S./G-6820-2011; Hoffmann, Federico/B-7134-2009
OI Santos, Claudia Duarte dos/0000-0001-8707-6638; Duarte dos Santos,
   Claudia/0000-0001-8707-6638; Teixeira, Bernardo R/0000-0001-9013-9492;
   Raboni, Sonia M/0000-0001-7907-7585; Bordignon,
   Juliano/0000-0002-1965-6152; Lemos, Elba/0000-0003-3761-0200; D'Andrea,
   Paulo Sergio/0000-0001-7880-8761; Hoffmann, Federico/0000-0001-5056-4929
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CNPq/ProsulNational Council for Scientific and Technological
   Development (CNPq); Fiocruz; Fundacao Arauciria; CYTED/RIVE; Fundo
   Parana
FX We are indebted to Giselia Rubio and Edson dos Santos from Departamento
   de Vigilincia, SESA-PR, Edilsom Semczuk from Centro de Controle de
   Zoonoses of Foz do lguacu for helping with rodent trapping logistics. We
   are also grateful to Drs Adriana Delfraro and Juan Arbiza from
   Universidad de la Republica, Montevideo, Uruguay, for confirming viral
   sequencing data and Dr Christian Probst for helpful discussions. We
   thank Paulo Arauco for technical assistance in sequencing. The authors
   thank CNPq, CNPq/Prosul, Fiocruz, Fundacao Arauciria, CYTED/RIVE and
   Fundo Parana for financial support. C. N. D. S., P. S. D. and C. R. B.
   are CNPq feflowship recipients.
CR CHILDS JE, 1994, J INFECT DIS, V169, P1271, DOI 10.1093/infdis/169.6.1271
   Chu YK, 2003, AM J TROP MED HYG, V69, P263, DOI 10.4269/ajtmh.2003.69.263
   Chu YK, 2006, AM J TROP MED HYG, V75, P1127, DOI 10.4269/ajtmh.2006.75.1127
   Delfraro A, 2008, EMERG INFECT DIS, V14, P1447, DOI 10.3201/eid1409.080455
   ELKHOURY MR, 2005, B EPIDEMIOLOGICO ELE, V5, P1
   Figueiredo LTM, 2009, EMERG INFECT DIS, V15, P561, DOI 10.3201/eid1504.080289
   Hoffmann FG, 2002, J MAMMAL, V83, P408, DOI 10.1644/1545-1542(2002)083<0408:SOOWDO>2.0.CO;2
   Jobb G, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-18
   Johnson AM, 1999, J MED VIROL, V59, P527, DOI 10.1002/(SICI)1096-9071(199912)59:4&lt;527::AID-JMV17&gt;3.0.CO;2-Y
   Lednicky JA, 2003, ARCH PATHOL LAB MED, V127, P30
   LUNDKVIST A, 1994, REV MED VIROL, V4, P177, DOI 10.1002/rmv.1980040304
   Mills JN, 1995, METHODS TRAPPING SAM
   de Sousa RLM, 2008, INTERVIROLOGY, V51, P299, DOI 10.1159/000171818
   Padula P, 2007, EMERG INFECT DIS, V13, P1211, DOI 10.3201/eid1308.061090
   Padula PJ, 1998, VIROLOGY, V241, P323, DOI 10.1006/viro.1997.8976
   Padula PJ, 2000, J MED MICROBIOL, V49, P149, DOI 10.1099/0022-1317-49-2-149
   Plyusnin A, 2001, CURR TOP MICROBIOL, V256, P47
   Plyusnin A, 1996, J GEN VIROL, V77, P2677, DOI 10.1099/0022-1317-77-11-2677
   Raboni SM, 2005, J MED VIROL, V76, P553, DOI 10.1002/jmv.20398
   Raboni SM, 2007, DIAGN MICR INFEC DIS, V58, P89, DOI 10.1016/j.diagmicrobio.2006.11.012
   RODRIGUEZ F, 1990, J THEOR BIOL, V142, P485, DOI 10.1016/S0022-5193(05)80104-3
   Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180
   Rosa EST, 2005, VECTOR-BORNE ZOONOT, V5, P11, DOI 10.1089/vbz.2005.5.11
   SCHMALJOHN CS, 2001, FIELDS VIROLOGY, P1293
   Suzuki A, 2004, EMERG INFECT DIS, V10, P2127, DOI 10.3201/eid1012.040295
   Tischler ND, 2003, BIOL RES, V36, P201, DOI 10.4067/S0716-97602003000200010
NR 26
TC 27
Z9 29
U1 0
U2 4
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 0022-1317
EI 1465-2099
J9 J GEN VIROL
JI J. Gen. Virol.
PD SEP
PY 2009
VL 90
BP 2166
EP 2171
DI 10.1099/vir.0.011585-0
PN 9
PG 6
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA 492RG
UT WOS:000269676300013
PM 19439554
OA Bronze
DA 2020-12-01
ER

PT J
AU Raboni, SM
   de Borba, L
   Hoffmann, FG
   de Noronha, L
   Azevedo, MLV
   Carstensen, S
   Mazzarotto, GACA
   Bordignon, J
   dos Santos, CND
AF Raboni, Sonia Mara
   de Borba, Luana
   Hoffmann, Federico G.
   de Noronha, Lucia
   Viola Azevedo, Marin Luize
   Carstensen, Suzana
   Mazzarotto, Giovanny A. C. A.
   Bordignon, Juliano
   Duarte dos Santos, Claudia Nunes
TI Evidence of circulation of Laguna Negra-like hantavirus in the Central
   West of Brazil: Case report
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE Hantavirus pulmonary syndrome; Genetic characterization; Phylogeny;
   Laguna Negra-like virus
ID PULMONARY SYNDROME; SOUTH-AMERICA; HPS; PHYLOGENIES; RESERVOIRS;
   INFECTION; PROTEIN; BOLIVIA; VIRUS
AB Background: Hantavirus pulmonary syndrome has been reported with increasing frequency in some Brazilian regions, but information about viral genetic identification is still limited. Recently, the state of Mato Grosso, in the Legal Amazon of Brazil, experienced a growing number of hantavirus pulmonary syndrome (HPS) cases but the genetic characterization of the causative hantavirus is still missing.
   Objectives: Our goal was to identify the hantavirus strain involved in a fatal HPS case in the Central region of Brazil.
   Study design: Nested RT-PCR was conducted on blood clot samples from an HIPS patient from Mato Grosso. PCR-positive samples were sequenced, and the resulting sequences were compared with reference samples. Viral antigens were detected by immunohistological analyses in lung and liver tissues.
   Results: Analyses of the viral RNA isolated from the patient identified a Laguna Negra (LN)-like virus as the causative agent and histological analysis of lung sections were compatible with the genetic characterization.
   Conclusions: This is the first report of circulation and human infection by a Laguna Negra-like hantavirus in Brazil. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Duarte dos Santos, Claudia Nunes] CIC, ICC Fiocruz PR, Inst Carlos Chagas, BR-81350010 Curitiba, Parana, Brazil.
   [Raboni, Sonia Mara] Univ Fed Parana, BR-80060000 Curitiba, Parana, Brazil.
   [de Noronha, Lucia; Viola Azevedo, Marin Luize] PUCPR, Ctr Ciencias Biol & Saude, Curitiba, Parana, Brazil.
RP dos Santos, CND (corresponding author), CIC, ICC Fiocruz PR, Inst Carlos Chagas, Rua Prof Algamunhoz Mader 3775, BR-81350010 Curitiba, Parana, Brazil.
EM clsantos@tecpar.br
RI Duarte dos Santos, Claudia/E-1857-2018; Publica, Inct Saude/J-9544-2013;
   Santos, Claudia Duarte dos/P-4868-2019; noronha, lucia/F-6339-2015; P,
   CM/B-1358-2013; Raboni, Sonia M/AAF-7142-2020; Bordignon,
   Juliano/Z-6268-2019; Raboni, Sonia Mara/F-7537-2012; Hoffmann,
   Federico/B-7134-2009
OI Duarte dos Santos, Claudia/0000-0001-8707-6638; Santos, Claudia Duarte
   dos/0000-0001-8707-6638; noronha, lucia/0000-0003-0310-7164; Raboni,
   Sonia M/0000-0001-7907-7585; Bordignon, Juliano/0000-0002-1965-6152;
   Hoffmann, Federico/0000-0001-5056-4929
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CNPq/ProsulNational Council for Scientific and Technological
   Development (CNPq); Fiocruz; Fundacao AraucariaFundacao Araucaria;
   CYTED/RIVE; Fundo Parana
FX We are indebted with Giselia Rubio from Departamento de Vigilancia,
   SESA-PR and Irene Skraba from LACEN-PR. The authors thank CNPq,
   CNPq/Prosul, Fiocruz, Fundacao Araucaria, CYTED/RIVE and Fundo Parana
   for financial support. LB, FGH, SC, GACA, JB and CNDS are CNPq
   fellowship recipients.
CR BUTLER JC, 1994, CLIN INFECT DIS, V19, P387, DOI 10.1093/clinids/19.3.387
   Carroll DS, 2005, AM J TROP MED HYG, V72, P42, DOI 10.4269/ajtmh.2005.72.42
   Delfraro A, 2008, EMERG INFECT DIS, V14, P1447, DOI 10.3201/eid1409.080455
   FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x
   Figueiredo LTM, 2008, BRAZ J MED BIOL RES, V41, P596, DOI 10.1590/S0100-879X2008000700008
   Figueiredo LTM, 2003, EMERG INFECT DIS, V9, P891
   Johnson AM, 1999, J MED VIROL, V59, P527, DOI 10.1002/(SICI)1096-9071(199912)59:4&lt;527::AID-JMV17&gt;3.0.CO;2-Y
   Johnson AM, 1997, VIROLOGY, V238, P115, DOI 10.1006/viro.1997.8840
   Padula P, 2002, EMERG INFECT DIS, V8, P437, DOI 10.3201/eid0804.010300
   Padula PJ, 2000, J CLIN MICROBIOL, V38, P3029, DOI 10.1128/JCM.38.8.3029-3035.2000
   Raboni SM, 2005, J MED VIROL, V76, P553, DOI 10.1002/jmv.20398
   Raboni SM, 2007, DIAGN MICR INFEC DIS, V58, P89, DOI 10.1016/j.diagmicrobio.2006.11.012
   ROSA ES, 2008, 2 WORKSH NAC PESQ AP
   Rosa EST, 2005, VECTOR-BORNE ZOONOT, V5, P11, DOI 10.1089/vbz.2005.5.11
   Suzuki A, 2004, EMERG INFECT DIS, V10, P2127, DOI 10.3201/eid1012.040295
   Tamura K, 2004, P NATL ACAD SCI USA, V101, P11030, DOI 10.1073/pnas.0404206101
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/mst197, 10.1093/molbev/msr121]
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   ZAKI SR, 1995, AM J PATHOL, V146, P552
NR 20
TC 22
Z9 22
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD JUN
PY 2009
VL 45
IS 2
BP 153
EP 156
DI 10.1016/j.jcv.2009.03.015
PG 4
WC Virology
SC Virology
GA 462WM
UT WOS:000267388700016
PM 19395308
DA 2020-12-01
ER

PT J
AU Nogueira, MB
   Stella, V
   Bordignon, J
   Batista, WC
   de Borba, L
   da Silva, LHP
   Hoffmann, FG
   Probst, CM
   dos Santos, CND
AF Nogueira, Meri Bordignon
   Stella, Vanessa
   Bordignon, Juliano
   Batista, Weber Cheli
   de Borba, Luana
   Pereira da Silva, Luis Hildebrando
   Hoffmann, Federico Guillermo
   Probst, Christian Macagnan
   Duarte dos Santos, Claudia Nunes
TI Evidence for the co-circulation of dengue virus type 3 genotypes III and
   V in the Northern region of Brazil during the 2002-2004 epidemics
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE dengue virus type 3; genotype III and V; co-circulation; phylogenetic
   analysis; Amazon
ID RIO-DE-JANEIRO; HEMORRHAGIC-FEVER; GENETIC-CHARACTERIZATION; MOLECULAR
   EPIDEMIOLOGY; INFECTION; EMERGENCE; STATE; SEROTYPE-3; SEQUENCE; STRAINS
AB The reintroduction of dengue virus type 3 (DENV-3) in Brazil in 2000 and its subsequent spread throughout the country was associated with genotype III viruses, the only DENV-3 genotype isolated in Brazil prior to 2002. We report here the co-circulation of two different DENV-3 genotypes in patients living in the Northern region of Brazil during the 2002-2004 epidemics. Complete genomic sequences of viral RNA were determined from these epidemics, and viruses belonging to genotypes V (Southeast Asia/South Pacific) and III were identified. This recent co-circulation of different DENV-3 genotypes in South America may have implications for pathological and epidemiological dynamics.
C1 [Stella, Vanessa; Bordignon, Juliano; de Borba, Luana; Hoffmann, Federico Guillermo; Probst, Christian Macagnan; Duarte dos Santos, Claudia Nunes] Fiocruz MS, Inst Carlos Chagas, BR-81350010 Curitiba, Parana, Brazil.
   [Nogueira, Meri Bordignon] Univ Fed Parara, Dept Patol Med, Curitiba, Parana, Brazil.
   [Nogueira, Meri Bordignon] Univ Fed Parara, Hosp Clin, Virol Lab, Curitiba, Parana, Brazil.
   [Batista, Weber Cheli; Pereira da Silva, Luis Hildebrando] Inst Pesquisa & Patol, Virol Unit, Porto Velho, RO, Brazil.
RP dos Santos, CND (corresponding author), Fiocruz MS, Inst Carlos Chagas, Rua Prof Algacyr Munhoz Maeder 3-775,Cidade Ind, BR-81350010 Curitiba, Parana, Brazil.
EM clsantos@tecpar.br
RI Duarte dos Santos, Claudia/B-4238-2009; Bordignon, Juliano/Z-6268-2019;
   Santos, Claudia Duarte dos/P-4868-2019; Probst, Christian/B-8678-2009;
   Hoffmann, Federico/B-7134-2009; Duarte dos Santos, Claudia/E-1857-2018;
   P, CM/B-1358-2013
OI Bordignon, Juliano/0000-0002-1965-6152; Santos, Claudia Duarte
   dos/0000-0001-8707-6638; Probst, Christian/0000-0001-9993-6375;
   Hoffmann, Federico/0000-0001-5056-4929; Duarte dos Santos,
   Claudia/0000-0001-8707-6638; 
CR Aquino VH, 2006, AM J TROP MED HYG, V75, P710, DOI 10.4269/ajtmh.2006.75.710
   Cordeiro MT, 2007, REV SOC BRAS MED TRO, V40, P605, DOI 10.1590/S0037-86822007000600001
   Cummings DAT, 2005, P NATL ACAD SCI USA, V102, P15259, DOI 10.1073/pnas.0507320102
   De Simone TS, 2004, T ROY SOC TROP MED H, V98, P553, DOI 10.1016/j.trstmh.2003.09.003
   Domingues RB, 2008, J NEUROL SCI, V267, P36, DOI 10.1016/j.jns.2007.09.040
   dos Santos CND, 2002, VIRUS RES, V90, P197, DOI 10.1016/S0168-1702(02)00180-6
   dos Santos CND, 2000, VIROLOGY, V274, P292, DOI 10.1006/viro.2000.0457
   Figueiredo LB, 2008, EMERG INFECT DIS, V14, P314, DOI 10.3201/eid1402.070278
   GUBLER DJ, 1995, EMERG INFECT DIS, V1, P55
   Guzman Maria G., 1996, Boletin de la Oficina Sanitaria Panamericana, V121, P102
   Halstead Scott B, 2005, Vaccine, V23, P849, DOI 10.1016/j.vaccine.2004.03.069
   Jobb G, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-18
   Leitmeyer KC, 1999, J VIROL, V73, P4738, DOI 10.1128/JVI.73.6.4738-4747.1999
   Mangada MNM, 1998, VIROLOGY, V244, P458, DOI 10.1006/viro.1998.9093
   Messer WB, 2003, EMERG INFECT DIS, V9, P800
   Miagostovich MP, 2006, MEM I OSWALDO CRUZ, V101, P307, DOI 10.1590/S0074-02762006000300015
   Miagostovich MP, 2002, BRAZ J MED BIOL RES, V35, P869, DOI 10.1590/S0100-879X2002000800002
   Mondini A, 2007, J CLIN VIROL, V40, P84, DOI 10.1016/j.jcv.2007.06.007
   Nogueira RMR, 2005, EMERG INFECT DIS, V11, P1376
   Nogueira RMR, 2001, MEM I OSWALDO CRUZ, V96, P925, DOI 10.1590/S0074-02762001000700007
   Ocazionez RE, 2006, MEM I OSWALDO CRUZ, V101, P725, DOI 10.1590/S0074-02762006000700004
   OSATOMI K, 1990, VIROLOGY, V176, P643, DOI 10.1016/0042-6822(90)90037-R
   PALACIO M, 1995, JAMA-J AM MED ASSOC, V273, P840
   Pandey BD, 2000, MICROBIOL IMMUNOL, V44, P179, DOI 10.1111/j.1348-0421.2000.tb02480.x
   Peyrefitte CN, 2005, EMERG INFECT DIS, V11, P757, DOI 10.3201/eid1105.040959
   Rico-Hesse R, 2003, ADV VIRUS RES, V59, P315, DOI 10.1016/S0065-3527(03)59009-1
   Rigau-Perez JG, 2006, CLIN INFECT DIS, V42, P1241, DOI 10.1086/501355
   Rocco Iray M., 2005, Rev. Inst. Med. trop. S. Paulo, V47, P281, DOI 10.1590/S0036-46652005000500008
   Shimodaira H, 1999, MOL BIOL EVOL, V16, P1114, DOI 10.1093/oxfordjournals.molbev.a026201
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Usuku S, 2001, ARCH VIROL, V146, P1381, DOI 10.1007/s007050170098
   Uzcategui NY, 2003, J GEN VIROL, V84, P1569, DOI 10.1099/vir.0.18807-0
   Wittke V, 2002, VIROLOGY, V301, P148, DOI 10.1006/viro.2002.1549
   Zhang CL, 2005, J VIROL, V79, P15123, DOI 10.1128/JVI.79.24.15123-15130.2005
NR 34
TC 20
Z9 20
U1 0
U2 1
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD AUG
PY 2008
VL 103
IS 5
BP 483
EP U28
DI 10.1590/S0074-02762008000500013
PG 8
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 349KH
UT WOS:000259279200013
PM 18797763
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Bordignon, J
   Probst, CM
   Mosimann, ALP
   Pavoni, DP
   Stella, V
   Buck, GA
   Satproedprai, N
   Fawcett, P
   Zanata, SM
   de Noronha, L
   Krieger, MA
   dos Santos, CND
AF Bordignon, Juliano
   Probst, Christian M.
   Mosimann, Ana Luiza P.
   Pavoni, Daniela P.
   Stella, Vanessa
   Buck, Gregory A.
   Satproedprai, Nusara
   Fawcett, Paul
   Zanata, Silvio M.
   de Noronha, Lucia
   Krieger, Marco A.
   Duarte dos Santos, Claudia N.
TI Expression profile of interferon stimulated genes in central nervous
   system of mice infected with dengue virus Type-1
SO VIROLOGY
LA English
DT Article
DE dengue virus; interferon; microarray; mice; central nervous system
ID WEST-NILE-VIRUS; I INTERFERON; PERIVASCULAR CELLS; IMMUNE-RESPONSES;
   VASCULAR LEAKAGE; MICROGLIAL CELLS; PROTEIN; INNATE; IDENTIFICATION;
   COMPLEMENT
AB Dengue virus (DENV) infection can cause a self-limiting disease (dengue fever) or a more severe clinical presentation known as dengue hemorrhagic fever (DHF)/dengue shock syndrome (DSS). Furthermore, data from recent dengue epidemics in Brazil indicate that the neurological manifestations are becoming more prevalent. However, the neuropathogenesis of dengue are not well understood. The balance between viral replication efficiency and innate immunity - in opposition during the early stages of infection - determines the clinical outcome of DENV infection. In this study, we investigated the effects of DENV infection on the transcription profile of the central nervous system (CNS) of mice. We observed in infected mice the upregulation of 151 genes possibly involved in neuropathogenesis of dengue. Conversely, they may have a protective effect. Ingenuity Systems software analysis demonstrated, that the main pathways modulated by DENV infection in the mouse CNS are involved in interferon signaling and antigen presentation. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Bordignon, Juliano; Probst, Christian M.; Mosimann, Ana Luiza P.; Pavoni, Daniela P.; Stella, Vanessa; Krieger, Marco A.; Duarte dos Santos, Claudia N.] Inst Mol Biol, BR-81350010 Curitiba, Parana, Brazil.
   [Bordignon, Juliano; Probst, Christian M.; Mosimann, Ana Luiza P.; Pavoni, Daniela P.; Stella, Vanessa; Krieger, Marco A.; Duarte dos Santos, Claudia N.] Fiocruz MS, Inst Carlos Chagas ICC, BR-81350010 Curitiba, Parana, Brazil.
   [Buck, Gregory A.; Satproedprai, Nusara] Virginia Commonwealth Univ, Ctr Study Biol Complex, Richmond, VA 23284 USA.
   [Fawcett, Paul] Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA 23298 USA.
   [Zanata, Silvio M.] Univ Fed Parana, Dept Patol Bas, BR-81531990 Curitiba, Parana, Brazil.
   [de Noronha, Lucia] Pontificia Univ Catolica Parana, Lab Patol Expt, BR-80215901 Curitiba, Parana, Brazil.
RP dos Santos, CND (corresponding author), Inst Mol Biol, Rua Prof Algacyr Munhoz Mader 3775, BR-81350010 Curitiba, Parana, Brazil.
EM clsantos@tecpar.br
RI Probst, Christian/B-8678-2009; Krieger, Marco/AAE-8611-2020; P,
   CM/B-1358-2013; noronha, lucia/F-6339-2015; Pavoni, Daniela
   P/L-3302-2014; Publica, Inct Saude/J-9544-2013; Duarte dos Santos,
   Claudia/B-4238-2009; Bordignon, Juliano/Z-6268-2019; Mosimann, Ana Luiza
   Pamplona/AAB-4714-2019; Santos, Claudia Duarte dos/P-4868-2019; Duarte
   dos Santos, Claudia/E-1857-2018
OI Probst, Christian/0000-0001-9993-6375; noronha,
   lucia/0000-0003-0310-7164; Pavoni, Daniela P/0000-0001-6776-4345;
   Bordignon, Juliano/0000-0002-1965-6152; Mosimann, Ana Luiza
   Pamplona/0000-0002-3504-5562; Santos, Claudia Duarte
   dos/0000-0001-8707-6638; Duarte dos Santos, Claudia/0000-0001-8707-6638;
   Zanata, Silvio/0000-0003-2818-6954
CR Avirutnan P, 2006, J INFECT DIS, V193, P1078, DOI 10.1086/500949
   BEARE R, 2004, SPOT CDNA MICROARRAY
   Bigger CB, 2004, J VIROL, V78, P13779, DOI 10.1128/JVI.78.24.13779-13792.2004
   Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N
   BOKISCH VA, 1973, NEW ENGL J MED, V289, P996, DOI 10.1056/NEJM197311082891902
   Bordignon J, 2007, J MED VIROL, V79, P1506, DOI 10.1002/jmv.20958
   Bourne N, 2007, J VIROL, V81, P9100, DOI 10.1128/JVI.00316-07
   Carroll MC, 2004, NAT IMMUNOL, V5, P981, DOI 10.1038/ni1113
   Cheroni C, 2005, NEUROBIOL DIS, V18, P509, DOI 10.1016/j.nbd.2004.12.007
   Clyde K, 2006, J VIROL, V80, P11418, DOI 10.1128/JVI.01257-06
   D'Andrea LD, 2003, TRENDS BIOCHEM SCI, V28, P655, DOI 10.1016/j.tibs.2003.10.007
   Delhaye S, 2006, P NATL ACAD SCI USA, V103, P7835, DOI 10.1073/pnas.0602460103
   DESPRES P, 1993, VIROLOGY, V196, P209, DOI 10.1006/viro.1993.1469
   Despres P, 1998, J VIROL, V72, P823
   Diaz-Hernandez M, 2003, J NEUROSCI, V23, P11653
   Fearon DT, 1999, QJM-MON J ASSOC PHYS, V92, P235, DOI 10.1093/qjmed/92.5.235
   GEHRMANN J, 1993, GLIA, V7, P50, DOI 10.1002/glia.440070110
   GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H
   GEHRMANN J, 1991, RESTOR NEUROL NEUROS, V2, P181, DOI 10.3233/RNN-1991-245605
   Gogate N, 1996, J NEUROPATH EXP NEUR, V55, P435, DOI 10.1097/00005072-199604000-00006
   Gould EA, 1985, VIROLOGY PRACTICAL A, P43
   GRAEBER MB, 1992, J NEUROPATH EXP NEUR, V51, P303, DOI 10.1097/00005072-199205000-00009
   GRAEBER MB, 1989, J NEUROSCI RES, V22, P103, DOI 10.1002/jnr.490220114
   Groettrup M, 1996, EUR J IMMUNOL, V26, P863, DOI 10.1002/eji.1830260421
   Gubler DJ, 2014, DENGUE AND DENGUE HEMORRHAGIC FEVER, 2ND EDITION, P1, DOI 10.1079/9781845939649.0001
   HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268
   HALSTEAD SB, 1977, J EXP MED, V146, P201, DOI 10.1084/jem.146.1.201
   HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004
   HICKEY WF, 1992, J NEUROPATH EXP NEUR, V51, P246, DOI 10.1097/00005072-199205000-00002
   Honda K, 2005, INT IMMUNOL, V17, P1367, DOI 10.1093/intimm/dxh318
   Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464
   Johnston C, 2001, J VIROL, V75, P10431, DOI 10.1128/JVI.75.21.10431-10445.2001
   JOLY E, 1992, NEURON, V8, P1185, DOI 10.1016/0896-6273(92)90138-4
   Kajaste-Rudnitski A, 2006, J BIOL CHEM, V281, P4624, DOI 10.1074/jbc.M508649200
   Kim KI, 2004, MOL CELL BIOL, V24, P9592, DOI 10.1128/MCB.24.21.9592-9600.2004
   Knapp S, 2003, GENES IMMUN, V4, P411, DOI 10.1038/sj.gene.6363984
   Kurane I, 1990, Southeast Asian J Trop Med Public Health, V21, P658
   LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4
   Lenschow DJ, 2005, J VIROL, V79, P13974, DOI 10.1128/JVI.79.22.13974-13983.2005
   Luplerdlop N, 2006, EMBO REP, V7, P1176, DOI 10.1038/sj.embor.7400814
   Malakhov MP, 2002, J BIOL CHEM, V277, P9976, DOI 10.1074/jbc.M109078200
   Malakhova OA, 2006, EMBO J, V25, P2358, DOI 10.1038/sj.emboj.7601149
   Malathi K, 2007, NATURE, V448, P816, DOI 10.1038/nature06042
   Mehlhop E, 2006, J EXP MED, V203, P1371, DOI 10.1084/jem.20052388
   MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992
   Mishto M, 2006, NEUROBIOL AGING, V27, P54, DOI 10.1016/j.neurobiolaging.2004.12.004
   Navarro-Sanchez E, 2005, ARCH MED RES, V36, P425, DOI 10.1016/j.arcmed.2005.04.007
   Olson JK, 2001, J VIROL, V75, P9780, DOI 10.1128/JVI.75.20.9780-9789.2001
   Pang T, 2007, IMMUNOL CELL BIOL, V85, P43, DOI 10.1038/sj.icb.7100008
   Pasieka TJ, 2006, J VIROL, V80, P7600, DOI 10.1128/JVI.00333-06
   Perelygin AA, 2002, P NATL ACAD SCI USA, V99, P9322, DOI 10.1073/pnas.142287799
   Poersch CD, 2005, J CLIN VIROL, V32, P272, DOI 10.1016/j.jcv.2004.08.008
   Redwine JM, 2001, AM J PATHOL, V159, P1219, DOI 10.1016/S0002-9440(10)62507-2
   Rempel LA, 2007, REPROD BIOL ENDOCRIN, V5, DOI 10.1186/1477-7827-5-13
   Ritchie KJ, 2004, NAT MED, V10, P1374, DOI 10.1038/nm1133
   Rothman AL, 2004, J CLIN INVEST, V113, P946, DOI 10.1172/JCI200421512
   Rothman AL, 2003, ADV VIRUS RES, V60, P397, DOI 10.1016/S0065-3527(03)60010-2
   Sariol CA, 2007, CLIN VACCINE IMMUNOL, V14, P756, DOI 10.1128/CVI.00052-07
   Sarkar SN, 2005, MODULATION OF HOST GENE EXPRESSION AND INNATE IMMUNITY BY VIRUSES, P35, DOI 10.1007/1-4020-3242-0_3
   Scherbik SV, 2007, VIROLOGY, V368, P232, DOI 10.1016/j.virol.2007.08.017
   Shaw ML, 2005, MODULATION OF HOST GENE EXPRESSION AND INNATE IMMUNITY BY VIRUSES, P1, DOI 10.1007/1-4020-3242-0_1
   Shresta S, 2004, J VIROL, V78, P2701, DOI 10.1128/JVI.78.6.2701-2710.2004
   Simmons CP, 2007, J INFECT DIS, V195, P1097, DOI 10.1086/512162
   Smith Kendall A, 2004, Med Immunol, V3, P3, DOI 10.1186/1476-9433-3-3
   STREIT WJ, 1989, EXP NEUROL, V105, P115, DOI 10.1016/0014-4886(89)90111-8
   *SVS MIN SAUD, 2007, BAL DENG
   Tumpey TM, 2007, J VIROL, V81, P10818, DOI 10.1128/JVI.01116-07
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Van den Eynde BJ, 2001, CURR OPIN IMMUNOL, V13, P147, DOI 10.1016/S0952-7915(00)00197-7
   VASS K, 1990, AM J PATHOL, V137, P789
   Venter M, 2005, VIROLOGY, V342, P119, DOI 10.1016/j.virol.2005.07.013
   Warke RV, 2008, J VIROL, V82, P555, DOI 10.1128/JVI.01694-06
   Warke RV, 2003, J VIROL, V77, P11822, DOI 10.1128/JVI.77.21.11822-11832.2003
   *WHO, 2002, 117 WHO
   Yang JJ, 2006, J NEUROIMMUNOL, V181, P34, DOI 10.1016/j.jneuroim.2006.07.018
   Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362
NR 76
TC 22
Z9 24
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD AUG 1
PY 2008
VL 377
IS 2
BP 319
EP 329
DI 10.1016/j.virol.2008.04.033
PG 11
WC Virology
SC Virology
GA 320HE
UT WOS:000257223500012
PM 18570970
DA 2020-12-01
ER

PT J
AU Bordignon, J
   Strottmann, DM
   Mosimann, ALP
   Probst, CM
   Stella, V
   Noronha, L
   Zanata, SM
   Duarte dos Santos, CN
AF Bordignon, Juliano
   Strottmann, Daisy M.
   Mosimann, Ana Luiza P.
   Probst, Christian M.
   Stella, Vanessa
   Noronha, Lucia
   Zanata, Silvio M.
   Duarte dos Santos, Claudia N.
TI Dengue neurovirulence in mice: Identification of molecular signatures in
   the E and NS3 helicase domains
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE envelope protein; RNA helicase; molecular markers; primary neurons;
   murine model
ID BORNE ENCEPHALITIS-VIRUS; AMINO-ACID SUBSTITUTION; MULTIPLE SEQUENCE
   ALIGNMENT; HEMORRHAGIC-FEVER; ENVELOPE GLYCOPROTEIN;
   GENETIC-DETERMINANTS; MEMBRANE-FUSION; RNA HELICASE; TYPE-1 VIRUS;
   PROTEIN
AB Recent observations indicate that the clinical profile of dengue virus (DENV) infection is changing, and that neurological manifestations are becoming frequent. The neuro pathogenesis of dengue, and the contribution of viral and host factors to the disease are not well understood. To define the amino acid substitutions in DENV potentially implicated in the acquisition of a neurovirulent phenotype we used a murine model to characterize two neuroadapted strains of DENV-1, FGA/NA a5c (previously obtained), and FGA/NA P6 (recently obtained). Only three amino acid substitutions were identified in the neurovirulent strains, mapping to the E and NS3 helicase domains. These mutations enhanced the ability of neuroadapted viral strains to replicate in the CNS of infected mice, causing extensive damage with leptomeningitis and encephalitis.
C1 Inst Biol Mol Paran FIOCRUZ, BR-81350010 Curitiba, Parana, Brazil.
   Univ Catolica Parana, Lab Patol Expt Pontif, PUC FR, Curitiba, Parana, Brazil.
   Univ Fed Parana, Dept Patol, BR-80060000 Curitiba, Parana, Brazil.
RP dos Santos, CND (corresponding author), Inst Biol Mol Paran FIOCRUZ, Rua Prof Algacyr Munhoz M 3775, BR-81350010 Curitiba, Parana, Brazil.
EM clsantos@tecpar.br
RI Mosimann, Ana Luiza Pamplona/AAB-4714-2019; noronha, lucia/F-6339-2015;
   Santos, Claudia Duarte dos/P-4868-2019; Bordignon, Juliano/Z-6268-2019;
   P, CM/B-1358-2013; Probst, Christian/B-8678-2009; Duarte dos Santos,
   Claudia/E-1857-2018; Duarte dos Santos, Claudia/B-4238-2009
OI Mosimann, Ana Luiza Pamplona/0000-0002-3504-5562; noronha,
   lucia/0000-0003-0310-7164; Santos, Claudia Duarte
   dos/0000-0001-8707-6638; Bordignon, Juliano/0000-0002-1965-6152; Probst,
   Christian/0000-0001-9993-6375; Duarte dos Santos,
   Claudia/0000-0001-8707-6638; Zanata, Silvio/0000-0003-2818-6954
CR Anderson R, 2003, ADV VIRUS RES, V59, P229, DOI 10.1016/S0065-3527(03)59007-8
   Benarroch D, 2004, VIROLOGY, V328, P208, DOI 10.1016/j.virol.2004.07.004
   Bhoopat L, 1996, ASIAN PAC J ALLERGY, V14, P107
   Brault AC, 2004, P NATL ACAD SCI USA, V101, P11344, DOI 10.1073/pnas.0402905101
   Bray M, 1998, J VIROL, V72, P1647, DOI 10.1128/JVI.72.2.1647-1651.1998
   Cam BV, 2001, AM J TROP MED HYG, V65, P848, DOI 10.4269/ajtmh.2001.65.848
   CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245
   CHATURVEDI UC, 1991, J GEN VIROL, V72, P859, DOI 10.1099/0022-1317-72-4-859
   CHOTMONGKOL V, 2004, ASIAN J TROP MED PUB, V35, P160
   Clyde K, 2006, J VIROL, V80, P11418, DOI 10.1128/JVI.01257-06
   COLE GA, 1969, AM J EPIDEMIOL, V89, P669, DOI 10.1093/oxfordjournals.aje.a120981
   Crotty S, 2001, P NATL ACAD SCI USA, V98, P6895, DOI 10.1073/pnas.111085598
   DELANO WL, 2004, PYMOL USERS MANUAL
   DESPRES P, 1993, VIROLOGY, V196, P209, DOI 10.1006/viro.1993.1469
   Despres P, 1998, J VIROL, V72, P823
   Despres P, 1996, J VIROL, V70, P4090
   Domingo E, 1997, ANNU REV MICROBIOL, V51, P151, DOI 10.1146/annurev.micro.51.1.151
   dos Santos CND, 2000, VIROLOGY, V274, P292, DOI 10.1006/viro.2000.0457
   Gould EA, 1985, VIROLOGY PRACTICAL A, P43
   Graner E, 2000, MOL BRAIN RES, V76, P85, DOI 10.1016/S0169-328X(99)00334-4
   Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480
   Guirakhoo F, 2004, J VIROL, V78, P9998, DOI 10.1128/JVI.78.18.9998-10008.2004
   HALSTEAD S, 1988, SCIENCE, V239, P46
   HALSTEAD SB, 1980, B WORLD HEALTH ORGAN, V58, P1
   HASEGAWA H, 1992, VIROLOGY, V191, P158, DOI 10.1016/0042-6822(92)90177-Q
   HE RT, 1995, J MED VIROL, V45, P451, DOI 10.1002/jmv.1890450417
   HEINZ FX, 1994, VIROLOGY, V198, P109, DOI 10.1006/viro.1994.1013
   IMBERT JL, 1994, J MED VIROL, V42, P228, DOI 10.1002/jmv.1890420304
   Jelachich ML, 1996, J VIROL, V70, P6856, DOI 10.1128/JVI.70.10.6856-6861.1996
   JIANG WR, 1993, J GEN VIROL, V74, P931, DOI 10.1099/0022-1317-74-5-931
   KAWANO H, 1993, J VIROL, V67, P6567, DOI 10.1128/JVI.67.11.6567-6575.1993
   Lee E, 1997, VIROLOGY, V232, P281, DOI 10.1006/viro.1997.8570
   Leitmeyer KC, 1999, J VIROL, V73, P4738, DOI 10.1128/JVI.73.6.4738-4747.1999
   Linderbach BD, 2001, FIELDS VIROLOGY, P991
   Liu WJ, 2006, J VIROL, V80, P2396, DOI 10.1128/JVI.80.5.2396-2404.2006
   Lum LCS, 1996, AM J TROP MED HYG, V54, P256, DOI 10.4269/ajtmh.1996.54.256
   Mandl CW, 2000, J VIROL, V74, P9601, DOI 10.1128/JVI.74.20.9601-9609.2000
   McMinn PC, 1996, J GEN VIROL, V77, P2085, DOI 10.1099/0022-1317-77-9-2085
   Messer WB, 2002, AM J TROP MED HYG, V66, P765, DOI 10.4269/ajtmh.2002.66.765
   Miagostovich MP, 2006, MEM I OSWALDO CRUZ, V101, P307, DOI 10.1590/S0074-02762006000300015
   Miagostovich MP, 1997, CLIN NEUROPATHOL, V16, P204
   Modis Y, 2003, P NATL ACAD SCI USA, V100, P6986, DOI 10.1073/pnas.0832193100
   Modis Y, 2004, NATURE, V427, P313, DOI 10.1038/nature02165
   Navarro-Sanchez E, 2005, ARCH MED RES, V36, P425, DOI 10.1016/j.arcmed.2005.04.007
   NIMMANNITYA S, 1987, Southeast Asian Journal of Tropical Medicine and Public Health, V18, P398
   Novella IS, 2004, J MOL BIOL, V342, P1423, DOI 10.1016/j.jmb.2004.08.004
   Palma-da Cunha-Matta A, 2004, REV NEUROLOGIA, V39, P233
   PATEY O, 1993, AM J TROP MED HYG, V48, P793, DOI 10.4269/ajtmh.1993.48.793
   Poersch CD, 2005, J CLIN VIROL, V32, P272, DOI 10.1016/j.jcv.2004.08.008
   Ramos C, 1998, J NEUROVIROL, V4, P465, DOI 10.3109/13550289809114548
   Rey FA, 2003, P NATL ACAD SCI USA, V100, P6899, DOI 10.1073/pnas.1332695100
   REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0
   ROSEN L, 1977, AM J TROP MED HYG, V26, P337, DOI 10.4269/ajtmh.1977.26.337
   Rothman AL, 1999, VIROLOGY, V257, P1, DOI 10.1006/viro.1999.9656
   SCHATZMAYR H G, 1986, Memorias do Instituto Oswaldo Cruz, V81, P245, DOI 10.1590/S0074-02761986000200019
   Solomon T, 2000, LANCET, V355, P1053, DOI 10.1016/S0140-6736(00)02036-5
   Stiasny K, 2005, J VIROL, V79, P6511, DOI 10.1128/JVI.79.10.6511-6515.2005
   Stiasny K, 1996, J VIROL, V70, P8142, DOI 10.1128/JVI.70.11.8142-8147.1996
   SUMARMO WULUR H., 1978, Lancet, P449
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Vignuzzi M, 2006, NATURE, V439, P344, DOI 10.1038/nature04388
   Wulur H, 1983, B WORLD HEALTH ORGAN, V61, P693
   Xu T, 2005, J VIROL, V79, P10278, DOI 10.1128/JVI.79.16.10278-10288.2005
   Yamamoto Yuuji, 2002, Journal of Infection and Chemotherapy, V8, P175, DOI 10.1007/s101560200030
NR 65
TC 20
Z9 21
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD OCT
PY 2007
VL 79
IS 10
BP 1506
EP 1517
DI 10.1002/jmv.20958
PG 12
WC Virology
SC Virology
GA 203JT
UT WOS:000248971600011
PM 17705192
DA 2020-12-01
ER

PT J
AU Debur, MDC
   Bordignon, J
   Duarte dos Santos, CN
   Vidal, LR
   Nogueira, MB
   de Almeida, SM
   Raboni, SM
AF Debur, Maria do Carmo
   Bordignon, Juliano
   Duarte dos Santos, Claudia Nunes
   Vidal, Luine Rosele
   Nogueira, Meri Bordignon
   de Almeida, Sergio Monteiro
   Raboni, Sonia Mara
TI Acute respiratory infection by human metapneumovirus in children in
   southern Brazil
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE human metapneumovirus; acute respiratory infection; RT-PCR;
   nucleoprotein cloning
ID TRACT INFECTIONS; SYNCYTIAL VIRUS; ACUTE BRONCHIOLITIS; FRENCH CHILDREN;
   PCR
AB Background: Human metapneumovirus (hMPV) has been described as an etiologic agent of acute respiratory infections (ARI), mainly in pediatric patients. Viral isolation is difficult and has low sensitivity, and consequently RT-PCR assays are currently used for detection.
   Objectives: Detect hMPV in ARI in hospitalized children in Southern Brazil; standardize a RT-PCR for routine hMPV diagnosis; validate a positive control for molecular tests; and perform phylogenetics analyses.
   Study design: Nasopharyngeal aspirates (NPA) from 156 hospitalized children were studied. A conserved region of the nucleoprotein gene was cloned, characterized and used to standardize an RT-PCR assay. Phylogenetic analyses were performed. Clinical data were obtained from medical records.
   Results: hMPV was detected in 6.4% of the samples. Dyspnea and wheezing were frequently reported symptoms and the most common diagnoses were bronchiolitis, acute respiratory insufficiency or laryngotracheobronchitis. Nucleotide sequence alignment revealed 97.7% identity with genotype A I of hMPV. The detection limit of hMPV genomes by RT-PCR in clinical samples was 180 copies/mu L.
   Conclusion: This is the first report of the detection and genetic characterization of hMPV infections in children with lower ARI in Southern Brazil. (c) 2007 Elsevier B.V. All rights reserved.
C1 Univ Fed Parana, Hosp Clin, Virol Lab, BR-80060000 Curitiba, Parana, Brazil.
   Inst Mol Biol Parana, Fiocruz, Parana, Brazil.
   Univ Fed Parana, Dept Patol, BR-80060000 Curitiba, Parana, Brazil.
RP Raboni, SM (corresponding author), Rua Padre Camargo 280,2nd Andar,Sala 203, BR-80060240 Curitiba, Parana, Brazil.
EM virologiahc@ufpr.br
RI Raboni, Sonia Mara/F-7537-2012; Duarte dos Santos, Claudia/B-4238-2009;
   P, CM/B-1358-2013; Santos, Claudia Duarte dos/P-4868-2019; Raboni, Sonia
   M/AAF-7142-2020; Bordignon, Juliano/Z-6268-2019; Duarte dos Santos,
   Claudia/E-1857-2018
OI Santos, Claudia Duarte dos/0000-0001-8707-6638; Raboni, Sonia
   M/0000-0001-7907-7585; Bordignon, Juliano/0000-0002-1965-6152; Duarte
   dos Santos, Claudia/0000-0001-8707-6638
CR Alto WA, 2004, J AM BOARD FAM PRACT, V17, P466, DOI 10.3122/jabfm.17.6.466
   Bach N, 2004, ARCH PEDIATRIE, V11, P212, DOI 10.1016/j.arcped.2003.12.009
   Bastien N, 2003, VIRUS RES, V93, P51, DOI 10.1016/S0168-1702(03)00065-0
   Boivin G, 2002, J INFECT DIS, V186, P1330, DOI 10.1086/344319
   Bouscambert-Duchamp M, 2005, J CLIN MICROBIOL, V43, P1411, DOI 10.1128/JCM.43.3.1411-1414.2005
   Chano F, 2005, J CLIN MICROBIOL, V43, P5520, DOI 10.1128/JCM.43.11.5520-5525.2005
   Cuevas LE, 2003, EMERG INFECT DIS, V9, P1626, DOI 10.3201/eid0912.030522
   Ebihara T, 2004, J CLIN MICROBIOL, V42, P5944, DOI 10.1128/JCM.42.12.5944-5946.2004
   Esper F, 2003, PEDIATRICS, V111, P1407, DOI 10.1542/peds.111.6.1407
   Freymuth F, 2003, PEDIATR INFECT DIS J, V22, P92, DOI 10.1097/00006454-200301000-00024
   Gray GC, 2006, EMERG INFECT DIS, V12, P347, DOI 10.3201/eid1202.051133
   Howe M, 2002, LANCET INFECT DIS, V2, P202, DOI 10.1016/S1473-3099(02)00257-8
   Jartti T, 2002, LANCET, V360, P1393, DOI 10.1016/S0140-6736(02)11391-2
   Konig B, 2004, J CLIN MICROBIOL, V42, P4632, DOI 10.1128/JCM.42.10.4632-4635.2004
   Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150
   Lopez-Huertas MR, 2005, J VIROL METHODS, V129, P1, DOI 10.1016/j.jviromet.2005.05.004
   Madhi SA, 2003, CLIN INFECT DIS, V37, P1705, DOI 10.1086/379771
   Maggi F, 2003, J CLIN MICROBIOL, V41, P2987, DOI 10.1128/JCM.41.7.2987-2991.2003
   Mahalingam S, 2006, MICROBES INFECT, V8, P285, DOI 10.1016/j.micinf.2005.07.001
   Mirazo S, 2005, MEM I OSWALDO CRUZ, V100, P715, DOI 10.1590/S0074-02762005000700005
   Mullins JA, 2004, EMERG INFECT DIS, V10, P700, DOI 10.3201/eid1004.030555
   Osterhaus A, 2003, LANCET, V361, P890, DOI 10.1016/S0140-6736(03)12785-7
   Peiris JSM, 2003, EMERG INFECT DIS, V9, P628
   Rao BL, 2004, J CLIN MICROBIOL, V42, P5961, DOI 10.1128/JCM.42.12.5961-5962.2004
   Stockton J, 2002, EMERG INFECT DIS, V8, P897, DOI 10.3201/eid0809.020084
   van den Hoogen BG, 2004, EMERG INFECT DIS, V10, P658, DOI 10.3201/eid1004.030393
   Van den Hoogen BG, 2004, PEDIATR INFECT DIS J, V23, pS25, DOI 10.1097/01.inf.0000108190.09824.e8
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   Xepapadaki P, 2004, J CLIN VIROL, V30, P267, DOI 10.1016/j.jcv.2003.12.012
NR 29
TC 22
Z9 23
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD MAY
PY 2007
VL 39
IS 1
BP 59
EP 62
DI 10.1016/j.jcv.2007.01.012
PG 4
WC Virology
SC Virology
GA 198MD
UT WOS:000248631300011
PM 17350886
DA 2020-12-01
ER

PT J
AU Raboni, SM
   Probst, CM
   Bordignon, J
   Zeferino, A
   dos Santos, CND
AF Raboni, SM
   Probst, CM
   Bordignon, J
   Zeferino, A
   dos Santos, CND
TI Hantaviruses in central South America: Phylogenetic analysis of the S
   segment from HPS cases in Parana, Brazil
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE hantavirus pulmonary syndrome; S segment genomic sequence; hantavirus
   phylogeny; nucleocapsid
ID MULTIPLE SEQUENCE ALIGNMENT; GENETIC DIVERSITY; PULMONARY SYNDROME;
   ANDES-VIRUS; NUCLEOTIDE-SEQUENCE; WESTERN PARAGUAY; HUMAN ISOLATE;
   ARGENTINA; OUTBREAK; EVOLUTION
AB We sequenced the complete S segments of hantaviruses detected from 12 HPS patients living in southern of Brazil. Samples were obtained from patients diagnosed in different years, in distinct areas, and with a broad spectrum of clinical signs. Despite these differences, all the S proteins of hantavirus from Parana were identical, except for one amino acid substitution. Phylogenetic analyses of the complete S segment nucleoticle and amino acid sequences indicated that hantaviruses from Parana form a distinct clade from those circulating in South and North America. Other hantaviruses from Brazil were not placed in the same clade. The Oligoryzomys nigripes-associated strains ITA37 and ITA38 from Paraguay were found to belong to the same clade as the hantaviruses from Parana. Paraguay and Parana state are located at the same latitude and some ecosystems are similar in both places. The geographic position and common rodent hosts could explain this phylogenetic relationship. (c) 2005 Wiley-Liss, Inc.
C1 IBMP, BR-81350010 Curitiba, Parana, Brazil.
   Univ Fed Parana, BR-80060000 Curitiba, Parana, Brazil.
RP dos Santos, CND (corresponding author), IBMP, Rua Prof Algacyr Munhoz Mader 3775,CIC, BR-81350010 Curitiba, Parana, Brazil.
EM clsantos@tecpar.br
RI Raboni, Sonia Mara/F-7537-2012; Probst, Christian/B-8678-2009; Raboni,
   Sonia M/AAF-7142-2020; P, CM/B-1358-2013; Bordignon,
   Juliano/Z-6268-2019; Santos, Claudia Duarte dos/P-4868-2019
OI Probst, Christian/0000-0001-9993-6375; Raboni, Sonia
   M/0000-0001-7907-7585; Bordignon, Juliano/0000-0002-1965-6152; Santos,
   Claudia Duarte dos/0000-0001-8707-6638
CR BEATY BJ, 1991, CURR TOP MICROBIOL, V169, P27
   Bohlman MC, 2002, J VIROL, V76, P3765, DOI 10.1128/JVI.76.8.3765-3773.2002
   BOWEN MD, 1995, VIRUS RES, V38, P279, DOI 10.1016/0168-1702(95)00058-X
   Chu YK, 2003, AM J TROP MED HYG, V69, P263, DOI 10.4269/ajtmh.2003.69.263
   Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186
   Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175
   Galeno H, 2002, EMERG INFECT DIS, V8, P657, DOI 10.3201/eid0807.010277
   Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195
   HJELLE B, 1994, J VIROL, V68, P592, DOI 10.1128/JVI.68.2.592-596.1994
   Hutchinson KL, 1996, VIROLOGY, V224, P139, DOI 10.1006/viro.1996.0515
   Iversson L B, 1994, Rev Assoc Med Bras (1992), V40, P85
   Johnson AM, 1999, J MED VIROL, V59, P527, DOI 10.1002/(SICI)1096-9071(199912)59:4&lt;527::AID-JMV17&gt;3.0.CO;2-Y
   Johnson AM, 1997, VIROLOGY, V238, P115, DOI 10.1006/viro.1997.8840
   Katz G, 2001, VECTOR-BORNE ZOONOT, V1, P181, DOI 10.1089/153036601753552549
   KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581
   Lednicky JA, 2003, ARCH PATHOL LAB MED, V127, P30
   Levis S, 1998, J INFECT DIS, V177, P529, DOI 10.1086/514221
   Lopez N, 1997, VIRUS RES, V50, P77, DOI 10.1016/S0168-1702(97)00053-1
   Meissner JD, 2002, VIRUS RES, V89, P131, DOI 10.1016/S0168-1702(02)00129-6
   Monroe MC, 1999, EMERG INFECT DIS, V5, P75, DOI 10.3201/eid0501.990109
   Nichol S. T., 2001, FIELDS VIROLOGY, P1603
   NICHOL ST, 1993, SCIENCE, V262, P914, DOI 10.1126/science.8235615
   Padula PJ, 1998, VIROLOGY, V241, P323, DOI 10.1006/viro.1997.8976
   Padula PJ, 2000, J CLIN MICROBIOL, V38, P3029, DOI 10.1128/JCM.38.8.3029-3035.2000
   PARRINGTON MA, 1990, VIROLOGY, V175, P167, DOI 10.1016/0042-6822(90)90197-Y
   Peters CJ, 2002, CLIN INFECT DIS, V34, P1224, DOI 10.1086/339864
   PINI N, 2003, HANTAVIRUS INFECT HU
   Plyusnin A, 2001, CURR TOP MICROBIOL, V256, P47
   Plyusnin A, 1996, J GEN VIROL, V77, P2677, DOI 10.1099/0022-1317-77-11-2677
   RABONI SM, 2005, IN PRESS AM J TROP M
   RAVKOV EV, 1995, VIROLOGY, V210, P482, DOI 10.1006/viro.1995.1366
   Schmaljohn C, 1997, EMERG INFECT DIS, V3, P95, DOI 10.3201/eid0302.970202
   SCHMALJOHN CS, 2001, FIELDS VIROLOGY, P1581
   Suzuki A, 2004, EMERG INFECT DIS, V10, P2127, DOI 10.3201/eid1012.040295
   Swofford D., 2003, PAUP PHYLOGENETIC AN
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Vapalahti O, 1999, J VIROL, V73, P5586, DOI 10.1128/JVI.73.7.5586-5592.1999
   VICENT MJ, 2000, VIROLOGY, V277, P14
   Wang H, 2000, VIROLOGY, V278, P332, DOI 10.1006/viro.2000.0630
   Williams RJ, 1997, AM J TROP MED HYG, V57, P274, DOI 10.4269/ajtmh.1997.57.274
   ZU ZY, 1985, J INFECT DIS, V152, P137
NR 42
TC 32
Z9 34
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD AUG
PY 2005
VL 76
IS 4
BP 553
EP 562
DI 10.1002/jmv.20398
PG 10
WC Virology
SC Virology
GA 941KZ
UT WOS:000230215000019
PM 15977228
DA 2020-12-01
ER

PT J
AU Bordignon, J
   Brasil-dos-Anjos, G
   Bueno, CR
   Salvatiera-Oporto, J
   Davila, AMR
   Grisard, EC
   Zanetti, CR
AF Bordignon, J
   Brasil-dos-Anjos, G
   Bueno, CR
   Salvatiera-Oporto, J
   Davila, AMR
   Grisard, EC
   Zanetti, CR
TI Detection and characterization of rabies virus in Southern Brazil by PCR
   amplification and sequencing of the nucleoprotein gene
SO ARCHIVES OF VIROLOGY
LA English
DT Article
ID POLYMERASE-CHAIN-REACTION; CALLITHRIX-JACCHUS; ANALYSIS SOFTWARE;
   DIAGNOSIS; DISCRIMINATION; REPLICATION; PROTECTION; PROTEIN; VARIANT;
   STATE
AB Due to the medical and socio-economical importance of both human and animal rabies infection, several studies have suggested the use of molecular techniques such as RT-PCR and DNA sequencing for diagnosis and phylogenetic studies of the rabies virus. Considering the conservancy of the nucleoprotein (N) gene of the virus, we herein describe a RT-PCR assay for rabies diagnosis and characterization. A total of 75 samples obtained from a variety of animal species in the state of Santa Catarina (SC), Southern Brazil, were comparatively studied by fluorescence antibody test (FAT), mouse inoculation test (MIT), cell infection assay and RT-PCR, which revealed itself to be as sensitive as FAT and MIT and less time-consuming than MIT. Direct sequencing of the 5' end of the N gene allowed the clustering of the SC samples with samples from the vampire bat-related or sylvatic cycle through comparative sequence analysis.
C1 Univ Fed Santa Catarina, MIP CCB, Dept Microbiol Immunol & Parasitol, BR-88040900 Florianopolis, SC, Brazil.
   CIDASC, Sao Jose, Brazil.
   Fiocruz MS, Inst Oswaldo Cruz, Dept Bioquim & Biol Mol, BR-21045900 Rio De Janeiro, Brazil.
RP Zanetti, CR (corresponding author), Univ Fed Santa Catarina, MIP CCB, Dept Microbiol Immunol & Parasitol, Campus Trindade, BR-88040900 Florianopolis, SC, Brazil.
EM zanetti@ccb.ufsc.br
RI Grisard, Edmundo C/A-7338-2015; Grisard, Edmundo C/AAS-9429-2020;
   Bordignon, Juliano/Z-6268-2019; P, CM/B-1358-2013
OI Grisard, Edmundo C/0000-0001-8916-8296; Grisard, Edmundo
   C/0000-0001-8916-8296; Bordignon, Juliano/0000-0002-1965-6152; Davila,
   Alberto/0000-0002-6918-7673
CR Arai YT, 2003, EMERG INFECT DIS, V9, P333, DOI 10.3201/eid0903.020252
   Batista-Morais N, 2000, MEM I OSWALDO CRUZ, V95, P609, DOI 10.1590/S0074-02762000000500003
   Bordignon J, 2001, BIOLOGICALS, V29, P67, DOI 10.1006/biol.2001.0278
   Burland T G, 2000, Methods Mol Biol, V132, P71
   Chang HGH, 2002, EMERG INFECT DIS, V8, P909, DOI 10.3201/eid0809.010524
   David D, 2002, VET MICROBIOL, V87, P111, DOI 10.1016/S0378-1135(02)00041-X
   Dean D J, 1973, Monogr Ser World Health Organ, P73
   DIETZSCHOLD B, 1987, VIRUS RES, V8, P103, DOI 10.1016/0168-1702(87)90023-2
   Favi M, 2002, EMERG INFECT DIS, V8, P79, DOI 10.3201/eid0801.010108
   Favoretto SR, 2001, EMERG INFECT DIS, V7, P1062, DOI 10.3201/eid0706.010630
   Gould AR, 1998, VIRUS RES, V54, P165, DOI 10.1016/S0168-1702(98)00025-2
   HAYASHI Y, 1984, ARQ BIOL TECNOL, V27, P27
   Heaton PR, 1997, J CLIN MICROBIOL, V35, P2762, DOI 10.1128/JCM.35.11.2762-2766.1997
   Ito M, 2003, J CLIN VIROL, V26, P317, DOI 10.1016/S1386-6532(02)00048-3
   Ito M, 2001, VIROLOGY, V284, P214, DOI 10.1006/viro.2000.0916
   KAMOLVARIN N, 1993, J INFECT DIS, V167, P207, DOI 10.1093/infdis/167.1.207
   Koprowski H, 1973, Monogr Ser World Health Organ, P85
   KUMAR S, 1994, COMPUT APPL BIOSCI, V10, P189
   LAFON M, 1985, J GEN VIROL, V66, P2125, DOI 10.1099/0022-1317-66-10-2125
   LODMELL DL, 1993, J VIROL, V67, P6080, DOI 10.1128/JVI.67.10.6080-6086.1993
   MACIEL HRR, 2000, PROGRAMA ESPECIALIZA, P157
   MESLIN FX, 1999, RAGE TECHNIQUES LAB, P17
   Nadin-Davis SA, 1998, J VIROL METHODS, V75, P1, DOI 10.1016/S0166-0934(98)00106-2
   Rodrigues da Silva Andrea De Cassia, 2000, Revista do Instituto de Medicina Tropical de Sao Paulo, V42, P95
   Romijn PC, 2003, AM J TROP MED HYG, V69, P81, DOI 10.4269/ajtmh.2003.69.81
   Rupprecht CE, 2002, LANCET INFECT DIS, V2, P327, DOI 10.1016/S1473-3099(02)00287-6
   SACRAMENTO D, 1991, MOL CELL PROBE, V5, P229, DOI 10.1016/0890-8508(91)90045-L
   SMITH JS, 2002, RABIES, P79
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   TORDO N, 1986, P NATL ACAD SCI USA, V83, P3914, DOI 10.1073/pnas.83.11.3914
   Wacharapluesadee S, 2002, CLIN INFECT DIS, V34, P874, DOI 10.1086/338872
   Zanetti CR, 1998, ARCH VIROL, V143, P1745, DOI 10.1007/s007050050413
NR 32
TC 11
Z9 12
U1 0
U2 3
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0304-8608
EI 1432-8798
J9 ARCH VIROL
JI Arch. Virol.
PD APR
PY 2005
VL 150
IS 4
BP 695
EP 708
DI 10.1007/s00705-004-0448-y
PG 14
WC Virology
SC Virology
GA 910CY
UT WOS:000227908300005
PM 15614435
DA 2020-12-01
ER

PT J
AU de Almeida, DF
   Hungria, M
   Guimaraes, CT
   Antonio, RV
   Almeida, FC
   de Almeida, LGP
   de Almeida, R
   Alves-Gomes, JA
   Andrade, EM
   Araripe, J
   de Araujo, MFF
   Astolfi, S
   Azevedo, V
   Baptista, AJ
   Bataus, LAM
   Batista, JD
   Belo, A
   van den Berg, C
   Bogo, M
   Bonatto, S
   Bordignon, J
   Brigido, MM
   Brito, CA
   Brocchi, M
   Burity, HA
   Camargo, AA
   Cardoso, DD
   Carneiro, NP
   Cavada, BS
   Chueire, LMO
   Creczynski-Pasa, TB
   da Cunha, NC
   Fagundes, N
   Falcao, CL
   Fantinatti, F
   Farias, LP
   Felipe, MSS
   Ferrari, LP
   Ferro, JA
   Ferro, MT
   Franco, GR
   de Freitas, NSA
   Furlan, LR
   Gazzinelli, RT
   Gomes, EA
   Goncalves, PR
   Grangeiro, TB
   Grattapaglia, D
   Grisard, EC
   Hanna, ES
   Jardim, SN
   Laurino, J
   Leoi, LCT
   Lima, LFA
   Loureiro, MD
   de Lyra, MDCP
   Madeira, HMF
   Manfio, GP
   Maranhao, AQ
   Martins, WS
   di Mauro, SMZ
   de Medeiros, SRB
   Meissner, RD
   Moreira, MAM
   do Nascimento, FF
   Nicolas, MF
   Oliveira, JG
   Oliveira, SC
   Paixao, RFC
   Parente, JA
   Pedrosa, FDP
   Pena, SDJ
   Pereira, JO
   Pereira, M
   Pinto, LSC
   Pinto, LD
   Porto, JIR
   Potrich, DP
   Ramalho-Neto, CE
   Reis, AMM
   Rigo, LU
   Rondinelli, E
   do Santos, EBP
   Santos, FR
   Schneider, MPC
   Seuanez, HN
   Silva, AMR
   da Silva, ALD
   Silva, DW
   Silva, R
   Simoes, ID
   Simon, D
   Soares, CMD
   Soares, RDA
   Souza, EM
   de Souza, KRL
   Souza, RC
   Steffens, MBR
   Steindel, M
   Teixeira, SR
   Urmenyi, T
   Vettore, A
   Wassem, R
   Zaha, A
   Simpson, AJG
   Cascardo, J
AF de Almeida, DF
   Hungria, M
   Guimaraes, CT
   Antonio, RV
   Almeida, FC
   de Almeida, LGP
   de Almeida, R
   Alves-Gomes, JA
   Andrade, EM
   Araripe, J
   de Araujo, MFF
   Astolfi, S
   Azevedo, V
   Baptista, AJ
   Bataus, LAM
   Batista, JD
   Belo, A
   van den Berg, C
   Bogo, M
   Bonatto, S
   Bordignon, J
   Brigido, MM
   Brito, CA
   Brocchi, M
   Burity, HA
   Camargo, AA
   Cardoso, DD
   Carneiro, NP
   Cavada, BS
   Chueire, LMO
   Creczynski-Pasa, TB
   da Cunha, NC
   Fagundes, N
   Falcao, CL
   Fantinatti, F
   Farias, LP
   Felipe, MSS
   Ferrari, LP
   Ferro, JA
   Ferro, MT
   Franco, GR
   de Freitas, NSA
   Furlan, LR
   Gazzinelli, RT
   Gomes, EA
   Goncalves, PR
   Grangeiro, TB
   Grattapaglia, D
   Grisard, EC
   Hanna, ES
   Jardim, SN
   Laurino, J
   Leoi, LCT
   Lima, LFA
   Loureiro, MD
   de Lyra, MDCP
   Madeira, HMF
   Manfio, GP
   Maranhao, AQ
   Martins, WS
   di Mauro, SMZ
   de Medeiros, SRB
   Meissner, RD
   Moreira, MAM
   do Nascimento, FF
   Nicolas, MF
   Oliveira, JG
   Oliveira, SC
   Paixao, RFC
   Parente, JA
   Pedrosa, FDP
   Pena, SDJ
   Pereira, JO
   Pereira, M
   Pinto, LSC
   Pinto, LD
   Porto, JIR
   Potrich, DP
   Ramalho-Neto, CE
   Reis, AMM
   Rigo, LU
   Rondinelli, E
   do Santos, EBP
   Santos, FR
   Schneider, MPC
   Seuanez, HN
   Silva, AMR
   da Silva, ALD
   Silva, DW
   Silva, R
   Simoes, ID
   Simon, D
   Soares, CMD
   Soares, RDA
   Souza, EM
   de Souza, KRL
   Souza, RC
   Steffens, MBR
   Steindel, M
   Teixeira, SR
   Urmenyi, T
   Vettore, A
   Wassem, R
   Zaha, A
   Simpson, AJG
   Cascardo, J
TI The complete genome sequence of Chromobacterium violaceum reveals
   remarkable and exploitable bacterial adaptability
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID PSEUDOMONAS-AERUGINOSA; SALMONELLA-TYPHIMURIUM; GENE; BIOGENESIS;
   INVASION; MUTATION; CYANIDE; AGENT; GOLD
AB Chromobacterium violaceum is one of millions of species of free-living microorganisms that populate the soil and water in the extant areas of tropical biodiversity around the world. Its complete genome sequence reveals (i) extensive alternative pathways for energy generation, (h) approximate to500 ORF's for transport-related proteins, (iii) complex and extensive systems for stress adaptation and motility, and (iv) widespread utilization of quorum sensing for control of inducible systems, all of which underpin the versatility and adaptability of the organism. The genome also contains extensive but incomplete arrays of ORF's coding for proteins associated with mammalian pathogenicity, possibly involved in the occasional but often fatal cases of human C violaceum infection. There is, in addition, a series of previously unknown but important enzymes and secondary metabolites including paraquat-inducible proteins, drug and heavy-metal-resistance proteins, multiple chitinases, and proteins for the detoxification of xenobiotics that may have biotechnological applications.
C1 Univ Chicago, Chicago, IL 60637 USA.
RP Simpson, AJG (corresponding author), Univ Chicago, Chicago, IL 60637 USA.
EM asimpson@licr.org
RI Maranhao, Andrea Q/L-4474-2013; Porto, Jorge/K-1441-2014; Vettore, Andre
   L/J-5168-2012; Soares, Celia/N-6395-2014; Fantinatti-Garboggini,
   Fabiana/F-3991-2012; Bataus, Luiz Artur/H-8869-2013; Grangeiro, Thalles
   Barbosa/E-9606-2010; Santos, Fabricio Rodrigues dos/H-2370-2011;
   Grattapaglia, Dario/AAB-6805-2020; Camargo, Anamaria A/E-9388-2012;
   Goncalves, Pablo R/F-7589-2013; Hungria, Mariangela/T-5630-2019;
   Maranh\\xc3\\xa3o, Andrea Queiroz/S-8696-2019; Pedrosa, Fabio
   0/C-1938-2013; Porto, Jorge/T-4694-2019; Almeida, Luiz GP/G-5829-2012;
   Brigido, Marcelo/A-1972-2015; Madeira, Humberto/C-2212-2008; da Silva
   Pinto, Luciano/M-9913-2019; da Silva Batista, Jacqueline/AAD-4349-2020;
   Batistuzzo de Medeiros, Silvia/H-2117-2015; Fagundes, Nelson
   JR/F-7490-2014; Grisard, Edmundo C/A-7338-2015; Silva,
   Artur/E-1474-2014; Urmenyi, Turan/C-4548-2013; DE MEDEIROS, SILVIA
   REGINA BATISTUZZO/ABC-2811-2020; Agnez-Lima, Lucymara/F-9655-2012; P,
   CM/B-1358-2013; NICOLAS, MARISA FABIANA/H-4930-2019; Azevedo, Vasco
   A/B-1556-2019; Bordignon, Juliano/Z-6268-2019; Farias, Izeni
   Pires/J-3069-2014; da Silva Pinto, Luciano/D-2504-2017; Hungria,
   Mariangela/D-8540-2013; de Souza, Emanuel Maltempi/C-1920-2013; Grisard,
   Edmundo C/AAS-9429-2020; van den Berg, Cassio/B-8968-2008; Alves-Gomes,
   Jose A/C-7075-2013; Franco, Gloria/I-3654-2013; de Lyra, Maria do Carmo
   Catanho Pereira/I-8886-2012; Vasconcelos, Ana Tereza R/I-1011-2012;
   Zaha, Arnaldo/D-3165-2013; SOARES, RENATA BA/B-6423-2011; Ferro, Jesus
   Aparecido/C-8251-2013; Creczynski-Pasa, Tania B/C-2925-2009; Azevedo,
   Vasco A.C/F-4315-2011; Moreira, Miguel/AAN-7405-2020; Grattapaglia,
   Dario/B-5864-2014; zingaretti, sonia m/C-1123-2013; Brigido,
   Marcelo/N-9277-2019; Felipe, Maria Sueli/L-6260-2016; Brigido,
   Marcelo/H-2718-2019; Bonatto, Sandro L/A-1240-2010; Maranhao,
   Andrea/AAC-3560-2019; Bogo, Mauricio R/D-7537-2013; Brocchi,
   Marcelo/E-3723-2012; Simon, Daniel/A-9087-2011; DE BASTOS ASCENCO
   SOARES, RENATA/G-4330-2019; HANNA, EBERT S/C-9569-2012; Almeida,
   Francisca/E-5849-2016
OI Maranhao, Andrea Q/0000-0002-1946-7191; Porto,
   Jorge/0000-0003-1393-6492; Vettore, Andre L/0000-0001-8526-5478; Bataus,
   Luiz Artur/0000-0002-5437-6762; Grangeiro, Thalles
   Barbosa/0000-0001-8276-3092; Santos, Fabricio Rodrigues
   dos/0000-0001-9088-1750; Grattapaglia, Dario/0000-0002-0050-970X;
   Camargo, Anamaria A/0000-0002-6076-9597; Goncalves, Pablo
   R/0000-0002-4923-2334; Almeida, Luiz GP/0000-0002-7124-2715; Madeira,
   Humberto/0000-0002-0567-8246; da Silva Pinto,
   Luciano/0000-0001-8656-4031; da Silva Batista,
   Jacqueline/0000-0002-6649-6200; Batistuzzo de Medeiros,
   Silvia/0000-0003-2431-0479; Fagundes, Nelson JR/0000-0003-0456-0323;
   Grisard, Edmundo C/0000-0001-8916-8296; Silva,
   Artur/0000-0002-4082-1132; Agnez-Lima, Lucymara/0000-0003-0642-3162;
   NICOLAS, MARISA FABIANA/0000-0002-5437-2737; Azevedo, Vasco
   A/0000-0002-4775-2280; Bordignon, Juliano/0000-0002-1965-6152; Farias,
   Izeni Pires/0000-0002-1416-4351; da Silva Pinto,
   Luciano/0000-0001-8656-4031; de Souza, Emanuel
   Maltempi/0000-0003-1546-9218; Grisard, Edmundo C/0000-0001-8916-8296;
   van den Berg, Cassio/0000-0001-5028-0686; Franco,
   Gloria/0000-0001-5245-2365; de Lyra, Maria do Carmo Catanho
   Pereira/0000-0003-1010-1692; Vasconcelos, Ana Tereza
   R/0000-0002-4632-2086; Ferro, Jesus Aparecido/0000-0002-3966-1303;
   Creczynski-Pasa, Tania B/0000-0002-6026-2948; Azevedo, Vasco
   A.C/0000-0002-4775-2280; Grattapaglia, Dario/0000-0002-0050-970X;
   zingaretti, sonia m/0000-0001-6755-4153; Brigido,
   Marcelo/0000-0002-7136-7059; Felipe, Maria Sueli/0000-0003-4347-6853;
   Bonatto, Sandro L/0000-0002-0064-467X; Maranhao,
   Andrea/0000-0002-1946-7191; Bogo, Mauricio R/0000-0002-5728-9576; Simon,
   Daniel/0000-0003-1122-8468; DE BASTOS ASCENCO SOARES,
   RENATA/0000-0003-1029-325X; Gazzinelli, Ricardo/0000-0003-2427-7699;
   Araujo, Magnolia/0000-0001-8811-7921; Martins,
   Wellington/0000-0002-9641-2565; Fantinatti-Garboggini,
   Fabiana/0000-0002-0096-047X; Tiraboschi Ferro, Maria
   Ines/0000-0003-3389-9131; Nascimento, Fabricia/0000-0001-9426-6835;
   Almeida, Francisca/0000-0001-6003-4657; Cavada,
   Benildo/0000-0002-5791-6170
CR ANDERSON PM, 1990, FEMS MICROBIOL LETT, V87, P247, DOI 10.1016/0378-1097(90)90462-Y
   Apweiler R, 2000, BIOINFORMATICS, V16, P1145, DOI 10.1093/bioinformatics/16.12.1145
   BOISBAUDRAN L, 1882, CR HEBD ACAD SCI, V941, P562
   Calamita G, 2000, MOL MICROBIOL, V37, P254, DOI 10.1046/j.1365-2958.2000.02016.x
   CALDA LR, 1990, VIENC HOJE, V11, P55
   CALDAS LR, 1978, P INT S CURR TOP RAD, P121
   Campbell SC, 2001, J IND MICROBIOL BIOT, V26, P134, DOI 10.1038/sj.jim.7000104
   Carraro DM, 2003, BIOTECHNIQUES, V34, P626, DOI 10.2144/03343dd05
   Chen G, 1996, J INVERTEBR PATHOL, V68, P101, DOI 10.1006/jipa.1996.0066
   Chernin LS, 1998, J BACTERIOL, V180, P4435, DOI 10.1128/JB.180.17.4435-4441.1998
   COLLAZO CM, 1995, MOL MICROBIOL, V15, P25, DOI 10.1111/j.1365-2958.1995.tb02218.x
   Cronin D, 1997, EUR J PLANT PATHOL, V103, P433, DOI 10.1023/A:1008662729757
   Darzins A, 1997, GENE, V192, P109, DOI 10.1016/S0378-1119(97)00037-1
   DURAN N, 1994, WORLD J MICROB BIOT, V10, P686, DOI 10.1007/BF00327960
   Duran N, 2001, CRIT REV MICROBIOL, V27, P201, DOI 10.1080/20014091096747
   DURAN N, 1983, AN ACAD BRAS CIENC, V55, P231
   DURAN N, 1990, CIENCIA HOJE, V11, P58
   Faraldo-Gomez JD, 2003, NAT REV MOL CELL BIO, V4, P105, DOI 10.1038/nrm1015
   FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800
   FORSYTH WGC, 1958, NATURE, V182, P800, DOI 10.1038/182800a0
   Francino MP, 1997, TRENDS GENET, V13, P240, DOI 10.1016/S0168-9525(97)01118-9
   Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322
   Gourson C, 1999, J APPL POLYM SCI, V74, P3040, DOI 10.1002/(SICI)1097-4628(19991220)74:13<3040::AID-APP5>3.0.CO;2-M
   Gray KM, 2001, MICROBIOL-SGM, V147, P2379, DOI 10.1099/00221287-147-8-2379
   Hanke J, 1996, BIOTECHNIQUES, V21, P686
   Ingalls RR, 1998, J IMMUNOL, V161, P5413
   JANSSEN DB, 1994, ANNU REV MICROBIOL, V48, P163, DOI 10.1146/annurev.mi.48.100194.001115
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kimbrough TG, 2002, MICROBES INFECT, V4, P75, DOI 10.1016/S1286-4579(01)01512-X
   Laville J, 1998, J BACTERIOL, V180, P3187, DOI 10.1128/JB.180.12.3187-3196.1998
   Leon LL, 2001, J ANTIMICROB CHEMOTH, V48, P449, DOI 10.1093/jac/48.3.449
   LICHSTEIN HC, 1945, J INFECT DIS, V76, P47, DOI 10.1093/infdis/76.1.47
   LICHSTEIN HC, 1946, J BACTERIOL, V52, P145, DOI 10.1128/JB.52.1.145-146.1946
   Lowe CA, 2001, MICROBIOL-SGM, V147, P1303, DOI 10.1099/00221287-147-5-1303
   McClean KH, 1997, MICROBIOL-UK, V143, P3703, DOI 10.1099/00221287-143-12-3703
   Melo PD, 2000, IN VITRO CELL DEV-AN, V36, P539
   MILLER DP, 1988, CAN J MICROBIOL, V34, P249, DOI 10.1139/m88-046
   Moe PC, 1998, MOL MICROBIOL, V28, P583, DOI 10.1046/j.1365-2958.1998.00821.x
   Nakai K, 2000, ADV PROTEIN CHEM, V54, P277, DOI 10.1016/S0065-3233(00)54009-1
   Nikaido H, 1996, J BACTERIOL, V178, P5853, DOI 10.1128/jb.178.20.5853-5859.1996
   Ochsner UA, 1999, J BACTERIOL, V181, P1099, DOI 10.1128/JB.181.4.1099-1109.1999
   OSUZA AO, 1999, REV I ADOLFFO LUTZ, V58, P59
   Parkhill J, 2000, NATURE, V404, P502, DOI 10.1038/35006655
   Parkhill J, 2001, NATURE, V413, P523, DOI 10.1038/35097083
   Patil RS, 2000, ENZYME MICROB TECH, V26, P473, DOI 10.1016/S0141-0229(00)00134-4
   RICHARD C, 1993, B SOC PATHOL EXOT, V86, P169
   Rietschel ET, 1998, MICROB DRUG RESIST, V4, P37, DOI 10.1089/mdr.1998.4.37
   Romling U, 2002, RES MICROBIOL, V153, P205, DOI 10.1016/S0923-2508(02)01316-5
   Salanoubat M, 2002, NATURE, V415, P497, DOI 10.1038/415497a
   SCHULTZ JE, 1991, J MOL BIOL, V218, P129, DOI 10.1016/0022-2836(91)90879-B
   SMITH AD, 1985, J CHEM TECH BIOT B, V35, P110, DOI 10.1002/jctb.280350208
   Stebbins CE, 2001, NATURE, V414, P77, DOI 10.1038/35102073
   STEINBUCHEL A, 1993, APPL MICROBIOL BIOT, V39, P443, DOI 10.1007/BF00205030
   STEISCHSBIER F, 1983, FEMS MICROBIOL LETT, V143, P3703
   Stover CK, 2000, NATURE, V406, P959
   Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33
   Tonjum T, 1997, GENE, V192, P155, DOI 10.1016/S0378-1119(97)00018-8
   Tyler BM, 2002, ANNU REV PHYTOPATHOL, V40, P137, DOI 10.1146/annurev.phyto.40.120601.125310
   UEDA H, 1994, BIOSCI BIOTECH BIOCH, V58, P1579, DOI 10.1271/bbb.58.1579
   Vergauwen B, 2003, J BACTERIOL, V185, P1572, DOI 10.1128/JB.185.5.1572-1581.2003
   WATSON PR, 1995, INFECT IMMUN, V63, P2743, DOI 10.1128/IAI.63.7.2743-2754.1995
   WILLIAMS MD, 1994, MOL MICROBIOL, V11, P1029, DOI 10.1111/j.1365-2958.1994.tb00381.x
NR 62
TC 168
Z9 172
U1 1
U2 28
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 30
PY 2003
VL 100
IS 20
BP 11660
EP 11665
DI 10.1073/pnas.1832124100
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 727XG
UT WOS:000185685700087
PM 14500782
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Bordignon, J
   Ferreira, SCP
   Caporale, GMM
   Carrieri, ML
   Kotait, I
   Lima, HC
   Zanetti, CR
AF Bordignon, J
   Ferreira, SCP
   Caporale, GMM
   Carrieri, ML
   Kotait, I
   Lima, HC
   Zanetti, CR
TI Flow cytometry assay for intracellular rabies virus detection
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE rabies; rabies virus; flow cytometry; BHK-21 cells; C6 cells
ID HERPES-SIMPLEX VIRUS; TISSUE-CULTURE; DIAGNOSIS; ROTAVIRUS; CELLS
AB Following previous studies reporting microbiological diagnosis by flow cytometry, the possibility of using this method was examined to monitor infection of susceptible cell lines by a fixed rabies virus strain (Pasteur Virus strain-PV) or a wild rabies virus strain (WRS). Suspensions of BHK-21 and C6 cells were infected with viruses and a time course of virus infection was established. Sequentially, at several time points, infected and control uninfected cells were fixed, permeabilized, and stained with a rabies virus-specific antibody conjugate. This was achieved by resuspending cells in a solution containing p-formaldehyde in FACS lysis fluid, which allowed the detection of intracellular virus with flourescein-coupled antibodies by flow cytometry. A Becton Dickinson FACSCalibur(R) flow cytometer was used to analyze the percentage of cells infected and the kinetics of the infection process was determined. As early as 12 h after inoculation with both rabies virus strains, significant levels (P < 0.01) of infection (from 4.7 to 7.1%) were detected by flow cytometry. The maximum level of infection was obtained at 48 h in C6 cells (88%) with both viruses. The advantages of this method for examination of intracellular virus infection are discussed. (C) 2002 Elsevier Science B.V. All rights reserved.
C1 Univ Fed Santa Catarina, Immunol Lab, Dept Microbiol & Parasitol, BR-88040900 Florianopolis, SC, Brazil.
   Hemosc, BR-88015240 Florianopolis, SC, Brazil.
   Inst Pasteur, BR-01311000 Sao Paulo, Brazil.
RP Zanetti, CR (corresponding author), Univ Fed Santa Catarina, Immunol Lab, Dept Microbiol & Parasitol, BR-88040900 Florianopolis, SC, Brazil.
EM imuno@hemosc.org; ikotait@uol.com.br; zanetti@ccb.ufsc.br
RI Bordignon, Juliano/Z-6268-2019; P, CM/B-1358-2013; Lima,
   Hermenio/A-1616-2010; Lima, Hermenio C/G-5379-2010
OI Bordignon, Juliano/0000-0002-1965-6152; Lima, Hermenio
   C/0000-0003-0950-3731
CR Abad FX, 1997, WATER SCI TECHNOL, V35, P451, DOI 10.1016/S0273-1223(97)00302-8
   ALVAREZ L, 1994, PEDIATR INFECT DIS J, V13, P1154, DOI 10.1097/00006454-199412000-00020
   Barardi CRM, 1998, J VIROL METHODS, V74, P31, DOI 10.1016/S0166-0934(98)00061-5
   Bordignon J, 2001, BIOLOGICALS, V29, P67, DOI 10.1006/biol.2001.0278
   GOLDWASSER RA, 1958, P SOC EXP BIOL MED, V98, P219, DOI 10.3181/00379727-98-23996
   HATTWICK MA, 1974, JAMA-J AM MED ASSOC, V227, P407, DOI 10.1001/jama.227.4.407
   Haupt W, 1999, VACCINE, V17, P1742, DOI 10.1016/S0264-410X(98)00447-2
   Hoffman RM, 1997, J AM WATER WORKS ASS, V89, P104
   HORAN M, 1975, EXP CELL RES, V91, P247, DOI 10.1016/0014-4827(75)90101-9
   HUMMELER K, 1996, LAB TECHNIQUES RABIE, P85
   JENSEN BD, 1989, METHOD ENZYMOL, V171, P549
   King A. A., 1996, P114
   KOPROWSKI H, 1996, LAB TECHNIQUES RABIE, P383
   MCHUGH TM, 1988, J CLIN MICROBIOL, V26, P1957, DOI 10.1128/JCM.26.10.1957-1961.1988
   MCSHARRY JJ, 1990, J CLIN MICROBIOL, V28, P1864, DOI 10.1128/JCM.28.8.1864-1866.1990
   MCSHARRY JJ, 1994, CLIN MICROBIOL REV, V7, P576, DOI 10.1128/CMR.7.4.576-604.1994
   PERRIN P, 1986, J BIOL STAND, V14, P217, DOI 10.1016/0092-1157(86)90006-5
   PORRAS C, 1976, ANN INTERN MED, V85, P44, DOI 10.7326/0003-4819-85-1-44
   RUDD RJ, 1989, J CLIN MICROBIOL, V27, P2522, DOI 10.1128/JCM.27.11.2522-2528.1989
   Tierkel E. S., 1996, P55
   Tordo N., 1995, POLYMERASE CHAIN REA, P125
   WEBSTER WA, 1987, CAN J VET RES, V51, P367
   Wilde H, 1996, CLIN INFECT DIS, V22, P228, DOI 10.1093/clinids/22.2.228
   YANG G, 1995, CYTOMETRY, V21, P197, DOI 10.1002/cyto.990210212
NR 24
TC 21
Z9 26
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD AUG
PY 2002
VL 105
IS 1
BP 181
EP 186
AR PII S0166-0934(02)00064-2
DI 10.1016/S0166-0934(02)00064-2
PG 6
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA 596EP
UT WOS:000178151400019
PM 12176155
DA 2020-12-01
ER

PT J
AU Bordignon, J
   Piza, AT
   Alvarez-Silva, M
   Caporale, GMM
   Carrieri, ML
   Kotait, I
   Zanetti, CR
AF Bordignon, J
   Piza, AT
   Alvarez-Silva, M
   Caporale, GMM
   Carrieri, ML
   Kotait, I
   Zanetti, CR
TI Isolation and replication of rabies virus in C6 rat glioma cells (clone
   CCL-107)
SO BIOLOGICALS
LA English
DT Article
DE rabies; C6 rat glioma cells; BHK-21 cell; NA cell; glycoprotein
ID CULTURE; PROTEIN; INVITRO; EXPRESSION; INFECTION; STRAINS; CER
AB The susceptibility of the C6 rat glioma cell line (ATCC; CCL-107) to rabies virus was characterized. The kinetics of infection performed with a fixed and a wild strain (from an infected cow) of rabies virus was monitored by direct immunofluorescence. Fluorescent cytoplasmic bodies were readily observed by UV microscopy from 24 hours post-infection (hpi) onwards. The ability of C6 to produce rabies infective virion particles was confirmed by determining the viral titres present in the supernatants of infected cultures, by both BHK-21 cell infection and mice inoculation. C6 cells produced similar viral titres to those produced by BHK-21 for both strains used. In addition, the yield of rabies glycoprotein was assessed by ELISA. In general, BHK-21 and C6 cells infected either by PV or with the wild rabies strain produced similar amounts of rabies glycoprotein. At 96 hpi, however, when the glycoprotein production peaked, BHK-21 infected with the wild strain produced significantly higher amounts of glycoprotein than C6. Subsequently, the optimal conditions for isolation of wild rabies virus strains from C6 cells were established and these proved to be as sensitive as NA cells in detecting 10 wild rabies samples. Due to the high sensitivity exhibited, C6 rat glioma cells present a new and useful system for rabies virus investigation. (C) 2001 The International Association for Biologicals.
C1 Univ Fed Santa Catarina, Dept Microbiol Immunol & Parasitol, MIP, CCB, BR-88040900 Florianopolis, SC, Brazil.
   Vallee SA, BR-04571010 Sao Paulo, Brazil.
   Univ Fed Santa Catarina, Dept Cell Biol Embryol & Genet, BEG, CCB, BR-88040900 Florianopolis, SC, Brazil.
   Inst Pasteur, BR-01311000 Sao Paulo, Brazil.
RP Zanetti, CR (corresponding author), Univ Fed Santa Catarina, Dept Microbiol Immunol & Parasitol, MIP, CCB, Campus Univ Trindade, BR-88040900 Florianopolis, SC, Brazil.
RI Bordignon, Juliano/Z-6268-2019; P, CM/B-1358-2013; Alvarez-Silva,
   Marcio/K-2432-2012
OI Bordignon, Juliano/0000-0002-1965-6152; Alvarez-Silva,
   Marcio/0000-0003-0708-7017
CR ALBERTS B, 1994, MOL BIOL CELL
   Barna M, 1996, VIROLOGY, V223, P331, DOI 10.1006/viro.1996.0484
   BENDA P, 1971, J NEUROSURG, V34, P310, DOI 10.3171/jns.1971.34.3.0310
   BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370
   CARBONE KM, 1993, J VIROL, V67, P1453, DOI 10.1128/JVI.67.3.1453-1460.1993
   CLARK HF, 1980, INFECT IMMUN, V27, P1012, DOI 10.1128/IAI.27.3.1012-1022.1980
   CLARK HF, 1979, RHABDOVIRUSES, V1, P23
   COYLE DE, 1995, J NEUROSCI RES, V41, P374, DOI 10.1002/jnr.490410310
   Crick J., 1988, Rabies., P47
   Dean D. J., 1973, Laboratory techniques in rabies. WHO Monograph Series No.23., P73
   Goya L, 1996, INT J DEV NEUROSCI, V14, P409, DOI 10.1016/S0736-5748(96)00026-3
   GUENTHER J, 1985, EMBO J, V4, P1963, DOI 10.1002/j.1460-2075.1985.tb03878.x
   Habel K., 1996, P369
   HUPRIKAR J, 1986, J VIROL, V58, P493, DOI 10.1128/JVI.58.2.493-499.1986
   IWASAKI Y, 1977, LAB INVEST, V36, P578
   King A. A., 1996, P114
   KOPROWISKI H, 1996, LAB TECHNIQUES RABIE, P85
   KOSCHEL K, 1984, P NATL ACAD SCI-BIOL, V81, P950, DOI 10.1073/pnas.81.3.950
   KUMAR G, 1994, VIROLOGY, V203, P116, DOI 10.1006/viro.1994.1461
   LANDER AD, 1983, COLD SPRING HARB SYM, V48, P611, DOI 10.1101/SQB.1983.048.01.065
   Perrin P., 1996, P383
   PORTNO DS, 1982, RABIES INFORMATION E, V6, P35
   RUDD RJ, 1980, J CLIN MICROBIOL, V12, P590, DOI 10.1128/JCM.12.4.590-593.1980
   RUDD RJ, 1987, J CLIN MICROBIOL, V25, P1456, DOI 10.1128/JCM.25.8.1456-1458.1987
   SMITH AL, 1977, INTERVIROLOGY, V8, P92, DOI 10.1159/000148883
   SMITH AL, 1978, INTERVIROLOGY, V9, P359, DOI 10.1159/000148958
   TOLLIS M, 1988, J VET MED B, V35, P504, DOI 10.1111/j.1439-0450.1988.tb00524.x
   TRAUB UE, 1983, J CELL SCI, V62, P129
   Trimarchi C. V., 1996, P193
   TSIANG H, 1983, J NEUROPATH EXP NEUR, V42, P439, DOI 10.1097/00005072-198307000-00006
   TSIANG H, 1985, B I PASTEUR, V83, P41
   VOLPE JJ, 1975, BIOCHEM J, V152, P701, DOI 10.1042/bj1520701
   Webster W.A., 1988, P201
   Wiktor T. J., 1975, The natural history of rabies,, P155
   Wilbur L. A., 1996, P360
NR 35
TC 6
Z9 6
U1 0
U2 1
PU ACADEMIC PRESS LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1045-1056
J9 BIOLOGICALS
JI Biologicals
PD JUN
PY 2001
VL 29
IS 2
BP 67
EP 73
DI 10.1006/biol.2001.0278
PG 7
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Pharmacology & Pharmacy
GA 485ET
UT WOS:000171741100002
PM 11580211
DA 2020-12-01
ER

EF